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Abstract 
There is an urgent need for Alzheimer´s disease (AD) biomarkers that can detect the 
disease at the early pre-symptomatic stages. Case versus control study designs often 
ignore clinical heterogeneity in patients and neuropathology in controls resulting in 
markers with doubtful clinical utility. Using markers of in vivo β-amyloid deposition 
(e.g. 11C-PiB) combined with positron emission tomography (PET) or MRI to derive 
biologically relevant biomarkers associated with established endophenotypes of 
disease pathology is a better approach. Neuropathological hallmarks of AD (β-
amyloid plaques and neurofibrillary tangles) are commonly reported in post-mortem 
brains of non-demented elderly individuals, suggesting these cases might represent 
preclinical AD and may be a good population in which to detect early AD 
biomarkers. Here we aimed to identify plasma biomarkers associated with AD 
endophenotypes of brain amyloid burden or brain atrophy in non-demented older 
individuals using two complimentary longitudinal discovery-phase proteomic 
analyses. 
Two-dimensional gel electrophoresis coupled with mass spectrometry was performed 
on longitudinal plasma samples from non-demented older individuals exhibiting a 
range of 11C-PiB PET measures of amyloid load. The relationship between protein 
levels and measures of brain atrophy, cognitive decline, and amyloid load were 
examined. A label-free LC-MS/MS approach targeted at low molecular weight 
proteins (<30kDa) was also performed on a subset of these subjects to enhance 
coverage of the plasma proteome. Validation of candidate biomarkers was performed 
in an independent cohort using quantitative immunoassays and aptamer-based arrays. 
We have identified 15 plasma proteins associated with brain amyloid load, brain 
atrophy and cognitive scores. Our longitudinal study design allowed us to explore 
dynamic changes in concentrations of plasma protein profiles in relation to rates of 
change in both measures of AD pathology and cognition. Validation experiments 
determined whether these candidate biomarkers of pathology performed in an AD 
cohort. 
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Chapter 1. Introduction 
Dementia is a broad term used to describe disorders which cause decline in various 
cognitive functions, including; memory, executive function, language, behaviour, 
and the ability to perform everyday activities. Different types of dementia include; 
Alzheimer’s disease, frontal temporal dementia, dementia with lewy bodies (DLB), 
and vascular dementia, with each type having different symptom patterns and brain 
abnormalities. 
Dementia prevalence rates are increasing rapidly. In 2010 35.6 million people 
worldwide (around 0.5% of the world’s population) were reported to be living with 
dementia. By 2030 it is estimated that this figure will almost double to 65.7 million 
people, and further double again to 115.4 million by 2050[1]. The single greatest risk 
factor for dementia is age, affecting approximately 1/100 of those aged 65-69, 
increasing to 1/3 at age 90 or older[2]. These numbers are not only alarming on an 
individual level, but they are also unsustainable for our economy. Dementia costs the 
global economy US$604 billion, and like prevalence rates this figure is also set to 
increase with an 85% rise in costs estimated by the year 2030[3].  
All of these figures can be revised if interventions are found to delay or prevent the 
onset of dementia. The most common form of dementia is Alzheimer’s disease (AD), 
accounting for around 60-80% of cases and this is the main contributor to the steep 
increase of dementia prevalence with age[2]. 
1.1 Alzheimer’s Disease (AD) 
Alzheimer’s disease (AD) was first identified in 1907 by Alois Alzheimer[4]. 
Although age is the greatest risk factor it is not entirely restricted to the elderly with 
over 16,000 people under the age of 65 with dementia in the UK[5]. According to the 
Diagnostic and Statistical Manual of Mental Disorders-IV-TR[6] AD is characterised 
by multiple cognitive deficits, including a memory deficit, which cause significant 
impairment to social or occupational functioning. The disease is also characterised 
by a gradual onset followed by continuing cognitive decline, with a mean duration of 
approximately 8.5 years from the onset of clinical symptoms to the death of the 
patient[7]. AD is diagnosed through a combination of patient history, clinical 
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symptoms, and neuropsychological tests (e.g. Clinical Dementia Rating scale (CDR) 
and the Mini Mental State Examination (MMSE)), and is also largely based on the 
exclusion of other dementias. Currently a definitive diagnosis of AD can only be 
given by examination of post-mortem brain tissue, consequently the clinical 
diagnosis is presently inaccurate in around 10-15% of patients[8]. 
1.2 Alzheimer’s Disease Pathology 
Alzheimer’s disease neuropathology is characterised by two key hallmarks; 
extracellular deposits of senile plaques and intracellular deposits of neurofibrillary 
tangles in the brain at autopsy[6]. The central component of senile plaques is the 
protein beta-amyloid (Aβ), generated by the cleavage of its precursor amyloid 
precursor protein (APP). The deposition of Aβ in the brain has been proposed as a 
central event in AD by the ‘amyloid cascade hypothesis’, a hypothesis which has 
dominated AD research for the past twenty years. This hypothesis proposes that APP 
mismetabolism and Aβ deposition are the primary events in AD neuropathology, 
initiating a cascade eventually leading to neuronal death[11].  
Neurofibrillary tangles consist of abnormally hyper-phosphorylated tau which self-
associates, winding into paired helical filaments and accumulating intracellularly. 
Tau is a microtubule associated protein, which promotes microtubule assembly and 
stabilisation when functioning correctly[9]. The density and distribution of 
neurofibrillary tangles is known to increase with AD severity[10]. Although the 
amyloid cascade hypothesis is the dominant model of AD pathogenesis, some 
scientists (sometimes called tauists) believe that changes to tau and the formation of 
neurofibrillary tangles are instead the key event in AD leading to neurodegeneration. 
It is also possible that a third event, common to both plaques and tangles, is instead 
crucial for the initiation of neurodegeneration in AD[11].  
Post-mortem analyses have identified the hippocampus and the entorhinal cortex as 
the first brain areas to be affected by plaques and tangles in AD with cortical 
association areas becoming increasingly affected as the disease progresses[12]. 
Overall the temporal lobe cortex and hippocampus are found to be the areas most 
severely affected by neurofibrillary tangle formation in AD[13], which is 
unsurprising as these areas are well known for their involvement in cognitive 
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function, particularly memory. Although post-mortem analysis is currently our sole 
method of a 100% accurate AD diagnosis, there are other signs of AD that we can 
look for in vivo. The pattern of brain atrophy characteristic of AD is a decrease in 
volume of the temporal lobes, hippocampus, and the thalamus, with a significant 
increase in the size of the lateral ventricles and an expansion of the circular sulcus of 
the insula[14]. AD patients also have regions of abnormal metabolic brain function, 
most notably in neocortical association areas such as the posterior cingulate, 
precuneus, temporoparietal and frontal multimodal association regions[15].  
There are many other features seen in AD, such as cerebral amyloid angiopathy, 
neuroinflammation and vascular disease, which on top of the presence of plaques, 
tangles, and brain atrophy, are likely to significantly contribute to disease 
progression[16].  
1.3 Genetic Risk Factors 
There are two subtypes of AD; early onset (familial) and late onset, both types have a 
genetic component. Familial AD (FAD) is rare, representing approximately 5% of 
AD cases, and onset normally occurs aged 30-60. All cases of FAD are inherited and 
caused by a genetic mutation. Three main known genetic mutations causing FAD 
are; amyloid precursor protein (APP)[17-19], and presenilin 1 and 2[20-22]. 
The majority of AD cases are sporadic, developing at an older age. The known 
genetic components of sporadic AD are not causal, but do increase the risk of 
developing the disease. The risk gene with the strongest influence is Apolipoprotein 
E, with the epsilon 4 allele (APOE ε4) considered a potent risk factor for AD. The 
risk associated with APOE ε4 varies between studies, but the majority of clinically 
diagnosed AD cases are normally found to carry at least one ε4 allele[23-24]. APOE 
ε4 has been found to not only increase the risk of AD, but to also significantly reduce 
the age of onset[24-25] and has also been shown to increase the rate of cognitive 
decline[26-28]. The risk factor linked to APOE ε4 has also been found to be stronger 
in women than men[29]. Although APOE ε4 increases the risk of AD it is not 
necessary or sufficient for AD pathology development[26], and therefore the 
sensitivity and specificity of APOE genotyping for AD is low. However APOE ε4 
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status is still relevant for biomarkers as it may influence biomarker activity or 
expression, and so is commonly included as a covariate in biomarker research. 
TREM2 is another genetic risk factor for AD; heterozygous rare variants of TREM2 
have been associated with an increased risk of AD and the expression of TREM2 has 
been shown to rise in parallel with an increase in cortical levels of Aβ[30]. One of 
the known roles of TREM2 is to regulate inflammation and the discovery of this 
genetic link to AD confirmed the inflammation element of the disease[31]. 
Genomewide association studies (GWAS) have recently identified many other genes 
as low-risk factors for sporadic AD, including; CLU, PICALM, CR1, BIN1, MS4A, 
CD2AP, CD33, ABCA7, and EPHA1[32-34]. Pathway analysis of susceptibility 
genes for AD can pinpoint biological pathways involved in disease development and 
hence provide targets for intervention strategies. This analysis approach has so far 
highlighted pathways such as inflammation and complement biology[35-36].  
1.4 Therapeutic interventions 
1.4.1 Symptomatic Treatments 
There is currently no cure or preventative for AD, however there are drug treatments 
that help with the cognitive and behavioural symptoms. There are two main groups 
of treatments for AD; cholinesterase inhibitors and NMDA receptor antagonists. 
Cholinesterase inhibitor drug therapies inhibit acetylcholinesterase; increasing the 
concentration of acetylcholine in the brain to replenish acetylcholine lost by 
cholinergic neuron death. This is based on the cholinergic hypothesis that states that 
the degeneration of cholinergic neurons and consequently the loss of cholinergic 
neurotransmission in certain brain areas contribute significantly to the deterioration 
in cognitive function observed in AD[7]. Therefore if drugs improve cholinergic 
neurotransmission, the patient’s cognitive function is also expected to improve.  
NMDA receptor antagonists work by blocking the activity of the neurotransmitter 
glutamate, which is released in excess quantities by damaged cells in AD brains. 
High levels of glutamate results in neurotoxicity, so NMDA receptor antagonists 
work to normalise the glutamatergic system and improve cognitive deficits[37]. 
However benefits of both types of drugs are modest, temporary, and do not affect 
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disease progression[38]. In fact there are no drugs currently in clinical use that can 
successfully alter AD progression.  
1.4.2 Disease Modifying Treatments 
At present the search for disease-modifying interventions is largely focused upon 
targeting the Aβ pathway. Based on the amyloid cascade hypothesis intervention 
strategies may focus upon inhibition of the formation of amyloid plaques or the 
alleviation of abnormal APP activity to successfully halt or slow the progression of 
the disease[39]. One example of this is both passive and active immunotherapy 
research that attempts immune-mediated Aβ reduction in the brain of AD patients, 
with the aim of consequently increasing their cognitive performance or at least 
slowing decline[38]. Active immunotherapy involves combining Aβ with an 
adjuvant to stimulate an immune response producing anti-Aβ antibodies, whilst 
passive immunotherapy involves directly injecting anti-Aβ antibodies[40]. Recent 
clinical trials in humans have shown promise but have also displayed serious 
complications. For example, a phase II clinical trial of AN1792 immunization 
successfully resulted in clearance of amyloid plaques whilst also showing CSF tau 
level reductions and minor cognitive benefits, however the trial was halted as 6% of 
patients developed meningoencephalitis, a life-threatening inflammation of the brain 
and meninges[41]. Although this trial was halted it does show encouraging signs that 
Aβ immunotherapy may be useful for AD. However this trial did not prevent 
progressive neurodegeneration or show long term cognitive benefits[42]. Clearly 
further developments are needed and improvements in disease models and 
biomarkers are essential for the advancement of such interventions. 
Beta-secretase (BACE1) and gamma secretase inhibitors are two other intervention 
strategies based upon the amyloid cascade hypothesis of AD. BACE1 and gamma 
secretase are APP cleaving enzymes, initiating the production of Aβ that is 
subsequently deposited in plaques. Inhibiting these enzymes is therefore expected to 
interrupt the formation of Aβ plaques and prevent neurodegeneration and so has been 
the target aim of many intervention strategies[43-44]. During the past few years 
much progress had been made on the development of BACE1 inhibitors, which have 
been shown to have positive effects in experimental animal models. For example the 
  34 
  
BACE1 inhibitor GRL-8234 was shown to rescue age-related cognitive decline in 
transgenic APP mice (Tg2576)[45]. There are now several BACE1 inhibitors 
currently in the first stages of human clinical trials[46-47]. Unfortunately clinical 
trials of gamma-secretase inhibitors have so far encountered complications [48], 
thought to be mainly due to a disruption of Notch signalling, but if future 
developments can avoid this then the intervention has great potential. 
Another potential therapeutic strategy distinct from Aβ-based interventions is the 
inhibition or reversal of tau aggregation, and treatments targeting neurofibrillary 
tangles are currently in development. The first tau-based phase 3 clinical trial is 
currently underway, testing methylthioninium (LMTX) a tau aggregation 
inhibitor[49]. It is hoped that more success is found with tau based treatments than 
achieved so far with Aβ based interventions.  
Although there has been great advancements in our understanding of dementias the 
results of clinical trials has so far been disappointing. Only a handful of drugs have 
been approved to treat dementia, including Razadyne, Exelon, and Aricept, and such 
drugs only temporarily treat symptoms and are not disease modifying. This lack of 
current clinical trial success together with laboratory research results indicates that 
earlier interventions may have a better success rate. Because of this, attention is now 
being directed towards prevention strategies. To do this we will need to identify 
individuals in the preclinical phase of the disorder; during the early stages of 
neuropathology development but prior to the onset of clinical manifestations. Certain 
Aβ antibodies which proved disappointing in immunotherapy clinical trials of AD 
patients are being re-considered for their utility as preventative treatments. For 
example a clinical trial of Solanezumab is planned to commence in 2014 aiming to 
test this drug in 1000 cognitively normal volunteers, aged 65-86, who are showing 
signs of AD pathology (Aβ plaques, as identified by a positron emission tomography 
(PET) brain scan)[50]. It is hoped trials like this will show that Aβ plaque removal or 
neurofibrillary tangle reduction at this early stage could prevent subsequent 
neurodegeneration and eventual cognitive decline. Successful recruitment of 
preclinical AD individuals will be a key factor for these preventative clinical trials. 
Subject selection using expensive imaging methods to detect AD pathology in 
cognitively healthy individuals will substantially increase the cost of these trials. A 
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more practical alternative would be to use a blood based biomarker of AD pathology. 
Using a blood test as a trial entry criterion would be minimally invasive and easy to 
implement, and could also be used to help triage subjects to further testing using 
imaging methods. 
1.5 Timeline of AD pathology and clinical symptom development 
The clinical presentation of Alzheimer’s disease is thought to be the end product of 
many years of silent gradual changes in various pathological processes. The timeline 
of AD development can be thought of in three stages; preclinical, prodromal (mild 
cognitive impairment (MCI)), and dementia, with each stage having its own 
continuum of severity. The timeline of AD pathology and clinical symptom 
development from the preclinical stages through to severe dementia can be 
investigated by looking at the behaviour of well established AD biomarkers 
throughout these stages, for example; PiB PET, CSF Aβ1-42, t-tau and p-tau, FDG 
PET, MRI, and cognitive measures. 
A comparison of cross sectional values of both global cortical PiB PET and 
hippocampal volumes for control, MCI, and AD individuals reveals that 
approximately 20% of healthy control individuals showed amyloid load levels 
comparable to that identified in AD individuals, whereas minimal overlap between 
the two groups was identified when measuring hippocampal volumes[51]. This 
suggests that significant plaque deposition occurs prior to neurodegeneration and 
clinical decline, with fairly high amyloid load already observed in presymptomatic 
individuals. This is further supported by CSF Aβ1-42 measurements that have been 
found to be reduced in some healthy individuals[52], thought to reflect the retention 
of Aβ in plaques. 
Longitudinal research measuring annual change in these markers revealed further 
information. Rates of change for PiB PET values are comparable across all three 
control, MCI and AD groups, with MCI showing the greatest variability. However 
rates of change in ventricular volume are shown to increase from control to MCI to 
AD [53]. This implies that longitudinal changes in cognition are closely coupled to 
the rate of neurodegenerative progression, not to the rate of amyloid deposition. This 
also supports the theory of brain amyloid deposition as an early initiating event, with 
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rates of accumulation then remaining fairly constant over time, from preclinical 
through to severe AD. 
Both CSF t-tau and p-tau have been shown to be elevated in cognitively healthy 
individuals and in those with mild cognitive impairments[52, 54], though changes are 
less pronounced than seen for CSF Aβ1-42. It is often assumed that accelerated 
neurofibrillary tangle formation occurs alongside an increased release of tau protein 
into CSF[54-55]. Based upon this assumption this data suggests that prior to 
presentation of clinical symptoms, amyloid deposition in cognitively healthy 
individuals is subsequently followed by an elevation of tau.  
Both individuals with very early Alzheimer’s disease, and cognitively healthy 
individuals who progress to MCI/dementia have shown marked brain metabolic 
reduction, as measured using FDG PET[56-59]. This shows that brain metabolic 
reductions are also initiated at an early, preclinical stage of AD. Regions showing 
early metabolic reductions have been reported to often overlap with the regions of 
greatest tangle pathology and also correlate with early increased CSF tau protein 
levels[54, 60-61].  
Both PiB PET and CSF Aβ1-42 show mild correlations with volume measurements of 
various brain regions in cognitively healthy individuals, which suggest that subtle 
brain atrophy also begins to occur at a preclinical stage[62-64]. CSF p-tau has been 
shown to correlate mildly with cognition in the early preclinical stages, however 
once individuals are clinically impaired MRI has a much stronger correlation with 
cognitive ability and retains this strong relationship with cognitive performance 
throughout the mid and late clinically symptomatic stages[65]. MRI is also able to 
predict future clinical function and conversion to MCI/AD better than CSF 
measures[65]. This relationship between MRI and cognition appears to be non-linear; 
with small amounts of brain atrophy reported preclinically and subsequent 
acceleration of atrophy once clinical symptoms manifest[66].  
Additionally very subtle cognitive changes which predict subsequent development of 
AD can be detected years before even reaching a diagnosis of mild cognitive 
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impairment[67]. These impairments are found in specific cognitive measures such as 
episodic and semantic memory and executive function tasks[67-69]. 
These studies reveal that AD biomarker abnormalities precede clinical symptoms and 
that different biomarkers change in an ordered manner over time. Amyloid 
accumulation (as measured by PiB PET and CSF Aβ1-42) becomes abnormal first, 
followed by changes in FDG PET and CSF t-tau and p-tau biomarkers, representing 
the subsequent development of neurofibrillary tangles. Following this small MRI 
changes are apparent prior to the onset of very mild cognitive impairments. All of 
these changes occur before conversion to a prodromal stage. The biomarkers will 
then increase in severity throughout the prodromal stage through to dementia, though 
each biomarker will show different rates of change and saturation points. It is also 
likely that changes in these biomarkers are non-linear when measured over long 
periods of time. Based upon similar conclusions Jack et al (2010, revised in 2013) 
proposed a time-dependent ordered model of well validated AD biomarkers and their 
relationships to the clinical symptoms (see Figure 1-1)[70-71]. This model is now 
well accepted as a good, simplified reflection of a typical AD time line. One 
hypothesis of this model is that a clinically asymptomatic individual with underlying 
pathological changes indicative of AD would ultimately develop the disease if they 
lived long enough. Additionally this model suggests that AD risk factors such as 
genetic risk alleles, low cognitive reserve, and other comorbidities can shift the onset 
of cognitive impairment to an earlier stage.  
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Figure 1-1: Model of AD timeline as taken from Jack et al, (2013). Cognitive 
impairment can be shifter earlier or later, as represented by the large green area, 
dependent on AD risk factors. 
1.6 Mild Cognitive Impairment (MCI) 
Individuals with MCI have regularly been included in AD research aiming to 
investigate the earlier stages of the disease, with the hypothesis that these individuals 
are prodromal AD. MCI individuals are known to have an increased risk of 
developing dementia, however a meta-analysis of 41 cohort studies where conversion 
to Alzheimer’s was documented revealed that only 30-34% of MCI individuals 
progressed to AD within 10 years[72]. Therefore although this is currently the best 
known population for studying prodromal AD, there is clearly large clinical 
heterogeneity in this group of individuals, and the majority of individuals with MCI 
will not progress to AD. Contributing to this heterogeneity is a lack of firm and 
appropriate clinical criteria for MCI diagnosis. Different researchers stress the 
importance of different symptoms and memory tests for which they base their 
inclusion and exclusion criteria on, impeding the comparison of results between 
studies. The large variability found in conversion rates of MCI patients to AD may 
be due to an inconsistency of criteria used across studies. Standardising these criteria, 
as well as including prognostic biomarkers, will increase accuracy and reduce 
variability in MCI diagnosis.  
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Research focusing on the differences between MCI individuals who convert to AD 
compared to those who remain stable can reveal information about the prodromal 
stages of AD. Unsurprisingly MCI convertors have been found to have a very similar 
pattern of brain atrophic changes to AD individuals, with neurodegeneration of 
medial temporal structures being the best indicator of AD conversion[73]. 
Neurodegeneration has been repeatedly reported as a reliable short-term prognosis of 
progression to AD. CSF biomarkers of brain amyloid show longer-term prognosis of 
progression to AD[74], which corresponds with the time line of AD development 
presented above. Differences in plasma proteins have also been reported in MCI 
individuals[75-77], these proteins reflect many different mechanisms but 
inflammatory proteins are frequently reported suggesting inflammation occurs early 
and significantly contributes to disease progression. 
Although individuals with MCI present an interesting population to study early AD, 
it is likely that to effectively treat or prevent the development of AD individuals in 
the preclinical stages of the disease need to be identified and targeted. As previously 
mentioned, it is known that AD pathology develops silently for many years in 
cognitively healthy individuals. Perhaps during this phase plasticity and 
compensatory mechanisms of the brain allow normal functioning to continue up until 
a damage threshold is reached. This preclinical phase allows a critical but 
challenging opportunity for therapeutic intervention. Intervention at this stage is 
likely to maximise treatment benefits, though identifying seemingly healthy 
individuals who will later develop clinical signs of dementia is difficult. 
Some preclinical studies have focused on cognitively healthy individuals at higher 
risk of AD development due to genetic risk factors, family history or other 
comorbidities known to increase the risk of AD. Other studies have used biomarkers 
of AD pathology to identify healthy control subjects with underlying AD pathology, 
classifying them as preclinical AD. However some elderly individuals displaying AD 
pathology do not ever progress to the clinical stages of MCI or dementia within their 
lifetimes. It is possible that some individuals are resistant to clinical decline due to 
various factors such as cognitive reserve, protective genetic factors, or environmental 
influences. Such influences may also just be extending the preclinical phase and if 
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they were to live longer it is thought that these individuals may still go on to develop 
dementia.  
More research is needed for preclinical AD. Biomarkers that can accurately identify 
individuals in a preclinical AD stage will benefit clinical trial recruitment and 
monitoring, and may also reveal therapeutic targets. AD-related changes detected at 
this early stage are likely to be very subtle and therefore longitudinal measures over 
time will be more sensitive than any one-time measure and so should be prioritised 
for preclinical AD research. Recently preclinical AD diagnostic criteria has been 
outlined by the NIA to aid research into this stage of the disease, the criteria includes 
biomarkers of brain changes including neuroimaging and CSF measures.[78-79].  
1.6.1 Ethical implications for pre-symptomatic testing of AD 
Although research into a biomarker screening tool for preclinical AD is in its 
infancy, it is important to consider the ethical, social, and legal implications such tool 
may have. If ‘clinically healthy’ individuals are given knowledge that they have 
preclinical AD, particularly prior to the development on disease modifying 
interventions, then this knowledge may lead to increased stress which could 
potentially accelerate the disease and reduce quality of life for their remaining years. 
Other personal and psychosocial considerations include; education, employment, 
marriage, family planning, and insurance.  
The appropriate use of this information is much debated, and while there are no 
disease modifying treatments an AD screening tool appears to have limited benefits 
to the individual affected. Therefore some argue that preclinical testing should 
remain within research protocols, and the results should not be shared with subjects 
until treatments become available. Though others argue that this disrespects the 
subject’s autonomy and that a few benefits to knowing do exist [347]. Firstly, 
preclinical screening can help relieve uncertainty in individuals who worry they may 
have inherited increased risk of AD. For some individuals the stress of uncertainty 
may be more considerable than the stress of knowing. Secondly, an early diagnosis 
will help individuals to plan, whether this obtaining relevant insurance or care 
packages, altering educational/career or family plans, or ensuring lifelong ambitions 
are achieved quickly.  
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Similar implications have been extensively discussed in relation to genetic testing for 
increased risk of AD, a much more established area of research (see 348 & 349 for 
good discussions). While it is clear that identifying individuals in the preclinical 
stage of the disease will hugely benefit AD research and clinical trials, it is 
imperative for the individuals involved in this research that informed consent is 
obtained, appropriate support and advice is available, and safeguards and legislation 
follow the results. 
1.7 Approaches of AD Biomarker Studies 
A biomarker is a measureable biological characteristic that correlates with normal or 
pathogenic processes in the body. Biomarkers can be used as indicators of disease 
presence, pathology, and progression, and they are implemented in drug development 
and clinical trials as surrogate endpoints, markers of efficacy or toxicity, and are also 
used for patient stratification and cohort enrichment.  
In many medical areas biomarkers are already having a powerful influence on patient 
treatment and drug development. Biomarkers are being implemented to help 
clinicians diagnose syndromes, monitor treatment effects, optimise treatments, and 
track progression. However for dementia the clinical use of biomarkers is relatively 
new, especially in the early stages, and their development and validity is still a work 
in progress.  In 1998 the Alzheimer’s Association and the National Institute on Aging 
proposed criteria that an ideal AD biomarker should fullfill[348]. These requirements 
include; the ability to detect a fundamental feature of disease pathology, well 
validated in neuropathologically-confirmed cases, both a sensitivity and specificity 
of >80%, reliable, non-invasive, simple to perform and inexpensive. These criteria 
are excellent guidelines to use for biomarker discovery, however it is important to 
consider that for different uses of biomarkers the importance of each of these criteria 
may change. For example; biomarkers for AD drug development would place 
emphasis their ability to indirectly measure disease severity, though high specificity 
is not a necessity for this biomarker use.  
Current AD diagnosis criteria (e.g. DSM-IV) are primarily exclusion criteria, poorly 
specific of the pathology, and lacking sensitivity in early stages. Biomarkers may 
help to improve the current level of accuracy of AD diagnosis. Tabaraud et al (2011) 
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found that the inclusion of CSF biomarkers in neurological daily practice improved 
AD diagnosis[80]. There are numerous other reasons as to why AD biomarkers are 
important. Most obviously biomarkers will allow us to predict who will develop AD, 
which is important for early treatment of the disease. Additionally biomarkers may 
also be used as indirect measures of disease severity [5]. More sensitive and specific 
markers of early AD progression will help monitor the effectiveness of new 
treatments, and lessen the time and cost of clinical trials. Current approaches to 
biomarker discovery for AD include neuroimaging and testing of body fluids such as 
cerebrospinal fluid (CSF) and blood (plasma). 
1.7.1 Neuroimaging biomarkers 
Currently, our best biomarkers for preclinical, prodromal and clinical AD are 
neuroimaging approaches. A variety of imaging techniques have been used as AD 
biomarkers with magnetic resonance imaging (MRI) and positron emission 
tomography (PET) as the most frequently employed. Although neuroimaging 
methods show very promising results these approaches are expensive and sometimes 
mildly invasive, whilst scanner availability and consistency limits widespread use 
and study comparisons.  
Amyloid imaging with positron emission tomography (PET) imaging agent 
Pittsburgh compound-B (PiB) 
PiB PET was developed to enable detection of amyloid plaques in vivo and is now 
established as a valid biomarker of fibrillar Aβ brain amyloid load. Compared to 
controls PiB PET scans of AD patients show higher PiB retention in areas known to 
contain large amounts of amyloid plaques post mortem (e.g. frontal cortex)[81-82] 
and comparisons with post mortem brain tissue show excellent concordance with 
anti-mortem amyloid load as measured by PiB PET[83]. PiB PET has been found to 
have around 90% accuracy for AD diagnosis detection[84] and can indicate 
preclinical AD individuals by detecting AD pathology in healthy controls[85-86]. 
Additionally through repeated PiB PET scans pathology progression can be 
monitored throughout the disease course. Similarly novel disease-modifying 
therapies for AD which aim to remove Aβ deposits from the brain now have an in-
vivo monitoring tool of the effectiveness of their drug outcome.  
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One of the problems with PiB is the short half-life of 11C (20 minutes). This means 
that a cyclotron has to be available on site for isotope production, increasing costs 
and severely limiting its widespread use. Alternatives to PiB are being developed and 
currently three 18F labelled tracers (110 minute half-life) for Aβ are in or have 
completed clinical trial stage. All of these tracers have so far shown promising 
results, for example flutemetamol has been found to have both a sensitivity and 
specificity of 93% for discriminating AD patients from controls[87]. In the USA 
flutemetamol has recently been approved by the US Food and Drug Administration 
(FDA) for the evaluation of amyloid in the brains of individuals with possible 
Alzheimer’s disease. Comparisons of PiB and flutemetamol have revealed that the 
results of the two tracers are highly correlated[88-89]. 
Tau neurofibrillary tangle imaging with positron emission tomography (PET) 
Some researchers argue that a successful technique to image tau pathology in the 
human brain would be a significant step forwards from Aβ plaque imaging as, unlike 
Aβ, neurofibrillary tangles have been found to reliably correlate with 
neurodegeneration and cognitive impairment[90]. There is currently no well 
established method for imaging neurofibrillary tangles, however there are 
radiotracers such as 18F-THK523 under development which look promising, 
especially for AD research[90]. 18F-THK523 has been shown to have high affinity 
and selectivity for tau neurofibrillary tangles in preference to Aβ or α-synuclein 
deposits, and it appears to selectively bind to tau lesions in AD brains but not in other 
non-AD tauopathies[91-92].  
Magnetic resonance imaging (MRI)  
Brain atrophy measured by structural MRI is repeatedly reported as a robust AD 
biomarker. In particular decreased hippocampal and entorhinal cortex volume is a 
distinguishing feature of an AD brain[93-94]. These regions have also been shown to 
be effected early on in the disease, with hippocampal volumes and cortical volumes 
in the right medial temporal, left lateral temporal, and the right posterior cingulate, 
able to predict the likelihood of progression from normal to MCI and also from MCI 
to AD[73, 94-96]. As expected, MRI measures strongly correlate with cognition, 
especially during the mid to late clinically symptomatic stages of AD, and are also 
good predictors of future cognitive decline[65].  
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Serial MRI measures taken from subjects followed from a preclinical stage through 
to moderately severe dementia show a non-linear relationship between cognition and 
brain atrophy, with the rate of atrophy increasing with disease severity[66]. This 
demonstrates that although MRI has biomarker ability preclinically its strength lies 
after the onset of clinical symptoms. These findings also indicate that early 
interventions are needed before the subsequent acceleration of brain atrophy. 
MRI has also been used as an indirect measure of neurofibrillary tangle 
pathology[97]. As neurofibrillary tangles are distributed in a fairly consistent pattern 
of progression in AD a staging system for neurofibrillary tangles was proposed by 
Braak and Braak[98]. This six-stage system is now well established for pathological 
AD severity staging. Although this progression cannot currently be imaged in-vivo 
directly an approximate measure of pathological staging can be obtained using 
information from MRI scans. For example, Vemuri et al (2011) demonstrated that 
optimally extracted atrophy information from MRI scans can be converted into an 
abnormality score (STructural Abnormality iNDex (STAND)) which shows good 
correlation with Braak staging post mortem[97]. 
18F Fluorodeoxyglucose-PET (FDG-PET) 
FDG PET scans measure brain glucose metabolism and investigations have shown 
that in AD a decline in glucose utilisation is progressive, correlates with AD severity 
and can also predict a diagnosis of AD post-mortem[8, 99]. Such studies have 
typically revealed metabolic reductions in the posterior cingulate, parietal, temporal, 
and prefrontal cortex to be correlated with AD severity and progression[100]. 
Glucose metabolism abnormalities identified using FDG-PET scans has also been 
found to successfully predict conversion from MCI to AD[101-102] with very early 
metabolic deficits reported in the medial parietal cortex[103]. Regions showing early 
metabolic reductions have been reported to often overlap with the regions of greatest 
tangle pathology and also correlate with early increased CSF tau protein levels[54, 
60-61]. 
1.7.2 Cerebralspinal fluid (CSF) biomarkers 
CSF is in direct contact with the extracellular space of the brain. Therefore 
biochemical changes in the brain are often reflected in the CSF, providing a good 
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source of biomarkers for such changes. In comparison with blood CSF has relatively 
low protein content and is therefore much less complex to analyse, though blood-
brain-barrier (BBB) disruption does increase the total amount of protein present in 
the CSF. For example, increasing levels of albumin are observed with increasing 
BBB impairment[104]. Along with neuroimaging certain CSF protein measurements 
are currently our best AD biomarkers. In particular CSF quantification of Aβ1-42, 
phosphorylated tau (P-tau) and total-tau (T-tau) have shown great biomarker abilities 
for AD, and are thought to reflect the core pathologic features of AD; amyloid 
plaques, neurofibrillary tangles and neuronal loss, respectively. These biomarkers 
have recently been included in AD diagnostic guidelines to help increase the 
accuracy of an early preclinical or prodromal AD diagnosis for research purposes by 
indicating pathology presence and severity in these early stages[78]. These three 
biomarkers are discussed in more detail below, though it is important to note that 
there have been many other promising CSF biomarkers also discovered, for example; 
BACE1[105-108], sAPPα/sAPPβ[109-112], and Aβ oligomers[113-115], see [116-
118] for good reviews of CSF biomarkers. 
CSF Aβ1-42 
CSF Aβ1-42 concentrations are consistently reported as reduced in AD patients 
compared to controls[119-120], thought to reflect the retention of Aβ in brain 
amyloid plaques. There is a clear inverse relationship between CSF Aβ1-42 and 
cortical PiB binding, suggesting this CSF measurement is a strong surrogate marker 
for in-vivo brain amyloid burden[52, 99, 121-122]. Also supporting this, low 
concentrations of CSF Aβ1-42 are correlated with brain Aβ neuropathology at 
autopsy[123]. Reductions in CSF Aβ1-42 have been reported preclinically indicating 
this biomarkers predictive ability for subsequent conversion to dementia[124]. 
Additionally there is also a mild, but significant, positive relationship between CSF 
Aβ1-42 and brain volume[62].  
CSF total-tau (t-tau) and phosphorylated tau (p-tau) 
Increases in CSF p-tau and t-tau have been associated with neocortical 
neurofibrillary pathology, cognition, and temporal lobe hypometabolism. Total tau 
has often been reported as increased in CSF of AD patients, with increases of 50-
300% reported compared to controls[125-127], and has also been found to have a 
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strong correlation with episodic memory[122]. P-tau is the main component of paired 
helical filaments that form neurofibrillary tau tangles, and so CSF p-tau is thought to 
reflect neuronal degeneration more accurately than t-tau. Like t-tau, p-tau can be 
used as a diagnostic biomarker for AD, with a sensitivity for AD of 85% 
reported[128]. Both t-tau and p-tau have also shown a significant correlation with 
cortical PiB binding in healthy individuals[52], though this correlation is much 
weaker than the previously mentioned relationship between CSF Aβ1-42 and cortical 
PiB binding. Abnormal CSF concentrations of t-tau and p-tau have been reported 
before the clinical onset of dementia, indicating their predictive ability of future 
conversion to dementia[124].  
CSF protein ratios 
Ratios of the above mentioned CSF markers have also been identified as useful AD 
biomarkers. CSF Aβ1-42/t-tau has been identified as a good predictive marker of 
future conversion from MCI to AD[65] and also of future cognitive decline in 
nondemented older adults[129]. CSF Aβ1-42/p-tau has also been reported as a 
biomarker; De Meyer et al (2010) identified a CSF Aβ1-42 and p-tau mixture as a 
biomarker of AD which was present in 90%, 72%, and 36% of patients in AD, MCI 
and normal groups, respectively [130]. These results were autopsy confirmed where 
the biomarker was 94% successful in predicting diagnosis, additionally MCI patients 
found to possess this biomarker all progressed to AD within 5 years. As this 
biomarker was also present in more than one-third of their control participants it may 
also be able to detect AD pathology at a preclinical stage. CSF Aβ1-42 and p-tau ratio 
has also been found to reflect disrupted default mode network functional connectivity 
in AD patients, particularly in the left precuneus/cuneus[131].  
While these CSF markers show interesting research results, their clinical utility is 
limited by the invasive nature of obtaining CSF (lumbar puncture), particularly from 
elderly individuals. This mainly restricts longitudinal studies or clinical progression 
monitoring where repeated CSF measures are needed. Therefore a CSF biomarker 
would have to have a considerably increased predictive ability over alternative 
methods to justify its addition to standard clinical procedures. However CSF 
acquisition is cheaper than some neuroimaging approaches, and compared to plasma 
based approaches CSF may be able to generate biomarkers that more accurately 
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reflect disease biology. For these reasons CSF biomarkers have high potential, but a 
more practical alternative would be preferential especially for longitudinal studies. 
1.7.3 Blood based biomarkers 
All of the biomarker approaches mentioned above have yielded promising results. 
However availability and cost of neuroimaging approaches and the moderately 
invasive nature of CSF lumbar puncture limits their usage and restricts longitudinal 
repeated measures studies. On the contrary blood/plasma based biomarker 
approaches are practical and minimally invasive, allowing repeated sampling in large 
cohorts. 
Various substances formed by the nervous system during its metabolic activity 
diffuse into the CSF. CSF is renewed four or five times daily and as it is renewed old 
CSF is absorbed into the bloodstream. As CSF is absorbed, products reflecting the 
condition of the brain are also passed into the blood. Additionally the blood-brain-
barrier is often compromised in neurodegenerative conditions such as AD which 
allows more analytes to pass into the blood stream[132]. Blood has therefore been 
the focus of much research into AD biomarkers, with the aim to develop a blood test 
for AD. A blood test would be practical to implement, relatively cheap, and 
minimally invasive and therefore has significant advantages over other biomarker 
modalities. Initially there was some speculation as to whether an AD signal can pass 
through the BBB from CSF into the blood, and if so whether this signal can be 
detected. Recent evidence suggests that there is detectable peripheral signal in the 
blood which reflects neuropathological features of AD and that this may be sensitive 
to both disease severity and progression.  
Comparisons between CSF and plasma research show that some AD biomarker 
signals known to be present in CSF are also present in plasma. For example; CSF 
transthyretin (TTR) has been reported to protect against brain Aβ deposition, and 
lower levels of CSF TTR are often related to AD diagnosis and severity[133-134]; 
this biomarker ability of TTR has been replicated in plasma[135-136]. 
Many other proteins have been identified as plasma based biomarkers of AD. One of 
the most promising is clusterin. High levels of clusterin have been found to be 
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associated with brain atrophy and a more rapid rate of cognitive decline in AD 
patients[137]. Furthering this, increased clusterin concentration has been found to be 
an antecedent marker of pathology in normal elderly individuals; baseline plasma 
clusterin concentrations predicted subsequent development of in vivo fibrillar 
amyloid burden ten years later[137]. Other work has identified clusterin as having 
roles in amyloid clearance, complement inhibition and apoptosis, and also peripheral 
concentrations of clusterin have been found to accurately reflect its concentration 
within brain regions known to be vulnerable to AD pathology[138]. Results from 
clusterin, and many other plasma proteins, show that plasma biomarkers, can reflect 
disease status and AD pathology, including in nondemented elderly individuals years 
before a clinical diagnosis can be made. 
It is unlikely that any one plasma protein will have sufficient power to be solely used 
as an AD biomarker. Their true strength is likely to instead lie as a biomarker panel 
of multiple proteins, each reflecting different aspects and mechanisms involved in 
the disease[76]. AD biomarker panels have been successfully identified and tested 
several times[76, 139-142]. Hye et al (2006) used a 2DGE proteomics approach and 
identified a panel of protein spots that together could discriminate between AD 
patients, normal controls, and other neurodegenerative diseases with 56% sensitivity 
and 80% specificity[142]. A panel of 18 plasma proteins identified by Ray et al 
(2007) could also categorise patients, and additionally predict MCI patients who 
would convert to AD within 5 years with nearly 90% accuracy[76]. Recently a panel 
of ten proteins strongly associated with disease severity and progression were found 
to be able to predict MCI progression to AD with 87% accuracy[75], showing that 
such biomarker panels could be used to enhance diagnostic specificity to identify 
MCI individuals in a prodromal AD stage. 
Recently considerable progress has been made into the investigation of biomarkers 
for AD. However further research is still required to clarify the transitional period 
from healthy aging to the first manifestations of AD. Different biomarkers may have 
individual strengths and therefore contribute differently to our understanding of this 
transitional period, but those that have high reliability and are easy to implement will 
be the most useful. The combination of plasma proteomics with in vivo brain 
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imaging will provide us with biologically relevant, clinically useful, peripheral 
markers of Alzheimer’s pathology. 
1.8 Detection and measurement of blood-based markers 
Whilst there are many advantages for using blood as an AD biomarker its use is still 
limited due its complex composition and therefore the technical difficulties it poses. 
Changes within the blood are often very small and reflect a wide range of both 
peripheral and central processes so pinpointing AD specific changes can be 
challenging. Separated by the blood-brain-barrier (BBB) the relationship between 
analytes found in the blood and changes in the brain is still uncertain. Yet in AD the 
BBB is known to be disrupted resulting in increased permeability [143], and this 
disruption should only strengthen the relationship between blood and brain. 
Nevertheless concentrations of most known potential biomarkers are several times 
lower in the blood than reported in CSF (e.g. Abeta peptide concentration is 100-fold 
lower in blood [144]). Additionally highly abundant plasma proteins such as albumin 
and IgG may repress signals from potential biomarkers, consequently increased 
sensitivity and power is needed for this research.  
Among the many technological platforms used to investigate AD blood biomarkers, 
proteomics is currently the most frequently employed. Detailed characterisation of 
proteins including changes in quantification, location, interactions, isoforms and 
post-translational modifications (PTMs) can help further our understanding of 
different biological states. The identification of these features is challenging as 
proteins need to be identified from within a matrix of cells, tissues, fluids, and other 
proteins of varying concentrations. Additionally the dynamic range of proteins in a 
blood sample is large, with those in a plasma sample spanning up to 12 orders of 
magnitude [145]. This complexity is reflected in the limitations of the different 
proteomic techniques. 
There are many analytical techniques available for biomarker discovery, each has its 
pros and cons meaning often a compromise will need to be taken. A wider 
understanding of many of the techniques available may facilitate biomarker research. 
Moreover, combining complimentary aspects of different techniques and adding 
other parameters such as neuroimaging data should increase our accuracy. For 
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example, two-dimensional gel electrophoresis (2DGE) and mass spectrometry (MS) 
are both highly useful techniques for AD blood biomarker discovery research in their 
own right. However the two methods have also been found to provide different but 
complementary information about proteins [146-147], suggesting that these two 
methods could be used in compliment to one another to improve discovery 
approaches. 
To get the best out of our currently available technologies we must ensure that we 
have an optimal experimental design and accurate interpretations. A common 
limitation of biomarker studies is that they rely on a case versus control study design, 
a design that ignores clinical heterogeneity in patients and neuropathology in 
controls. Therefore biomarkers identified may instead reflect secondary changes 
specific to the cohort used rather than the disease biology. Using markers of in vivo 
β-amyloid deposition (e.g. 11C-PiB) combined with positron emission tomography 
(PET) or structural MRI (sMRI) to derive biologically relevant biomarkers 
associated with established endophenotypes of disease pathology is a better 
approach. A marker found through this approach should be more robust and have 
greater clinical utility. Endophenotype approaches for blood based biomarkers have 
already successfully been conducted for various Alzheimer’s disease pathologies 
such as brain atrophy[137, 148] and metabolism[149], and amyloid-beta burden[150-
151], though much more work is needed especially in the early preclinical stages.  
Additionally it is important to consider that surrogate markers of AD for which 
biomarkers are discovered, need to be well established and accurately reflect disease 
progression and severity. One area where more focus should be encouraged is 
measures of cognitive decline. MMSE classification is often used as a reference point 
to discover biomarkers reflecting cognition, yet we are aware that MMSE itself has 
an error rate of approximately 20%, is influenced by age and education, and is 
subject to ceiling and floor effects [152-154]. Without an objective standard to 
compare to an issue of circularity is introduced when assessing the validity of a 
potential AD biomarker. 
  51 
  
1.9 Conclusion 
Biomarker changes in AD are dynamic with disease development, and these changes 
start at an early preclinical stage. Many biomarkers have been identified but more 
work is required to identify robust preclinical biomarkers reflecting early AD 
pathology, and predicting future outcomes. AD-related changes detected at this early 
stage are likely to be very subtle and therefore longitudinal measures are required to 
sensitively detect these changes. The most suitable application in biomarker 
investigation at a preclinical stage is venepuncture for blood analysis; allowing large 
nondemented populations to be studied and followed longitudinally, and increasing 
future clinical utility of discovered biomarkers. Due to the complex composition of 
blood multiple technical platforms may need to be utilised in combination to provide 
a comprehensive coverage of the proteome for the discovery of biomarkers. 
This work will therefore aim to identify and validate longitudinal blood based 
biomarkers of preclinical Alzheimer’s disease pathology, using multiple proteomic 
platforms to enhance their discovery.  
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Chapter 2. Aims and Methods 
2.1 Aims 
Broad Aim: To discover longitudinal blood based protein biomarkers of early 
Alzheimer’s disease pathology in healthy elderly individuals. 
Specific aims: 1) To use two complementary longitudinal discovery phase proteomic 
analyses (2DGE and LC-MS/MS) to investigate plasma proteins related to amyloid 
load in the brain as measured using Pittsburgh compound B (PiB) PET imaging, 
brain atrophy as measured using structural MRI (sMRI), and cognitive decline as 
measured using various cognitive assessments. 2) To select target proteins from the 
discovery phase proteomic data and validate proteins in an independent cohort using 
quantitative immunoassays and aptamer-based arrays. 3) To determine whether the 
identified markers of Alzheimer’s disease pathology can also be used as a diagnostic 
tool for Alzheimer’s disease.  
2.2 Participants 
2.2.1 Discovery cohort: Baltimore Longitudinal Study of Aging (BLSA) 
The BLSA was initiated in 1958 as a prospective longitudinal study of healthy 
human aging[155-158]. The primary objective of the study is to understand the 
physical and cognitive changes associated with normal aging. Over the past 50 years 
other issues have also been addressed by the study including the relationship between 
disease and age related changes. To date the BLSA has recruited over 1,300 healthy 
volunteers to the cohort ranging from 20 to 90 years old[159-162]. Participants 
include healthy, community-dwelling, middle to upper-middle class volunteers. 
Originally the study recruited only men, with the inclusion of women from 1978. 
Participants aged under 60 are cognitively assessed every 4 years, those aged 60-79 
years are assessed every 2 years, and those aged 80 and over are assessed annually. 
BLSA neuroimaging substudy 
Currently in its 19th year (commenced in 1996) the neuroimaging substudy includes a 
subset of BLSA volunteers who return annually for imaging and clinical evaluations. 
The neuroimaging substudy is described in detail by Resnick et al (2003)[163].  
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Inclusion and exclusion criteria 
All BLSA participants were selected for inclusion to the neuroimaging substudy if 
they were aged between 55-85 years and had prior cognitive and memory 
assessments. Exclusion criteria at baseline included; central nervous system (CNS) 
diseases (e.g. epilepsy, stroke, dementia), severe cardiovascular disease (e.g. 
myocardial infarction coronary artery disease), pulmonary disease or metastatic 
cancer. Exclusions were minimised to allow a representative sample of the main 
BLSA cohort and individuals displaying small signs of cognitive impairment (whilst 
not meeting criteria for dementia) and those with past or current depression were 
included since these factors may be dementia risk factors. 
Consent 
Written informed consent was obtained annually from all participants in conjunction 
with each neuroimaging visit.  
MRI image acquisition and analysis 
A GE Sigma 1.5 Tesla MRI scanner was utilised to acquire volumetric ‘spoiled 
grass’ (SPGR) scans (repetition time (RT) = 35; echo time (TE) = 5; flip angle = 45; 
field of view = 24; matrix = 256x256; number of excitations = 1; voxel dimensions 
of 0.94x0.94x1.5mm slice thickness). Head movement was reduced through the use 
of a custom thermoplastic mask and head-holder, which also aided repositioning for 
repeated longitudinal assessments. 
A semi-automated approach was used to analyse the MRI volumes as described in 
Goldszal et al (1998)[164]. Briefly, images were firstly reformatted parallel to the 
anterior and posterior commissures. Extracranial tissue, the cerebellum, and 
brainstem structures inferior to the mamillary bodies were removed using both a 
semi-automatic and manual procedure. Remaining tissue was then classified into 
grey matter, white matter, and CSF. Ventricular CSF was defined by drawing a crude 
region of interest (ROI) used to then eliminate any non-ventricular CSF. The 
segmented images are then normalised using an elastic deformation approach[165] 
within Talairach stereotaxic coordinate space[166]. The number of voxels classified 
as gray matter, white matter, ventricular CSF, and other ROIs are then extracted for 
statistical analysis.  
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PiB PET image acquisition and analysis 
Dynamic 11C-PiB PET scans were performed in a GE Advance scanner in 3-
dimensional mode, and 37 time frames (90 minutes) were obtained at rest. PET 
scanning started immediately after an intravenous bolus injection of approximately 
15mCi. During the scan participants were fitted with a thermoplastic mask to 
minimise head movement. Transmission scans in 2-dimensional mode were used for 
attenuation correction of the emission scans. Dynamic images were reconstructed 
using filtered backprojection with a ramp filter (image size = 128x128; pixel size = 
2x2mm, slice thickness = 4.25mm) yielding a spatial resolution of approximately 
4.5mm full width half maximum at the centre of the field of view. Partial volume 
effect was minimised by excluding edges of tissue in definition of volumes of 
interest. Parametric images of distribution volume ratios (DVR) were calculated by 
simultaneous fitting of a reference tissue model using linear regression and spatial 
constraint (SPM5; Wellcome Department of Imaging Neuroscience, London, UK). 
The cerebellum was used as a reference region and 15 other regions of interest 
(ROIs) were defined; caudate, putamen, thalamus, lateral temporal, medial temporal, 
orbital frontal, prefrontal, occipital, superior frontal, parietal, anterior cingulate, 
posterior cingulate, pons, midbrain, and white matter. The mean cortical DVR was 
calculated by averaging values from orbitofrontal, prefrontal, superior frontal, 
parietal, lateral temporal, occipital, and anterior and posterior cingulate regions. 11C-
PiB parametric DVR images were spatially normalised and smoothed using a 
Gaussian filter of 8, 8, and 8mm in the x,y, and z planes[167]. 
Cognitive assessment 
Various cognitive assessments are conducted annually for memory (California 
Verbal Learning Test[168] and Benton Retention Test[169]), word knowledge and 
verbal ability (Primary Mental Abilities Vocabulary[170]), verbal fluency 
(Letter[171] and Category fluency tests[172]), attention and working memory (Digit 
Span test of the Wechsler Adult Intelligence Scale-Revised[173]), executive function 
(Trails Making test A and B[174], and Digits Backward[173]), and visuospatial 
function (Card Rotations test[175]). Additionally the Mini-Mental State Examination 
(MMSE)[176] was conducted to assess cognitive impairment and the Centre for 
Epidemiologic Studies Depression Scale (CES-D)[177] was administered to measure 
depressive symptoms. 
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Blood samples 
All blood samples were drawn by venipuncture and collected into EDTA glass tubes. 
Subjects were required to fast overnight prior to collection. Samples were 
centrifuged at 3000rpm for 30 minutes at 4ᵒC. Plasma was then carefully collected, 
aliquotted and stored at -80̊C until further use.  
2.2.2 Validation cohorts: AddNeuroMed, Dementia Case Register (DCR) and 
Alzheimer’s Research UK (ARUK) 
AddNeuroMed is part of Innovative Medicines in Europe (InnoMed) program and is 
a multi-centre European study for the identification of Alzheimer’s disease 
biomarkers funded by the European Union and members of the European Federation 
for Pharmaceutical Industries and Associations (EFPIA). AD subjects are assessed at 
three monthly intervals in their first year of assessment, and annually thereafter. MCI 
and control groups are assessed annually. All subjects are white Europeans recruited 
from six centres: King’s College London, UK; University of Kuopio, Finland; 
University of Perugia, Italy; Aristotle University of Thessaloniki, Greece; University 
of Lodz, Poland; and University of Toulouse, France.  
The Maudsley and King’s Healthcare Partners DCR cohort was designed as a tool 
aiming to accelerate biomarker discovery, develop new therapies and generate 
testable hypotheses about the causes and symptoms of the dementia. The ARUK 
cohort is funded by Alzheimer’s Research UK, has parallel aims to the DCR and 
sample collection and protocols between the two cohorts are identical. All subjects in 
these two cohorts are white UK citizens with grandparents born in the UK and are 
assessed annually.  
Inclusion and exclusion criteria 
Exclusion criteria included other neurological or psychiatric disease, significant 
unstable systemic illness or organ failure, and alcohol or substance misuse. 
Alzheimer’s disease subjects were included if they met the ADRDA/NINCDS[178] 
and DSM-IV[179] criteria for probable Alzheimer’s disease, had an MMSE score in 
the range of 12-28, a Clinical Dementia Rating (CDR)[180] scale score of above 0.5, 
and were aged 65 years or above. Individuals were classed as MCI if their MMSE 
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score ranged between 24 and 30, were aged 65 years or above, and scored 0.5 on the 
CDR. Control subjects were included if they scored 0 on the CDR. 
Consent 
Informed consent was obtained for all subjects according to the Declaration of 
Helsinki (1991)[181]. In cases where dementia compromised capacity then assent 
from the patient and consent from a relative, according to local law, was obtained.  
MRI image acquisition and analysis 
MRI data was obtained from AddNeuroMed subjects only. The AddNeuroMed sMRI 
protocol is described in detail by Simmons et al (2009)[182]. Briefly, MRI 
acquisition was completed at all six centres using six different 1.5T MR systems 
(four General Electric (General Electric Healthcare, Milwaukee, WI); one Siemens 
(Siemens Medical Solutions, Erlangen, Germany); and one Picker (General Electric 
Healthcare)). Whole-brain sagittal three-dimensional MP-RAGE images (TR=8.6, 
TE=3.8, 256x192 acquisition matrix, 180x1.2mm slices, 1.1x1.1x1.2mm voxel size) 
were acquired. To control quality across the six centres an MRI scan of a phantom 
was regularly acquired at each centre and assessed using ImageOwl web-based 
automated quality control system (http://www.imageowl.com/). Additionally two 
volunteers were scanned at each site and their scans were processed and analysed 
using the same tools as the cohort images. Structural MRI data analysis consisted of 
image intensity nonuniformity correction (N3 algorithm), segmentation of brain 
tissue (grey matter, white matter, CSF, and lesion subtype), regional brain 
parcellation (Automated Non-linear Image Matching and Anatomical Labelling 
(ANIMAL)), and cortical thickness measurement (Constrained Laplacian anatomic 
segmentation (CLASP)).  
Cognitive and clinical assessments 
The CDR, MMSE, Geriatric Depression Scale, sensory/motor impairment measure, 
global deterioration scale, and the Consortium to Establish a Registry for 
Alzheimer’s Disease (CERAD)[183] cognitive battery were assessed for each 
participant. AD subjects were additionally assessed using the Alzheimer’s Disease 
Assessment Scale (ADAS-Cog)[184] and the Cambridge Mental Disorders of the 
Elderly Examination (CAMDEX)[185]. 
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For the AddNeuoMed cohort MMSE scores were obtained at five visits, three 
months apart. MMSE scores for ARUK and DCR cohorts were obtained annually 
over a period of two years (3 visits).  
Blood samples 
All blood samples were drawn by venipuncture and collected into EDTA glass tubes. 
Subjects were required to fast for at least 2 hours prior to collection. Both 
AddNeuroMed and DCR samples were centrifuged at 2000rpm for 10 minutes at 
4ᵒC. ARUK samples were centrifuged at 3000rpm for 8 minutes at 4ᵒC. All samples 
were centrifuged within 2 hours of collection. Plasma supernatant was collected, 
divided into aliquots, and frozen at -80̊C until further use.  
2.3 Materials 
The following is a list of reagents and the suppliers they were purchased from. 
Reagent Supplier Catalogue # 
Acetic acid, 100% glacial VWR 20102.32 
Acetronitrile (ACN) 
Fisher 
Scientific Ltd A0627OB17 
Acrylamide PAGE, PlusOne, 40% 
Fisher 
Scientific Ltd 17-1303-01 
Agarose, low melting point Sigma A9414 
Alpha-1-Microglobulin/Bikunin Precursor 
(A1M) ELISA Kit 
USCN Life 
Science E90217Hu 
Amicon Ultrafree-MC centrifugal filter tubes, 
0.5ml 3,000 MWCO Millipore UFC3LTK00 
Ammonium Bicarbonate (Ambic) Sigma A6141 
Ammonium hydroxide Sigma 221228 
Ammonium persulphate (APS) Sigma A3678 
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Bradford protein assay Bio-Rad 500-0006 
Bromophenol blue Sigma B8026 
Citric acid Sigma C1857 
Desalt Spin Column, 0.5mL Zeba Fisher 
Scientific Ltd 89882 
DeStreak rehydration solution WVR 17-6003-19 
Dithiothreitol (DTT), >98% (TLC), >99% 
(titration) Sigma D0632 
Dithiothreitol (DTT), BioXtra, >99% (titration) Sigma D5545 
Ethanol VWR 283047K 
Formaldehyde solution, 37 wt. % in H2O Sigma 252549 
Glutaraldehyde solution Sigma G6403 
Glycerol, for molecular biology, min.99% Sigma G5516 
Human Zinc-Alpha-2-Glycoprotein (ZAG) 
ELISA kit BT Labs E3056Hu 
Hydrochloric acid, 37% (HCl) VWR 20252.244 
Immobiline Drystrip gels, pH 3-11 NL,  18cm VWR 17-6003-76 
Iodoacetamide Sigma I1149 
IPG Buffer, 3-11 NL VWR 17-6004-40 
Isopropanol VWR 20839322 
Mineral Oil Sigma M3516 
Nathelene sulphonic acid Sigma 70240 
Piperazine diacrylamide (PDA) Bio-Rad 161-0202 
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Proteoprep Immunoaffinity Albumin & IgG 
Depletion Kit Sigma 
PROTIA-
1KT 
SDS PAGE Tank Buffer, (10X) Tris-Glycine 
SDS Geneflow Ltd EC-870 
SDS, 20 % solution Sigma 5030 
Silver nitrate VWR 21572.235 
Sodium acetate, SigmaUltra, min. 99% Sigma S7545 
Sodium hydroxide, >=99% Sigma S8045 
Sodium thiosulphate pentahydrate, SigmaUltra, 
min. 99.5% Sigma S6672 
Tetramethylethylenediamine (TEMED) Sigma T9281 
Tickopur r 30 neutral cleaner SLS Z660043 
TMD-8, mixed bed resin Sigma M8157 
Trifluoroacetic acid (TFA) Merk 
Millipore 1.08262.0100 
Trizma base Sigma T6791 
Trypsin, Modified Sequencing Grade Roche 11418025001 
Urea, SigmaUltra Sigma U0631 
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2.4 Solutions 
All solutions were made up using 18.2MΩcm ultra-pure water (ddH20) unless 
specified otherwise.  
Stock Procedure 
0.1% Nathelene sulphonic 
acid solution 
2g  Nathelene sulphonic acid 
2l ddH20 
10% Acrylamide Gel Solution 
(12 gels) 
250ml Acrylamide Stock 
187.5ml Resolving Buffer Solution 
3.75ml SDS 
3ml Sodium thiosulphate (20% in ddH20) 
300ml ddH20 
5ml APS (10% in ddH20) 
500µl TEMED 







15mg DTT (BioXtra) 
1ml ddH20 
Dilute 10 fold with 100mM Ambic 
200mM Iodoacetamide (IAA) 40mg Iodoacetamide 
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1ml 100mM Ambic 
50mM Ambic 
40ml 100mM Ambic 
40ml ddH20 
50mM Dithopthreitol 
15mg DTT (BioXtra) 
1ml 100mM Ambic 
Dilute 2 fold with 100mM Ambic 
55mM Iodoacetamide (IAA) 
10mg Iodoacetamide 





3-4 large scoops TMD-8* 
*once solution is de-ionised filter out. 
Agarose Sealing Gel 
0.5g Agarose 
100ml SDS Running Buffer 
200µl Bromophenol blue (0.002% in ddH20) 




2ml Citric acid (5% in ddH20) 
5.4ml Formaldehyde 
1992ml ddH20 
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Displacing Solution 
25ml Resolving Buffer 
50ml Glycerol 
25ml ddH20 
200µl Bromophenol Blue (0.002%) 
Resolving Buffer 
181.7g Trizma base 
750ml ddH20 
pH adjusted to 8.8 with HCl (6M) 
Solution made to 1l with ddH20 
SDS Equilibration Buffers: 
Equilibration DTT and 
equilibration IAA solutions 
6.7ml Resolving Buffer Solution 
72.07g Urea 
70ml ddH20 
Let Urea dissolve overnight then add: 
60.6ml Glycerol 
20ml SDS 
400µl Bromophenol blue (0.002% in ddH20) 
Solution made to 200ml with ddH20 
Prior to use divide into 2x100ml 
Add 1g DTT to 1x100ml 
Add 2.5g Iodoacetamide to the second 100ml. 
Silver nitrate solution 
Solution A: 
16g Silver nitrate 




26.6ml Ammonium hydroxide (14.8M) 
4ml Sodium Hydroxide (10M) 
1000ml ddH20 
Add solution A to B slowly whilst mixing 
Add 800ml ddH20 
Sodium acetate-
glutaraldehyde solution 




100g Trizma base 
40ml Glacial acetic acid 
1860ml ddH20 
Strong Fix Solution 
800ml Ethanol 
200ml Glacial acetic acid 
1000ml ddH20 
Trypsin 0.1% TFA 
250µl 0.1% TFA (5ml ddH20, 5µl TFA) 
25µg Trypsin 
Weak Fix Solution 
100ml Ethanol 
100ml Glacial acetic acid 
1800ml ddH20 
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2.5 Methods: Discovery 1 
2.5.1 Bradford assay 
Protein concentrations of plasma samples needed to be determined in order to be able 
to keep the amount of protein assessed in the various proteomic techniques uniform 
across subjects, allowing comparisons to be possible. Protein concentrations of each 
plasma sample were therefore determined according to the method of Bradford[186] 
using bovine serum albumin (BSA) as a standard. Briefly, BSA standards of 7 
concentrations ranging from 2-0.125mg/ml plus a blank sample (0mg/ml) were used 
to create a standard curve. Plasma sample dilutions were prepared (1:100). 10µl of 
each standard and sample was added in triplicate to a 96 well plate. Bradford reagent 
was diluted 1:4 with double distilled H20 (ddH20) before adding 190µl to each well. 
The plate was then incubated at room temperature for 10 minutes before reading 
absorbance values with a spectrophotmeter at 595nm. Standard curves were then 
created by plotting the 595nm values (y-axis) versus their concentration in µg/ml (x-
axis). The standard curve was used to determine the concentration of each plasma 
sample, adjusting for the dilution factor used.  
2.5.2 Two dimensional gel electrophoresis (2DGE): analytical gel 
Global analyses of all proteins present in a sample in combination with cognitive 
and/or imaging data allows for the discovery of novel biomarkers and confirmation 
of those previously reported. Two dimensional gel electrophoresis (2DGE) is a well-
established proteomic discovery technique for the separation and, when coupled with 
mass spectrometry, for the identification of large numbers of proteins present on a 
gel. Here 2DGE was utilised to screen plasma samples for a protein profile of 
Alzheimer’s disease endophenotypes. As shown in Figure 2-1 2DGE comprises 9 
steps: (1) sample preparation, (2) separation in the first dimension, (3) second 
dimension separation, (4) Protein visualisation (staining), (5) image analysis, (6) 
statistical analysis, (7) preparative gel (8) spot selection and digestion, (9) mass 
spectrometry identification. 
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Figure 2-1: 2DGE workflow 
Sample preparation 
For each plasma sample 1:10 dilutions were prepared. Having previously calculated 
the protein concentration of each sample the 1:10 dilutions were then aliquotted into 
two aliquots each containing 50µg of protein (each sample was to be run in 
duplicate). Each aliquot was then made up to 350µl with DeStreak rehydration 
solution in which IPG buffer (7-11 NL) had been added just prior to use. Samples 
were then vortexed, pulse centrifuged and left at room temperature for 15 minutes to 
solubilise proteins. 
  66 
  
First dimension – Rehydration and isoelectric focussing (IEF). 
Rehydration buffer/sample solution aliquots were applied to Immobiline DryStrips 
(pH 3-11, 18cm) placed in strip holders. Using IPGphor™ (Amerham Bioscience) 
apparatus the strips were then rehydrated for 12 hours and IPG electrofocused for 16 
hours using the protocol detailed in Table 2-1 below.  
Table 2-1: 2DGE first dimension rehydration and isoelectric focusing experimental 
settings 
Phase Voltage (V) Duration (hours) 
Rehydration 50 μA/strip 12 
1. Hold 500 2 
2. Gradient 500-1000 2 
3. Hold 1000 2 
4. Gradient 1000-8000 2 
5. Hold 8000 8 
Following electrofocusing the strips were frozen at -80C until required for second 
dimension. 
Second dimension: SDS-PAGE 
The second dimension consists of four steps: (1) Gel preparation, (2) IPG strip 
equilibration, (3) IPG strip electrophoresis preparation (4) electrophoresis.   
(1) Gel preparation. Acrylamide gels were prepared using the Ettan Dalt II gel caster 
system (Amersham Bioscience, UK). A 10% acrylamide solution was prepared and 
poured into the casting system, followed by a displacing solution. Using a pipette 
1ml of isopropanol was then overlaid on top of each gel to minimize exposure to 
oxygen and to create an even gel surface. The gels were allowed to polymerise for 1 
hour before being covered in water and left overnight to fully polymerise.  
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(2) IPG strip equilibration. Previously rehydrated and IPG electrofocused strips were 
equilibrated in a two-step process. Firstly strips were equilibrated in an equilibration 
DTT solution for 15 minutes to reduce disulphide bonds, immediately followed by an 
equilibration iodoacetamide solution for 15 minutes to prevent the reformation of 
these bonds.   
(3) IPG strip electrophoresis preparation. After equilibration, the IPG gel strips were 
cut at both extremities to remove sections of salt build up. The strips were then 
placed on top of the polymerized acrylamide gels, making sure there were no bubbles 
between the gel and the strip, and then sealed in place with agarose sealing gel. 
(4) Electrophoresis. Electrophoresis was performed using the Ettan Dalt ™ II large 
vertical system (Amersham Bioscience, UK). The electrophoresis was achieved 
through two phases; resolving and separating. Table 2-2 below details the settings for 
each of these stages. The Ettan Dalt ™ system was set to maintain a constant 
temperature of 15°C throughout. 
Table 2-2: 2DGE electrophoresis settings 
Protein Visualisation (silver staining) 
After electrophoresis gels were fixed for 1 hour in strong fixing solution in separate 
staining boxes. They were then transferred to weak fixing solution and left overnight 
at room temperature. Protein detection was achieved using silver staining according 
to the Hochstrasser protocol[187]. The gels were fixed and stained using the 
solutions and incubation steps shown in Table 2-3. 
Phase Power (W) Duration (hours) 
Resolving 5 W/gel 1 h 
Separating Increase to 80 W 6-8hrs/12 gels 
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Table 2-3: Hochstrasser silver staining protocol steps 
Silver staining step Time 
Strong Fixing Solution 1 h 
Weak Fixing Solution overnight 
Wash (ddH20) 5 min 
Sodium acetate-glutaraldehyde solution 1.5 h 
Wash (ddH20) 4x15 min 
Nathelene sulphonic acid solution 2x30 min 
Wash (ddH20) 4x15 min 
Silver nitrate solution 25 min 
Wash (ddH20) 4x4 min 
Develop solution As required 
Stop Solution As required 
Image analysis: Gel pre-processing 
The silver stained gels were scanned using a GS-800 calibrated densitometer at 
medium resolution (72 dpi) and saved as TIFF images for image analysis. Spot 
detection and analysis was performed using Nonlinear Progenesis SameSpots 
software version v.3.3.3420.25059 (Nonlinear Dynamics, Newcastle upon Tyne, 
UK). Scanned gel images were firstly added into the software where quality checks 
were performed and images were edited (cropped and rotated) if required. One gel 
image with a clear, representative spot pattern with minimal distortion was selected 
as a reference image for the other images to be later aligned to. A mask of disinterest 
was applied to exclude areas around the edge of the gel before manual and then 
automatic alignment was performed. The reference gel was then automatically 
matched against all the individual gels to identify spots that could be confidently 
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matched on every gel across the whole sample cohort. Filtering of these spots was 
then performed to include only single, well defined spots. A within subject 
experimental design was then specified and gel images were grouped by time point. 
The results of this time point comparison allowed individual spots to again be viewed 
in detail using the spot expression profile and 2D/3D montage view. Using these 
tools further filtering of spots was performed at this stage by a manual review of 
every spot, removing any overlapping and less defined spots. Normalised volume 
values for the remaining spots were exported into an excel spreadsheet for further 
statistical analysis. 
Statistical analyses 
As each sample had been run in duplicate the coefficient of variation (CV) was 
calculated for every duplicate spot using R version 3.0.0 software (R Foundation for 
Statistical Computing, Austria). If the CV between the duplicates was <40% then an 
average of the two normalised spot volumes was calculated to be used as the value 
for further statistical analyses. If the CV was >40% then the spot closest in value to 
the overall normalised spot volume mean was selected to be used for further 
analyses. Normality tests (Kolmogorov-Smirnov) were then calculated for every 
spot. The data was then logged (base 10) to minimise skewness and non-normal spot 
distributions. The remaining statistical analysis was split into three sections: cross 
sectional analysis with PiB PET DVR, longitudinal analysis with sMRI volumes, and 
longitudinal analysis with cognitive scores. Covariates included in statistical tests 
were; age, gender, education (years), body mass index (BMI), cholesterol, and APOE 
ε4 status. All of these factors have known impacts upon the risk of AD, and were 
included as covariates to remove their influence and enable any relationship between 
protein and AD to be identified. Although 6 is a large number of covariates to 
include, as this study was investigating preclinical AD a blood based biomarker 
signal is likely to be weak, and therefore it was considered necessary to remove as 
much additional variance as possible.  
Cross sectional analysis with PiB PET DVR 
Cross sectional analyses were performed with the aim to identify protein spots at 
each time point significantly related to PiB PET DVR 12 years later, 6 year later, and 
concurrently (see Figure 2-2). Using R version 3.0.0 software with package ‘ppcor’ a 
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partial correlation was performed correlating every spot with PiB PET DVR scores 
whilst controlling for age, gender, education (years), body mass index (BMI), 
cholesterol, and APOE ε4 status. Spots found to be significantly correlated with PiB 
PET DVR were then manually assessed to determine whether they could be 
successfully picked out of the gel for later identification. Spots that were not visually 
well defined and discrete were discarded. Using R package ‘glmnet’ the remaining 
significant spots were entered into a penalised elastic-net regression model with 
leave-one-out cross validation. To provide an indication of how well the resulting 
panels of significant spots from each time point could predict PiB PET DVR the 
spots were entered into a standard linear regression model using SPSS version 20 
(IBM Statistics Software, USA).  
 
Figure 2-2: Cross sectional analysis; finding 2DGE spots related to PiB PET DVR at 
each time point. 
Longitudinal analysis with MRI volumes 
To identify MRI brain volumes that significantly changed over time one-way 
repeated measures ANOVAs were conducted on all regions using SPSS version 20. 
Regions that changed non-linearly were discarded as further analysis using 
regression models used could only model linear change over time. Regions that 
showed significant atrophy were then ranked based on their percentage change in 
volume over time. The region with most change was taken forwards and using R 
version 3.0.0 software mixed-effect regression models were conducted to perform a 
slope comparison between protein spot normalised volumes and sMRI brain volume 
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whilst controlling for age, education (years), gender, BMI, cholesterol, and APOE ε4 
status.  
Longitudinal analysis with cognitive scores 
To identify cognitive scores that significantly changed over time, one-way repeated 
measures ANOVAs were conducted on all measures using SPSS version 20. 
Measures that changed non-linearly were discarded leaving only one remaining 
significant cognitive measurement. Using R version 3.0.0 software mixed-effect 
regression models were conducted to perform a slope comparison between protein 
spot normalised volumes and cognitive score whilst controlling for age, education 
(years), gender, BMI, cholesterol, and APOE ε4 status.  
2.5.3 Two dimensional gel electrophoresis (2DGE): preparative gel 
To identify proteins present in a given spot using mass spectrometry a 2DGE 
preparative gel was needed. Protocol was kept the same as for the analytical gel 
except for the following three amendments; (1) Sample aliquots contained 300-
400µg protein (2) sodium-acetate glutaraldehyde solution contained no 
glutaraldehyde, (3) develop solution had 50% less formaldehyde.  
2.5.4 Two-dimensional gel electrophoresis (2DGE): Mass spectrometry protein 
identification 
Spot picking 
Protein spots showing a statistically significant relationship between their normalised 
volumes and Alzheimer’s disease pathology were selected as biomarker candidates 
and taken forward to be identified by mass spectrometry. Spot picking was 
completed manually. Gels were kept in stop solution throughout. A 1:1 size-matched 
print-out copy of the scanned gels was created and spots of interest were highlighted 
to aid with picking. Gels were placed on top of a light box during picking to help 
view the spots. Pipette tips were cut so that the opening was approximately the size 
of the spot of interest. Approximately 100µl of water was drawn into the tip before 
the opening was carefully pressed down on top of the spot into the gel to remove the 
spot. The picked spot was then transferred to an eppendorf tube by pushing the water 
out of the tip. 
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In gel tryptic digestion 
Excised gel spots were cut into small 2mm3 pieces and transferred back into an 
eppendorf tube. The gel spots were then washed with 100mM Ambic (added in 
excess) for 5 minutes then decanted. Next acetonitrile (ACN) was added in excess, 
decanted, and then the same volume was added again to fully and quickly dehydrate 
the gel pieces. ACN was then removed and gel spots were dried in a speed vac for 5 
minutes. Gel spots were then rehydrated with 10mM dithiothreitol (DTT) and heated 
at 56̊C for 30 minutes. DTT was removed and ACN was again added twice, as in 
earlier step, to dehydrate before again drying in a speed vacuum for 5 minutes. Next 
55mM iodoacetamide (IAA) was added to the gel spots and incubated at ambient 
temperature for 20 minutes in the dark. The supernatant was discarded and gel spots 
were washed briefly with 100mM Ambic buffer that was then replaced and spots 
were washed for a further 5 minutes before the buffer was discarded. Gel spots were 
dehydrated as before with ACN and dried in a speed vacuum for 5 minutes. 200µl of 
50mM Ambic was added to each trypsin 0.1% trifluoroacetic acid (TFA) aliquot 
(30µl) to give a final trypsin concentration of 13ng/µl. Gel pieces were rehydrated in 
a minimal volume of this trypsin solution (i.e. enough to cover and rehydrate the gel 
pieces) at 4̊C for 20 minutes. Unabsorbed trypsin was then removed and a minimal 
volume of 50mM Ambic (10-20µl) was added to cover the gel pieces and keep them 
wet during enzyme cleavage. Gel spots were incubated at 37̊C for 2 hours then 
overnight at room temperature. 
Peptide extraction 
Supernatant was decanted from gel pieces and collected into a new eppendorf tube. 
Using a minimal volume to immerse the gel pieces they were washed with 50mM 
Ambic for 5 minutes at 37̊C, which was then decanted and supernatant pooled into 
the same eppendorf tube as before. Gel pieces were next dehydrated with ACN for 
10 minutes at 37̊C, after which the supernatant was again decanted and pooled into 
the eppendorf tube. The above wash and dehydrate steps were then repeated once. 
The pooled supernatant was then frozen and dried down to completion whilst 
avoiding over drying and then stored at -80̊C until required. 
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Mass spectrometry 
After digestion and extraction the resulting peptide mixture was loaded into an 
orbitrap mass spectrometer for protein identification. Samples were firstly 
reconstituted in 20µl 50mM Ambic, 10µl of which was loaded into an orbitrap 
loading vial. 8µl of each sample was injected onto a Thermo C18 pre-column, using 
the Proxeon EASY-nLC II system (Thermo Fisher Scientific Inc, USA). Peptides 
were resolved by reverse phase chromatography over an increasing gradient of 0.1% 
formic acid (FA) in ACN through a Thermo C18 analytical column. Mass spectra 
were acquired on an LTQ Orbitrap Velos Pro (Thermo Fisher Scientific Inc, USA) 
throughout the chromatographic run (35 minutes) using 20x collision-induced 
dissociation (CID) scans following each Fourier transform mass spectrometry 
(FTMS) scan (2x µScans at 30,000 resolving power @ 400 m/z). CID was carried 
out on 20 of the most intense ions from each FTMS scan. Blank samples were run in 
between every four samples to avoid protein cross over. 
Mass spectrometry data pre-processing 
Peak lists were extracted from Xcalibur raw data files using Proteome Discoverer 1.4 
that were then searched against the UniProtKB/Swiss-Prot database 
(uniprot_sprot.fasta, downloaded from http://www.uniprot.org/downloads on 
20/02/13) using Mascot 2.2.06 search engine. Taxonomy was set to Homo-sapiens 
(human). The search was programmed to include tryptic peptides with up to 3 missed 
cleavages, with variable modifications set as Carbamidomethyl (C), Oxidation (M), 
and Acetyl (Protein N-term). Precursor mass tolerance was set to 10 ppm and 
fragment mass tolerance 0.8 Da. A percolator filtered identifications based on a false 
discovery rate (FDR) of 0.5%, set at the peptide level, based on a target-decoy search 
approach.  
Protein quantification 
Several proteins were often identified as present in each gel spot. These were ranked 
for abundance using three different approaches; peptide spectral matches (PSM), area 
under the curve (AUC), and unique peptide count. Abundance ranking based on 
PSMs uses the number of tandem spectra matched to peptides of a certain protein to 
determine a total spectral count. This count is considered to be positively associated 
with the abundance of the protein and so can be used as an indicator of relative 
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abundance. The second approach (AUC) suggests that for each protein identified, the 
average signal of the three most efficiently ionised peptides directly correlates to the 
protein abundance. Thirdly, unique peptide count is based upon the fact that proteins 
within a 2DGE spot have roughly the same weight and charge. This approach 
therefore assumes that the proteins within a spot will have similar numbers of amino 
acids, so similar numbers of lysine and arginine frequencies for trypsin to cleave, and 
therefore roughly the same number of potential peptides. If the number of potential 
peptides is equivalent and the ionisation efficiency on the mass spectrometer is 
similar (as proteins within a spot have similar isoelectric points) then the number of 
unique peptides can be said to represent the relative abundance.  
The ‘Precursor Ions Area Detector’ of Proteome Discoverer 1.4 was utilised to 
calculate the area AUC of each precursor ion using integration. This information was 
exported from Proteome Discoverer to Excel along with the number of peptide 
spectral matches (PSMs) and unique peptide number. Proteins were stringently 
filtered so that only the most likely candidates survived (rank of peptide match= 1, is 
bold (match assigned only once) = 1, peptide match score >30, peptide match 
expectation value <0.01, number of peptide sequences >3). Any keratin or trypsin 
present in the dataset was removed. Proteins were then ranked on abundance using 
each of the three approaches. For each method of quantification proteins that were 
contributing to less than 5% of a spot’s total protein quantity were removed from the 
spot. Out of the remaining proteins those included in 2/3 of the quantification 
approaches were considered to be abundantly present and were suggested candidates 
for the statistical signal found from that spot. 
2.6 Methods: Discovery 2 
2.6.1 Liquid chromatography-tandem mass spectrometry (LC-MS/MS) 
LC-MS/MS is a quantitative and sensitive approach for proteomic analyses. It offers 
superior sensitivity and specificity for low molecular weight analytes compared to 
2DGE. Here through prior depletion of abundant and high molecular weight plasma 
proteins allowing for the extraction of proteins with a low molecular weight (<30ka), 
LC-MS/MS was performed to provide a complementary evaluation of the proteome 
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to that already conducted using 2DGE (20-250kDa range). Figure 2-3 displays the 
workflow used for this discovery phase. 
 
Figure 2-3: Label free LC-MS/MS workflow 
Depletion of albumin and IgG from plasma samples 
Depletion columns were firstly equilibrated using equilibration buffer provided in the 
depletion kit. 15mg of protein (~25µl of plasma sample) was then loaded onto the 
depletion column medium bed and incubated for 10 minutes. Next the column was 
centrifuged at 8000xg for 1 minute. The eluate in the collection tube was then re-
applied to the medium bed and incubated for a further 10 minutes. Next the column 
was centrifuged again at 8000xg for 1 minute. The twice depleted plasma remained 
in the collection tube to be combined with the following wash for optimal protein 
recovery. 125µl of equilibration buffer was added to the medium bed and centrifuged 
for 60 seconds to wash through any remaining unbound proteins from the spin 
column. 
Removal of remaining large proteins (>30kDa) 
Depleted plasma samples were each pipetted into a 30kDa cut off filter cup placed 
inside a filtrate collection tube. The filter was then centrifuged at 5000xg for 45 
minutes. The protein concentration of the filtrate was determined using a NanoDrop 
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instrument (Thermo Fisher Scientific Inc, USA) before being divided into two 15µg 
aliquots and stored at -80̊C.  
In-solution trypsin digest 
Samples were reconstituted in 100µl 50mM Ambic. 11µl of 50mM DTT was then 
added and incubated at 56̊C to reduce cysteine residues. Samples were next alkylated 
by treatment with 12µl 200mM iodoacetamide in the dark for 20 minutes at ambient 
temperature. Then samples were digested with 10µl trypsin 0.1% TFA and incubated 
at 37̊C for 2 hours and then overnight at room temperature. Samples were then frozen 
and dried down to completion and stored at -80̊C until required. 
LC-MS/MS analysis 
Samples were reconstituted in 30µl 20% ACN, 0.1% FA. All 30µl was loaded into 
an orbitrap loading vial whilst avoiding any precipitate. 8µl of each sample was 
injected onto a Thermo C18 pre-column and mass spectra were acquired as described 
previously throughout a 35 minute chromatographic run. Samples were run in 
triplicate and blank samples were run in between every triplicate to avoid cross over 
between subjects.  
LC-MS/MS data pre-processing 
Peak lists were extracted and searched as previously described, except for precursor 
mass tolerance and fragment mass tolerance that were set to 5ppm and 0.5Da 
respectively. Data was then loaded into Scaffold 4 (Proteome Software Inc, USA) 
allowing the merging of the triplicate sample injections into one BioSample. Proteins 
were filtered using the following cut off values; protein threshold = 95%, minimum 
number of peptides = 2, peptide threshold = 80%. Decoy proteins, keratin and any 
trypsin were removed. To enable comparisons across samples the Normalised Total 
Spectra quantitative value was selected. This value is calculated by averaging the 
spectrum count for all of the BioSamples, then the number of spectra assigned to one 
protein is multiplied by the ratio of the average spectrum count and the number of 
spectra in that sample. This data was then exported to Excel for further analysis.  
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Statistical analysis 
Statistical analysis was conducted using R version 3.0.0. For each time point a partial 
correlation was performed correlating every protein with PiB PET DVR whilst 
controlling for six co-variables; age, gender, education (years), body mass index 
(BMI), cholesterol, and APOE ε4 status. Additionally mixed-effect regression 
models were conducted to perform slope comparisons between proteins and sMRI 
brain volumes and cognitive measures whilst controlling for the same six co-
variables as previously stated. 
2.7 Methods: Validation 
2.7.1 Validation of proteomic data using an aptamer based array (SOMAscan) 
and enzyme-linked immunosorbent assays (ELISA).  
Aptamer based array: SOMAscan (SomaLogic, Inc, Boulder, Colorado) 
A Slow Off-rate Modified Aptamer (SOMAscan) array uses chemically modified 
nucleotides to measure 1,001 different human proteins by transforming their protein 
signal into a nucleotide signal that can then be quantified using relative florescence 
on microarrays. SOMAscan is conducted by SomaLogic as a fee-for-service; Figure 
2-4 displays the SOMAscan mechanism. Briefly, SOMAmers attached via a linker to 
streptavidin beads bind to proteins in a sample. The bound proteins are then 
biotinylated before the SOMAmer-protein complexes are released by photocleaving 
a linker. Biotinylated proteins are then bound to a second streptavidin bead and the 
bound SOMAmers are removed from the proteins. These SOMAmers are then 
collected and denatured before being measured using standard DNA analysis 
techniques such as microarrays.  
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Figure 2-4: Mechanism of SOMAscan assay, adapted from 
http://somalogic.com/Technology/How-it-works.aspx  
SOMAscan statistical analysis 
SomaLogic SOMAscan aptamer-based assays were available for a subset of the 
candidate biomarkers requiring validation. Analysis was conducted as reported in 
Kiddle et al (2014)[188], but was conducted here only for candidate biomarkers of 
interest. Using R the candidate proteins were analysed individually for their 
association with AD phenotypes: AD disease status (AD v control), sMRI volumes 
(left and right entorhinal volume, left and right hippocampal volume) and rate of 
cognitive decline (change in MMSE per day; slope coefficient from a linear mixed 
effect model using longitudinal MMSE scores[188]). Disease status was analysed 
using logistic regression whilst adjusting for age, gender, APOE ε4 status, and 
research centre. Partial Spearman’s Rank Correlation (SRC) was performed to 
investigate the correlation between sMRI volumes and proteins whilst controlling for 
age, gender, research centre and APOE ε4 status. SRC was also used to investigate 
the correlation between cognitive decline and proteins. False discovery rate (FDR) 
multiple testing corrections were applied to the resulting p-values. Both a strict (q-
value = 0.05) and less strict (q-value = 0.1) were considered.  
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Enzyme-linked Immunosorbent Assay (ELISA) 
Two candidate biomarkers for which SOMAscan assays were not available were 
instead analysed using commercially available ELISA assays to provide an 
independent comparison and validation of the discovery phase experiments.  
ELISA for Alpha-1-Microglobulin/Bikunin Precursor (a1M) 
This sandwich ELISA was carried out according to the USCN assay instruction. 
Briefly, all reagents, samples (500 fold dilution) and standards (0-300ng/ml dilution 
range) were prepared. 100µl of standard, blank, or sample was added in duplicate to 
the appropriate well and incubated for 2 hours at 37̊C. The liquid of each well was 
then removed by inverting the plate and blotting it against absorbent paper. 100µl of 
detection reagent A provided was then added to each well and the plate was 
incubated for 1 hour at 37̊C. The plate was then washed 3 times with 300µl of the 
washing buffer provided before 100µl of detection reagent B was added to each well 
and incubated for 30 minutes at 37̊C. The plate was then washed 5 times with 
washing buffer before 90µl of substrate solution was added to each well and 
incubated for 25 minutes at 37̊C in the dark. 50µl of stop solution was then added to 
each well. The plate was immediately read on a microplate reader at 450nm. The 
plate was also read at 595nm allowing the subtraction of noise. Sample replicates 
were averaged and standard values were used to create a standard curve in SigmaPlot 
version 12.5 (Systat Software Inc, USA) from which protein concentrations could be 
determined. 
ELISA for Zinc-Alpha-2-Glycoprotein (ZAG) 
This sandwich ELISA was carried out according to the BT Laboratory assay 
instruction. Briefly, reagents, standards (0-480µg/µl) and samples (neat) were 
prepared. Blank and standards (50µl) and samples (40µl, plus 10µl ZAG antibodies) 
were added in duplicate into the appropriate wells and 50µl of streptavidin-HRP was 
then added and incubated for 60 minutes at 37̊C. The plate was then washed 5 times 
with 300µl of the washing buffer provided before 50µl of chromogen solution A and 
B was added to each well and incubated for 10 minutes at 37̊C in the dark. 50µl of 
stop solution was next added to each well and the plate was read on a microplate 
reader at 450nm. The plate was also read at 595nm to allow the subtraction of noise. 
Sample replicates were averaged and standard values were used to create a standard 
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curve in SigmaPlot version 12.5 from which protein concentrations could be 
determined. 
ELISA statistical analysis 
Protein concentrations were analysed using SPSS. T-tests were used to determine 
differences in concentrations between AD and control subject groups. Pearsons 
correlation was performed to identify proteins correlated to brain atrophy and/or 
cognitive decline. 
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Chapter 3. Longitudinal blood based biomarker discovery of early 
Alzheimer’s disease pathology and cognitive decline using two-
dimensional gel electrophoresis 
3.1 Introduction 
Two dimensional gel electrophoresis (2DGE) is a well established technique that has 
been employed for protein separation since 1975[189-190]. 2DGE has so far been 
extremely useful as an analytical tool for biomarker discovery in many areas of 
research, and in the past decade has shown its utility for blood-based biomarker 
research for Alzheimer’s disease[142, 151]. 2DGE enables the separation of proteins 
in a complex sample according to charge (pH/pI) in the first dimension followed by 
molecular weight (MW) in the second dimension. This technique also allows the 
separation of different protein isoforms due to naturally occurring protein cleavage 
and post translational modifications, such as glycosylation and phosphorylation, 
which affect both charge and mass. Proteins are then visualised by one of many 
staining techniques available revealing a pattern of proteins present characteristic to 
the sample type used. Gels can then be scanned and converted to digital images 
allowing in depth analysis by informatics and statistical software. Following analysis 
2DGE spots of interest can be extracted from the gel and identified by liquid 
chromatography-tandem mass spectrometry (LC-MS/MS), which also enables 
relative quantification of the proteins present.  
In 2010 Thambisetty et al performed a retrospective preclinical AD biomarker study 
investigating plasma proteins reflecting brain amyloid load 10 years later[151]. 
Using an elderly healthy cohort (Baltimore Longitudinal Study of Aging) they 
performed 2DGE and discovered a panel of 18 protein spots that could differentiate 
between healthy individuals who would have high or low brain amyloid load 10 
years later, accounting for 59% of the variance in PiB PET distribution volume ratio 
(DVR). This confirmed that a peripheral signal of preclinical Alzheimer’s pathology 
could be detected in cognitively healthy individuals. This project aimed to repeat and 
expand upon this work. Here, using 2DGE, plasma proteins were assessed for their 
relationship to amyloid load 12 years later (baseline), 6 years later (T6), and 
concurrently (T12) to the PiB PET scan. Additionally the plasma proteome was 
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investigated for a correlation with two more indicators of Alzheimer’s disease 
(cognitive decline and brain atrophy) over a longitudinal 12 year period. 
3.2 Aims 
To identify proteins predictive of amyloid load using 2DGE coupled with LC-
MS/MS. To discover the most predictive protein panels at each time point (12 years 
prior, 6 years prior, and concurrently) using multivariate analyses of proteins against 
quantitative amyloid imaging measures (11C-PiB PET DVR). Additionally using the 
same proteomic technique, proteins longitudinally related to brain atrophy and 
cognitive decline will be identified.  
3.3 Results 
3.3.1 Demographic characteristics 
Individuals (n=68) were selected from the Baltimore Longitudinal Study of Aging 
(BLSA) neuroimaging cohort previously described (Chapter 2). These individuals 
must have had serial MRI scans, serial cognitive assessments and serial blood 
sampling to be included in the study. The majority of these individuals (n=54) also 
had one PiB PET scan. Plasma samples were drawn at three time points (1.5ml 
aliquots in EDTA; a total of 204 samples). Time points corresponded to 
neuroimaging visits ~6 years apart (baseline, T6 = 6+/-2 years, and T12 = 12+/-2 
years) (Figure 3-1). The third time point samples (T12) were concurrent to the 
subjects PiB PET scan. 2DGE analysis of each sample was performed in duplicate, 
or more if gels of poor quality required repetition. 
 
Figure 3-1: Diagram illustrating information available at each time point (baseline, T6, 
and T12); plasma samples, clinical measurements, structural MRI volumes, and PiB 
PET DVR 
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Table 3-1 below summarises the demographic characteristics of the study population 
at baseline.  
Table 3-1: Subject demographics 
 N Mean age at baseline Std. dev  
Female 29 66.34 6.55 
Male 39 67.82 5.54 
Total 68 67.19 5.99 
Table 3-2 below displays the number of these subjects whom had PiB PET scan 
information available, mean distribution volume ratios (DVR), and when the PiB 
PET scan was conducted (mean number of years after baseline (baseline)). Figure 
3-2 shows the distribution of PiB PET DVR values across these subjects. This 
histogram displays a wide range of PiB PET DVR values, with approximately half of 
the subjects forming a cluster at the lower end of the distribution, and the remaining 
half spread out over higher DVR values.  
Table 3-2: Subject PiB PET DVR information 
 N Mean PiB PET 
DVR 
Mean no. years between baseline 
plasma sample and PiB PET scan 
Female 29 1.17 11.39 
Male 25 1.13 11.45 
Total 54 1.15 11.43 
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Figure 3-2: Histogram displaying the distribution of PiB PET DVR values across 
subjects 
3.3.2 2DGE gel image pre-processing 
In addition to the automatic processes applied by the analysis software a substantial 
manual review of every spot was completed. 2DGE gel images can be influenced by 
a number of complex issues including co-migration (2DGE captures large numbers 
of proteins and so it is likely that some will have similar pI and MW and therefore 
co-migrate) and spot saturation (highly abundant proteins may stain to saturation 
resulting in difficulty distinguishing between spots)[191]. Furthermore, heavy tails of 
abundant protein spots may mask other proteins in the surrounding area and artefacts 
such as gel cracks and stain binding to non-protein contaminants may challenge the 
automated spot detection software. Additionally variations in gel casting and 
polymerisation, buffers and electric field can all contribute to geometrical 
deformation resulting in difficulty matching spots. Although it is not possible to 
eliminate all of these issues from an analysis, manual intervention during image 
preprocessing can help to minimise their influence. Spots were therefore reviewed 
individually and those that were not well defined, discrete, and present in the 
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majority of gels were removed. Figure 3-3 displays a comparison between two 2DGE 
spots; one included and one rejected from further analysis based on a manual review. 
 
Figure 3-3: A comparison of two 2DGE spots and their presence on four gels. Spot A 
was not well defined or present in the majority of gels, and so was rejected from further 
analysis. Spot B was well defined, discrete, and present in the majority of gels, and so 
was included for further analysis.  
1386 spots were selected to be included in statistical analysis; included spots are 
outlined in Figure 3-4. Volumes for each of these spots were exported for statistical 
analysis. 
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Figure 3-4: 2DGE reference gel highlighting 1386 spots selected for statistical analysis 
3.3.3 Coefficient of variation (CV) 
For statistical analysis both R version 3.0.0 (R Foundation for Statistical Computing, 
Austria) and SPSS version 20 software (IBM Statistics Software, USA) were used. 
As 2DGE had been completed in duplicate for every sample, the coefficient of 
variation (CV) for every spot volume between duplicate gels was calculated. These 
CVs were then averaged to obtain an overall experiment within-subject CV of 
33.52% (Table 3-3). In addition, to assess whether there was a similar variation 
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across time points the mean CV per time point was also calculated, these are detailed 
in Table 3-4 and illustrated in Figure 3-5. The mean CV’s at each time point were: 
baseline = 34.98%; T6 = 33.87%, and T12 = 31.72%. 
Table 3-3: Overall experiment mean within subject spot CV 
 N (spots) Minimum Maximum Mean Std. Deviation 
CV 4158 11.68 64.41 33.52 7.77 
 
Table 3-4: Mean within subject spot CV's per time point 
Time point N (spots) Minimum Maximum Mean Std. Deviation 
BASELINE 1386 12.80 64.41 34.98 7.83 
T6 1386 11.80 62.27 33.87 7.75 
T12 1386 11.68 60.47 31.72 7.38 
 
Figure 3-5: Mean within subject CV's per time point 
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A one-way analysis of variance (ANOVA) was conducted to compare differences 
between CV’s at each time point. This revealed statistically significant differences 
between mean CV’s at each time point (F(2,4155) = 65.37, p<0.001). Post hoc 
comparisons using the Bonferroni test indicated that at all three time points the mean 
CV’s were significantly different from each other (p<0.001).  
As analytical variance normally ranges 16-40% in 2DGE experiments[192-194] a 
40% threshold was selected for an acceptable spot CV. Using this threshold of 40%, 
data from duplicate gels were combined either by averaging the spot volumes (if CV 
= <40%) or by taking the value closest to the overall spot mean (if CV= >40%) (see 
Figure 3-6). These values were used for further statistical analysis. 
 
Figure 3-6: Data quality improvement based on the coefficient of variation between 
duplicate gels 
3.3.4 Normality tests 
Normality tests were performed to determine the normality of the spot volume 
distributions. A Kolmogorov-Smirnov test for normality indicated that 34% of the 
spot distributions were normally distributed (p<0.05). Spot data was then logged 
(base 10) to minimise skewness and non-normal spot volume distributions, and 
normality tests were repeated. Kolmogorov-Smirnov tests on logged spot data 
indicated that 80% of the spot distributions were normally distributed (p<0.05). 
Logged data was therefore used for the following statistical analysis. 
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3.3.5 2DGE analysis of plasma protein spots associated with amyloid load as 
measured by PiB PET DVR 
Partial correlations 
Partial correlation was used as a first step to identify spots that have a relationship 
with amyloid load. Protein spot volumes correlating with 11C-PiB PET DVR at each 
time point, whilst controlling for age, gender, education (years), body mass index 
(BMI), cholesterol, and APOE ε4 status were identified. Partial correlations at 
baseline, T6, and T12 revealed 119, 47, and 73 proteins spots, respectively, which 
significantly correlated with PiB PET DVR 12 years later, 6 years later and 
concurrently (p<0.05). Significant results are displayed in Table 3-5 for baseline, 
Table 3-6 for T6, and Table 3-7 for T12. Full results are reported in appendix 1 
(baseline) appendix 2 (T6) and appendix 3 (T12). 
Table 3-5: Significant baseline partial correlation results for 2DGE spots with PiB PET 



























X1370 -0.532 0.000 
X1310 -0.492 0.000 
X1793 -0.484 0.000 
X696 0.481 0.001 
X749 -0.466 0.001 
X1365 -0.451 0.001 
X1554 -0.451 0.001 
X2279 -0.445 0.002 
X1671 -0.427 0.003 
X1239 -0.423 0.003 
X595 0.419 0.004 
X2063 -0.416 0.004 
X1258 -0.414 0.004 
X632 0.409 0.005 
X1295 -0.404 0.005 
X529 0.401 0.006 
X1331 -0.400 0.006 
X1224 -0.399 0.006 
X639 0.392 0.007 
X716 -0.391 0.007 
X758 -0.384 0.009 
X1534 -0.383 0.009 
X1525 -0.383 0.009 
X1056 -0.380 0.009 
X1029 0.378 0.010 
X2245 0.374 0.011 
X938 -0.374 0.011 
X393 0.374 0.011 
X1260 -0.371 0.012 
X1583 -0.369 0.012 
X1402 -0.368 0.012 
X1432 -0.367 0.013 
X1524 -0.365 0.013 
X1292 -0.365 0.013 
X1400 -0.365 0.013 
X697 -0.364 0.014 
X1551 0.359 0.015 
X1303 -0.359 0.015 
X872 0.358 0.015 
X825 -0.355 0.016 
X1054 -0.353 0.017 
X1317 0.352 0.018 
X1188 -0.352 0.018 
X2026 -0.351 0.018 
X1272 -0.351 0.018 
X1312 -0.349 0.018 
X625 0.349 0.018 
X766 0.349 0.019 
X1265 -0.348 0.019 
X1284 0.348 0.019 
X1268 -0.346 0.020 
X1314 -0.343 0.021 
X1732 0.342 0.021 
X1155 -0.342 0.022 
X1128 -0.341 0.022 
X1297 0.341 0.022 
X2048 0.340 0.022 
X732 0.340 0.022 
X1287 -0.338 0.023 
X2143 -0.337 0.024 
X1930 0.336 0.024 
X1264 -0.336 0.024 
X2031 0.335 0.024 
X765 0.334 0.025 
X1574 -0.333 0.026 
X1332 -0.331 0.026 
X1283 0.328 0.028 
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X991 0.328 0.028 
X2187 0.328 0.028 
X1561 -0.327 0.029 
X1357 -0.327 0.029 
X2181 -0.326 0.029 
X754 -0.326 0.029 
X1621 -0.326 0.029 
X1313 0.325 0.030 
X652 -0.325 0.030 
X2105 0.323 0.031 
X733 0.322 0.031 
X953 0.322 0.031 
X1273 0.321 0.032 
X740 -0.317 0.035 
X1339 -0.316 0.035 
X1241 -0.316 0.035 
X1237 -0.316 0.035 
X1636 -0.316 0.035 
X1394 0.313 0.037 
X1855 -0.313 0.037 
X925 -0.312 0.038 
X699 -0.312 0.038 
X1792 -0.312 0.038 
X1052 -0.311 0.038 
X746 -0.311 0.038 
X1702 -0.311 0.039 
X2182 -0.309 0.040 
X1333 0.309 0.040 
X1857 -0.308 0.040 
X1315 -0.308 0.041 
X2103 -0.308 0.041 
X1988 0.308 0.041 
X624 0.306 0.042 
X2020 0.306 0.042 
X1730 0.305 0.043 
X1361 -0.305 0.043 
X1408 -0.304 0.043 
X1059 -0.304 0.044 
X1110 -0.304 0.044 
X1953 0.302 0.045 
X653 0.302 0.045 
X1410 -0.301 0.046 
X680 0.301 0.046 
X1508 0.301 0.046 
X805 -0.301 0.046 
X727 0.300 0.047 
X591 0.300 0.047 
X1074 -0.299 0.047 
X1619 -0.299 0.048 
X1966 0.298 0.048 
X2157 0.298 0.048 
X1189 -0.297 0.049 
Table 3-6: Significant T6 partial correlation results for 2DGE spots with PiB PET DVR 



























X558 0.524 0.000 
X527 0.494 0.000 
X1699 -0.461 0.001 
X842 -0.454 0.001 
X808 -0.445 0.001 
X2063 -0.444 0.001 
X1309 -0.422 0.003 
X2267 0.383 0.007 
X1648 -0.383 0.007 
X831 -0.369 0.010 
X1054 -0.363 0.012 
X2177 0.360 0.012 
X1245 -0.360 0.012 
X1833 0.356 0.014 
X1787 0.353 0.014 
X869 -0.351 0.015 
X2209 0.348 0.016 
X815 0.342 0.018 
X875 -0.339 0.019 
X2344 -0.335 0.021 
X2345 -0.332 0.022 
X797 -0.332 0.022 
X1770 -0.331 0.023 
X1660 -0.330 0.024 
X1527 0.327 0.025 
X822 -0.324 0.027 
X1267 -0.322 0.027 
X1941 -0.318 0.029 
X1694 -0.314 0.032 
X1406 0.314 0.032 
X2271 0.312 0.033 
X802 -0.312 0.033 
X1394 0.311 0.034 
X949 0.311 0.034 
X1197 -0.311 0.034 
X1544 -0.310 0.035 
X1917 0.310 0.035 
X1334 -0.309 0.035 
X1619 -0.306 0.038 
X1695 -0.303 0.039 
X1409 -0.303 0.039 
X1763 -0.302 0.040 
X1298 0.300 0.041 
X1257 -0.300 0.042 
X819 0.298 0.043 
X1261 0.298 0.043 
X255 0.297 0.044 
X1615 0.294 0.046 
X1556 -0.294 0.046 
X1365 -0.293 0.047 
X1015 -0.293 0.047 
X791 -0.293 0.047 
X1696 0.291 0.049 
X1495 -0.290 0.050 
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Table 3-7: Significant T12 partial correlation results for 2DGE spots with PiB PET 



























X2143 -0.533 0.000 
X1309 -0.500 0.000 
X630 -0.468 0.000 
X635 -0.439 0.001 
X1110 0.428 0.002 
X598 -0.424 0.002 
X1496 0.424 0.002 
X966 -0.423 0.002 
X1780 0.415 0.002 
X899 -0.410 0.003 
X381 -0.406 0.003 
X1171 -0.398 0.004 
X1500 0.392 0.004 
X589 -0.391 0.004 
X1718 0.390 0.004 
X969 -0.389 0.005 
X2141 -0.388 0.005 
X996 -0.385 0.005 
X1549 0.382 0.006 
X593 -0.380 0.006 
X911 -0.377 0.006 
X584 -0.369 0.008 
X2177 0.366 0.008 
X1015 -0.365 0.009 
X596 -0.364 0.009 
X1377 0.360 0.010 
X1597 0.359 0.010 
X1593 0.359 0.010 
X1557 0.356 0.011 
X386 -0.353 0.011 
X641 -0.353 0.011 
X642 -0.350 0.012 
X1112 0.349 0.012 
X1710 -0.342 0.015 
X1662 -0.340 0.015 
X1303 -0.339 0.015 
X587 -0.337 0.016 
X685 -0.335 0.017 
X629 -0.334 0.017 
X272 -0.331 0.019 
X1399 0.329 0.019 
X2024 -0.329 0.020 
X1929 0.328 0.020 
X2040 -0.327 0.020 
X993 -0.327 0.020 
X2235 0.325 0.021 
X1129 0.322 0.022 
X585 0.321 0.023 
X1170 -0.318 0.024 
X1580 0.317 0.025 
X1738 -0.317 0.025 
X705 -0.315 0.026 
X1172 -0.312 0.027 
X634 -0.311 0.028 
X1963 0.310 0.029 
X1617 0.309 0.029 
X1017 -0.309 0.029 
X1299 0.308 0.030 
X1078 -0.307 0.031 
X1067 -0.303 0.033 
X1402 -0.302 0.034 
X640 -0.299 0.035 
X2214 0.296 0.038 
X1966 0.295 0.038 
X525 -0.293 0.040 
X1762 -0.293 0.040 
X971 -0.292 0.041 
X905 -0.290 0.042 
X1362 0.289 0.043 
X906 -0.289 0.043 
X1367 0.288 0.044 
X1474 0.286 0.045 
X669 -0.286 0.045 
X1071 0.285 0.046 
X654 -0.283 0.047 
X281 -0.283 0.048 
2DGE protein spots significant in the partial correlation were visually re-assessed to 
identify those that would be possible to manually ‘pick’ for later mass spectrometry 
analysis. Spots that were too small or faint to be accurately located by eye were 
removed. After these visual inspections the number of spots remaining was: 53 spots 
for baseline, 6 spots for T6, and 33 spots for T12. These proteins were taken forward 
for further analysis. 
Elastic-net penalised regression model with leave-one-out cross validation 
The remaining significant spots were entered into a penalised elastic-net regression 
model with leave-one-out cross validation. Colinearity is common in 2DGE datasets 
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perhaps as different forms of the same protein may be present within multiple 2DGE 
spots. An elastic-net regression model was chosen as it accounts for multi-colinearity 
between predictors (spots) through encouraging a grouping effect where strongly 
correlated predictors tend to be in or out of the model together. This type of 
regression model also performs well when there are a large number of variables, but 
not a large sample size. For each time point an elastic-net penalised regression model 
with leave-one-out cross validation was performed on the remaining spots with seven 
co-variates included; age, gender, BMI, cholesterol, education (years), APOE ε4 
status, and prediction time (years between plasma sample and PiB PET scan). The 
elastic-net model with the minimum error was selected as the model of interest. 
At baseline the value of lambda which resulted in minimum mean cross validated 
error was 0.025 (see Figure 3-7).  The corresponding regression model included 20 
significant protein spots plus two co-variates; age and APOE ε4 status. The 
regression coefficient values for these variables are displayed in Table 3-8.  
 
Figure 3-7: Graph illustrating baseline elastic-net leave-one-out cross validation 
models. The value of lambda that resulted in minimum mean cross validated error = 
0.025 (logged value = -3.68) 
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Table 3-8: Baseline elastic-net regression model coefficient values for variables 























APOE ε4 0.178 
(Intercept) 1.421 
At T6 the value of lambda which resulted in minimum mean cross validated error 
was 0.007 (see Figure 3-8). The corresponding regression model included 5 
significant protein spots plus all seven co-variates. The regression coefficient values 
for these variables are displayed in Table 3-9. 
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Figure 3-8: Graph illustrating T6 elastic-net leave-one-out cross validation models. The 
value of lambda that resulted in minimum mean cross validated error = 0.007 (logged 
value = -4.958) 
Table 3-9: T6 elastic-net regression model coefficient values for variables included in 










APOE ε4 0.255 
Education 0.013 
Prediction years -0.015 
(Intercept) 1.659 
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At T12 the value of lambda that resulted in minimum mean cross validated error was 
0.029 (see Figure 3-9). The corresponding regression model included 14 significant 
protein spots plus three co-variates; age, APOE ε4 status, and prediction years. The 
regression coefficient values for these variables are displayed in Table 3-10. 
 
Figure 3-9: Graph illustrating T12 elastic-net leave-one-out cross validation models. 
The value of lambda that resulted in minimum mean cross validated error = 0.029 
(logged value = -3.536) 
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Table 3-10: T12 elastic-net regression model coefficient values for variables included in 

















APOE ε4 0.205 
Prediction Years 0.001 
(Intercept) 1.396 
The proteins included in each elastic-net regression model were selected for 
identification with mass spectrometry. Figure 3-10, Figure 3-11, and Figure 3-12 
show the location of the proteins selected and picked for baseline 1, T6 and T12, 
respectively.  
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Figure 3-10: Protein spots related to PiB PET DVR selected for mass spectrometry 
identification at baseline 
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Figure 3-11: Protein spots related to PiB PET DVR selected for mass spectrometry 
identification at T6 
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Figure 3-12: Protein spots related to PiB PET DVR selected for mass spectrometry 
identification at T12 
Multiple linear regression 
To obtain a measure of how well these protein models can predict PiB PET DVR 
multiple linear regressions were performed: 
At baseline the resulting elastic-net regression model of 20 protein spots and 2 
covariates (age and APOE ε4 status) were entered into a multiple linear regression 
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model. Rsquare = 0.828, (F(22,30)=6.575, p<0.001) indicating that this model can 
explain 83% of the variance in PiB PET DVR levels 12 years later.  
At T6 the resulting elastic-net regression model of 5 protein spots and 6 covariates 
(age, gender, education, APOE ε4 status, cholesterol, and prediction years) were 
entered into a multiple linear regression model. Rsquare = 0.527 (F(12,38)=3.524, 
p<0.005) indicating that this model can explain 53% of the variance in PiB PET 
DVR levels 6 years later.  
At T12 the resulting elastic-net regression model of 14 protein spots and 3 covariates 
(age, APOE ε4 status, and prediction years) were entered into a multiple linear 
regression model. Rsquare = 0.898 (F(17,36)=18.728, p<0.001) indicating that this 
model can explain 90% of the variance in PiB PET DVR levels concurrently. 
3.3.6 2DGE analysis of plasma proteins longitudinally associated with brain 
atrophy 
One-way repeated measures ANOVA  
Longitudinal volume data was available for 22 sMRI regions. It was important to 
firstly assess which sMRI regions were significantly changing over time and identify 
the region most interesting for analysis. One-way repeated measures ANOVAs with 
Greenhouse-Geisser corrections were conducted for each of the sMRI regions for all 
68 subjects to determine whether the regions significantly differed at each time point 
and so to identify those that significantly changed over time. Parahippocampal gyrus 
was the only region that did not significantly change over time (p=0.51). The 
remaining 21 regions were found to significantly change over time (p<0.005) and the 
results are reported in Table 3-11 below. 
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Table 3-11: One-way repeated measures ANOVA with a Greenhouse-Geisser 
correction results for 21 sMRI regions to determine whether volumes significantly 
changed over time. Post hoc tests using the Bonferonni correction reveal which time 
points significantly differ. 
sMRI region F value Degrees of 
freedom 
P value Significant post hoc 
comparisons  
 (p<0.05, Bonferonni) 
White Matter 58.934 1.66,69.78 0.001 BASELINE-T6 (p<0.001), 
T6-T12 (p<0.001) 
Grey Matter 131.726 1.47,61.61 0.001 BASELINE-T6  (p<0.001),  
BASELINE-T12 (p<0.001),  
T6-T12 (p<0.001) 
Ventricles 148.477 1.25,52.34 0.001 BASELINE-T6 (p<0.001),  




83.617 2,84 0.001 BASELINE-T6 (p<0.001),  




96.982 1.55,64.98 0.001 BASELINE-T6 (p<0.001),  




91.206 1.59,67.10 0.001 BASELINE-T6 (p<0.001),  




47.953 2,84 0.001 BASELINE-T12 (p<0.001),  
T6-T12 (p<0.001) 








93.355 1.49,62.67 0.001 BASELINE-T6 (p<0.01),  




78.622 2,84 0.001 BASELINE-T6 (p<0.01),  




73.345 1.68,70.53 0.001 BASELINE-T6 (p<0.001),  
BASELINE-T12 (p<0.001),  
T6-T12 (p<0.001) 




4.515 1.72,72.13 0.05 BASELINE-T6 (p<0.05) 
Inferior 
Occipital Gyrus 
6.653 1.60,67.21 0.01 BASELINE- T6 (p<0.05), 
BASELINE-T12 (p<0.01) 
Cingulate Gyrus 93.053 1.54,64.53 0.001 BASELINE-T6 (p<0.001),  
BASELINE-T12 (p<0.001),  
T6-T12 (p<0.001) 
Insula 36.766 2,84 0.001 BASELINE-T12 (p<0.001),  
T6-T12 (p<0.001) 
Wholebrain 171.126 1.63,68.53 0.001 BASELINE-T6 (p<0.001),  
BASELINE-T12 (p<0.001),  
T6-T12 (p<0.01) 








70.146 1.65,69.29 0.001 BASELINE-T6 (p<0.001),  








9.219 1.67,69.96 0.01 BASELINE-T12 (p<0.01),  
T6-T12 (p<0.05) 
Assessing direction and linearity of change 
For each region found to significantly change over time, the mean volume at each 
time point was plotted on a line graph to visually assess direction and linearity of 
change. This assessment was especially important for smaller regions of interest 
(ROIs) where volume identification is more difficult and susceptible to measurement 
error. Five regions had a non-linear change over time; white matter (Figure 3-13), 
temporal white matter (Figure 3-14), orbito frontal gyrus (Figure 3-15), entorhinal 
cortex (Figure 3-16), and insula (Figure 3-17). The remaining 16 regions had a linear 
change over time; grey matter (Figure 3-18), ventricles (Figure 3-19), frontal grey 
matter (Figure 3-20), temporal grey matter (Figure 3-21), medial frontal gyrus 
(Figure 3-22), superior parietal lobule (Figure 3-23), superior temporal gyrus (Figure 
3-24), middle temporal gyrus (Figure 3-24), hippocampus (Figure 3-26), inferior 
occipital gyrus (Figure 3-27), cingulate gyrus (Figure 3-28), wholebrain (Figure 
3-29), superior frontal gyrus (Figure 3-30), middle frontal gyrus (Figure 3-31), 
superior occipital gyrus (Figure 3-32), and middle occipital gyrus (Figure 3-33).  
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Figure 3-13: White matter mean volumes at each time point (1=baseline, 2=T6, 3=T12) 
 
Figure 3-14: Temporal white matter mean volumes at each time point (1=baseline, 
2=T6, 3=T12) 
 
Figure 3-15: Orbito frontal gyrus mean volumes at each time point (1=baseline, 2=T6, 
3=T12) 
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Figure 3-16: Entorhinal cortex mean volumes at each time point (1=baseline, 2=T6, 
3=T12) 
 
Figure 3-17: Insula mean volumes at each time point (1=baseline, 2=T6, 3=T12) 
 
Figure 3-18: Grey matter mean volumes at each time point (1=baseline, 2=T6, 3=T12) 
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Figure 3-19: Ventricular mean volumes at each time point (1=baseline, 2=T6, 3=T12) 
 
Figure 3-20: Frontal grey matter mean volumes at each time point (1=baseline, 2=T6, 
3=T12) 
 
Figure 3-21: Temporal grey matter mean volumes at each time point (1=baseline, 2=T6, 
3=T12) 
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Figure 3-22: Medial frontal gyrus mean volumes at each time point (1=baseline, 2=T6, 
3=T12) 
 
Figure 3-23: Superior parietal lobule mean volumes at each time point (1=baseline, 
2=T6, 3=T12) 
 
Figure 3-24: Superior temporal gyrus mean volumes at each time point (1=baseline, 
2=T6, 3=T12) 
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Figure 3-25: Middle temporal gyrus mean volumes at each time point (1=baseline, 
2=T6, 3=T12) 
 
Figure 3-26: Hippocampus mean volumes at each time point (1=baseline, 2=T6, 3=T12) 
 
Figure 3-27: Inferior occipital gyrus mean volumes at each time point (1=baseline, 
2=T6, 3=T12) 
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Figure 3-28: Cingulate gyrus mean volumes at each time point (1=baseline, 2=T6, 
3=T12) 
 
Figure 3-29: Wholebrain mean volumes at each time point (1=baseline, 2=T6, 3=T12) 
 
Figure 3-30: Superior frontal gyrus mean volumes at each time point (1=baseline, 
2=T6, 3=T12) 
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Figure 3-31: Middle frontal gyrus mean volumes at each time point (1=baseline, 2=T6, 
3=T12) 
 
Figure 3-32: Superior occipital gyrus mean volumes at each time point (1=baseline, 
2=T6, 3=T12) 
 
Figure 3-33: Middle occipital gyrus mean volumes at each time point (1=baseline, 2=T6, 
3=T12) 
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Percentage change over time of sMRI brain regions 
For the 16 regions known to significantly change over time, percentage change was 
calculated and the regions were ranked from largest to smallest change (Table 3-12). 
Ventricles showed the biggest percentage change over time (mean per year = 4.72%), 
which was also considered a biologically significant change ([195]see discussion for 
more detail) and therefore this region was selected as the ROI for subsequent sMRI 
analyses. 
Table 3-12: Percentage change over time (per year) for sMRI regions. sMRI regions 
ranked from largest to smallest percentage change 
sMRI region 
Mean percentage change over 
time (% per year) 
Ventricles 4.72 
Superior parietal lobule 1.61 
Cingulate gyrus 1.41 
Middle frontal gyrus 1.41 
Superior temporal gyrus 1.33 
Superior occipital gyrus 1.09 
Middle temporal gyrus 1.08 
Frontal grey matter 1.07 
Grey matter 1.03 
Superior frontal gyrus 1.00 
Temporal grey matter 0.95 
Medial frontal gyrus 0.93 
Middle occipital gyrus 0.87 
Inferior occipital gyrus 0.80 
Wholebrain 0.54 
Hippocampus 0.25 
Longitudinal analysis: Mixed-effects regression model 
Mixed-effect regression models (MRM) enable longitudinal slope comparisons of 
observations (spot and brain volumes) per individual subject, and then extend these 
comparisons to the whole sample population whilst considering covariates. Here a 
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longitudinal slope comparison between protein spot volume and ventricular 
expansion was conducted per spot (1386) using MRMs with age, gender, education, 
BMI, cholesterol and APOE ε4 status as covariates. MRMs for 35 protein spots 
reported a significant longitudinal relationship with ventricular expansion. These 
significant results are reported in Table 3-13 below, for full results see appendix 4.  
Table 3-13: Mixed-effects regression model results for the 35 protein spots significantly 
longitudinally related to ventricular expansion. 
Spot ID Coefficient p value 
X1595 -5622.09 0.000543 
X1948 -10591.9 0.001269 
X1406 -6316.04 0.003753 
X767 -4875.01 0.004717 
X1068 6049.642 0.00568 
X1586 -4200.86 0.006049 
X1643 5407.359 0.009337 
X1470 -4813.45 0.015904 
X1351 4521.493 0.021022 
X1412 -3934.76 0.021512 
X1590 -3594.51 0.025876 
X865 -5258.35 0.025906 
X2174 4028.063 0.026012 
X988 -4212.2 0.026781 
X471 4921.971 0.027109 
X2292 4607.122 0.028906 
X1435 -3311.15 0.032718 
X1837 4719.904 0.033362 
X1495 -4054.4 0.033829 
X2157 7679.915 0.034074 
X1297 5368.935 0.036631 
X1284 3836.693 0.038436 
X1165 5265.663 0.041349 
X933 -4304.7 0.041744 
X1624 4594.943 0.044159 
X1694 -3550.88 0.045329 
X432 4430.796 0.045723 
X1550 -6216.19 0.046278 
X1689 -3310.46 0.046992 
X1050 6968.624 0.047168 
X1156 4743.363 0.047843 
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X1085 7165.327 0.04795 
X1501 -3377.37 0.048327 
X594 -3201.58 0.049544 
X1022 5436.878 0.049806 
The 35 proteins with a significant longitudinal relationship with ventricular 
expansion were then visually inspected to determine whether they could be 
accurately picked (accurately locate by eye) and identified with mass spectrometry.  
Based on the visual inspection 22 spots were discarded and 13 were taken forward 
for identification (Figure 3-34). 
 
Figure 3-34: 13 protein spots significantly related to ventricular expansion selected for 
identification with mass spectrometry 
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3.3.7 2DGE analysis of plasma proteins longitudinally associated with 
cognitive decline 
One-way repeated measures ANOVA 
Longitudinal cognitive data was available for 12 cognitive measurements. To 
identify which measurements significantly and linearly changed over time one-way 
repeated measures ANOVAs with a Greenhouse-Geisser correction were conducted 
for each of the measurements for all 68 subjects to determine whether the 
measurements significantly differed at each time point. 10 cognitive measures did 
not significantly change over time (p<0.05). Two remaining cognitive measures were 
found to significantly change over time and the results are reported in Table 3-14 
below. 
Table 3-14: One-way repeated measures ANOVA with a Greenhouse-Geisser 
correction results for PMA vocabulary and Trails B test. Post hoc tests using the 
Bonferonni correction reveal which time points significantly differ 
Cognitive 
measure 
F value Degrees of 
freedom 
P value Significant post hoc 
comparisons  
 (p<0.05, Bonferonni) 
PMA vocabulary  3.889 2,122 0.023  
Trails B 10.413 2,120 0.001 BASELINE-T12 (p<0.001),  
T6-T12 (p<0.01) 
Assessing direction and linearity of change 
For the two measures found to significantly change over time the mean cognitive 
score at each time point was plotted on a line graph to visually assess direction and 
linearity of change. This assessment was important for cognitive measurements as 
practice effects may influence results. PMA vocabulary test had a non-linear change 
over time (Figure 3-35). Trails B had a linear change over time (Figure 3-36). 
Although all subjects remained cognitive healthy throughout the study, many 
subjects did change in their Trails B age appropriate percentile membership[196] in a 
negative direction, supporting significant cognitive decline over time (see discussion 
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for more detail). Therefore for the combination of these reasons Trails B was 
selected as the cognitive measure of interest for subsequent analyses. 
 
Figure 3-35: PMA vocabulary mean test scores at each time point (1=baseline, 2=T6, 
3=T12) 
 
Figure 3-36: Trails B mean score at each time point (1=baseline, 2=T6, 3=T12) 
Longitudinal analysis: Mixed-effects regression model 
A longitudinal slope comparison between protein spot volume and Trails B score 
was conducted per spot (total number of spots = 1386) using mixed-effect regression 
models with age, gender, education, BMI, cholesterol and APOE ε4 status as 
covariates. Mixed-effects regression models for 89 protein spots reported a 
significant longitudinal relationship with Trails B decline. These significant results 
are reported in Table 3-15 below, for full results see appendix 5. 
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Table 3-15: Mixed-effects regression model results for the 89 protein spots 
significantly longitudinally related to Trails B. 
Spot ID Coefficient P-value 
X779 -38.8492329 0.000129 
X1138 -22.6147243 0.001265 
X2187 44.18654861 0.0014 
X767 -25.8127413 0.001442 
X1543 -24.764491 0.002762 
X849 -21.3638027 0.00312 
X1307 39.64948297 0.003603 
X1302 35.67988648 0.004902 
X1644 -25.9229164 0.005499 
X2184 30.82080343 0.005551 
X1656 -23.4113819 0.005726 
X1492 -13.7809576 0.006758 
X1368 -16.3115874 0.007011 
X1228 -15.2270665 0.007089 
X1758 34.06306507 0.00758 
X1595 -19.2328974 0.008156 
X2256 26.91087468 0.008471 
X324 21.46611472 0.010289 
X865 -29.0653696 0.011975 
X1639 -19.9488006 0.012429 
X2188 33.83091186 0.01316 
X1538 -26.5877435 0.013985 
X2142 30.02389939 0.014312 
X2111 32.17498689 0.014767 
X1879 21.76259571 0.015948 
X688 -22.5864682 0.016207 
X1095 -25.6577157 0.01682 
X1401 -20.7567029 0.016832 
X1134 29.60979672 0.01701 
X2232 19.88615869 0.017103 
X1037 30.89805589 0.017657 
X1036 10.48178108 0.017812 
X2031 23.28869105 0.017885 
X782 -16.1362958 0.01847 
X2091 15.10258622 0.018686 
X1694 -19.6434596 0.019307 
X682 21.61107032 0.020827 
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X1427 -27.5135054 0.022179 
X1755 32.18365359 0.023301 
X1297 25.36407848 0.024246 
X1359 -16.9147605 0.024872 
X1693 -25.2178795 0.024905 
X1057 -17.2591557 0.025338 
X887 -16.0460346 0.0256 
X2274 -16.9932297 0.026973 
X1590 -15.6650304 0.027109 
X1296 30.42412166 0.027331 
X763 -20.2976746 0.027794 
X2341 16.15078578 0.028154 
X1495 -19.4584054 0.029494 
X1347 -22.9767284 0.029749 
X1511 -22.0383665 0.029792 
X1499 -14.3737404 0.030476 
X804 -19.2768316 0.030818 
X1431 -16.0895998 0.031042 
X1743 16.75944942 0.031338 
X661 19.48381126 0.031421 
X1785 -20.2840052 0.032761 
X1990 16.74274954 0.032982 
X1283 25.48531274 0.034231 
X1640 -17.5831067 0.034311 
X1671 -18.6216857 0.035148 
X1463 -17.197246 0.036268 
X1196 -12.9554852 0.037104 
X1649 -19.6685034 0.037119 
X663 15.35375583 0.038327 
X758 -20.7793545 0.039644 
X1732 27.0881448 0.040093 
X1163 -23.3349569 0.040317 
X1631 -24.5003442 0.041297 
X1153 -22.6541249 0.042028 
X931 12.40310856 0.042028 
X1271 21.49938078 0.042199 
X813 14.51678027 0.042937 
X1459 -15.3047626 0.043009 
X1367 22.66852487 0.044395 
X1022 23.26224815 0.044732 
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X2255 -18.3771034 0.044869 
X2202 -19.0059032 0.046178 
X1516 -19.4738434 0.046449 
X793 -20.0510331 0.047364 
X2210 -21.0433851 0.047386 
X1513 -18.3121775 0.047616 
X2250 -16.7490082 0.048107 
X811 14.1477596 0.049033 
X799 -18.3947516 0.049093 
X1058 -19.7344176 0.049152 
X815 13.96285968 0.049244 
X839 -31.5325736 0.049551 
These 89 proteins with a significant longitudinal relationship with Trails B decline 
were then visually inspected to determine whether they could be accurately picked 
(accurately located by eye) and identified with mass spectrometry. Based on the 
visual inspection 59 spots were removed and 30 were taken forward for identification 
(Figure 3-37). 
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Figure 3-37: 30 protein spots significantly related to Trails B decline selected for 
identification with mass spectrometry 
3.3.8 Mass spectrometry identification and abundance ranking 
Manual spot picking of significant spots was performed as described in the methods 
chapter (chapter 2). The proteins present in a given spot were trypsin digested and 
the peptides subjected to LC-MS/MS where protein identification relies on 
identification of the peptide sequence. An orbitrap velos pro (Thermo Fisher 
Scientific Inc, USA) was used for LC-MS/MS protein identification of picked 2DGE 
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spots. This mass spectrometer has improved sensitivity and resolution compared to 
older models (e.g. LTQ) and therefore a greater amount of data was produced from 
each 2DGE spot. However extracting reliable protein abundance information from 
the produced data remains challenging. Several proteins were identified as present in 
each spot. This presented a challenge to determine the most abundant protein(s) and 
therefore those most likely to be contributing to the statistical signal detected from 
the spot. There are several different analysis approaches to determine protein 
abundance from LC-MS/MS data. Here three approaches to protein abundance 
quantification were considered; peptide spectral matches (PSM, for spectral 
counting), area under the curve (AUC), and unique peptide count.  
Peptide spectral matches (PSM) 
PSMs is the most common approach used for protein quantification for label free 
LC-MS/MS data. This approach uses the number of tandem spectra matched to 
peptides of a certain protein to determine a total spectral count. This count is 
considered to be positively associated with the abundance of the protein and can 
therefore be used as an indicator of relative abundance. Although simple and widely 
used, there are also issues with this approach to be considered. The acquisition of 
spectral counts is highly dependent on the mass spectrometer setup, sample type, and 
complexity[197], and so between study comparisons may be difficult. In addition the 
individual properties of the proteins measured can influence the acquisition through 
factors such as MS/MS fragmentation and precursor competition, leading to 
misestimation of protein abundance. Other factors such as protein load can cause 
issues with spectral counting with higher protein concentrations suffering from 
saturation effects. However PSMs is still an important approach to consider as it is 
quick and simple to employ, also the vast amount of literature utilising this approach 
allows data comparisons. Further supporting its utility here Tabb et al (2010) found 
the statistical analysis of PSMs to be more robust when using orbitrap mass 
spectrometers compared to older LTQ instruments[198]. 
Area under the curve (AUC) 
Top 3 protein quantification (T3PQ) is an AUC approach suggested by Silva et al 
(2006)[199] and can be automatically calculated in proteome discoverer. This 
method suggests that for each protein identified the average signal of the three most 
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efficiently ionised peptides directly correlates to the protein abundance and can 
therefore be used as an indicator of relative abundance of a protein. Grossman et al 
(2010) found that precursor signal intensity based methods including T3PQ are the 
most robust methods of relative quantification and are suitable for complex samples 
with a large dynamic ranges[200]. In T3PQ proteins with less than 2 peptides 
identified are either discarded or the ion score needed to pass the acceptance 
threshold is increased.  
Unique peptide count 
This is a unique approach to apply to 2DGE spot data. It is an approach that is 
specifically tailored for a sample that has undergone separation, such as 2DGE spots 
that have been separated based on their isoelectric point (pI/pH) and their molecular 
weight. Due to this separation all of the proteins in a 2DGE spot have roughly the 
same weight and charge. This method assumes that as the proteins are roughly the 
same weight they also therefore will have similar numbers of amino acids, and 
therefore similar numbers of lysine and arginine frequencies for trypsin to cleave. 
Therefore each protein in a 2DGE spot has roughly the same number of potential 
peptides (Figure 3-38A). As the proteins have similar pIs the ionisation efficiency of 
these peptides will also be similar; while the mass spectrometer is in the positive 
charge mode more acidic peptides ionise less efficiently whilst more basic peptides 
ionise more efficiently. If the number of potential peptides and their ionisation 
efficiency on the mass spectrometer is equivalent then the difference in number of 
unique peptides detected can be said to accurately represent the relative abundance of 
a protein in the gel spot. This is because during within-gel tryptic digest inner 
sections of a protein may have less chance of being cleaved to form peptides. The 
higher the abundance of a protein in the gel the increased chance that these inner-
sections will be cleaved into peptides, resulting in more unique peptides for that 
protein (Figure 3-38B). Although unique peptide count has many assumptions the 
two other approaches for relative abundance detailed above are critically dependent 
upon the performance of the mass spectrometer whereas this approach is less so and 
therefore lesser influenced by liquid chromatography biases. It is also the only 
approach aimed specifically at gel based experiments and so good to consider here. 
Nevertheless the large number of assumptions on which this approach is based 
makes it necessary for other, more traditional, approaches to be considered.  
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Figure 3-38: Assumptions of the unique peptide approach to relative protein 
abundance. A) Proteins within a 2DGE spot have same molecular weight (MW), 
therefore similar numbers of amino acids and so similar frequency of lysine and 
arginines resulting in same number of potential peptides. B) Highly abundant proteins 
have increased chance of tryptic cleavage and so produce larger numbers of unique 
peptides. 
Combining approaches 
The three approaches outlined above do not make full use of the wealth of 
information that is provided by the orbitrap mass spectrometer when considered 
separately, though utilising them in combination may boost efficiency. Here the three 
analysis methods were considered in combination to determine relative protein 
abundance, as described in the methods chapter (chapter 2). Firstly, for each 
approach proteins contributing to less than 5% of a spot’s total protein quantity were 
discarded. This 5% threshold was selected based on the 0.05 statistical threshold 
commonly adhered to; there was a 95% probability that discarded proteins were not 
contributing to the statistical signal from the 2DGE spot. Out of the remaining 
proteins those included in 2/3 of the quantification approaches were considered to be 
abundantly present and were suggested candidates for the statistical signal found 
from that spot, as illustrated in Figure 3-39. This 2 out of 3 approach ensured that if 
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one of the abundance ranking methods was stricter than the others then that one 
method would not dictate the results.  
 
Figure 3-39: '2 out of 3' criteria for proteins ranked as abundantly present within a 
2DGE spot. The tables on the left show proteins ranked as abundant for each method; 
PSM, AUC, and unique peptide count. Proteins ranked as abundant in 2 or more of 
these methods were included in the final list of proteins considered to be abundantly 
present within the 2DGE spot. 
Based on this 2/3 criteria, the tables below detail the proteins found to be abundantly 
present in the 2DGE spots significantly related to PiB PET DVR at baseline (Table 
3-16), T6 (Table 3-17), and T12 (Table 3-18), and those longitudinally related to 
ventricular expansion (Table 3-19), and Trails B decline (Table 3-20). 
Table 3-16: Most abundant proteins identified in baseline 2DGE spots significantly 
related to PiB PET DVR 




Beta-2-glycoprotein 1  
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Fibrinogen beta chain  
Ig gamma-1 chain C region  
X1128 
Fibrinogen gamma chain  
Serum albumin  
X1155 
Fibrinogen gamma chain 
Serum albumin  
X1273 
Alpha-1-antitrypsin  
Apolipoprotein A-IV  
Haptoglobin  








Ig gamma-1 chain C region  
Ig gamma-2 chain C region  
Ig kappa chain C region  
Inter-alpha-trypsin inhibitor heavy chain H4  
X1702 Ig kappa chain C region 
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Serum albumin  
X1730 
Ig kappa chain C region  
Ig lambda-2 chain C regions  
Immunoglobulin lambda-like polypeptide 5  
Serum albumin  
Serum amyloid P-component  
X1792 Apolipoprotein A-I  
X1988 
Alpha-2-macroglobulin  
Serum albumin  
X2020 
Alpha-2-macroglobulin 
Complement C3  
Ig gamma-1 chain C region  









Inter-alpha-trypsin inhibitor heavy chain H4  
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X2157 
Beta-2-glycoprotein 1  
Fibrinogen beta chain  
Ig gamma-1 chain C region  
Ig gamma-2 chain C region  
Serum albumin  
X393 
Alpha-2-macroglobulin  




Ig alpha-1 chain C region  




Serum albumin  
X639 
Alpha-2-macroglobulin  
Complement C3  
Complement component C6  
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Complement C1r subcomponent  
Ig alpha-1 chain C region 
Serum albumin  
X765 
Alpha-2-macroglobulin 
Serum albumin  
 
Table 3-17: Most abundant proteins identified in T6 2DGE spots significantly related to 
PiB PET DVR 
Spot ID Most abundant proteins identified in 2DGE spot 
X1309 
Alpha-2-macroglobulin  
Complement C4-B  
Haptoglobin 








Ig kappa chain C region  
Serum albumin  
X2271 Alpha-2-macroglobulin  
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Ceruloplasmin  
Complement factor H 
Serum albumin  
X949 
Fibrinogen alpha chain 
Serum albumin 
 
Table 3-18: Most abundant proteins identified in T12 2DGE spots significantly related 
to PiB PET DVR 
Spot ID Most abundant proteins identified in 2DGE spot 
X1110 
Fibrinogen beta chain 
Fibrinogen gamma chain  
Ig gamma-1 chain C region 
Ig gamma-2 chain C region  
Serum albumin  
X1170 
Alpha-2-macroglobulin  
Complement C3  
Fibrinogen gamma chain  
Serum albumin  
Serum paraoxonase/arylesterase 1  
X1172 
Alpha-2-macroglobulin  
Fibrinogen gamma chain 
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Serum albumin  
X1303 
Apolipoprotein L1  
Complement C4-A  
Dermcidin  
Haptoglobin  
Serum albumin  
x1309 
Alpha-2-macroglobulin  
Complement C4-B  
Haptoglobin 




Protein AMBP  
X1597 
Alpha-1-antitrypsin 
Alpha-amylase 1  
Annexin A1  
Complement C4-A  
Desmoplakin  
Fibrinogen alpha chain  
Ig gamma-1 chain C region  
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Complement C4-A  
Fibrinogen beta chain  
Ig gamma-1 chain C region  
Ig kappa chain C region  
Ig kappa chain C region  
Ig lambda-2 chain C regions  
Serum albumin  




Apolipoprotein A-I  
Ig kappa chain C region  
Serum albumin  
X381 
Alpha-2-macroglobulin 
Complement C3  
Serum albumin  
X386 Alpha-2-macroglobulin 






Ig alpha-1 chain C region 




Complement component C6 
Serum albumin  
 
Table 3-19: Most abundant proteins identified in each 2DGE spot significantly related 
to ventricular expansion 
Spot ID Most abundant proteins identified 
X1022 
Alpha-1-antitrypsin 




Ig alpha-1 chain C region 
Ig alpha-2 chain C region  
Serum albumin  
X1085 Fibrinogen beta chain  
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Ig gamma-1 chain C region  
X1284 
Alpha-2-macroglobulin  
Apolipoprotein A-IV  
Haptoglobin 
Serum albumin  
Serum paraoxonase/arylesterase 1  
X1297 





Haptoglobin-related protein  




Serum albumin  
X1590 
Complement C4-A  
Fibrinogen beta chain 
Haptoglobin  
Ig gamma-2 chain C region  
Protein AMBP 
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Complement C4-A  





Beta-2-glycoprotein 1  
Fibrinogen beta chain  
Ig gamma-1 chain C region  
Ig gamma-2 chain C region  
Serum albumin  
X594 
Alpha-2-macroglobulin  
Complement C3  
Haptoglobin  





Fibrinogen alpha chain  




Table 3-20: Most abundant proteins identified in each 2DGE spot significantly related 
to Trails B decline 
Spot ID Most abundant proteins identified in 2DGE spot 
X1022 
Alpha-1-antitrypsin 
Ig alpha-1 chain C region  
X1057 
Ig alpha-1 chain C region  
Haptoglobin 
Alpha-1-antitrypsin  




Complement C3  





Serum paraoxonase/arylesterase 1  
Fibrinogen gamma chain  
Serum albumin 
  135 
  
Ig alpha-1 chain C region 
Alpha-1-antitrypsin 
X1163 





Serum paraoxonase/arylesterase 1 
Haptoglobin 
Ig alpha-1 chain C region 
Serum albumin  






Sex hormone-binding globulin  
Complement C3  
Complement C4-A  
Ig gamma-1 chain C region  
Serum albumin 
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Serum paraoxonase/arylesterase 1  
Apolipoprotein A-IV  
X1296 
Haptoglobin  
Ig alpha-1 chain C region  
Serum albumin  
X1297 







Complement C3  
X1307 
Haptoglobin  
Serum albumin  
Complement C3  
Serum paraoxonase/arylesterase 1  
X1368 Complement C3  
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Clusterin  
Ig kappa chain C region  
X1499 
Haptoglobin  
Inter-alpha-trypsin inhibitor heavy chain H4  
Apolipoprotein A-I  
Clusterin 
Complement C3  
Serum paraoxonase/arylesterase 1  
Serum albumin  
X1590 
Complement C4-A  
Fibrinogen beta chain 
Haptoglobin  
Protein AMBP 
Ig gamma-2 chain C region  
Serum albumin  
X1631 
Haptoglobin 
Ig kappa chain C region  
Serum albumin  
Complement C3  
X1732 Ig kappa chain C region  
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Serum amyloid P-component  
Ig kappa chain V-IV region Len  
Ig kappa chain V-III region SIE  
Apolipoprotein A-I  
Serum albumin  
X1755 
Ig kappa chain C region  
Serum albumin 
Apolipoprotein A-I  
Haptoglobin  
Fibrinogen gamma chain  
X1990 





Serum albumin  
Inter-alpha-trypsin inhibitor heavy chain H4  
X2091 
Complement C4-A  
Serum albumin  
Complement C3  
X2142 Ig alpha-1 chain C region  
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Haptoglobin  
Ig alpha-2 chain C region  
Serum albumin  
X2184 
Haptoglobin  
Serum albumin  




Serum albumin  
Complement C3  
X2256 
Ig kappa chain C region  




Ig gamma-1 chain C region  
Complement C3 
Ig gamma-2 chain C region  
Haptoglobin  
Serum albumin  
X663 Serum albumin  
  140 
  
Plasminogen  








Ig mu chain C region 
X887 
Complement C3  
Serum albumin 
A summary of the proteins related to PiB PET DVR at baseline, T6, and T12, 
ventricular expansion, and Trails B decline are summarised in Table 3-21, Table 
3-22, Table 3-23, Table 3-24, Table 3-25 below, respectively.  
Table 3-21: Summary of proteins related to PiB PET DVR at baseline 
Protein No. of 2DGE spots 
Alpha-1-antitrypsin 4 
Alpha-2-macroglobulin 11 
Apolipoprotein A-I  1 
Apolipoprotein A-IV  1 
Beta-2-glycoprotein 1  2 
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Ceruloplasmin  3 
Complement C1r subcomponent  1 
Complement C3 4 
Complement component C6  1 
Fibrinogen beta chain  2 
Fibrinogen gamma chain 2 
Haptoglobin  3 
Ig alpha-1 chain C region 2 
Ig gamma-1 chain C region  4 
Ig gamma-2 chain C region 3 
Ig kappa chain C region 4 
Ig lambda-2 chain C regions  1 
Immunoglobulin lambda-like polypeptide 5  1 
Inter-alpha-trypsin inhibitor heavy chain H4  3 
Serum albumin 15 
Serum amyloid P-component  1 
 
Table 3-22: Summary of proteins related to PiB PET DVR at T6 
Protein No. of 2DGE spots 
Alpha-2-macroglobulin 4 
Apolipoprotein A-I 1 
  142 
  
Ceruloplasmin  1 
Complement C4-B  1 
Complement factor H 1 
Fibrinogen alpha chain 1 
Haptoglobin 1 
Ig kappa chain C region  1 
Protein AMBP 1 
Serum albumin 5 
 
Table 3-23: Summary of proteins related to PiB PET DVR at T12 
Protein No. of 2DGE spots 
Alpha-1-antitrypsin 7 
Alpha-2-macroglobulin 8 
Alpha-amylase 1  1 
Annexin A1  1 
Apolipoprotein A-I  1 
Apolipoprotein L1  1 
Complement C3 3 
Complement C4-A  3 
Complement C4-B  1 
Complement component C6 1 
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Dermcidin  1 
Desmoplakin  1 
Fibrinogen alpha chain  1 
Fibrinogen beta chain 2 
Fibrinogen gamma chain 3 
Haptoglobin 2 
Ig alpha-1 chain C region 1 
Ig gamma-1 chain C region 3 
Ig gamma-2 chain C region  1 
Ig kappa chain C region  4 
Ig lambda-2 chain C regions  1 
Protein AMBP  1 
Serum albumin 11 
Serum amyloid P-component  1 
Serum paraoxonase/arylesterase 1  1 
 
Table 3-24: Summary of proteins related to ventricular expansion 
Protein No. of 2DGE spots 
Alpha-1-antitrypsin 2 
Alpha-2-macroglobulin 7 
Apolipoprotein A-IV  2 
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Beta-2-glycoprotein 1  1 
Ceruloplasmin  1 
Complement C3 2 
Complement C4-A  2 
Fibrinogen alpha chain  1 
Fibrinogen beta chain 3 
Haptoglobin 5 
Haptoglobin-related protein  1 
Ig alpha-1 chain C region 3 
Ig alpha-2 chain C region  1 
Ig gamma-1 chain C region  2 
Ig gamma-2 chain C region  2 
Protein AMBP 1 
Serum albumin 10 
Serum paraoxonase/arylesterase 1  1 
Zinc-alpha-2-glycoprotein  2 
 
Table 3-25: Summary of proteins related to Trails B decline 
Protein No. of 2DGE spots 
Alpha-1-antitrypsin 4 
Alpha-2-macroglobulin 6 
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Antithrombin-III  2 
Apolipoprotein A-I  4 
Apolipoprotein A-IV  3 
Ceruloplasmin  1 
Clusterin 2 
Complement C3 14 
Complement C4-A  4 
Fibrinogen beta chain 1 
Fibrinogen gamma chain  4 
Haptoglobin 19 
Ig alpha-1 chain C region  6 
Ig alpha-2 chain C region  1 
Ig gamma-1 chain C region  3 
Ig gamma-2 chain C region  2 
Ig kappa chain C region  5 
Ig kappa chain V-III region SIE  1 
Ig kappa chain V-IV region Len  1 
Ig mu chain C region 1 
Inter-alpha-trypsin inhibitor heavy chain H4  2 
Plasminogen  3 
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Protein AMBP 1 
Serotransferrin 2 
Serum albumin 25 
Serum amyloid P-component  1 
Serum paraoxonase/arylesterase 1  5 
Sex hormone-binding globulin 1 
Zinc-alpha-2-glycoprotein 3 
3.3.9 Assessing dependant variable relationship 
There was large overlap in proteins found to be related to all three dependant 
variables (PiB PET DVR, ventricular expansion, and Trails B decline). Therefore the 
relationship between the dependant variables was assessed to see whether the 
protein-DV relationship was reflecting the same pattern for each DV. Pearsons 
correlation coefficient revealed that there was no correlation between PiB PET DVR 
and ventricle size or between PiB PET DVR and Trails B at any time point (p<0.05). 
No correlation was also found between rate of decline for Trails B and rate of 
ventricular expansion. Though when correlating ventricle size and Trails B score at 
each time point a moderate positive correlation was found at T12 (r=0.35, p<0.05) 
(Figure 3-40). No significant correlation was found between ventricle size and Trails 
B score at baseline or T6 (p>0.05). 
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Figure 3-40: Pearsons correlation between ventricle size and Trails B score at T12 
(r=0.35, p<0.05) 
3.4 Discussion 
3.4.1 Two dimensional gel electrophoresis experimental performance and 
analysis 
This study utilised a well established proteomic discovery tool; two dimensional gel 
electrophoresis. It is known that technical variability can be high in 2DGE 
experiments. For this reason samples were run in duplicate and the coefficient of 
variation (CV) was determined to indicate the level of analytical variance achieved. 
The overall CV was 33.5%, this was deemed acceptable as previous reports of 2DGE 
variance in the literature suggest an approximate normal range to be 16-40%[192-
194]. However to further improve the quality of the data a clean-up was conducted to 
remove individual data points where the CV of duplicates exceeded the 40% 
‘normal’ threshold. Therefore a good level of data quality was achieved and 
statistical analysis was conducted with confidence. 
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A comparison of the CV achieved between time points revealed a sample storage 
effect on the 2DGE technique. 2DGE had increased experimental performance for 
samples that had been stored for less time, shown by a decreased CV between sample 
replicates at the most recent time point. This is an interesting point to consider for 
future experiments, including other proteomic techniques, especially retrospective 
studies that aim to use samples stored for many years to predict current events such 
as conversion to disease or rate of decline. This prediction may be influenced by 
sample age and must be considered. Predictive biomarker abilities are often 
discovered in stored samples and it may be interesting to compare how these 
biomarkers perform when obtained from a fresh/recent sample.  
2DGE involves many steps for which different protocols or analysis techniques can 
be used. For example, there are many staining techniques available each with their 
own strengths and weaknesses. Here 2DGE was conducted using a silver staining 
protocol. Silver stain has a limited dynamic range, poor stoichiometry, and involves 
multiple steps during which subtle differences in timing can contribute to between-
gel variability. This method does however have high sensitivity, is relatively cheap 
compared to other methods, and it allows gel scanning using a standard desktop 
scanner. Silver stain was chosen as the most appropriate staining method for this 
study due to equipment availability and cost. As samples were completed in 
duplicate, staining related variability could be monitored and gels were repeated if 
visual inspection was not satisfactory (e.g. saturation or high background staining). 
Once stained the gels were scanned and digital gel images were pre-processed for 
statistical analysis using Progenesis SameSpots. Progenesis SameSpots is one of 
many commercially available 2DGE analysis software packages. Reports comparing 
these packages show that Progenesis SameSpots performs well, especially in spot 
matching accuracy [201-202]. 
Another step for which there were many options was the analysis of protein 
abundance within a 2DGE spot. Here a novel approach for determining protein 
abundance using LC-MS/MS data was presented. This approach combined three 
current methodologies; peptide spectral matches, area under the curve, and unique 
peptide count. Proteins that were ranked as highly abundant (>5% contribution to the 
spot) in at least 2 out of these 3 approaches were considered to be abundant. Using 
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this 2 out of 3 criteria ensured that the results were not biased towards one method, 
which may be stricter than the other methods. The three approaches often ranked 
proteins differently based on abundance, highlighting that 2DGE experiments cannot 
be compared if this analysis step differs. ‘Unique peptide count’ was the most 
relaxed of the ranking methods and resulted in a larger number of abundant proteins 
per spot. Whereas ‘Area under the curve’ was the strictest method tending to only 
rank one or two proteins as abundant per spot. Using the combination of the three 
approaches allowed their strengths to be combined and individual weaknesses to be 
diluted. Until a definitive way in which protein abundance can be ranked is 
determined it is important to consider as much information in your analysis as 
possible at this stage. The limitation to this approach was that more proteins per spot 
were considered to be abundant than usually presented in 2DGE experiments. The 
use of an orbitrap mass spectrometer, with improved sensitivity compared to older 
models, will have also contributed to this. This presented a problem when 
determining which abundant protein(s) may be producing the statistical signal 
detected, and it was decided to consider all abundant proteins in a spot as candidate 
biomarkers. Although this increases the number of false positive biomarkers found it 
also ensures true positives remain in contention. As a discovery experiment, ensuring 
that all true biomarkers are identified is the main concern. Validation experiments are 
necessary to confirm biomarker utility of the candidates, and discard any false 
positive findings. Furthermore, lack of false discovery rate (FDR) significance 
thresholds throughout this study will also increase the number of false positive 
findings reported. FDRs were not considered here due to the vast amount of 
statistical tests performed that would result in extremely few 2DGE spots passing an 
FDR correction. An uncorrected 0.05 p-value was considered an acceptable 
significance level for this discovery stage experiment, with subsequent validation 
experiments important to confirm true positives and discard false positive findings.  
3.4.2 Selecting measures of cognitive decline and brain atrophy 
A limitation of 2DGE here was that the number of spots that could be picked for LC-
MS/MS protein identification was limited by time and cost. This restricted the 
amount of analysis that could be completed. Here, data was available for 22 
structural MRI regions and 12 cognitive measures, though due to time and cost only 
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the singular most interesting and relevant sMRI region and cognitive measure were 
selected to be used for analysis. This was done by identifying which sMRI regions 
and cognitive measures were significantly changing over time and were therefore 
most relevant to include in a longitudinal analysis. Linearity of change was also 
assessed as the statistical tests used only considered linear change.  
16 sMRI regions showed significant, and linear, atrophy over the 12 year period 
measured in these healthy individuals. Of these the ventricles were shown to have the 
greatest percentage change per year and were therefore selected as the single region 
of interest for further analysis. Ventricular expansion reflects atrophy of the 
surrounding brain regions; for example the temporal horn of the ventricles lies next 
to the hippocampus and so will reflect hippocampal atrophy. Deficits in many 
functions associated with the surrounding regions (e.g. memory) may therefore be 
reflected in ventricular expansion. Longitudinally, ventricular expansion has been 
found as an excellent marker of change over time in cognition, disease status and 
severity, outperforming other MRI regions including the hippocampus[195, 203-
205], although the hippocampus does outperform in cross sectional studies. Perhaps 
this is due to an increased ability of the ventricles to reflect changes in multiple 
cognitive domains over time. Additionally with continued cognitive decline 
ventricular expansion will continue to increase, whereas hippocampal atrophy will 
plateau. The focus of this investigation was longitudinal measures of change and 
therefore ventricular expansion was very appropriate. Furthermore along with the 
hippocampus and the entorhinal cortex, ventricles have been identified as one of the 
first brain regions affected in dementia and so it is a logical area to investigate in 
preclinical AD subjects. Higher ventricular expansion has been reported in healthy 
subjects who converted to MCI or AD compared to those that remain stable[203, 
206] showing its utility in preclinical AD studies. Carlson et al, (2008)[195] reported 
ventricular expansion rates in healthy individuals aged 75-95 vary according to 
future diagnosis. Individuals who remained stable at follow-up were found to have 
expansion rates of 3-4.1% per year, 2.4-5.6% for those who converted to MCI over 
2.3 years later, and 4.9-8.7% for those who converted to MCI within 2.3 years[195]. 
In this study ventricular expansion rates ranged from 0.35-13.96% per year, with a 
mean of 4.72%, although individuals included here were younger (age range = 57-
81). Compared to Carlson et al (2008) these rates of ventricular expansion indicate 
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that the change measured in these individuals is biologically significant. For these 
reasons the inclusion of ventricles as the measure of brain atrophy was a confident 
selection, backed up by statistics and previous literature.  
Trails B was the only cognitive measure that changed significantly and linearly over 
time, and was selected as the measure by which cognitive decline would be 
determined for this study. Trails B is one of two parts of the Trails Making Test, a 
commonly used clinical tool, and is a measure of executive function [207]. In the 
Trails B task subjects have to connect-the-dots of 25 targets of alternative numbers 
and letters in sequence (1, A, 2, B, etc.) (Figure 3-41). The goal is to finish the test as 
quickly as possible and time taken to complete it is used as the performance 
measurement.  
 
Figure 3-41: Trails B task: subjects have to connect the circles in sequence; 1, A, 2, B, 
etc. 
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Tombaugh (2004)[196] present normative percentile data for Trails B performance 
(time) for community dwelling individuals, stratified for both age (in 5 year 
increments) and education (<12 years and >12 years in education). For an example 
see Table 3-26: Trails B percentiles for subjects aged 75-79 years, taken from 
Tombaugh (2004). Using these norms as a guideline, many individuals in our study 
remained in the same percentile over time, and even a handful improved showing 
less than expected cognitive decline with age. However 1/3 of the cohort decreased 
in their percentile group membership from baseline to T12 (average = 22% 
decrease). This indicates that in this cohort many individuals showed cognitive 
decline at a faster rate than you would expect merely from an increase in age. 
Table 3-26: Trails B percentiles for subjects aged 75-79 years, taken from Tombaugh 
(2004) 
Percentiles (for 
individuals aged 75-79) 
Education 0-12 years, 
Trails B time (seconds) 
Education 12+ years, 
Trails B time (seconds) 
90 78 57 
80 92 59 
70 96 66 
60 107 73 
50 120 87 
40 140 106 
30 456 126 
20 167 141 
10 189 178 
Executive function is known to be an early indicator of dementia and like memory it 
is one of the first functions to show deterioration[69, 208]. In particular executive 
function tasks like Trails B which include set shifting, sequencing, and self-
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monitoring are particularly impaired early on in the disease[209]. Trails B has 
previously been shown to predict group membership of healthy individuals based on 
cognition and disease outcomes 3 years later[210] indicating its utility as an early 
preclinical marker. For these reasons, in addition to showing the greatest change over 
time, Trails B was considered a good cognitive measure to utilise here to find 
markers of longitudinal cognitive decline in healthy individuals. 
3.4.3 Dependent variable relationship 
Many of the same proteins were found to be significantly related to all three 
dependent variables (PiB PET DVR, brain atrophy, and cognitive decline). An 
analysis, conducted to determine whether the protein-DV relationship was reflecting 
the same pattern for all three DVs, revealed that there was very minimal correlation 
between the three DV measures. Only a moderate correlation was found between 
ventricle size and Trails B at T12, but no other correlations were reported between 
any DV at any time point. This suggests that either the sensitivity of these measures 
differ or perhaps different forms of the same protein are related to the three DVs. The 
latter is supported by the varied gel locations for many proteins, indicating protein 
modification or cleavage, discussed further below.  
The finding that the three DVs are, on the whole, not correlated to one another also 
provides insights into the onset of AD pathology and cognitive decline in preclinical 
AD. These results suggest that, at least initially, larger brain atrophy does not 
significantly reflect poorer cognition, and that their onset and initial developments 
are independent of one another. Though it is important to consider compensatory 
mechanisms for cognitive functions may influence these results. Although data for 
amyloid load was only available at the final time point, the results also suggest that 
brain atrophy and cognitive decline are independent of increased amyloid deposition, 
at this assumed preclinical stage. Jack et al, (2010 and 2013) presented a temporal 
model of AD in which amyloid accumulation occurs first, followed by brain atrophy, 
and finally cognitive impairment[70-71]. However later in 2013 they also presented 
evidence showing that approximately half of the individuals measured that were 
‘amyloid PET positive’ had evidence of neurodegeneration prior to amyloid 
positivity, whereas the other half reached amyloid positivity prior to brain 
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abnormalities[211]. This finding of both amyloid-first and neurodeneration-first 
profiles in preclinical AD shows that individuals may reach a clinical AD diagnosis 
via different pathways. Perhaps this explains why hardly any correlation was 
reported between the three DVs in this study. Nevertheless this finding is still 
surprising, and likely also reflects heterogeneity within the cohort.   
3.4.4 Candidate biomarkers of all three markers of AD 
Many candidate biomarkers of AD pathology and cognitive decline were identified 
here. Of these 14 proteins were found as candidate biomarkers for all three markers 
of AD. These 14 proteins are therefore very strong biomarker candidates for 
preclinical AD and are discussed below.  
Alpha-2-macroglobulin (α2M) 
α2M is a large, major circulating protease inhibitor known to block a wide variety of 
proteases, regulate the immune response[212], and is released in response to 
inflammatory stimuli[213]. Here α2M was found to be significantly related to all 
three markers of AD, including PiB PET DVR at every time point (Table 3-27). 
Literature shows strong links between α2M and AD; it has been shown to be present 
in senile plaques in AD[214], binds to beta-amyloid1-42[215-216], attenuates 
fibrillogenesis and neurotoxicity of beta-amyloid[215-216], though has also been 
found to mediate beta-amyloid degradation and clearance[217-218]. Genetic 
variation in the A2M gene has been linked to an increase in AD risk[219-220] and it 
has also been suggested that α2M is a sex-specific biomarker strongly correlating 
with female AD progression but not with males[221]. α2M has also previously been 
found as an AD biomarker using 2DGE; Hye et al (2006)[142], and Thambisetty et al 
(2008)[149] reported plasma α2M as a biomarker of disease status and hippocampal 
metabolism, respectively. Other studies using various proteomic platforms have 
identified plasma α2M as an AD biomarker. In fact α2M is one of the most 
reproducible plasma protein markers of AD, associating with AD-related phenotypes 
in five independent cohorts across 21 studies[188]. With all of these possible links it 
is likely that α2M is also implicated in the early stages of the disease, as the results 
here suggest. 
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Table 3-27: α 2M summary; number of significant 2DGE spots in which α2M was 
present for each surrogate marker of AD, and their coefficient directions 
PiB PET DVR Longitudinal measures: 
Baseline T6 T12 Trails B Ventricles 
11  4 8  6 7 
For each surrogate marker of AD α2M was found in multiple spots and showed both 
positive and negative relationships with pathology. A similar finding was reported by 
Zabel et al (2012)[222] who found A2M to have a significant negative relationship 
with disease status when measured by ELISA, though a significant positive 
relationship when measured by LC-MS/MS. They explain this as sensitivity 
differences between the two methods. It is likely that both approaches yield correct 
results and are measuring different parts or forms of the same protein. Additionally 
Sui et al (2014)[223] also reported this discrepancy in serum from triple transgenic 
mice (PS1M146V/APPSwe/TauP301L); certain isoforms of α2M were decreased 
whilst others were significantly elevated when compared to wild type mice. They 
suggest that this may be due to differences in post-translational modifications. Visual 
inspection of the 2DGE gel may allow an insight into this suggestion; significant 
spots containing α2M were found at various molecular weights and pIs indicating 
α2M modifications, or fragments, are present (Figure 3-42). 
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Figure 3-42: 2DGE spots containing α2M which are longitudinally related to: A) 
Ventricular expansion, B) Cognitive decline (Trails B). Positive and negative signs 
indicate the direction of the statistical relationship reported.  
Opposite coefficient directions between 2DGE spots containing the same protein was 
not limited to α2M and was found for many proteins discussed below. It is therefore 
likely that these other results are also a consequence of protein modifications and/or 
cleavage. Therefore such results may not be conflicting, but instead reflect the 
strength of the 2DGE technique in detecting and measuring many different forms of 
a singular protein in one experiment. 
Serum albumin 
Serum albumin is the most abundant protein in human plasma, and unsurprisingly it 
was the most commonly identified protein in this study, present in 66 significant 
spots and related to all three DVS. Serum albumin is known to be involved in many 
functions including transportation of hormones, fatty acids, drugs, and metabolites, 
and maintaining oncotic pressure. Serum albumin is also commonly used as a 
biomarker of blood-brain-barrier (BBB) integrity, with an increase of albumin in 
CSF reflecting BBB disruption[104]. In AD various protective mechanisms of 
albumin have been suggested including preventing oxidative damage, binding beta 
amyloid for clearance, and preventing misfolding and aggregation of proteins such as 
beta amyloid[224-225]. Serum albumin often appears as a biomarker candidate for 
AD[142, 151, 226], though due to its high abundance it is difficult to determine its 
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validity as it is sometimes considered to contaminate findings and mask other 
biomarkers.  
Table 3-28: Serum albumin, summary; number of significant 2DGE spots in which 
serum albumin was present for each surrogate marker of AD, and their coefficient 
directions 
PiB PET DVR Longitudinal measures: 
Baseline T6 T12 Trails B Ventricles 
15  5 11 25 10 
Serum albumin was found in many spots located throughout the gel, indicating the 
presence of modifications/fragments. Recently, Ramos-Fernandez et al, (2014) found 
albumin is significantly glycated and nitrated in both plasma and CSF of AD patients 
compared to controls[225]. These modifications resulted in changes in the 
physiological properties of albumin; it was more prone to aggregation, and it also 
was found to bind significantly more beta amyloid. The results here suggest serum 
albumin may be a longitudinal biomarker of preclinical AD, perhaps in a native or 
modified form. 
Immunoglobulins; Ig alpha-1 chain C region, Ig gamma-1 chain C region, and 
Ig gamma-2 chain C region 
Like serum albumin, immunoglobulins (IgGs) are abundantly present in human 
plasma, and also like albumin IgGs were found to be present in numerous 2DGE 
spots significantly related to AD pathology and cognitive decline. Three IgGs were 
consistently identified and were shown to be related to all three DVs; Ig gamma-1 
chain C region, Ig gamma-2 chain C region, and Ig alpha-1 chain C region (Table 
3-29). Immunoglobulins are found abundantly present in AD brains; diffusely 
present in brain tissue, connected to amyloid (in plaques and vessels), and in glial 
cells and neurons. Certain IgGs, have been reported to possess anti-amyloidogenic 
properties and are considered to have therapeutic potential [227]. Ig gamma-1 chain 
C region and Ig alpha-1 chain C region have previously been reported as a biomarker 
of AD diagnosis [142] and Ig gamma-1 chain C region has also been found as a 
predictive biomarker of amyloid load in preclinical AD[151]. These results support 
  158 
  
the biomarker abilities of IgGs in the early stages of AD, and provide further support 
to claims that AD may be an autoimmune disease[228].  
Table 3-29: Immunoglobulins summary; number of significant 2DGE spots in which 
immunoglobulins were present for each surrogate marker of AD, and their coefficient 
directions 
 PiB PET DVR Longitudinal 
measures: 
 Baseline T6 T12 Trails B Ventricles 
Ig alpha 1 chain C region 2  1 6 3 
Ig gamma 1 chain C region 4  3 3 2 
Ig gamma 2 chain C region 3  1 2 2 
Complement C3 & C4a 
The complement is an important system in both the innate and adaptive immune 
system, and has been previously associated with many neurodegenerative diseases 
including Alzheimer’s disease. The complement system is divided into three 
pathways; classical, alternate and the mannose-binding lectin (MBL) pathway. The 
classical pathway primarily acts to lyse cells and bacteria already recognised and 
opsonised by plasma antibodies as well as targeting these cells for immunological 
clearance. The alternate pathway acts independently of plasma antibodies and binds 
to cells and bacteria that do not express complement decay accelerating factor 
(DAF). The MBL pathway recognises lectins and ficolins, common bacterial surface 
proteins, and acts primarily to lyse bacteria and target them for immunological 
clearance. Complement C3 is a central component in the complement system, linking 
all three of these complement pathways (see Figure 3-43).  
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Figure 3-43: Basic illustration of proteins involved in the three complement pathways. 
Colour coded proteins are those found in this study to be candidate biomarkers 
Here C3 was found to be significantly related to all three DVs (see Table 3-30). C3 is 
one of the most common proteins to be reported as an AD biomarker[188] and, like 
the findings shown here, both positive and negative associations of C3 and AD 
pathology have been reported in the literature. For example; plasma levels of C3 
have been found to associate with brain amyloid burden both positively[150] and 
negatively[151]. Studies showing a negative relationship between C3 levels and 
disease severity suggest a protective role of C3[222]. Maier et al, (2008) investigated 
this using a complement C3-deficient amyloid precursor protein (APP) transgenic 
AD mouse model and found a beneficial role of C3 in plaque clearance and neuronal 
health, with decreased C3 levels leading to accelerated beta amyloid deposition and 
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neurodegeneration[229]. Other results conflict this protective hypothesis and indicate 
a detrimental association with increased C3; both Thambisetty et al (2011) and 
Zhang et al, (2004) reported elevated C3 levels in AD patients relative to 
controls[148, 230].  
Table 3-30: Complement C3 summary; number of significant 2DGE spots in which C3 
was present for each surrogate marker of AD, and their coefficient directions 
PiB PET DVR Longitudinal measures: 
Baseline T6 T12 Trails B Ventricles 
4  3 14 2 
C4a, involved in both the classical and lectin pathway, is an anaphylatoxin product of 
the complement cascade. Here C4a was found to be associated with all three DVs 
(Table 3-31). Like C3 C4a has also been reported as an AD biomarker previously. 
Here both positive and negative directions with DV were observed for this protein, 
though the literature mainly supports a positive relationship; Increased plasma levels 
of C4a have been found in AD patients compared to controls[231]. This increase has 
also been seen in CSF of AD patients compared to controls, and also compared to 
patients with vascular dementia[232].  
Table 3-31: Complement C4a summary; number of significant 2DGE spots in which 
C4a was present for each surrogate marker of AD, and their coefficient directions 
PiB PET DVR Longitudinal measures: 
Baseline T6 T12 Trails B Ventricles 
  
3 4 2 
Other complement proteins were found to be related to one or two DVs; C1r, Factor 
H, C6, C4b, and clusterin. Together these results suggest that the complement 
cascade in the periphery is broadly altered in AD, and effects are not limited to one 
specific complement pathway. These results support findings which indicate 
complement proteins as AD biomarkers, whilst also providing evidence of their 
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longitudinal utility as biomarkers in preclinical AD. In addition to the periphery, 
other studies reporting multiple complement proteins as AD biomarkers show that 
this broad complement alteration may also be occurring in the CNS[233-234]. 
Complement proteins show large potential to be used as early blood based 
biomarkers. However these proteins are known to be particularly susceptible to 
sample preparation and storage[188, 235], which can vary between research centres 
and may therefore impede further research. Additionally the study of complement 
proteins in relation to AD can be complicated by other inflammatory comorbidities 
that are commonly found in the elderly population.  
Alpha-1-antitrypsin (AAT) 
Alpha-1-antitrypsin (AAT) is a serine protease inhibitor involved in controlling 
proteases during inflammation, coagulation, and fibrinolysis[236]. It has previously 
been identified as an AD biomarker in a number of studies[150, 237] with higher 
AAT levels reported in AD plasma and CSF compared to controls[237-238]. In fact 
AAT is one of the most replicated plasma based AD biomarkers[188]. 
Unsurprisingly then in this study AAT was one of the most commonly detected 
proteins in significant 2DGE spots, abundantly present in 17 spots throughout the 
study and associating with all three DVs (Table 3-32). Increased AAT in its oxidised 
form has previously been found in AD plasma, showing that specific isoforms of 
AAT may have biomarker ability[239-240], a feature that is also supported by the 
varied locations of 2DGE spots in which this protein was detected. Further 
implicating AAT in AD immunocytochemistry has located AAT in both 
neurofibrillary tangles and senile plaques in AD brain tissue[241]. This suggests 
AAT may be functionally involved in AD pathology. Here AAT is found related to 
very early AD pathology (amyloid burden and brain atrophy) and cognitive decline, 
suggesting any AD related function of the protein occurs at an early stage. 
Table 3-32: Alpha-1 antitrypsin summary; number of significant 2DGE spots in which 
AAT was present for each surrogate marker of AD, and their coefficient directions 
PiB PET DVR Longitudinal measures: 
Baseline T6 T12 Trails B Ventricles 
4  7 4 2 
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Fibrinogen 
2DGE spots significantly related to fibrinogen were found for all three DVs. This 
included a significant relationship at all three time points for PiB PET DVR, 
indicating a longitudinal relationship to all three DVs; amyloid load, cognitive 
decline, and brain atrophy. Fibrinogen consists of three chains; β, α, and γ. 
Fibrinogen β-chain was found in spots related to all three DVs, whereas fibrinogen 
α-chain and γ-chain were found to be related to only two DVs(Table 3-33). All three 
chains were related to amyloid load.  
Table 3-33: Fibrinogen summary; number of significant 2DGE spots in which 
fibrinogen was present for each surrogate marker of AD, and their coefficient 
directions 
 
PiB PET DVR Longitudinal measures: 
 
Baseline T6 T12 Trails B Ventricles 
Fibrinogen α-chain  1 1  1 
Fibrinogen β-chain 2  2 1 3 
Fibrinogen γ-chain 2  3 4  
Fibrinogen is involved in the coagulation cascade by yielding monomers that 
polymerise into fibrin, it also acts as a bridge between platelets to encourage 
aggregation, and is also a marker of inflammation. Fibrinogen contributes to plasma 
viscosity which may reduce cerebral blood flow[242], it is a major predictor of 
ischemic stroke, and may also be associated with cerebral lesions detected in stroke-
free individuals using MRI[243]. Although the direction of causality is unknow, it is 
thought that cerebral infarcts increase the risk of dementia, and may therefore 
mediate any relationship with cognitive decline.  
Fibrinogen has been previously identified as a potential biomarker of AD in both 
CSF[140, 244-245] and plasma studies[148, 150, 246]. Elevated fibrinogen has been 
reported in AD subjects, linked to cognitive decline[242, 247], and brain 
atrophy[148], and it has also been shown to increase the risk of developing AD[248]. 
Mouse models also support these findings with decreased fibrinogen levels appearing 
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beneficial; lessening cerebral amyloid angiopathy, reducing BBB permeability, 
reducing microglial activation, and improving cognitive performance[249]. In 
healthy individuals fibrinogen is normally confined to the periphery, however it has 
been found to pass through the BBB in the brains of individuals with AD[250-251]. 
AD subjects often show increased clot formation, decreased fibrinolysis, and 
elevated levels of coagulation factors. This may also be true in this study as 
antithrombin-III (AIII), a coagulation inhibitor, was found to be negatively related to 
AD pathology. AIII prevents excessive blood clotting and individuals with AIII 
deficiency have increased risk of blood clots and hypercoagulability. Here AIII was 
found longitudinally negatively related to Trails B score in two 2DGE spots; with 
reduced levels of AIII related to increased cognitive decline over time. This link 
between hypercoagulability and cognitive decline has been reported before,  
dementia patients have been seen to have increased coagulation activity compared to 
controls[252], and Fibrin degradation products (D-dimers), have also shown 
predictive ability of cognitive decline in a large elderly population[253]. Additionally 
correlation between senility and AIII was previously found in elderly obese 
individuals[254]. Further evidence to support AIIIs involvement in AD comes from 
immunocytochemical studies which show AIII to localize to both amyloid plaques, 
and neurofibrillary tangles in the brain[255-256], suggesting a potential role in AD 
pathogenesis. 
Fibrinogen and Aβ have also been found to interact, increasing aggregation, and 
fibrinogen is found in Aβ deposits in the brains of AD subjects. After a review of the 
involvement of fibrinogen in AD Cortes-Canteli et al (2007)[257] suggest that 
fibrinogen-Aβ binding and altered hemostasis elevates fibrinogen levels in AD, 
resulting in increased Aβ deposition, decreased cerebral blood flow, increased 
neuroinflammation, and eventual neurodegeneration. They therefore suggest that 
blocking the fibrinogen-Aβ interaction may be a therapeutic target for AD. Targeting 
a fibrinogen-Aβ complex for intervention may allow the prevention of abnormal 
clotting whilst avoiding affecting other normal coagulation activity. Our findings 
here implicate fibrinogen in preclinical AD suggesting that such interventions may 
need to be implemented at a very early stage in the disease.  
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The evidence reported above support a detrimental effect of increased fibrinogen on 
cognition and AD pathology. In this study many 2DGE spots did show increased 
levels of fibrinogen to be detrimental. However conversely some 2DGE spots 
showed a negative relationship with AD surrogate markers, especially fibrinogen γ-
chain for which the majority of 2DGE spots had a negative coefficient. One 
explanation is that another activity of fibrinogen is to act as a complement 
inhibitor[258-259], in fact many proteins involved in the coagulation cascade are 
also able to active/inhibit the complement cascade[260]. An overactive complement 
system is often reported in AD, and this would correspond to a reduction in 
complement inhibitors, including fibrinogen. Complement inhibition will be 
discussed in further detail later in relation to clusterin. 
Apolipoprotein A-IV (ApoA-IV) 
Apolipoprotein A-IV (ApoA-IV) is one of many apolipoproteins; a group of proteins 
related to cholesterol and lipid metabolism. Various apolipoproteins have been 
reported as AD biomarkers, including at a preclinical stage[261-262]. ApoA-IV has 
been found to bind to beta amyloid[263] and transgenic AD mice show increased AD 
pathology with an ApoA-IV deficit[264], indicating a potential therapeutic function 
ApoA-IV in AD. The results here appear to oppose this hypothesis; ApoA-IV was 
found to have a positive association with all three DVs (in 5/6 spots) (Table 3-34), 
though it is possible that in preclinical AD ApoA-IV increases as a protective 
mechanism.  
Table 3-34:  ApoA-IV summary; number of significant 2DGE spots in which ApoA-IV 
was present for each surrogate marker of AD, and their coefficient directions 
PiB PET DVR Longitudinal measures: 
Baseline T6 T12 Trails B Ventricles 
1   3 2 
Serum paraoxonase/arylesterase 1(PON1) 
Serum paraoxonase/arylesterase (PON1) is an enzyme that associates with high 
density lipoproteins (HDL) and is often found associated to various apolipoproteins 
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(ApoA-I, ApoA-II, and ApoJ)[265]. It has also been shown that PON1 can protect 
low density lipoproteins (LDL) from oxidative stress, and as oxidised LDLs are 
present in amyloid plaques[266] PON1 may play a protective role in disease[265]. 
Supporting this low serum PON1 activity has been identified as a risk factor for 
AD[267-268]. Lower PON1 protein concentration is also associated with an 
increased risk for Parkinson’s disease and multiple sclerosis[269] 
Here PON1 was found to be positively associated with cognitive decline and amyloid 
load (concurrently), and both positively and negatively associated with ventricular 
expansion (Table 3-35). If PON1 is involved in protective mechanisms then perhaps 
this positive relationship with AD pathology and cognition reflects an increase in 
these protective mechanisms at this early preclinical stage of AD.  
Table 3-35: PON1 summary; number of significant 2DGE spots in which PON1 was 
present for each surrogate marker of AD, and their coefficient directions 
PiB PET DVR Longitudinal measures: 
Baseline T6 T12 Trails B Ventricles 
 
 1 5 1 
Ceruloplasmin 
Ceruloplasmin plays an important role in copper transport and metabolism, with 
approximately 95% of copper in human serum bound to ceruloplasmin[270]. Copper 
homeostasis dysfunction has been suggested to contribute to AD related 
neurodegeneration and predict MCI-AD conversion, with an increase in non-
ceruloplasmin-copper (i.e. ‘free’ copper) reported in AD individuals[270-272]. 
However the mechanistic relationship between plasma ceruloplasmin and copper in 
AD is unclear.  
Here ceruloplasmin was identified in 2DGE spots significantly related to all three 
DVs, with varying coefficient directions (Table 3-36). Most interestingly the 
coefficients for the two longitudinal measures disagree with a positive relationship 
found for Trails B decline (increase in time completing task), whereas a negative 
relationship was found for ventricular expansion. All bar one of the significant spots 
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containing ceruloplasmin were found at high molecular weights indicating that the 
majority of spots probably contained a form of the full length protein. One spot, 
longitudinally related to ventricular expansion, identified ceruloplasmin at a low 
molecular weight (<50kDa) indicating a fragment of the protein was identified. In 
CSF, increased amounts of low-molecular weight fragments of ceruloplasmin have 
been reported in AD patients compared to controls[270]. It was suggested that this 
increased fragmentation reflected impairment in the incorporation of copper into the 
protein. However here a negative relationship was reported between low MW 
ceruloplasmin and ventricular expansion, conflicting this hypothesis.  
Table 3-36: Ceruloplasmin summary; number of significant 2DGE spots in which 
ceruloplasmin was present for each surrogate marker of AD, and their coefficient 
directions 
PiB PET DVR Longitudinal measures: 
Baseline T6 T12 Trails B Ventricles 
3 1  1 1 
Reduced ceruloplasmin has been previously identified in plasma samples from AD 
individuals[273] with a suggestion of reduced oxidative activity of this protein being 
a cause or consequence of the disease. Though confusingly both an increase in 
ceruloplasmin levels[274] and no significant difference in ceruloplasmin 
concentration[275] has also been found in AD serum compared to controls. A meta-
analysis focusing on oxidative stress in AD concludes that a statistically significant 
change in serum ceruloplasmin levels are not often reported in AD, rather a reduction 
in activity is reported[276].  Perhaps a deeper assessment of the 2DGE spots 
containing ceruloplasmin would reveal that the preclinical biomarker signal detected 
here resulted from changing quantities of different forms of the protein, rather than 
quantity of ceruloplasmin as a whole.  
Haptoglobin  
Haptoglobin was found to be abundantly present in many 2DGE spots significantly 
related to all three DVs, including at all three time points for PiB PET DVR (Table 
3-37). Haptoglobin is a haemoglobin binding protein, involved in the protection of 
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hemolysis and inhibiting oxidative activity. Decreased haptoglobin is known to 
indicate an increase in free plasma haemoglobin[277]. Haptoglobin has also been 
identified to play a role in suppressing inflammatory responses[278] with larger 
amount of plasma haptoglobin found in response to inflammation[279]. Additionally 
it has also been suggested to be a chaperone protein involved in defence mechanisms 
against extracellular protein aggregation such as Aβ, and has been found in amyloid 
plaques in vivo[278, 280]. Oxidisation of haptoglobin has been shown to increase 
and its expression downregulate with disease status (control-MCI-AD)[281], 
suggesting a progressive impairment of function throughout disease progression. 
Perhaps an increase in oxidisation suppresses haptoglobin’s chaperone activity 
reducing its ability to suppress the aggregation of Aβ. 
Table 3-37: Haptoglobin summary; number of significant 2DGE spots in which 
haptoglobin was present for each surrogate marker of AD, and their coefficient 
directions 
PiB PET DVR Longitudinal measures: 
Baseline T6 T12 Trails B Ventricles 
3 1 2 19 5 
For each DV both negative and positive relationships with haptoglobin were 
reported. This may be a reflection of the proteins involvement with the previously 
mentioned mechanisms such as inflammation and Aβ aggregation defence, which in 
AD would result in an increase and decrease in haptoglobin levels respectively. 
Different forms of haptoglobin may be related to each mechanism.  
Haptoglobin has previously been reported as an AD biomarker in both plasma and 
CSF[151, 230, 282]. This finding supports it utility as an AD biomarker in the 
preclinical stage, it also provides evidence that its biomarker abilities remain stable 
over time.  
Protein Alpha-1-microglobulin/bikunin precursor (AMBP) 
The final protein found to be related to all three DV is Protein AMBP (Table 3-38). 
Protein AMBP is cleaved into three distinctly functioning protein chains; alpha-1-
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microglobulin (α1M), bikunin, and trypstatin. The approximate molecular weight of 
the significant 2DGE spots containing protein AMBP (30-40kDa) indicate that the 
protein identified is either the full length AMBP protein (39kDa), or its largest chain 
α1M. Like haptoglobin, alpha-1-microglobulin is involved in hemolysis and protects 
against oxidative stress.  
Table 3-38: Protein AMBP summary; number of significant 2DGE spots in which 
protein AMBP was present for each surrogate marker of AD, and their coefficient 
directions 
PiB PET DVR Longitudinal measures: 
Baseline T6 T12 Trails B Ventricles 
 1 1 1 1 
α1M has been shown to be involved in cell protection against oxidants, free radicals, 
and hemolysis[283-285], it has also shown immunoregulation properties; inhibiting 
interleukin-2 production of lymphocytes and inhibiting inflammatory 
responses[284]. This study reveals a mainly negative relationship of protein 
AMBP/α1M with AD pathology, indicating a reduction in the protective mechanisms 
of α1M may result in increased AD pathology. Plasma α1M had previously been 
identified as an biomarker of brain atrophy in AD[148] and a urinary α1M:ulinastatin 
ratio has been suggested as a biomarker to differentiate between AD and vascular 
dementia[286]. These results support its role as a longitudinal biomarker in 
preclinical AD. 
3.4.5 Clusterin/ApoJ 
Many other proteins were identified here as candidate biomarkers of one or two of 
the DVs were investigated. From these remaining candidate biomarkers clusterin is 
the protein for which the strongest links to Alzheimer’s disease have previously been 
reported.  
Clusterin, an inhibitor of the complement immune system and a chaperone 
glycoprotein, was found in two 2DGE spots shown to have a longitudinal 
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relationship with Trails B score. Normally chaperone proteins function to stabilise 
proteins and clear damaged and unfolded proteins, however the role of clusterin in 
AD is unclear. Here, in both spots, a decrease in clusterin over time was significantly 
related to increased cognitive decline. 
The complement system is thought to be overactive in AD and clusterin is a known 
complement inhibitor (Figure 3-43). It is therefore possible that in individuals with 
pre-clinical AD, clusterin levels will decline overtime allowing a larger, overactive, 
immune response prior to clinical manifestations of the disease. This would support a 
reduction in plasma clusterin in the early preclinical disease stages as seen in this 
study. This result also indicates that increased clusterin levels may have a protective 
effect on cognition in healthy individuals, with higher clusterin levels correlating 
with less cognitive decline. Cascella et al (2013)[287] also found a protective effect 
of clusterin on learning and memory in rats. They injected the hippocampus of rat 
brains with Aβ42, when this Aβ42 was preincubated with clusterin the Aβ42-related 
memory impairments as well as glia inflammation and neuronal degeneration were 
prevented. Although a very different experimental platform from that utilised here 
this does support a potential mechanism of clusterin as a neuroprotective Aβ42 
chaperone and complement inhibitor. Thambisetty et al (2012)’s human plasma 
proteomic study of plasma clusterin levels further supports this as they found higher 
clusterin levels were related to lower rates of brain atrophy in individuals with 
MCI[138]. Though in their previous cross sectional investigation Thambisetty et al 
(2010) reported a contrasting association; higher concentrations of plasma clusterin 
were associated with greater atrophy of the entorhinal cortex in AD[137]. The 
difference between these two studies showing conflicting results appears to be that 
they focus on different temporal states of the disease; MCI compared to AD. Perhaps 
this shows that in MCI individuals the protective mechanism of clusterin is in effect, 
though once AD is established this mechanism fails. The results from this study 
would further support this hypothesis. Increased plasma clusterin has been found to 
be related to disease severity in AD subjects in other studies [188, 288], Schrijvers et 
al (2011) hypothesized that this reflects a neuroprotective response once AD is 
established.  
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In other amyloidogenic diseases peripheral clusterin has also been shown to have a 
protective effect. In light chain amyloidosis (AL) an overproduction of 
amyloidogenic immunoglobulin light chain protein (LC) causes toxicity to blood 
vessels, cardiac, and other tissues. In AL clusterin has been found to co-localise with 
amyloid deposits in cardiac tissue and decreased levels of serum clusterin have been 
reported in individuals with AL[289]. Franco et al (2012)[289] report that increased 
clusterin has been found to prevent LC-induced cell death and arteriole endothelial 
dysfunction. 
In inflammatory diseases such as psoriasis and rheumatoid arthritis increased levels 
of clusterin in plasma and synovial fluid, respectively, has also been suggested to 
have a positive role[290-291] suggesting reduced clusterin may be used as an 
indicator of systemic inflammatory activity. 
As well as inhibiting the complement system, evidence also suggests that clusterin 
plays a protective role through Aβ clearance, reduces apoptosis and oxidative stress, 
induces synapse formation and increases neuronal network complexity. Interestingly, 
clusterin has been found to prevent deterioration and restore breakdown of the blood-
retinal-barrier (BRB)[292], the BRB shares similar properties to the blood-brain-
barrier which is disrupted in AD. 
Results from CSF studies conflict with this neuroprotective hypothesis; Deisken et al 
2014[293] reported that elevated levels of CSF clusterin correlated with larger brain 
atrophy in the entorhinal cortex in healthy and MCI individuals with high CSF Aβ1-
42. However it is not known whether blood and CSF results should correspond. 
Cellular level experiments show neuronal treatment with Aβ increases intracellular 
clusterin and decreases clusterin secretion[294]. It is possible that in these preclinical 
AD individuals where increased CSF levels of clusterin have been reported, plasma 
clusterin levels may be corresponding with a decrease in extracellular CSF clusterin. 
The results reported here indicate that increased clusterin levels had a protective 
effect on cognition, with a decline in clusterin levels over time shown to be related to 
a decline in cognition. Together with supporting literature this backs up a hypothesis 
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of a neuroprotective effect of peripheral clusterin in AD, at least in the preclinical 
stages, and that this effect can be observed longitudinally over a period of 12 years. 
3.4.6 Comparison to Thambisetty et al, (2010) 
This study aimed to replicate, and expand, upon the work conducted by Thambisetty 
et al, (2010)[151]. They identified a panel of 18 2DGE spots that could effectively 
discriminate between healthy individuals who would have high and low brain 
amyloid burden 10 years later. In these 18 spots 6 proteins were identified, 4 of 
which we were able to replicate here; complement C3, Haptoglobin, serum albumin, 
and Ig gamma-1 chain C region (highlighted in Table 3-39). 
Table 3-39: Thambisetty et al, (2010) findings: Plasma proteins identified by LC-
MS/MS  in 18 2DGE spots consituting the PLS-DA model for predicting brain amyloid 
burden 10 years later. Proteins highlighted are those successfully replicated in this 
discovery study.  
Spot ID Protein ID Accession No. 
370 Apolipoprotein-E precursor P02649 
1679 Apolipoprotein-E precursor P02649 
1676 Apolipoprotein-E precursor P02649 
1659 Apolipoprotein-E precursor P02649 
1669 Apolipoprotein-E precursor P02649 
1644 Apolipoprotein-E precursor P02649 
534 Plasminogen precursor P00747 
533 Plasminogen precursor P00747 
713 No ID obtained  
784 Complement C3 precursor P01024 
748 Complement C3 precursor P01024 
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91 Complement C3 precursor P01024 
660 Complement C3 precursor P01024 
385 Haptoglobin precursor P00738 
1340 Serum albumin precursor P02768 
925 Serum albumin precursor P02768 
1544 Serum albumin precursor P02768 
1595 Ig gamma-1 chain C region P01857 
However their main finding was protein apolipoprotein-E (ApoE), which was present 
in 6 out of their 18 spots, and was previously known to be associated with AD. Using 
enzyme-linked immunosorbent assays (ELISA) they also validated ApoE in plasma 
samples concurrent to the PiB PET scan, showing that it could predict amyloid 
burden concurrently as well as 10 years prior. Although this study used the same 
cohort of healthy individuals (BLSA), and same proteomic discovery tool, ApoE was 
not found as a candidate biomarker of amyloid burden at any time point. This may be 
explained by different statistical analysis approaches; Thambisetty et al (2010) used a 
PLS-DA regression model to predict group classification (high and low amyloid 
burden), whereas this study used an elastic-net regression model and kept amyloid 
load as a continuous variable. Additionally, differences in protein identification from 
LC-MS/MS data may be responsible for the discrepancy between the studies. Here 
we used a novel ‘2 out of 3’ approach to determine abundant proteins present in a 
2DGE spot. ApoE was in fact present in 1 spot significantly related to amyloid load 
at T12 (concurrently). Abundance ranking using a ‘unique peptide count’ approach 
ranked ApoE as abundantly present in the spot, however the protein did not pass the 
2 out of 3 criteria and was therefore not considered as a candidate biomarker. This 
highlights the importance of analysis methodology selection. More work is needed to 
determine the best approaches and to then standardise them across studies.  
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3.4.7 Conclusions 
Using a well established discovery proteomic technique this investigation identifies 
longitudinal biomarker signatures in plasma that differ between individuals with and 
without neuropathological and clinical hallmarks of AD. Our findings support 
previous reports that plasma biomarkers have the potential to be used as a screening 
tool for AD. These findings also provide novel insights into the longitudinal 
preclinical stages of AD and suggest that we may also be able to screen for the 
disease at a preclinical stage. We identified numerous candidate biomarkers, many of 
which have been previously been reported as AD biomarkers in case v control 
cohorts, providing further evidence for such biomarkers and supporting their utility 
as biomarkers longitudinally throughout the disease. Quantitative assays are now 
needed to validate the proteins reported here as candidate biomarkers. Approaches to 
such assays also need to be standardised across studies. If validated these proteins 
may, independently or in combination, provide a biomarker for preclinical AD 
diagnosis or allow predication of disease onset.  
In a lot of cases, both in the literature and in the results reported here, reports show 
conflicting evidence of a proteins role in AD. The 2DGE results here show that for 
some candidate biomarkers the protein was present in many different areas of the gel 
indicating that perhaps the proteins have undergone conformational or post 
translational changes. These changes themselves may be biomarkers of AD 
pathology and it would be interesting to further investigate these. 
The proteins found here to be longitudinally implicated in preclinical AD are 
involved in a variety of systems, including; complement and inflammation, 
coagulation, hemostasis, fibrinolysis, and BBB integrity. Such systems may be 
causally related to AD onset, or be affected as a result of the disease. Additionally 
the involvement of these systems in AD pathology may be inter-linked or they may 
act independently, further work is needed to clarify these relationships. It may be 
possible to identify the resulting contribution of some of these pathways (e.g. chronic 
inflammation) as high risk factors for the development of AD in healthy individuals, 
comparable to that of more-established risk factors such as APOE ε4 status. At the 
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very least, the presence of these biomarkers in healthy elderly individuals indicates 
potential early intervention targets worthy of further investigation.  
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Chapter 4. Discovering low molecular weight proteins as 
longitudinal biomarkers of early Alzheimer’s disease pathology 
and cognitive decline using liquid chromatography-tandem mass 
spectrometry 
4.1 Introduction 
Low abundant proteins play important roles in major biological processes such as 
cell cycle control and stress response. Despite their importance they are under-
represented in the current proteomic literature, most likely due to difficulty in 
detection compared to more abundant proteins. The plasma protein concentration 
range spans up to twelve orders of magnitude[295] and many current proteomic 
approaches are only capable of sensitively covering three or four of these. The 20 
most abundant proteins account for approximately 97% of the total protein mass, 
these include; albumin, immunoglobulin, fibrinogen, alpha 1-antitrypsin, alpha 2-
macroglobulin, transferrin and lipoproteins. Albumin on its own can represent over 
50% of total plasma protein. Highly abundant proteins like these increase the protein 
concentration to around 80mg/ml yet there are many proteins present in the ng/ml 
range, or lower, which can be masked by such abundant proteins and so remain 
undetected. Dynamic range coverage will be a limitation of most proteomic 
techniques. Methods that help to access low abundance proteins by reducing the 
complexity of the plasma through depletion and prefractionation strategies are 
needed to enable the detection of less abundant and low molecular weight (LMW) 
proteins, especially when using complex samples such as plasma. 
In Chapter 3 a discovery phase investigation into longitudinal preclinical AD 
biomarkers was presented using ‘two dimensional gel electrophoresis’ (2DGE). 
Although an extremely useful proteomic technique 2DGE does have limitations that 
need to be addressed when aiming to conduct a thorough analysis of the plasma 
proteome. The main limitation 2DGE places on our biomarker discovery 
investigation is its restricted dynamic range (~104)[296]. In our 2DGE experiments a 
10% polyacrylamide gel was used which is able to accurately resolve proteins in a 
molecular weight range of approximately 20-250kDa. This study aimed to provide a 
complementary evaluation of the proteome and so focused on the extraction and 
analysis of proteins with a molecular weight of <30kDa. Together it was hoped that a 
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more comprehensive analysis of the plasma proteome could be achieved for the 
discovery of preclinical AD biomarkers. 
Liquid chromatography-tandem mass spectrometry (LC-MS/MS) is an analytical 
technique that measures the mass-to-charge ratio of ionised particles and offers 
superior sensitivity and specificity for LMW analytes compared to 2DGE. LC-
MS/MS also enables a clear identification of proteins whose levels change as 
biomarkers, unlike 2DGE where multiple proteins may be identified within a 
statistically significant spot. The use of complex samples such as plasma can increase 
the variability of the liquid chromatography separation stage, however as the 
majority of steps taken in LC-MS/MS are automated the technique overall is subject 
to less variance than 2DGE. For these reasons LC-MS/MS was chosen as the 
discovery tool here. LC-MS/MS methodology was firstly optimised for the discovery 
of LMW proteins. Following optimisation LMW proteins were targeted and analysed 
for the discovery of preclinical AD biomarkers. 
4.2 Aims 
To optimise an in-solution label free LC-MS/MS methodology to allow the detection 
of LMW, low abundance, plasma proteins, enabling a complementary evaluation of 
the proteome to that already conducted using 2DGE. 
To identify LMW, low abundance proteins predictive of amyloid load using the 
optimised LC-MS/MS methodology.  To discover the most predictive proteins at 
each time point (12 years prior, 6 years prior, and concurrently) using multivariate 
analyses of proteins against quantitative amyloid imaging measures (11C-PiB PET 
DVR). Additionally using the same proteomic technique LMW, low abundance 
proteins longitudinally related to brain atrophy and cognitive decline will be 
identified.  
4.3 Results 
4.3.1 LC-MS/MS optimisation 
LC-MS/MS has shown great utility in detecting LMW analytes in clinical 
applications such as drug and toxicology testing, biochemical genetics, and 
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endocrine testing of steroids (Grebe et al, (2011)[297] and Ponnayyan-Sulochana et 
al, (2014)[298] review some of these), However, work is still needed to optimise LC-
MS/MS for the detection of LMW protein/peptides as biomarkers. In order to target 
and quantify LMW proteins in this study LC-MS/MS sample preparation needed to 
be optimised. 
Firstly an in-solution based approach was chosen as it is simpler in terms of sample 
handling and has increased speed over gel based approaches. Secondly we 
considered labelled versus label-free approaches for protein quantification with mass 
spectrometry. Although technological advancements in mass spectrometers have 
dramatically enhanced their sensitivity and resolution, extracting reliable protein 
abundance information from either approach remains challenging. Although labelled 
approaches are more quantitative and require less sample runs, label free approaches 
are increasingly popular and were chosen for this experiment due to the quick and 
straightforward sample preparation, cheaper costs, and less complex data analysis 
compared to a labelled approach. Label free approaches also avoid the biases and 
reduced sensitivity that chemical derivatisation can cause in labelled approaches.  
Sample preparation options considered and compared during optimisation 
experiments included; proteolytic digestion, abundant protein depletion, molecular 
weight cut off filter, and de salting. Other factors affecting the extraction of LMW 
proteins explored include; the duration of the chromatography separation and the 
gradient conditions, number of sample injections, volume and concentration of 
starting plasma used, and plasma loading volume for the orbitrap mass spectrometer. 
For method optimisation experiments three random healthy control plasma samples 
were selected to be used throughout the optimisation (mean protein concentration = 
66.2mg/ml). These samples had been in frozen storage since 2010 and had one 
previous freeze-thaw cycle. For optimisation experiments, all data was analysed in 
Excel. The numbers of LMW proteins detected by each method were summed and 
the protocol with the greatest number of LMW proteins was selected, whilst 
considering the time and cost taken to complete each step. 
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Depletion of high MW proteins, LMW cut off filter (30kDa), and desalt (ZipTip) 
To enable access to LMW proteins, molecular weight (MW) cut off filters can be 
used to obtain a plasma filtrate containing only proteins smaller than the MW filter 
of choice. In addition depletion strategies aiming to remove highly abundant, high 
MW proteins are often successfully implemented, allowing easier access to the 
LMW proteome. Here a 30kDa cut off filter was considered and its performance was 
measured when used independently or in combination with a depletion column. In 
addition, buffers used during these two methods may introduce excess salt into the 
sample, and therefore a ZipTip desalt was also considered (Figure 4-1). 50µl of each 
plasma sample was analysed and all techniques were conducted as described in the 
methods chapter. The number of proteins identified for each approach is detailed in 
Table 4-1. 
 
Figure 4-1: Label free LC-MS/MS optimisation for low molecular weight (MW) 
proteins (<30kDa). Green; 30kDa cut off filter only. Red; Depletion of albumin and 
IgG, followed by a 30kDa cut off filter. Blue; Depletion, 30kDa cut off filter, and 
ZipTip desalt. All samples were trypsin digested before analysis by LC-MS/MS. 
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Table 4-1: Number of proteins detected by LC-MS/MS following depletion, LMW 
protein cut off filter, and desalt. 
Method No. of proteins 
identified by  
LC-MS/MS 
30kDa cut off filter 138 
Depletion (albumin and IgG) & 30kDa cut off filter 109 
Depletion (albumin and IgG), 30kDa cut off filter, & desalt 117 
Although the 30kDa cut off only method identified the highest number of proteins, 
when looking in detail at the mass spectrometry output a lot of albumin and other 
high MW proteins were still being detected. As a CID top 20 search was being 
conducted the high MW proteins still present in the sample were preventing other 
less abundant, LMW, proteins from being identified. Therefore, although adding the 
depletion step reduced the overall number of proteins detected, it increased the 
detection of smaller less abundant, LMW, proteins. The ZipTip desalting step did 
further increase the number of proteins detected, though not dramatically. When 
factoring in the time taken to perform this additional step it isn’t likely to be 
worthwhile.  Therefore depletion and 30kDa cut off filter was selected as the optimal 
prefractionation methodology. 
Proteolytic digestion (trypsin digest) 
An important step in sample preparation for mass spectrometry proteomics is the 
conversion of proteins to peptides and in most cases trypsin is used as the proteolytic 
enzyme. Trypsin is a protease that specifically cleaves the proteins creating peptides 
in the preferred mass range for MS sequencing and with a basic residue at the 
carboxyl terminus of the peptide. This produces information-rich, easily interpretable 
peptide fragmentation mass spectra. However, due to their size, LMW proteins 
produce low numbers of proteolytic peptides through tryptic digestion. After plasma 
depletion (albumin and IgG) and MW filtering (30kDa cut off) it may be possible to 
detect many very small proteins via LC-MS/MS without a digestion step. Therefore 
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using depleted and filtered plasma a comparison between undigested and digested 
aliquots was performed to investigate the benefit of performing a digestion step and 
determine whether the time invested in this step was worthwhile for the detection of 
LMW proteins (Figure 4-2). 
 
Figure 4-2: Experimental design for comparison of trypsin digest (red) versus non-
digested plasma (blue).  
50µl of each plasma sample was firstly depleted of albumin and IgG, the depleted 
sample was then passed through the 30kDa cut off filter column. Approximately 
50µl of filtrate was produced (mean filtrate concentration = 0.46mg/ml), from which 
two 25µl aliquots were prepared. One aliquot was digested using trypsin, the other 
aliquot was left undigested. Table 4-2 below details the number of proteins identified 
via LC-MS/MS for each approach. Performing a tryptic digest enabled the 
identification of many more proteins.  
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Table 4-2: Number of proteins identified by LC-MS/MS for a trypsin digested and non-
digested sample. 
Method No. of proteins identified 
Endogenous 32 
Trypsin 241 
Run time: 35min, 1 hour, and 2 hour gradients 
In a complex sample such as plasma many peptides will co-elute at any given time 
point during reverse-phase chromatography. Many of these co-eluting peptides will 
not be identified. One way in which to improve the chromatographic performance is 
to increase the gradient length, which in turn generally increases the number of 
peptides identified[299]. However this also drastically increases the sampling time of 
the entire analysis. Here we considered three gradients of varying lengths (35 
minutes, 1 hour, and 2 hours) and compared the number of unique proteins identified 
by each, whilst considering the time taken to perform each option.  
50ul of each depleted (albumin and IgG), filtered (30kDa cut off), and trypsin 
digested plasma sample was loaded onto the mass spectrometer for LC-MS/MS 
analysis. Each sample was injected three times with varying gradient lengths (35 
minutes, 1 hour, and 2 hours) (Figure 4-3).  
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Figure 4-3: Experimental design for the comparison of gradient lengths; 35 minutes, 1 
hour, and 2 hours. 
Table 4-3 lists the number of proteins identified via LC-MS/MS for samples with 
varying liquid chromatography gradient lengths. The longer the gradient the more 
proteins were identified, however the 1 hour run was optimal as very few additional 
proteins were identified by doubling the run time to 2 hours.  
Table 4-3: Number of proteins identified by LC-MS/MS for samples with varying 
liquid chromatography gradient lengths 
Method No. of proteins identified 
35 minutes 71 
1 hour 172 
2 hours 179 
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Starting plasma volume and protein concentration 
The Sigma depletion column protocol suggests that up to 50µl of plasma can be 
loaded onto the columns but that the column efficiency will improve with smaller 
volumes. The suggested range in which binding of IgG and albumin will be optimal 
is 25-50µl of plasma. Therefore 25µl and 50µl of starting plasma were compared for 
their performance when aiming to detect LMW, low abundance proteins. In addition, 
the effects of protein concentrations on tryptic digestion performance were 
considered; before digestion each sample was split into two aliquots of 15µg and 
30µg total protein (Figure 4-4).  
 
Figure 4-4: Experimental design for the comparison of 25ul (red) and 50ul (blue) 
starting plasma volumes, and subsequent protein concentration for trypsin digestion 
(15ug and 30ug). 
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25µl and 50µl of each plasma sample were pipetted onto depletion columns. Each 
depleted plasma eluate was then filtered through a 30kDa cut off column. Next, 
protein concentration of the resulting filtrate was determined by a nanodrop, then the 
sample was split into two aliquots of 15µg and 30µg of total protein. These aliquots 
were then trypsin digested and analysed by LC-MS/MS. The results below were 
obtained whilst the orbitrap was not functioning at peak level due to high analytical 
column pressure, and deteriorating electron multiplyer performance. This appeared to 
reduce the overall number of proteins detected for this experiment. Although protein 
detection may be higher when the orbitrap is optimally functional, the relative 
amount of proteins detected for each method tested should be similar allowing me to 
draw conclusions from these results. 
Table 4-4 displays the results of these comparisons. From these results 25µl/15µg 
was selected as the optimal combination.  
Table 4-4: Number of proteins identified by LC-MS/MS for 25µl and 50µl starting 
plasma 15µg and 30µg concentrations. 







To ensure an equal amount of protein was depleted across samples it was important 
to standardise the protein load onto the depletion columns. Discovery experiments 
would utilise samples from BLSA subjects; previous 2DGE experiments had shown 
the average protein concentration for these samples to be around 60mg/ml. 
Consequently a 25µl plasma sample aliquot would have approximately 1500µg 
(1.5mg) protein. Therefore 1500µg protein was selected to be loaded onto the 
depletion column. The first step of the depletion protocol was to dilute the plasma 
sample to 100ul in equilibration buffer. This ensured that equal volumes were being 
loaded onto the depletion columns. 
  185 
  
Protein concentration for LC-MS/MS analysis 
The suggested capacity of the orbitrap loading columns is 2µg of protein. This 
capacity may be flexible when using a depleted plasma sample consisting mainly of 
LMW proteins without the heavy presence of large abundant proteins such as 
albumin and IgG. To identify the optimal amount of protein to load onto the LC-
MS/MS column a comparison of 1µg, 2µg, 3µg, and 4µg amounts was performed, 
and the number of proteins identified with each was compared. 
Plasma samples were pooled together, depleted (albumin & IgG), filtered (>30kDa 
cut off), and then trypsin digested. Protein concentration of the resulting plasma was 
determined by a nanodrop, and a 15µg aliquot was prepared. This aliquot was 
lyophilised and re-suspended in 30µl (0.1% FA, 20% ACN, ddh20) resulting in a 
concentration of 0.5µg/µl. This sample was then loaded onto the mass spectrometer 
for LC-MS/MS analysis with three injections of 2µl, 4µl, 6µl, and 8µl (Figure 4-5). 
 
Figure 4-5: Experimental design for the comparison of protein loads for LC-MS/MS 
analysis 
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Table 4-5 lists the number of proteins identified for each protein quantity injected for 
LC-MS/MS analysis. As noted for the previous experiment the orbitrap was not 
functioning at peak level for this experiment, resulting in reduced protein detection, 
though relative amount of proteins detected for each method tested should be similar 
allowing me to draw conclusions from these results. 
Overall each injection yielded comparable numbers of proteins, indicating that the 
column may already be saturated at 1µg. However, 8µl (4µg) did result in slightly 
increased protein detection and will therefore be selected as the optimal loading 
amount.  
Table 4-5: Number of proteins identified by LC-MS/MS 
Injection volume No. of proteins identified 
2ul (1µg) 46 
4ul (2µg) 50 
6ul (3µg) 51 
8ul (4µg) 58 
4.3.2 LC-MS/MS discovery study 
Following optimisation experiments the resulting method selected to detect and 
analyse LMW proteins for preclinical AD biomarker discovery was; ~25µl starting 
plasma volume (1500µg protein), albumin and IgG depletion, 30kDa cut off filter 
column, tryptic digestion of 15µg, 8ul injection (0.5µg/µl), and a 1 hour gradient. All 
stages were performed as detailed in the methods chapter (chapter 2).  
Tabb et al 2010[198] found that the repeatability of a label free proteomic sample 
was poor in that only half of the peptides discovered in an initial LC-MS/MS sample 
will be identified in a second replicate. This implies that the total number of peptides 
identified grows rapidly for the first few replicates. The authors suggest that by 
collecting data on a sample in triplicate is a way in which researchers can improve 
the sampling of complex samples. Therefore the plasma samples here were injected 
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in triplicate. This was also considered to aid spectral counting as larger numbers of 
peptides (summed data across triplicates) will enhance the ability to detect subtle 
changes in protein abundance. The final experimental workflow is illustrated in 
Figure 4-6. 
 
Figure 4-6: Final experimental workflow following optimisation for LMW protein 
discovery. 
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4.3.3 Demographic characteristics 
Discovery phase experiments included 25 healthy individuals from the Baltimore 
Longitudinal Study of Aging (BLSA) neuroimaging cohort previously described 
(Chapter 2). These individuals all had one PiB PET scan, serial structural MRI 
(sMRI) scans and serial cognitive assessments. Samples from all 25 individuals had 
previously been included in the 2DGE discovery phase experiments.  
From all 25 individuals, plasma samples were drawn from three time points (75 
sample aliquots in EDTA). Time points corresponded to neuroimaging visits ~6 
years apart (baseline, T6 = 6+/-2 years, and T12 = 12+/-2 years). Samples at the third 
time point (T12) were concurrent to the subjects PiB PET scan. Table 4-6 below 
summarises the demographic characteristics of the study population at baseline.  
Table 4-6: Subject demographics 
 N Mean age at baseline Std. dev  
Female 13 66.31 6.25 
Male 12 66.67 4.98 
Total 25 66.48 5.56 
Table 4-7 below displays the mean distribution volume ratios (DVR) per gender, and 
when the PiB PET scan was conducted (mean number of years after baseline). 
Table 4-7: Subject PiB PET DVR information 
 N Mean PiB PET DVR Mean no. years post 
baseline of PiB PET scan 
Female 13 1.08 11.71 
Male 12 1.10 11.55 
Total 25 1.09 11.63 
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4.3.4 Protein count 
To enable a full longitudinal analysis proteins must be measured at all three time 
points. A simple Venn diagram was constructed to illustrate the number of proteins 
at each time point and where they overlap. Figure 4-7 displays the number of 
proteins identified at each time point. 107 proteins were measured at all three time 
points allowing a longitudinal analysis of these proteins. 
 
Figure 4-7: Venn diagram illustrating the number of proteins identified by LC-MS/MS 
at each time point, following strict filtering in Scaffold (95% protein threshold, 
minimum of 2 peptides matched, and 80% peptide threshold). 
4.3.5 Coefficient of variation (CV) 
To be able to discriminate proteomic differences between samples based upon 
spectral counts, the spectral count data across multiple injections of the same sample 
must normally be found to have low variability. Coefficients of variation (CVs), 
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which compare the standard deviation to the mean for these counts, were therefore 
computed.  
CV calculations were performed on normalised total spectral counts for each run 
rather than absolute values as with no blank runs in between replicates slight 
variations in the chromatography sensitivity may be present. These normalised 
values were automatically calculated by Scaffold software. This normalisation 
entailed averaging the spectral counts for all of the samples and then multiplying the 
spectrum counts in each sample by this average, divided by the individual sample’s 
sum. This normalisation procedure works when individual proteins may be up or 
down regulated within a sample, but the total amount of protein within each sample 
is approximately the same.  
As proteins with >50% missing data were to be excluded from statistical analysis 
CVs were only calculated for proteins with <50% missing data. The overall 
experiment mean within-subject CV was 34.6982%. The mean CV’s per time point 
were: baseline = 30.88%; T6 = 35.72%, and T12 = 37.47%. 
It is important to consider that CVs are not ideal for this form of data as LMW 
proteins with very low numbers of peptides identified are more likely to have very 
high CVs. Additionally it is known that in complex samples such as plasma the 
repeatability of peptides discovered in an initial LC-MS/MS injection compared to 
following replicates is low, with only approximately 50% replicating [198]. 
Therefore the CVs achieved were considered to be acceptable for this dataset, though 
further statistical analysis would be conducted on summed spectral count values, 
rather than means. 
4.3.6 Normality tests 
LC-MS/MS data was pre processed using Proteome Discoverer 1.4 and Scaffold 4 
(Proteome Software Inc, USA) as previously described (chapter 2). Spectral counts 
for triplicate injections were summed and combined into one BioSample and the 
Normalised Total Spectra quantitative values were calculated and exported into 
Excel for statistical analysis. 
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Normality tests were performed to determine the normality of the protein 
distributions. Proteins with more than 50% missing data were discarded. A 
Kolmogorov-Smirnov test for normality indicated that 48%, 67%, and 32% of the 
remaining protein distributions were normally distributed (p>0.05) at baseline, T6, 
and T12 respectively. Protein data was then logged (base 10) to minimise skewness 
and non-normal distributions and normality tests were repeated. Kolmogorov-
Smirnov tests on logged spot data indicated that 90%, 71%, and 87% of the protein 
distributions were normally distributed (p>0.05). Logged data was therefore used for 
the following statistical analyses. 
4.3.7 Analysis of plasma proteins associated with amyloid load as measured by 
PiB PET DVR 
Partial correlations 
Partial correlation was used to identify small proteins that have a relationship with 
amyloid load. Proteins correlating with 11C-PiB PET DVR at each time point, whilst 
controlling for age, gender, education (years), body mass index (BMI), cholesterol, 
and APOE ε4 status were identified.  
Partial correlations at baseline, T6, and T12 revealed 5, 2, and 2 proteins, 
respectively, which significantly correlated with PiB PET DVR 12 years later, 6 
years later and concurrently (p<0.05). Additionally 3 proteins at baseline, and 1 
protein at T12 tended towards significance (p<0.1). Significant and tending towards 
significance results are displayed in Table 4-8 for baseline, Table 4-9 for T6, and 
Table 4-10 for T12. Full results are reported in appendix 6 (baseline) appendix 7 (T6) 
and appendix 8 (T12). 
 
  192 
  
Table 4-8: Baseline partial correlation results for proteins with PiB PET DVR. Table 
lists significant (red, p<0.05) and tending towards significance (green, p<0.1) proteins. 
Proteins ranked in order of significance based on p value. Full length protein MW and 













































Complement C4 B -0.498 0.022 193 96 
Leucine rich alpha 2 glycoprotein 1 0.607 0.022 39 64 
Zinc alpha 2 glycoprotein 0.478 0.025 34 100 
Ig kappa chain C region 0.455 0.035 12 100 
Fibrinogen beta chain -0.471 0.038 56 92 
Fibrinogen alpha chain -0.429 0.050 95 100 
Apolipoprotein A IV -0.420 0.056 45 100 
Beta 2 microglobulin 0.482 0.068 14 76 
Table 4-9: T6 partial correlation results for proteins with PiB PET DVR. Table lists 
significant proteins (red, p<0.05). No proteins were found here to be tending towards 
significance (p<0.1). Proteins ranked in order of significance based on p value. Full 













































Complement C3 -0.567 0.017 187 91 
Fibrinogen alpha chain -0.477 0.042 95 100 
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Table 4-10: T12 partial correlation results for proteins with PiB PET DVR. Table lists 
significant (red, p<0.05) and tending towards significance (green, p<0.1) proteins. 
Proteins ranked in order of significance based on p value. Full length protein MW and 














































Alpha 1 acid glycoprotein 2 0.520 0.043 24 73 
Beta 2 microglobulin 0.574 0.047 14 61 
Complement C4 B -0.391 0.079 193 92 
4.3.8 Analysis of plasma proteins longitudinally associated with brain atrophy 
Longitudinal volume data was available for 22 sMRI brain regions. Based on the 
ANOVAs conducted on these volumes in Chapter 3, 16 brain regions were known to 
display a linear change over time and were therefore suitable to be longitudinally 
assessed using mixed-effects regression models (MRM) as follows. 
Mixed-effects regression model 
Longitudinal slope comparisons between protein values and sMRI brain volumes 
were performed using mixed-effect regression models with age, gender, education, 
BMI, cholesterol and APOE ε4 status as covariates. Significant results (p<0.05) and 
those tending towards significance (p<0.1) are reported in Table 4-11 below, for full 
results see appendix 9.  
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Table 4-11: Mixed-effects regression model results for protein values with sMRI brain 
regions. Table lists significant (red, p<0.05) and tending towards significance (green, 
p<0.1) proteins. Proteins ranked in order of significance based on p value. Full length 














































Antithrombin III -1674.270 0.002 53 79% 
Zinc alpha 2 
glycoprotein 1022.783 0.034 34 97% 
Alpha 1 acid 
glycoprotein 1 1155.158 0.100 24 100% 
Frontal Gray 
Matter 
Alpha 1 acid 
glycoprotein 1 8162.499 0.044 24 100% 
Zinc alpha 2 
glycoprotein 5446.128 0.052 34 97% 
Complement C3 -5151.136 0.053 187 89% 
Grey Matter 
Zinc alpha 2 
glycoprotein 15675.255 0.046 34 97% 
Antithrombin III -15127.422 0.089 53 79% 
Hippocampus 
Apolipoprotein E 285.516 0.034 36 68% 
Serum albumin -209.756 0.069 69 77% 
Inter alpha trypsin 
inhibitor heavy chain 
H4 -208.944 0.080 103 100% 




Transthyretin 786.319 0.025 16 100% 
Apolipoprotein A IV 539.710 0.087 45 94% 
Medial Frontal 
Gyrus 
Antithrombin III -1312.703 0.027 53 79% 
Serotransferrin -1124.889 0.063 77 100% 
Middle Frontal 
Gyrus 
Alpha 1B glycoprotein -1750.054 0.033 54 75% 
Antithrombin III -2063.618 0.036 53 79% 
Alpha 1 acid 
glycoprotein 2 -2241.501 0.078 24 74% 
Apolipoprotein E 2980.132 0.081 36 68% 
Middle 
Occipital Gyrus 
Complement C3 -833.235 0.029 187 89% 
Zinc alpha 2 
glycoprotein 873.585 0.056 34 97% 
Ig kappa chain C region 1256.919 0.063 12 83% 
Alpha 1B glycoprotein 815.878 0.098 54 75% 
Middle 
Temporal Gyrus 
Zinc alpha 2 
glycoprotein 1869.463 0.036 34 97% 
Ig kappa chain C region -2493.314 0.041 12 83% 
Antithrombin III -1672.213 0.060 53 79% 
Transthyretin 1823.895 0.097 16 100% 
Superior Frontal 
Gyrus 
Antithrombin III -1079.660 0.077 53 79% 
Transthyretin 1146.474 0.081 16 100% 
  196 
  
Superior 
Occipital Gyrus Beta 2 microglobulin -1331.366 0.026 14 71% 
Superior 
Temporal Gyrus 
Alpha 1 antitrypsin 2688.158 0.021 47 100% 
Zinc alpha 2 
glycoprotein 1584.460 0.027 34 97% 
Apolipoprotein A I -1502.111 0.078 31 75% 
Temporal Gray 
Antithrombin III -3831.437 0.075 53 79% 
Zinc alpha 2 
glycoprotein 3379.500 0.092 34 97% 
Ig kappa chain C region -4767.157 0.099 12 83% 
Ventricles Transthyretin -3403.640 0.053 16 100% 
Whole brain 
Apolipoprotein E 17064.433 0.073 36 68% 
Antithrombin III -12999.327 0.079 53 79% 
4.3.9 Analysis of plasma proteins longitudinally associated with cognitive 
decline 
Longitudinal cognitive data was available for 12 cognitive measurements. Based on 
the ANOVAs conducted on these measures in Chapter 3, only one measure, Trails B, 
was known to show a linear change over time and was therefore suitable to be 
assessed using a mixed effects regression model as follows.  
Mixed-effects regression model 
A longitudinal slope comparison between protein values and Trails B score was 
performed using a mixed effects regression model with age, gender, education, BMI, 
cholesterol and APOE ε4 status as covariates. Significant results (p<0.05) and those 
tending towards significance (p<0.1) are reported in Table 4-12 below, for full 
results see appendix 10. 
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Table 4-12: Mixed-effects regression model results for protein values with cognitive 
measures. Table lists significant (red, p<0.05) and tending towards significance (green, 
p<0.1) proteins. Proteins ranked in order of significance based on p value. Full length 


















































Fibrinogen alpha chain -26.689 0.008 95 97% 
Apolipoprotein A IV -22.119 0.025 45 94% 
Apolipoprotein E -21.913 0.086 36 68% 
 
4.4 Discussion 
4.4.1 Optimisation of label free LC-MS/MS for the detection of LMW proteins 
Optimisation experiments revealed that, from the methods considered here, the best 
way in which to access low abundance, LMW proteins for analysis is to utilise 
depletion and MW cut off filter columns in combination. It is important to remember 
though that potentially important biological information may be lost during depletion 
as certain proteins/peptides may be bound to the highly-abundant proteins 
removed[300]. Nevertheless it is important to access this LMW fraction of the 
proteome for biomarker discovery and previous studies have shown the successful 
use of depletion strategies for this purpose[301]. The method presented here was a 
simple and fast procedure to remove the most abundant proteins obscuring low 
abundance, LMW proteins, and hindering their detection. The removal of albumin 
and IgG allowed a higher load of less abundant, LMW proteins to be included in 
mass spectrometry analysis and increased the number of LMW proteins detected.  
4.4.2 LC-MS/MS experimental performance and analysis 
Many LMW proteins were identified using the optimised methodology, however 
they were not all consistently identified between individuals. Consequently many 
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LMW proteins had large amounts of missing data. Here proteins with >50% missing 
data were excluded from statistical analysis, and although this included many LMW 
proteins it was necessary to discard these as there was not sufficient data from which 
meaningful conclusions could be drawn. Furthermore, within-subject protein 
detection and quantification was not consistent between sample injections, with an 
overall mean CV of 37% even when proteins with >50% missing data had been 
removed. This is comparable to the CV the 2DGE experiments (33.52%, chapter 3). 
Yet for our purposes this level of replication was acceptable for two reasons. Firstly 
LMW proteins were expected to have high CVs, due to the low number of peptides 
available for detection. Secondly, it is known that only 50% of the peptides 
discovered in an initial LC-MS/MS injection may be replicated in a second, 
drastically increasing the expected CV[198]. The purpose of completing three 
injections for this experiment was not to accurately replicate between injections, but 
rather to increase the number of peptides and proteins identified for each individual 
so that a summation of the data obtained across injections, rather than mean values, 
could be used for analysis. This approach should have also reduced the amount of 
missing data, by allowing three attempts at detecting protein levels across 
individuals. However large amounts of missing data were still present, indicating the 
methodology needs to be further optimised, perhaps by further increasing the number 
of injections. 
To account for poor repeatability, samples were analysed in triplicate to obtain a 
greater chance of detecting all peptides present. The data from the triplicate 
injections was then summed, and this summed value was used for analysis. However 
this approach causes an issue for the analysis of proteins of low abundance that 
should be considered: more abundant proteins are likely to be detected in all three 
triplicate injections and therefore a summation of all three would lead to large values 
of these proteins for statistical analysis. Conversely, less abundant proteins may be 
detected in only one or two injections, resulting in small values for statistical 
analysis. It would therefore be easier to detect a significant change in the proteins of 
larger abundance for which more data has been acquired. This is a hindrance to the 
aims of this study; to detect and analyse smaller, less abundant proteins. One way in 
which this issue could be overcome is to create a mass spectrometry rejection list for 
the proteins identified in a run and apply this to subsequent runs. This would ensure 
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that only novel proteins would be detected from each injection and all proteins would 
have a fair chance of obtaining equivalent amounts of data (data obtained from one 
injection each). However creating a rejection list after each sample run is time 
consuming and outside the timeframe available for this study.  
Many of the highly abundant proteins detected were identified as proteins of high 
MW, even though all proteins had been filtered through a 30kDa cut off filter. This 
indicates that fragments of these high MW proteins were present that were small 
enough to pass through the MW filter. The detection of high MW protein fragments, 
as well as LMW proteins, still allowed an interesting analysis for preclinical AD 
biomarkers complementary to the previous 2DGE discovery study. 
Normalised total spectral counts was considered here as a value indicating relative 
abundance, on which statistical analysis was then conducted. In the previous 2DGE 
discovery study three abundance approaches were considered and applied to LC-
MS/MS data. However, here the focus of the analysis was different; changes in 
protein abundance between samples/subjects were considered, but proteins were not 
ranked within a sample (2DGE spot) based on abundance. This allowed a simpler 
approach for analysis as it was assumed that as long as the experimental setup was 
the same for each sample any differences in spectral counts between samples must be 
due to abundance changes. For example, liquid chromatography biases may 
influence the abundance ranking of proteins within a sample, but as long as these 
biases are kept constant comparisons between samples can be drawn. Spectral 
counting is the most commonly employed method of determining relative abundance 
and was therefore selected for this study. This approach uses the number of tandem 
spectra matched to peptides of a certain protein to determine a total spectral count. 
This count is considered to be positively associated with the abundance of the protein 
and can therefore be used as an indicator of relative abundance. 
Like the previous discovery chapter, no false discovery rate (FDR) corrections were 
applied to the statistical results obtained here. Although this will have increased the 
number of false positive findings reported, an uncorrected 0.05 p-value was 
considered an acceptable significance level for this discovery stage experiment. 
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Subsequent validation experiments are important to confirm true positives and 
discard false positive findings. 
4.4.3 Detection of low molecular weight proteins as preclinical AD biomarker 
candidates, complementary to discovery 1 
This study successfully discovered LMW proteins as preclinical AD biomarkers that 
had not been detected in previous 2DGE experiments. These results in combination 
provide a greater coverage and analysis of the proteome for preclinical AD 
biomarker discovery. The proteins found as biomarkers, complementary to the 2DGE 
discovery study, are discussed below. Most of these proteins are <30kDa, though for 
some the full length protein is slightly larger, indicating the presence of a fragment 
due to the 30kDa cut off filter used during sample preparation.  
Alpha 1 acid glycoprotein 1 & 2 
Alpha 1 acid glycoprotein (AGP) is a known acute phase protein, with an increase in 
concentration found as a response to injury, inflammation, or infection[302], though 
the exact functional role of AGP is poorly understood. In a cohort of 17,345 
individuals, AGP has recently been identified as one of four proteins which can 
predict short term risk of death from any cause, with AGP found as the strongest 
multivariate predictor of death risk[303]. This association has also been reported 
previously in smaller cohorts[304-305]. With an increase in AGP reported as a risk 
factor of death of any cause, it is unsurprising that it has also been previously 
reported as a biomarker for AD[230]. Here two forms of AGP were identified as 
candidate biomarkers of preclinical AD; alpha 1 acid glycoprotein 1 (AGP1) and 
alpha 1 acid glycoprotein 2 (AGP2). Interestingly the direction of relationship with 
AD pathology found differed between these two proteins. 
AGP1 was here found to be significantly longitudinally related to brain atrophy over 
time; positively related to the frontal grey matter, and also tending towards a 
significant positive relationship with atrophy of the cingulate gyrus. These results 
suggest that as brain volume decreases over time, AGP1 concentration also 
decreases. This conflicts with the literature mentioned above. However the findings 
for AGP2 are in line with the previous literature; a positive relationship was found 
with concurrent amyloid load (at T12). Additionally a negative relationship, tending 
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towards significance, was reported with brain atrophy of the middle frontal gyrus. 
These results suggest that AGP2 concentration increases with increased amyloid 
burden and brain atrophy. Therefore AGP2 appears to fit the more typical findings of 
an increase in AGP as detrimental to health, whereas AGP1 seems to have an 
opposite relationship. 
As much literature suggests AGP as a general risk factor of death, including cancer 
and vascular disease outcomes, it is therefore unlikely to perform as a specific AD 
biomarker, even at a preclinical stage. Instead AGP may be most useful as a marker 
of general decline in health, and may show its greatest utility as an AD biomarker 
when used in combination with other AD specific proteins in a biomarker panel. 
However it would be interesting to further investigate the differences between AGP1 
and AGP2 and their relationship with AD pathology. Perhaps one, or a ratio of both 
forms, would be more specific to AD. 
Transthyretin (TTR) 
Like AGP, Transthyretin (TTR) has also been found as a marker of short term death 
of any cause, with low levels of TTR indicating increased risk[304]. However TTR 
has also been specifically related to AD, and even implicated in its pathogenesis. 
TTR has been found as an AD biomarker in CSF[133-134], serum[306], and 
plasma[135-136], with lower levels of TTR related to AD diagnosis and severity.  
TTR was here significantly and positively related to brain atrophy over time of the 
superior frontal gyrus. It was also tending towards significance with three other brain 
regions; the middle temporal gyrus, inferior occipital gyrus, and ventricles. These 
findings support previous reports that TTR levels decrease with increased pathology, 
and provide evidence that this association occurs even at a preclinical stage.  
A decrease in TTR has previously been related to protective effects of the protein on 
Aβ pathology. Serum and CSF TTR has been found to bind to and cleave Aβ in vitro, 
this mechanism is thought to prevent Aβ aggregation, and therefore inhibit Aβ 
induced neurotoxicity[307-308]. As TTR has also been found to co-localise with Aβ 
plaques [309-310] this suggests that in vivo TTR may also express proteolytic 
activity on Aβ deposits. This indicates a potential therapeutic role of TTR in AD 
  202 
  
treatment. The results here suggest that TTR levels are disrupted preclinically and 
therefore any TTR-based interventions may need to be implemented at this early 
stage.  
Beta 2 microglobulin (B2M) 
Beta 2 microglobulin (B2M) is a component of the major histocompatibility complex 
(MHC) class I molecules, and is commonly used as a biomarker for some blood cell 
cancers, known to indicate severity and prognosis[311]. B2M is also the major 
constituent protein of dialysis-associated amyloidosis; B2M accumulates in the 
plasma of chronically uraemic patients leading to the formation and deposition of 
B2M-amyloid. In Alzheimer’s disease B2M has been found as an biomarker in CSF 
and plasma, with increased levels of B2M reported in AD patients compared to 
controls[139, 312-313].  
Here B2M was positively related to concurrent amyloid load (at T12), and was 
tending towards significance with amyloid load at baseline. This supports previous 
findings that B2M is related to amyloid accumulation, and shows this relationship 
exists in preclinical AD individuals. B2M was also shown here to have longitudinal 
biomarker utility; B2M was negatively associated with brain atrophy of the superior 
occipital gyrus, with increased levels of B2M related to decreasing brain volume.  
Leucine rich alpha 2 glycoprotein 1 (LRG1) 
The exact function of LRG1 is unknown, though it is considered an acute phase 
protein with an up-regulation of LRG1 found in various diseases[314-316]. LRG1 
levels have been found to increase in response to acute inflammation in mice[317] 
indicating that it may have diagnostic or prognostic biomarker ability for 
inflammatory conditions. Leucine rich alpha 2 glycoprotein (LRG1) was here found 
significantly, and positively, related to amyloid load at baseline. LRG1 has not 
previously been linked to AD, although increased CSF LRG1 has been reported as a 
biomarker of idiopathic normal pressure hydrocephalus[318], considered a form of 
reversible dementia. 
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Alpha 1β glycoprotein (ABGP) 
Relatively little is also known about alpha 1β glycoprotein (ABGP), though it has 
previously been shown to have AD biomarker ability, with altered levels of ABGP in 
CSF of AD patients compared to controls[319]. Here ABGP was significantly, 
negatively related to brain atrophy of the middle frontal gyrus over time. This 
provides support for the utility of ABGP as a longitudinal plasma biomarker for 
preclinical AD.  
Apolipoprotein E (ApoE) 
The gene encoding for Apolipoprotein E4 allele (APOE ε4) is a well-established 
genetic risk factor for sporadic AD, known to increase the risk of developing AD and 
decrease the age of onset[24]. There is also evidence that plasma and serum ApoE 
levels may have strong biomarker ability. Both total ApoE and ApoE E4 levels in 
plasma have been found to be reduced in AD individuals compared to controls, 
though the biomarker effect of total ApoE does appear to be driven by ApoE E4 
levels[320]. A meta analysis of the association between peripheral levels of ApoE 
and AD was conducted by Wang et al (2014) [321], which concluded that lower 
peripheral ApoE levels is significantly associated with an AD diagnosis and may be 
an important risk factor for the development of AD. The results found in this 
discovery study support these conclusions. Here total ApoE was positively related to 
brain atrophy of the hippocampus, with lower levels of ApoE associated with lower 
hippocampal volume over time. As the hippocampus is one of the first regions 
effected in AD[205] this relationship is particularly interesting to preclinical AD 
biomarker research. ApoE was also positively, longitudinally related to two further 
brain regions for which the association was tending towards significance; middle 
frontal gyrus and whole brain volume. Also tending towards significance was a 
longitudinal relationship with Trails B score, where lower levels of ApoE were 
related to an increase in time spent completing the Trails B task, indicating cognitive 
decline.  
Mechanisms behind the association between low ApoE protein levels and AD are 
unclear. Normally, plasma ApoE is known to modulate lipid metabolism and 
cholesterol, and it is possible that a decrease in ApoE impairs these normal 
physiological functions, which then in turn disrupts central nervous system functions 
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leading to degeneration. The results here indicate that any disruption related to 
decreasing levels of this protein happen at an early, preclinical AD stage. The ability 
of ApoE as a preclinical marker of AD was previously found in BLSA individuals by 
Thambisetty et al, (2010)[151] using both 2DGE and ELISA assays, these results 
therefore replicate their findings using a different proteomic platform.  
4.4.4 Proteins replicating discovery phase 1 2DGE experiments 
Although the aim of this study was to complement the findings from the 2DGE 
discovery experiments by exploring an additional fraction of the proteome, there are 
many overlapping candidate biomarkers between the two studies. Some of these 
proteins, and their relationship to AD, were discussed previously in chapter 3, and a 
comparison of results found for these proteins between the two discovery studies is 
summarised in Table 4-13 below. These results provide a form of replication for 
these proteins as preclinical AD biomarkers within the BLSA cohort using a different 
proteomic discovery platform. However, it is important to consider that in each study 
different forms of the same protein (fragments/modifications) may be producing the 
statistical signal observed. This is especially true for larger proteins, such as 
Complement C3, which due to the 30kDa cut off filter employed here must have 
been detected in fragment form, whereas in the previous 2DGE study C3 was 
detected in many 2DGE spots throughout the length of the gel indicating both full 
length protein and fragment detection. It is important to consider that as well as 
cleavage, any fragments detected may also be a result of sample degradation during 
storage. Detection of multiple forms of the sample protein may explain why 
coefficient directions found for the same protein-dependant variable relationship may 
differ between the two studies. In addition, the 2DGE discovery study often 
identified multiple proteins in each spot as candidate biomarker which will have 
resulted in some false positive findings. This may also explain the difference in some 
results reported below. However some findings do appear to correspond between 
studies such as Fibringogen β chain, which displayed a negative coefficient with 
cognitive decline in both discovery studies, and as 2DGE spots containing this 
protein were located at an approximate molecular weight of 30-35kDa it is possible 
that the same fragment is being measured in both studies.  
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Table 4-13: Proteins identified as biomarkers of preclinical AD in both discovery 
studies. +/- indicates coefficient direction. 









47kDa + Brain volume 
(ventricular 
expansion). 
+/- Cognitive decline 
(Trails B) 
+/- PiB PET DVR 
(Baseline & T12) 
Brain volume = ~65-
70kDa 
Cognitive decline = 
~60-70kDa 
PiB PET DVR = ~45-
60kDa (BASELINE), 
25-40kDa (T12) 





95kDa + PiB PET DVR (T6 
& T12) 
- Brain volume 
(ventricular 
expansion) 
PiB PET DVR = 
~70kDa (T6) ~35kDa 
(T12) 
Brain volume = ~70-
75kDa 




56kDa +/- PiB PET DVR 
(Baseline & T12) 
- Cognitive decline 
(Trails B) 
+/- Brain volume 
(ventricular 
expansion) 
PiB PET DVR = 55-
60kDa (Baseline), 30-
55kDa (T12) 
Brain volume = ~55-
60kDa (+), ~35kDa (-) 
Cognitive decline = 
~30-35kDa 
- PiB PET DVR 
(baseline & T6) 
- Cognitive decline 
(Trails B) 
ApoA-IV 45kDa + PiB PET DVR 
(Baseline) 
+/- Cognitive decline 
(Trails B) 
+ Brain volume 
(ventricular expanion) 
PiB PET DVR = 
~45kDa 
Brain volume = ~45kDa 
Cognitive decline = 
~42-55kDa 
- Cognitive decline 
(Trails B) 
 






 +/-PiB PET DVR 
(Baseline) 
- PiB PET DVR (T12) 
+/- Cognitive decline 
(Trails B) 
- Brain volume 
(ventricular 
expansion) 
PiB PET DVR =~150-
190kDa 
Brain volume = ~70-
115kDa 
Cognitive decline = 30-
110kDa 
-  PiB PET DVR 
(T6) 
- Brain volume 
(middle occipital 
gyrus) 
Proteins found as significant in both studies, but not previously discussed in Chapter 
3, are discussed below. 
Complement C4b 
Table 4-14: Complement C4b summary; Significant relationships of C4b with 
surrogate markers of AD and coefficient directions (+/-). Findings from both discovery 
studies displayed. p<0.05. 
MW Discovery 1: 2DGE 
(p<0.05) 




193kDa + PiB PET DVR (T6) 
- PiB PET DVR (T12) 
PiB PET DVR T6 = 
~45kDa 
PiB PET DVR T12 = 
~45kDa 
- PiB PET DVR 
(baseline)  
 
Complement C4b was found to be significantly related to amyloid load at baseline, 
and was also tending towards significance at T12, both with a negative coefficient 
direction. In the 2DGE discovery study C4b was found related to amyloid load at 
both T6 and T12, though with opposite coefficients at each time point. Together 
these results show biomarker potential of C4b over all three time points (Table 4-14), 
suggesting a longitudinal ability of C4b as a biomarker of amyloid load. Mainly a 
negative relationship of C4b was found with PiB PET DVR, indicating that as 
amyloid load increased the concentration of C4b decreases.  
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In Chapter 3 the complement cascade was discussed; C4b is involved in both the 
classical and lectin complement pathways (refer back to Figure 3-44). It was 
previously concluded that the complement system is broadly altered in preclinical 
AD, and the results of this study also support that.  
Antithrombin-III (AIII) 
Table 4-15: Antithrombin-III summary; Significant relationships of AIII with 
surrogate markers of AD and coefficient directions (+/-). Findings from both discovery 
studies displayed. p<0.05 




Discovery 2: LC-MS/MS 
(p<0.05) 
53kDa - Cognitive decline 
(Trails B) 
Cognitive decline = 
~50-65kDa 
- Brain volume (cingulate 
gyrus, medial frontal 
gyrus, and middle frontal 
gyrus volume)  
 
Antithrombin-III is involved in the coagulation pathway and prevents excessive 
blood clotting. Individuals with AIII deficiency have increased risk of blood clots 
and hypercoagulability which has been associated with increased incidence of 
myocardial infarction, cerebrovascular disease, and peripheral arterial disease. These 
cardiovascular problems are dementia risk factors, hinting at a link between 
coagulation and dementia. AIII has previously been found as an AD biomarker, as 
well as a marker of blood-brain-barrier integrity (BBB), and has also been found to 
co-localise with both amyloid plaques and neurofibrillary tangles[252-256].  
Here AIII was negatively related to volumes of three brain regions (Table 4-15), and 
showed a tendency towards significance with five further regions, also all with a 
negative coefficient. This negative relationship is surprising as it conflicts previous 
literature in which decreased AIII has been linked to cognitive decline[254]. It also 
conflicts the results from chapter 3 where a longitudinal decrease in AIII was 
associated with cognitive decline as measured by Trails B (time taken). Significant 
2DGE spots containing AIII were located between approximate molecular weights of 
50-65kDa, indicating full length AIII protein. It is therefore likely that a different 
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form of AIII is related to cognitive decline, than that which was found related to 
brain atrophy in this study. 
Ig kappa chain C region (IGKC) 
Table 4-16: Ig kappa chain C region summary; significant relationships of IGKC with 
surrogate markers of AD and coefficient directions (+/-). Findings from both discovery 
studies displayed. p<0.05 




Discovery 2: LC-MS/MS 
(p<0.05) 
12kDa +/- PiB PET DVR 
(baseline & T12) 
- PiB PET DVR (T6) 
+/- Cognitive decline 
(Trails B) 
PiB PET DVR 
Baseline = ~25(+) 30--
40kDa(-) 
PiB PET DVR T6 = 
~28kDa 
PiB PET DVR T12 = 
~28-30kDa(-), ~32kDa 
(+) 
Cognitive decline = 
~25-40kDa 
+ PiB PET DVR (baseline)  
- Brain volume (middle 
temporal gyrus)  
 
Immunoglobulins and their relation to AD were discussed generally in Chapter 3. 
Here Ig kappa chain C region (IGKC), a LMW protein of 12kDa, was found to be 
significantly positively associated with amyloid load 12 years later. Increased levels 
of IGKC also appeared detrimental to brain volume with a significant negative 
association found with longitudinal atrophy of the middle temporal gyrus. 
Additionally a longitudinal negative relationship with temporal grey matter volume 
was tending towards significance. 
In the previous discovery study IGKC was found to be significantly related to 
amyloid load at all three time points, and it was also significantly longitudinally 
related to Trails B score, although mixed coefficient directions were found (Table 
4-16). When the two discovery phases are combined IGKC was found as a candidate 
biomarker for all three DVs, and therefore is a very strong candidate as a preclinical 
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AD biomarker. The majority of findings between both studies agree that an increase 
in IGKC is related to increased AD pathology and cognitive decline. Further 
supporting IGKC as an AD biomarker Hye et al (2006) [142] reported IGKC to be 
present in 4 2DGE spots significantly related to AD diagnosis. All 4 spots had a 
positive relationship with diagnosis. Together these results suggest IGKC is related 
to AD both preclinically and into the clinical onset of the disease.  
Zinc-alpha-2-glycoprotein (ZAG) 
Table 4-17: Zinc alpha 2 glycoprotein summary; significant relationships of IGKC with 
surrogate markers of AD and coefficient directions (+/-). Findings from both discovery 
studies displayed. p<0.05 
MW Discovery 1: 2DGE 
(p<0.05) 
Approximate 
2DGE spot MW 
Discovery 2: LC-MS/MS 
(p<0.05) 
34kDa +/- Brain atrophy 
(ventricular expansion) 
+ Cognitive decline 
(Trails B) 
 
Cognitive decline = 
40-45kDa 
+ PiB PET DVR (baseline)  
+ Brain volume (cingulate 
gyrus, middle temporal gyrus, 
superior temporal gyrus, and 
temporal gray matter)  
ZAG is a multifunctional protein, implicated in several biological processes such as 
lipid mobilisation, fertilisation, cell adhesion, and immunoregulation [322]. Research 
into ZAG to date has mainly focused on its involvement in cancer and obesity[323]. 
ZAG had been found over-expressed in several types of tumours, such as 
breast[324], prostate[325], and bladder cancer[326]. Increased serum levels of ZAG 
have been reported in individuals with prostate [325, 327] and cervical cancer[328] 
and therefore ZAG is considered a biomarker for these. As well as cancer, other 
conditions associated with increased serum ZAG levels include pre-eclampsia[329], 
chronic heart failure[330], and acute kidney disease[331]. However the most well 
studied property of ZAG is its involvement in the regulation of body weight; 
showing an inverse relationship with adiposity; being unregulated in cachexia, and 
reduced in obesity[332]. In adipose tissue ZAG gene expression has been found to be 
down-regulated with increased adiposity and circulating insulin[323], and plasma 
levels of ZAG in obese (ob/ob) mice are also decreased compared to lean mice[333].  
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In AD ZAG has previously been found as a biomarker in CSF, though the reason for 
a relationship with AD is unclear, as is the direction of this relationship. Increased 
CSF ZAG levels have been found in individuals with mild AD compared to controls 
suggesting ZAGs suitability as an early AD biomarker[256]. This is supported by the 
results of our preclinical study. However a comparison of CSF ZAG levels between 
autopsy confirmed AD, non-demented elderly controls, and non-AD dementias, AD 
subjects revealed reduced CSF ZAG levels compared to the other two groups[334]. 
This unclear picture of the direction of the relationship between ZAG and AD was 
also reflected in the results of this study.  
Here ZAG was found positively associated with amyloid load at baseline; indicating 
that higher ZAG levels are predictive of higher amyloid burden 12 years later. 
However a longitudinal analysis with brain atrophy revealed that over time 
decreasing levels of ZAG was related to increased atrophy of four brain regions 
(Table 4-17). When also considering results tending towards significance ZAG was 
longitudinally positively related to three further brain regions: grey matter, frontal 
grey matter, and middle occipital gyrus. Although the associations with amyloid load 
and brain atrophy appear conflicting, perhaps ZAG is increased initially in 
preclinical AD, indicative of later increased amyloid burden, but over time ZAG 
levels decline which correlates with brain atrophy. More longitudinal work is needed 
to explore this potentially complex relationship. A significant longitudinal 
relationship between ZAG and brain atrophy (ventricular expansion) was also 
reported in the previous discovery study; though with conflicting coefficient 
directions. The previous discovery study also found a significant longitudinal 
relationship with ZAG and cognitive decline (Trails B – measured by time taken), in 
which all significant spots had a positive coefficient. When combining the results of 
both discovery studies ZAG is related to all three DVs. Although the directions of the 
relationships are inconclusive, these findings do highlight ZAG as a strong 
biomarker candidate for preclinical AD.  
4.5 Conclusions 
This discovery study detected LMW proteins as candidate markers of preclinical AD, 
adding to those found in the previous 2DGE discovery study. The additional 
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biomarkers discovered here shows the importance in targeting less abundant, LMW 
proteins for analysis as they are often masked by larger more abundant proteins. 
Together the two studies provide a more comprehensive analysis of the plasma 
proteome for the discovery of preclinical AD biomarkers. These results also provide 
further support that plasma biomarkers have the potential to be used as a screening 
tool for AD, including proteins from a LMW fraction. 
However the identification of these LMW proteins varied greatly between 
individuals and sample injections, resulting in a vast number being discarded from 
analysis due to lack of data available. A more robust way to detect and quantify these 
proteins is needed. Isobaric labelling approaches, such as Tandem Mass Tagging 
(TMT), could be used to overcome the issue of missing data values and would also 
enable multiplexing of up to 10 samples.  
Many of the candidate biomarkers found here had also been discovered in the 
previous 2DGE discovery study. This provides a form of replication, though it is 
likely that different forms of each protein (fragment or modification) were assessed 
by each approach; due to the prefractionation employed here and also because 2DGE 
had already identified many of these proteins in multiple spots, indicative of multiple 
forms of many proteins (modified and/or cleaved) as biomarkers.   
Quantitative assays in an independent cohort are now needed to validate the proteins 
reported here as candidate biomarkers. If validated these proteins may, independently 
or in combination, provide a biomarker for preclinical AD diagnosis or allow 
predication of disease onset.  
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Chapter 5. Validation of candidate biomarkers of Alzheimer’s 
disease pathology and cognitive decline 
5.1 Introduction 
In chapters 3 and 4 the discovery of biomarkers of preclinical AD pathology and 
cognitive decline was presented. The candidate biomarkers identified now require 
validation in an independent cohort using an alternative proteomic platform. This 
will determine whether the results are reproducible and if they can be generalised to 
a wider population. 
The candidate biomarkers discovered are related, at a preclinical stage, to one or 
more DVs; amyloid load, brain atrophy, and cognitive decline. However an ideal 
biomarker would also enable a clear distinction between AD cases and healthy 
controls. This would also confirm the biomarkers involvement in AD after the 
clinical onset of the disease, increasing the confidence of its association to the 
disease preclinically, rather than acting as markers of general decline or other co-
morbidities. It would additionally show their utility longitudinally throughout the 
disease. For these reasons the validation experiments here will be performed using 
cohorts of AD subjects and healthy age matched controls. Over the two discovery 
studies 15 proteins were identified as candidate biomarkers of all three DVs. These 
proteins therefore have the strongest potential as specific AD biomarkers and this 
validation will focus upon this subset of 15 candidate biomarkers. 
Proteomic results from the discovery-phase experiments were obtained using 2DGE 
and LC-MS/MS proteomic techniques, both of which generate data from 
enzymatically digested peptides. Therefore, as an orthogonal approach, specific 
aptamer and antibody based techniques (SOMAlogic’s SOMAscanTM and enzyme-
linked immunosorbent assay (ELISA)) were chosen to validate the candidates 
previously identified in an independent cohort of plasma samples.  
Sattlecker et al (2014)[141] conducted a large scale multiplexed plasma protein study 
(n=691), screening for AD biomarkers using SOMAscan technology. 1,001 proteins 
were tested for their biomarker ability against seven outcome measurements; clinical 
diagnosis, MCI to AD conversion, rate of cognitive decline, and brain atrophy of the 
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hippocampus (left/right) and entorhinal cortex (left/right). Both previously known 
and novel biomarkers were identified, and a multivariate analysis identified 13 
proteins which together could predict AD with an accuracy of AUC of 0.70. From 
this dataset SOMAscan aptamer-based assays were available for 7 of the 15 proteins 
chosen to be validated in our validation experiments; α1-antitrypsin (AAT), 
fibrinogen (α/β/γ chain), α2-macroglobulin (A2M), serum paraoxonase/arylesterase 1 
(PON1), complement C3, serum albumin, and haptoglobin. Therefore to make 
efficient use of previously acquired assay data this dataset will here be re-analysed as 
a targeted validation approach for these 7 proteins. Multivariate analysis will be kept 
consistent with that employed by Sattlecker et al (2014), however false discovery 
rate corrections will be tailored specifically for the targeted protein set. 
The remaining 8 proteins requiring validation are: Zinc alpha 2 glycoprotein (ZAG), 
Protein AMBP/alpha 1 microglobulin (A1M), Ceruloplasmin, Apolipoprotein A IV 
(ApoA-IV), Ig kappa chain C region, Ig gamma 1 chain C region, Ig gamma 2 chain 
C region, and Ig alpha 1 chain C region. Time and cost restrictions of this study 
meant that only two of the above proteins could be validated by ELISA. From these 
8 proteins, ZAG and Protein AMBP are the two most novel AD biomarker 
candidates for which reliable ELISA assays could be obtained. These two proteins 
were therefore selected for further validation by ELISA, using a subset of subjects 
from the same cohorts as the SOMAscan study. 
5.2 Aims 
To validate previously discovered candidate biomarkers of preclinical AD pathology 
and cognitive decline in an independent cohort using an orthogonal proteomic 
platform. Specifically, to validate candidate biomarkers relationship with AD using 
SOMAlogic and ELISA in case versus control cohorts. To use multivariate analyses 
to identify proteins related to diagnosis status, brain atrophy and cognitive decline. 
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5.3 Results 
5.3.1 Demographic characteristics 
SOMAscan 
SOMAscan assays were performed on plasma samples from 691 subjects recruited 
from AddNeuroMed (n=415), Maudsley and King’s Healthcare Partners Dementia 
Case Register (DCR) (n=38), and Alzheimer’s Research UK (ARUK) (n=238) 
cohorts, previously described in chapter 2. All subjects with the relevant information 
available were recruited from these cohorts. Table 5-1 displays the demographic 
characteristics for these subjects, stratified by cohort.   
Table 5-1: SOMAscan assay; subject demographics, stratified by cohort 

























29 27.5 21 29 27 17 21 
All subjects had undergone cognitive assessment, including the Mini Mental State 
Examination (MMSE). Structural MRI data was obtained from 273 AddNeuromed 
subjects (Controls = 93, MCI = 81, AD = 99). 
ELISA (A1M and ZAG) 
ELISA assays were performed on a subset of the subjects included in the SOMAscan 
assays detailed above. Differences in ELISA plate set-up between the A1M and ZAG 
  215 
  
assays allowed slightly different sample numbers to be tested (A1M n=140, ZAG 
n=144). Table 5-2 and Table 5-3 display the demographic characteristics for these 
subjects, stratified by cohort, for A1M and ZAG ELISAs respectively. Structural 
MRI data was obtained from all AddNeuromed subjects. 
Table 5-2: A1M ELISA; subject demographics, stratified by cohort 









Age (mean) 72.0 75.7 84.5 84.0 
Gender (M/F) 33/28 11/27 6/2 7/26 
Baseline MMSE (mean) 29.1 20.8 29.5 17.8 
Table 5-3: ZAG ELISA; subject demographics, stratified by cohort 









Age (mean) 72.0 75.7 84.5 83.8 
Gender (M/F) 33/28 13/28 6/2 7/27 
Baseline MMSE (mean) 29.1 21.3 29.5 17.9 
Calculation of rate of cognitive decline 
The rate of cognitive decline was calculated for AD subjects with at least three 
MMSE assessments over a period of up to 2 years (SOMAscan n=329, A1M n=70; 
ZAG n=74). This was calculated as detailed in Sattlecker et al (2014)[141]. Briefly, 
linear mixed effects regression models were generated, using R, with samples and 
test centre entered as random effects, and years of education and home environment 
(e.g. nursing home) included as fixed effects. The slope coefficient for MMSE score 
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was used as the rate of cognitive decline for further statistical analysis, defined as the 
change in MMSE per day. 
5.3.2 SOMAscan 
Candidate biomarker association with disease status (AD versus control) 
For each of the 7 candidate biomarkers, logistic regression was employed to detect 
associations with disease status. All AD and control subjects from the combined 
AddNeuroMed, ARUK, and DCR cohort, described above, were included in this 
analysis. For each protein, False Discovery Rate (FDR) corrections were applied in 
order to correct for multiple testing. FDR q-values of <0.1 were considered 
significant, those <0.2 were considered as tending towards significance.  
The single analyte logistic regression for AD cases versus controls showed that 1 
protein, AAT, was associated with disease status at both a significance level of 
p<0.05 and a q-value of <0.1 (Odds Ratio (OD) =2.67, Beta = 0.98, q-value = 0.06). 
Full results are reported in Table 5-4. 
Table 5-4: Logistic regression results for AD versus control, in order of significance 
Protein Beta OR p-Value q-Value 
α1-Antitrypsin 0.984 2.675 0.008 0.056 
Fibrinogen α/β/γ chain 0.334 1.397 0.242 0.377 
α2-Macroglobulin -0.418 0.658 0.280 0.377 
Serum 
paraoxonase/arylesterase 1 -0.799 0.450 0.286 0.377 
Complement C3 -0.233 0.792 0.297 0.377 
Serum albumin -0.629 0.533 0.323 0.377 
Haptoglobin, Mixed Type 0.141 1.151 0.471 0.471 
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Candidate biomarker association with volume of brain regions 
Linear regression was used to analyse the plasma levels of the 7 proteins for their 
association to volumes of brain regions known to be strongly related to AD 
pathology (left and right entorhinal cortices, and left and right hippocampi). Age, 
gender, APOE ε4 status, and recruitment centre were all entered as covariates in the 
regression model. 
Linear regression results revealed that AAT was the only protein found to be 
significantly related to brain volume. AAT was associated with left entorhinal 
volume and right hippocampal volume at both a significance level of p<0.05 and a q-
value of <0.1. AAT was also associated with left hippocampal volume p<0.05, 
tending towards a significant FDR correction (q-value = 0.11). Full results are 
reported in Table 5-5 (left entorhinal), Table 5-6 (right entorhinal), Table 5-7 (left 
hippocampus), and Table 5-8 (right hippocampus). 
Table 5-5: Linear regression results for candidate biomarkers with left entorhinal 
volume 
Protein Beta R-squared p-Value q-Value 
α1-Antitrypsin -0.0001 0.163 0.007 0.047 
Serum albumin 0.0001 0.148 0.102 0.358 
Haptoglobin, Mixed Type -0.0000 0.141 0.428 0.718 
Fibrinogen α/β/γ chain 0.0000 0.141 0.431 0.718 
Serum 
paraoxonase/arylesterase 1 0.0000 0.140 0.558 0.718 
Complement C3 0.0000 0.140 0.615 0.718 
α2-Macroglobulin 0.0000 0.139 0.952 0.952 
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Table 5-6: Linear regression results for candidate biomarkers with right entorhinal 
volume 
Protein Beta R-squared p-Value q-Value 
α1-Antitrypsin -0.0001 0.108 0.104 0.665 
α2-Macroglobulin 0.0001 0.103 0.318 0.665 
Serum 
paraoxonase/arylesterase 1 0.0001 0.102 0.420 0.665 
Serum albumin 0.0000 0.101 0.543 0.665 
Complement C3 0.0000 0.101 0.562 0.665 
Fibrinogen α/β/γ chain 0.0000 0.100 0.657 0.665 
Haptoglobin, Mixed Type 0.0000 0.100 0.665 0.665 
Table 5-7: Linear regression results for candidate biomarkers with left hippocampal 
volume 
Protein Beta R-squared p-Value q-Value 
α1-Antitrypsin -0.0002 0.296 0.016 0.110 
Haptoglobin, Mixed Type -0.0001 0.288 0.096 0.306 
Serum 
paraoxonase/arylesterase 1 0.0001 0.286 0.162 0.306 
Serum albumin 0.0001 0.286 0.175 0.306 
Fibrinogen α/β/γ chain 0.0001 0.283 0.327 0.458 
Complement C3 0.0000 0.281 0.684 0.799 
α2-Macroglobulin 0.0000 0.281 0.831 0.831 
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Table 5-8: Linear regression results for candidate biomarkers with right hippocampal 
volume 
Protein Beta R-squared p-Value q-Value 
α1-Antitrypsin -0.0002 0.284 0.014 0.099 
Complement C3 0.0001 0.272 0.190 0.665 
Serum 
paraoxonase/arylesterase 1 0.0001 0.270 0.350 0.768 
α2-Macroglobulin 0.0001 0.269 0.495 0.768 
Haptoglobin, Mixed Type 0.0000 0.269 0.549 0.768 
Fibrinogen α/β/γ chain 0.0001 0.268 0.690 0.804 
Serum albumin 0.0000 0.268 0.917 0.917 
Candidate biomarker association with rate of MMSE decline 
The mean change in MMSE points per year for AD patients in each cohort are 
detailed in Table 5-9. 
Table 5-9: Mean loss in MMSE points per year for AD patients within each cohort 
Cohort Mean change in MMSE 
(points per year) 
Standard deviation 
AddNeuroMed 1.5 1.5 
ARUK 2.9 1.4 
DCR 2.2 1.4 
Linear regression was used to analyse the association between the 7 candidate 
biomarkers and each AD subject’s rate of cognitive decline (MMSE change). 
Covariates were not included in this analysis as they had been adjusted for in the rate 
of cognitive decline slope calculation.  
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Both C3 and haptoglobin were significantly associated with rate of cognitive decline 
(p<0.05) and both proteins were tending towards significance after FDR correction 
(q-value = 0.116). Full results are reported in Table 5-10. 
Table 5-10: Linear regression results for candidate biomarkers with rate of cognitive 
decline (MMSE change) 
Protein Beta 
R-
squared p-Value q-Value 
Complement C3 0.367 0.023 0.018 0.116 
Haptoglobin, Mixed Type 0.367 0.019 0.033 0.116 
Serum 
paraoxonase/arylesterase 1 -0.996 0.007 0.184 0.429 
Serum albumin -0.326 0.002 0.490 0.857 
Fibrinogen α/β/γ chain -0.052 0.000 0.805 0.993 
α1-Antitrypsin 0.053 0.000 0.855 0.993 
α2-Macroglobulin 0.003 0.000 0.993 0.993 
5.3.3 Enzyme linked immunosorbant assay (ELISA) for Alpha 1 
microglobulin (A1M) and Zinc alpha 2 glycoprotein (ZAG) 
Coefficient of variation (CV) 
As every plasma sample had been run in duplicate on each ELISA plate the 
coefficient of variation (CV) between duplicate samples was calculated. These CVs 
were then averaged to obtain an overall mean within-subject CV; A1M = 6.48% and 
ZAG = 6.55%. 
Influence of ELISA plate 
For both A1M and ZAG four ELISA plates were completed in total, each on 
consecutive days. Although every effort is taken to ensure the procedure is 
standardised across plates very subtle differences in manual or environmental factors 
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can influence the results obtained from each plate. Although samples were 
randomised across plates these differences can still have an effect on the results and 
it is therefore important to check for and if necessary control for any changes found 
between plates. 
The mean A1M values obtained from each plate are listed in Table 5-11 and 
illustrated in Figure 5-1. A one way univariate ANOVA was conducted to check for 
differences between these mean A1M values, whilst controlling for age, diagnosis, 
gender, and sample freeze-thaw. A significant main effect of ELISA plate was found, 
F(3,132)=22.836, p<0.001, showing that there was a significant difference between 
the mean A1M values between plates. It was therefore important to ensure that 
ELISA plate is controlled for within subsequent statistical analysis.  
Table 5-11: Number of subjects, mean value, and standard deviation, for A1M ELISA 
plates 
A1M ELISA plate N Mean A1M value (ng/ml) Std. Deviation 
 1 23 49762.94 20295.55 
 2 39 50355.28 16721.01 
 3 39 34594.63 9702.15 
 4 39 60220.67 17230.34 
 Total 140 48615.72 18507.78 
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Figure 5-1: Mean A1M value for each ELISA plate. 
The mean ZAG values obtained from each plate are listed in Table 5-12 and 
illustrated in Figure 5-2. A one way univariate ANOVA was conducted to check for 
differences between these mean ZAG values, whilst controlling for age, diagnosis, 
gender, and sample freeze-thaw. No main effect of ELISA plate was found, p>0.05, 
showing that there was no significant difference between the mean ZAG values 
between plates. 
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Table 5-12: Number of subjects, mean value, and standard deviation, for ZAG ELISA 
plates 
ZAG ELISA Plate N Mean ZAG value (µg/ml) Std. Deviation 
1 25 113.29 33.64 
2 41 94.80 35.01 
3 38 75.51 19.53 
4 33 93.32 127.28 
Total 137 92.47 68.097 
 
 
Figure 5-2: Mean ZAG value for each ELISA plate 
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Normality tests 
Normality tests were performed to determine the normality of the A1M and ZAG 
data distributions. Kolmogorov-Smirnov tests for normality indicated that both A1M 
and ZAG datasets were non-normally distributed (p<0.05).  
As skewness can affect the normality of a dataset, outliers were identified and 
removed so to minimize skewness. For both proteins the removal of outliers was 
completed in two ways, producing two separate datasets for each protein. Firstly, 
outliers were calculated and removed per diagnosis group (see Figure 5-3 and Figure 
5-4); these datasets would be used for AD versus control comparisons. Secondly 
outliers were removed from the dataset as a whole (see Figure 5-5 and Figure 5-6); 
these datasets would be used to detect associations with brain atrophy and cognitive 
decline. 
 
Figure 5-3: Box and whisker diagram identifying outliers (stars and circles) for each 
diagnosis group (AD and control), for A1M ELISA values 
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Figure 5-4: Box and whisker diagram identifying outliers (stars and circles) for each 
diagnosis group (AD and control), for ZAG ELISA values 
 
Figure 5-5: Box and whisker diagram identifying outliers (circles) for A1M ELISA 
values 
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Figure 5-6: Box and whisker diagram identifying outliers (stars and circles) for ZAG 
ELISA values 
Once outliers had been removed normality tests were repeated. Kolmogorov-
Smirnov tests for normality indicated that all A1M and ZAG datasets were now 
normally distributed (p>0.05). 
A1M and ZAG associations with disease status (AD versus control) 
Figure 5-7 and Figure 5-8 display the mean values for A1M and ZAG for AD and 
control subjects. 
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Figure 5-7: Bar chart displaying mean A1M values for AD and control subjects 
 
Figure 5-8: Bar chart displaying mean ZAG values for AD and control subjects 
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Whilst conducting these analyses it was observed that both A1M and ZAG mean 
values for cases and controls differed slightly between genders (see Figure 5-9 and 
Figure 5-10). A one-way analysis of co-variance (ANCOVA) revealed that 
differences between AD and control subjects within each gender were not significant 
for either A1M or ZAG (p>0.05), though this was an important consideration for 
subsequent analyses.  
 
Figure 5-9: Bar chart displaying mean A1M values for AD and control subjects, split 
by gender 
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Figure 5-10: Bar chart displaying mean ZAG values for AD and control subjects, split 
by gender 
A1M and ZAG associations with brain volume and cognitive decline 
Partial correlations were performed for both A1M and ZAG to identify significant 
relationships with brain volumes, cognition (MMSE), and cognitive decline (MMSE 
change). No significant correlations were found for either A1M or ZAG (p>0.05), 
though for A1M three regions were tending towards significance; left and right 
entorhinal thickness, and left entorhinal volume (p<0.1). Full results are reported in 
Table 5-13 and Table 5-14 below. 
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Table 5-13: Partial correlation results for A1M, in order of significance 
Dependant variable 
Correlation 
coefficient P-value q-value 
Left entorhinal cortical thickness -0.200 0.057 0.302 
Left entorhinal volume -0.195 0.063 0.302 
Right entorhinal cortical thickness -0.179 0.090 0.302 
Right entorhinal volume -0.100 0.348 0.735 
Whole brain -0.096 0.367 0.735 
MMSE 0.066 0.455 0.758 
Left hippocampus -0.059 0.581 0.829 
Ventricles 0.045 0.673 0.842 
MMSE loss per year 0.032 0.802 0.874 
Right hippocampus 0.017 0.874 0.874 
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Table 5-14: Partial correlation results for ZAG, in order of significance 
Dependant variable 
Correlation 
coefficient P-value q-values 
MMSE -0.071 0.425 0.793 
Right hippocampus 0.078 0.465 0.793 
MMSE loss per year 0.092 0.468 0.793 
Right entorhinal volume 0.076 0.477 0.793 
Ventricles -0.068 0.523 0.793 
Whole brain 0.064 0.549 0.793 
Right entorhinal cortical thickness 0.061 0.569 0.793 
Left entorhinal cortical thickness 0.051 0.634 0.793 
Left hippocampus 0.016 0.880 0.948 
Left entorhinal volume 0.007 0.948 0.948 
Previously a subtle difference in A1M and ZAG levels between males and females 
had been observed. Therefore partial correlations were repeated separately for each 
gender.  
For A1M no significant correlations were found for female subjects. For male 
subjects significant correlations were found between A1M and both right and left 
entorhinal cortical thickness values (p<0.05), with the left entorhinal cortical 
thickness still remaining significant after FDR correction (q-value<0.1). Full results 
are reported in Table 5-15. 
  
  232 
  







































































-0.206 0.13 0.983 -0.222 0.220 0.620 
Right entorhinal 
volume 
-0.134 0.329 0.983 -0.210 0.248 0.620 
Left hippocampus -0.085 0.536 0.983 0.034 0.853 0.948 
Ventricles 0.083 0.548 0.983 -0.084 0.650 0.929 
Left entorhinal 
cortical thickness 
-0.044 0.75 0.983 -0.457 0.006 0.060 
Right hippocampus -0.022 0.874 0.983 0.037 0.844 0.948 
MMSE -0.018 0.877 0.983 0.138 0.365 0.730 
Whole brain -0.01 0.944 0.983 -0.131 0.478 0.797 
MMSE loss per year 0.004 0.981 0.983 0.007 0.981 0.981 
Right entorhinal 
cortical thickness 
-0.003 0.983 0.983 -0.354 0.041 0.205 
For ZAG no significant correlations were found for male subjects. For female 
subjects a correlation between ZAG and left entorhinal volume was tending towards 
significance (p<0.1), though after FDR correction no relationship was found (q-value 
= 0.6). Full results are reported in Table 5-16. 
  233 
  




































































cortical thickness -0.044 0.76 0.988 0.121 0.484 0.703 
Left entorhinal 
volume -0.251 0.073 0.617 0.196 0.25 0.703 
Left hippocampus 0.004 0.975 0.988 0.04 0.816 0.907 
MMSE -0.065 0.576 0.988 -0.111 0.448 0.703 
MMSE loss per year 0.108 0.474 0.988 -0.146 0.609 0.761 
Right entorhinal 
cortical thickness 0.002 0.988 0.988 0.136 0.43 0.703 
Right entorhinal 
volume  -0.207 0.143 0.617 0.256 0.127 0.703 
Right Hippocampus 0.023 0.873 0.988 0.119 0.492 0.703 
Ventricles -0.053 0.714 0.988 -0.182 0.289 0.703 
Whole brain 0.188 0.185 0.617 0.019 0.914 0.914 
5.4 Discussion  
The previous two chapters detailed the discovery of many candidate biomarkers for 
preclinical AD. From these, 15 proteins were found to associate with all three DVs 
measured (amyloid load, brain atrophy and cognitive decline). These 15 proteins 
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were therefore the strongest contenders to be biomarkers specific to AD and were 
considered for validation here.  
Validation was performed using two different proteomic techniques, SOMAscan and 
ELISA, using a multi-centre cohort consisting of subjects from AddNeuroMed, 
ARUK and DCR cohorts. Biomarkers were here validated for their association to 
disease status, brain atrophy, and cognitive decline. Brain atrophy measurements 
were obtained from two brain regions; entorhinal cortex and hippocampus. These 
two brain regions are highly associated with AD; known as excellent imaging 
biomarkers of AD progression and severity[203-204, 206, 335-337]. MMSE was 
used as the measure of cognitive decline. MMSE is a brief test of general cognitive 
function and is widely used for the clinical assessment of AD; used as a screening 
tool as well as an indicator of disease progression[338-339]. Discovery phase 
experiments used Trails B as a marker of preclinical cognitive decline, and MMSE 
has shown utility as a predictive tool of later AD development[338, 340-341]. 
However MMSEs utility is mainly well-established for the assessment of clinical 
populations, appropriate to the cohorts used here.  
SomaLogic SOMAscan validation 
Using SomaLogic’s SOMAscan proteomics technology 7 of these proteins were 
assessed for their relationship with AD status, brain atrophy and cognition. One 
protein, AAT, validated as an AD biomarker of disease status and brain atrophy of 
both the left entorhinal volume and right hippocampal volume, at the 0.1 FDR level. 
Increased AAT was found in AD subjects compared to controls, and higher levels of 
AAT correlated with decreased brain volume. This is consistent with the findings of 
the 2DGE discovery study where AAT was one of the most commonly detected 
proteins in significant 2DGE spots, with the majority of spots displaying a positive 
relationship with increased AD pathology and cognitive decline. Together these 
results provide evidence that AAT is associated with AD pathology throughout the 
preclinical and clinical stages. This detrimental increase in AAT has here been 
observed in healthy controls and AD individuals, across multiple cohorts and 
different proteomic techniques. These results are also consistent with previous 
research where increased AAT levels have been found in AD plasma and CSF 
compared to controls [237-238]. Although this is a very strong finding, not all of the 
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results found in the discovery phase experiments agree with a positive relationship 
between AAT and AD pathology and cognitive decline. Specifically the LC-MS/MS 
LMW protein discovery study identified AAT as a biomarker of brain atrophy, with 
decreased AAT related to increased atrophy of the superior temporal gyrus. This 
highlights that AAT may have a more complex relationship with AD than the 
previous results suggest, with, for example, AAT fragments behaving differently to 
the full length protein. It is important for future experiments to define which epitope 
of AAT the aptamers are measuring so that results can be accurately compared.  
At a slightly more relaxed FDR level of 0.2 this study also validated both 
complement C3 and haptoglobin as biomarkers of cognitive decline. Both proteins 
were found to be positively related with MMSE score; with lower C3 and 
haptoglobin levels indicating cognitive decline. Although discovery phase 
experiments revealed mixed coefficient directions for these proteins with the DVs, 
many of the results found do agree with the findings of these validation experiments.  
For all three DVs many 2DGE spots containing C3 displayed a detrimental 
relationship with decreased C3 levels; associating with increased amyloid deposition, 
larger ventricular expansion, and increased time taken to complete Trails B task. LC-
MS/MS discovery experiments also revealed the same direction of relationship with 
increased amyloid load (at T6). Together with the validation experiments these 
results support a decrease in C3 as detrimental, and specifically provide evidence for 
its utility as a biomarker of cognitive decline, both preclinically and during the 
clinical stages of AD. These results also correspond with previous literature 
suggesting a protective role of C3[222, 229].   
The 2DGE discovery experiments also reported haptoglobin as a candidate 
biomarker for all three DVs, with each DV showing both positive and negative 
relationships with haptoglobin. The results of this SOMAscan study validate the 
2DGE spots showing a negative relationship with Trails B (decreased haptoglobin 
with increased time taken). These results suggest a longitudinal relationship between 
haptoglobin and cognitive decline. This is supported by literature which suggests a 
progressive impairment of haptoglobins functions throughout disease 
progression[281]. 
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A1M and ZAG ELISA validation 
8 of the 15 proteins selected for validation did not have SomaLogic SOMAscan 
assays available: ZAG, Protein AMBP, Ceruloplasmin, ApoA-IV, Ig kappa chain C 
region, Ig gamma 1 chain C region, Ig gamma 2 chain C region, and Ig alpha 1 chain 
C region. ELISA was selected as a targeted proteomic technique by which further 
validation could be conducted, though time and cost limited the number of proteins 
which could be validated by ELISA to two. These two proteins were selected based 
upon novelty to AD research and the availability of reliable ELISA assay. 
Ceruloplasmin, ApoA-IV and the various IgGs have a good evidence base for their 
involvement in AD[142, 151, 270, 273, 276, 342-343], as discussed in detail in 
chapters 2 and 3. ELISA availability for immunoglobulins was also relatively poor. 
To date comparatively less AD-related research is available for protein AMBP and 
ZAG, whilst many ELISA assays were available for these two proteins, therefore 
they were selected for validation. The coefficient of variation for these two plates 
was low (6.48% and 6.55%), indicating that a good level of data quality was 
achieved and statistical analysis was conducted with confidence. 
In chapter 2 the approximate molecular weight of the significant 2DGE spots 
containing protein AMBP was 30-40kDa. This indicated that the protein identified 
was either the full length AMBP protein (39kDa), or its largest chain α1M. Therefore 
here an ELISA specific to the alpha-1-microglobulin (A1M) chain of protein AMBP 
was chosen for validation. The results here show that A1M was tending towards a 
significant relationship with three brain regions; right and left entorhinal cortical 
thickness and left entorhinal volume, with an increase in A1M found with increased 
brain atrophy. This relationship with right and left entorhinal cortical thickness was 
highly significant when considered for male subjects only. Although these results 
provide further support for A1M as a biomarker of AD pathology, they do not 
validate the 2DGE discovery phase findings where protein AMBP was found to 
decrease with increased brain atrophy (ventricular expansion). It is possible that a 
different section of protein AMBP was measured by 2DGE, not the A1M chain. It is 
also possible that the relationship of this protein with AD changes over time from the 
preclinical stage into the clinical disease onset. However discovery results did also 
report an increase in protein AMBP with higher amyloid load at T12, providing a 
form of validation for an increase in A1M with increased pathology. Although these 
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results are confusing, it does indicate that there is a relationship between protein 
AMBP/A1M and AD that needs further clarification. 
ZAG was not found to be a biomarker of any of the measures tested here. Though 
when focusing on female subjects only it did show small potential as a marker of left 
entorhinal volume, tending towards significance (p<0.1) but not passing FDR 
corrections. Although this significance level renders the result doubtful, the direction 
of the relationship (negative) corresponds to the majority of findings in both 
discovery phase experiments, with all three DVs. This perhaps gives more credibility 
to the validation result, which with a larger cohort may have shown increased 
significance.  
Both A1M and ZAG showed gender specific results highlighting the importance of 
assessing biomarker abilities for each gender separately. Gender differences in AD 
research are often reported; the prevalence of AD is higher in women than men, 
behavioural and cognitive functions are often expressed differently between genders, 
and brain morphology and function also differ (see [344-345] for reviews). It is 
therefore unsurprising that plasma biomarkers would also reflect these gender 
specific differences and so themselves differ between genders. Future studies should 
stratify and report data by gender for all aspects of the disease.  
5.5 Conclusions 
Proteins AAT, C3, haptoglobin, and protein AMBP showed results that validated 
discovery phase findings, with AAT found to be the strongest biomarker candidate. 
This validation provided evidence of the biomarker utility of these proteins in AD 
patients, indicating that their preclinical biomarker utility previously discovered is 
also likely to be specific for AD. Therefore these proteins can be considered as 
related to AD both clinically and preclinically and are able to measure disease 
progression from a preclinical stage throughout to a clinical diagnosis. Although the 
relationship with AD was tested here, the sensitivity and specificity of the 
biomarkers need to be further tested by assessing their relationships with other 
neurological diseases in future studies.  
  238 
  
Proteins that were not found to be significant in these validation experiments may 
still have biomarker ability which was not tested here. Discovery phase experiments 
identified proteins as candidate biomarkers of amyloid load, brain atrophy and 
cognitive decline, therefore their strength as biomarkers may be in reflecting one of 
these three DVs, specifically at a preclinical stage. In addition, although brain 
atrophy and cognitive decline were included in this validation study, the 
measurements of these differed between the studies which may have hindered 
validation. Discovery phase experiments assessed both of these measures 
longitudinally over a 12 year period, whereas validation experiments measured 
cognitive decline over a maximum of 2 years, and brain atrophy was only measured 
at a single time point cross-sectionally. Furthermore information on brain amyloid 
load was not available for these subjects and so protein relationships with amyloid 
burden could not be tested. These differences were unavoidable and it is rare that 
cohorts match exactly on the information that they have available; another reason 
that comparisons between studies is difficult. For these reasons non-validating 
proteins should still be considered for future validation experiments.  
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Chapter 6. Conclusions 
6.1 Overall Discussion 
Recently, research has shown that it is possible to detect a peripheral signal of AD. 
Whilst it is unclear whether changes found in the periphery reflect direct disease 
mechanisms or secondary changes to disease processes in the brain, it is now clear 
that plasma is a rich source of biomarkers for the disease. Much research has focused 
upon the ability of differentially expressed proteins to classify individuals into 
diagnosis groups (e.g. AD versus healthy controls). Very high sensitivity and 
specificity has been found with these approaches, and whilst this is encouraging 
these approaches have their limitations. Mainly clinical heterogeneity in patients and 
neuropathology in controls is ignored with these approaches and so biomarkers 
identified may instead reflect secondary changes specific to the cohort used rather 
than the disease biology. Therefore using disease status as the primary outcome 
variable in a large scale discovery study may result in the identification of 
biomarkers with limited/no involvement in disease. Additionally these biomarkers 
may have limited clinical utility as they may lack sensitivity to disease severity or 
progression. Using well established surrogate markers of AD as primary outcome 
measurements to discover AD biomarkers can help to avoid these issues.  
The main aims of this project were to discover candidate plasma biomarkers of 
preclinical AD pathology and cognitive decline. Increasingly research is focusing on 
the early preclinical stages of AD as results of clinical trials and laboratory research 
indicate that interventions may only be beneficial at an early stage. Biomarkers will 
play a crucial role in the identification and monitoring of preclinical AD individuals, 
and plasma based biomarkers would be most practical. In 2010 Thambisetty et al 
performed a retrospective preclinical AD biomarker study investigating plasma 
proteins reflecting brain amyloid load 10 years later[151]. This project aimed to 
repeat and expand upon this work. Here, plasma proteins were assessed for their 
relationship to amyloid load 12 years prior, 6 years prior, and concurrently to the PiB 
PET scan. Additionally the plasma proteome was investigated for a correlation with 
two more measures of Alzheimer’s disease (cognitive decline and brain atrophy) 
over a longitudinal 12 year period.  
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This project used two complimentary discovery proteomic techniques for the 
discovery of biologically relevant plasma biomarkers of preclinical AD. 2DGE was 
used to discover larger proteins as biomarkers (~20-250kDa), whereas LC-MS/MS 
methodology was tailored to focus on the discovery of LMW proteins (<30kDa) and 
less abundant proteins as biomarkers. Together these two techniques provided a more 
comprehensive analysis of the plasma proteome for the discovery of preclinical AD 
biomarkers. Each technique identified unique candidate biomarkers, highlighting the 
importance of increasing molecular weight and dynamic range coverage in 
biomarker discovery; ensuring as many proteins as possible are included for analysis. 
In addition, many candidate proteins overlapped between the two techniques, 
providing a form of replication. Although it cannot be confirmed that the same forms 
of these proteins were being identified with each technique, these findings add 
confidence to the proteins ability as a preclinical AD biomarker.  
Discovery stage experiments were very successful in identifying many candidate 
biomarkers for preclinical AD. However it was considered important to establish 
whether these proteins are involved in AD after clinical onset. This was to increase 
confidence in their relationship with AD development at the preclinical stage, rather 
than as markers of general decline in health or other co-morbidities. Therefore 
validation experiments were conducted using plasma samples from AD patients as 
well as healthy controls. In addition to testing biomarker ability for disease status, the 
proteins’ relationship with cognitive decline and brain atrophy was also assessed 
during validation experiments.  
Aptamer and antibody based techniques (SOMAlogic’s SOMAscanTM and enzyme-
linked immunosorbent assay (ELISA)) were chosen to validate targeted proteins. 
Multiple proteins had been discovered as candidate biomarkers but due to time and 
cost restraints only a subset could be validated. 15 proteins were considered to have 
the strongest likelihood of being specifically involved in AD; these were proteins 
which were found to be associated with all three DVs preclinically (brain amyloid 
burden, brain atrophy, and cognitive decline). From these 15, 7 were analysed using 
a pre-exisiting SOMAscan dataset, and a further 2 were selected for validation by 
ELISA. 
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Five proteins (α1-antitrypsin (AAT), complement C3, haptoglobin, protein AMBP 
(A1M), and zinc- α2 glycoprotein) all validated for at least one of the measures 
tested, though with varying significance strengths. AAT was by far the strongest 
biomarker candidate, showing highly significant relationships with both disease 
status and brain atrophy. C3 and haptoglobin both showed a relationship with 
cognitive decline, and A1M and ZAG displayed relationships with brain atrophy. 
These five proteins are therefore very interesting markers to use for these measures 
in preclinical individuals. These findings merit independent confirmation in future 
preclinical studies. If further replicated these preclinical biomarkers are likely to be 
examined for their utility as markers of disease in healthy individuals, being 
considered for clinical trials, and for treatment response at an early, preclinical stage. 
As mentioned above, proteins that associated with all three DVs preclinically were 
considered for validation experiments. However proteins that were found to be 
specifically related to only one or two DVs in the discovery phase experiments are 
also very interesting. Although these proteins were not validated here they should 
still be considered for future studies. Many of these proteins already have a strong 
body of evidence for their biomarker ability in AD, and therefore their ability as 
biomarkers of preclinical AD can be considered seriously even without validation 
phase confirmation. For example, 2DGE experiments identified clusterin as a 
biomarker for cognitive decline in healthy individuals, and much previous literature 
has established a relationship between clusterin and AD severity, pathology, and 
progression[137, 288], some of which has already implicated a potentially important 
role for clusterin in the earliest stages of AD related neurodegeneration[261-262, 
293]. 
Discovery phase analyses revealed unique sets of significant proteins as biomarkers 
for the three different DVs. Whilst all three DVs are strongly linked to AD they 
capture different temporal and mechanistic aspects of the disease. Brain atrophy and 
cognitive measures are continuous and were measured longitudinally here. Although 
compensatory mechanisms can delay cognitive decline, brain atrophy and cognition 
will be intrinsically linked. Amyloid load was only measured cross sectionally at the 
final time point, though this may be the most independent of the surrogate markers 
measured and may be capable of capturing earlier disease specific changes[70]. For 
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each surrogate marker it is likely that some of the proteins identified as biomarkers 
will correlate with each other or be involved in the same pathways or mechanisms; 
therefore they may be surrogates for each other. Combining proteins that capture 
unique aspects of AD preclinically will increase their utility as preclinical AD 
biomarkers. Further experiments are needed to reveal the optimal combination of 
these markers.  
Many proteins displayed opposite coefficient directions for the significant 
relationships detected between studies. This highlights the complexity of the 
relationships some of these proteins may have with disease, and the importance of 
future experiments to determine exactly which parts and forms of the protein they are 
measuring and correlating with an outcome measure. It is not rare for different 
studies to report conflicting relationships of a protein with AD. Perhaps if more 
effort is directed towards specifying the precise protein epitope which is being 
measured then these conflicts would be much rarer.  
The proteins found here to be implicated in preclinical AD are involved in a variety 
of systems, including; complement and inflammation, coagulation, hemostasis, 
fibrinolysis, and BBB integrity. Such systems may be causally related to AD onset, 
or be affected as a result of the disease. Additionally the involvement of these 
systems in AD pathology may be inter-linked or they may act independently, further 
work is needed to clarify these relationships. The involvement of these systems has 
also been highlighted in recent large-scale genetics studies [351], showing that 
results from both genetics and biology agree on the pathways of interest. It may be 
possible to identify the resulting contribution of some of these pathways (e.g. chronic 
inflammation) as high risk factors for the development of AD in healthy individuals, 
comparable to that of more-established risk factors such as APOE ε4 status. At the 
very least, the presence of these biomarkers in healthy elderly individuals indicates 
potential early intervention targets worthy of further investigation.  
6.2 Summary 
In conclusion, this project adds further evidence that plasma is a rich resource for AD 
biomarkers. Biological variation and the dynamic range of plasma complicates the 
discovery, but through the use of complimentary techniques these issues can be 
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minimised. Here we show it is also possible to detect these plasma based biomarkers 
at a stage long before the onset of clinical disease manifestations. Preliminary 
discovery studies detected many candidate biomarkers for surrogate markers of AD 
pathology and cognitive decline in a healthy elderly cohort. Some of these candidate 
biomarkers were then validated for their involvement in AD, providing support for 
their preclinical AD biomarker utility. As early indicators of AD these proteins may 
become targets of treatment or preventative healthcare measures once the 
mechanisms behind their involvement becomes better understood.   
6.3 Future studies 
Research into plasma based preclinical AD biomarkers is still an emerging field. This 
study provides more evidence in a growing body of literature, but more work is 
needed to expand upon the findings presented here and develop this research field 
further. Suggestions for future studies and research aims to expand upon these results 
are outlined below.  
6.3.1 Further expand 2DGE data analysis  
A limitation of 2DGE in this study is that the number of spots that can be picked for 
LC-MS/MS protein identification was constrained by time and cost. This restricted 
the amount of analysis that could be completed. Data was available for many 
cognitive measures and brain regions but only the measures showing the greatest 
linear change over time were selected for analysis. This could be expanded and 
would be of particular interest for brain regions, such as the entorhinal cortex and 
hippocampus, known to be effected early on in AD.  
6.3.2 Assess post translational modifications and protein fragments for 
biomarker ability 
2DGE experiments showed that many of the proteins identified as candidate 
biomarkers were found in multiple 2DGE spots located throughout the gel, this is 
indicative of multiple forms of the proteins (modified and/or cleaved) as biomarkers. 
Additionally, many of the same proteins were identified in the LC-MS/MS discovery 
experiments where a prefractionation stage had been completed; indicating different 
forms of these proteins were detected compared to those found in 2DGE spots of 
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high molecular weight. These results show that it would be highly interesting to 
assess post translational modifications and cleavage of the proteins identified as 
candidate biomarkers. A first approach to this could be completed through an in 
depth re-analysis of the mass spectrometry data generated here for proteins of 
interest from both discovery studies. 
6.3.3 Validate candidate biomarkers of preclinical AD in an independent 
healthy elderly cohort. 
Candidate biomarkers were here discovered in the Baltimore Longitudinal Study of 
Aging cohort. Validation was focused upon determining their involvement in AD, 
though validation is also needed for their preclinical AD biomarker ability in other 
healthy elderly cohorts. This will determine whether they are robust results across 
cohorts and studies. Reproducible results are necessary to add confidence for future 
clinical utility.  
6.3.4 Identify a preclinical AD biomarker panel 
Here proteins were individually assessed for their biomarker ability. However their 
true strength is likely to lie as a biomarker panel of multiple proteins, each reflecting 
different aspects and mechanisms involved in the development of the disease. This 
approach has been successfully employed in AD biomarker research several 
times[76, 139-141], similar approaches can be applied preclinically. 
6.3.5 Determine sensitivity and specificity of preclinical biomarkers against 
other types of dementias and neurodegenerative diseases.  
Validation of biomarkers in cohorts including patients with other types of dementias 
and neurodegenerative diseases would determine which biomarkers are specific for 
AD, helping to achieve a greater diagnostic accuracy for early AD detection.  
6.3.6 Identify gender specific biomarkers for preclinical AD 
Validation studies revealed gender effects on plasma biomarkers. It is likely that 
differences in the development of AD might also differ between genders, and such 
differences may be reflected in the periphery. Therefore future experiments 
investigating preclinical AD biomarkers should stratify based on gender.  
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6.4 Limitations 
6.4.1 Using blood for biomarker discovery 
Although blood biomarkers have significant potential in early AD detection, 
limitations of using blood as a source of biomarkers should be considered. Blood has 
a complex composition with a large dynamic range, which can pose technical 
difficulties for biomarker discovery. Changes within the blood are often very small 
and reflect a wide range of both peripheral and central processes, so pinpointing AD 
specific changes can be challenging. Proteomics has so far shown great success in 
identifying AD blood biomarkers, however detailed characterisation of these proteins 
including changes in quantification, location, interactions, isoforms and post-
translational modifications (PTMs) is now needed to further our understanding of 
different biological states. The identification of these features in blood is challenging 
as proteins need to be identified from within a matrix of cells, tissues, fluids, and 
other proteins of varying concentrations. Other modalities, such as CSF, may be a 
simpler option to identify and characterise these biomarker candidates.  
Currently some of the best AD biomarkers are CSF based (CSF tau and Aβ). Often 
results of blood based biomarker studies are compared to those from CSF to provide 
further support for their findings. However this should be done with some caution as 
these two modalities may not be comparable, at least not for all proteins. Differences 
in CSF and plasma composition (e.g. presence of cells and protein concentration) 
will influence the type proteins identified, protein functions may differ, and so may 
biomarker ability between the two modalities. 
6.4.2 Aβ and tau not detected 
CSF quantification of Aβ1-42, phosphorylated tau (P-tau) and total-tau (T-tau) have 
shown great biomarker abilities for AD, and are thought to reflect the core pathologic 
features of AD; amyloid plaques, neurofibrillary tangles and neuronal loss, 
respectively. However in plasma the results of Aβ and tau are often contradictory, 
measurements are subjected to more sources of variability than CSF measurements, 
and increased assay sensitivity is needed to detect these proteins. Further clinical 
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research and assay development are needed before measures of plasma Aβ and tau 
can be accurately interpreted. 
Throughout this study neither Aβ or tau protein was identified. Although the 
discovery proteomic methods used here were not expected to detect either protein 
without experimental optimisation it is unfortunate that the two key proteins 
reflecting AD neuropathology could not be detected and investigated as AD 
biomarkers.  
6.4.3 No biomarker concentration thresholds 
Threshold values for biomarkers must be determined for them to be of use as a 
diagnostic/screening tool. This threshold is normally calculated as the value which 
produces the highest test sensitivity and specificity. However in this study neither 
proteomic discovery technique (2DGE/LC-MS/MS) provided absolute quantification 
of proteins, therefore estimation of optimal thresholds could not be computed. 
Further testing of candidate biomarkers should be quantitative to enable this 
calculation.  
6.4.4 Specificity of PiB PET DVR, Trails B, and ventricular expansion to 
Alzheimer’s disease 
Currently there is a lack of a 100% accurate gold standard for AD for which 
biomarkers can be discovered. Post mortem neuropathology analysis is considered 
the most accurate indicator of AD, however even this method has limitations; it is 
subjective, dependent upon the neuropathiologist, and is often combined with 
patients’ clinical history to form a diagnosis. Here PiB PET DVR, Trails B and 
ventricular expansion were used and considered as indicators of early AD 
development. As previously discussed these measures have all been found to be 
linked to AD and change at an early, preclinical, stage. However these 
measurements, especially the latter two, are not specific to AD and are often altered 
in various other disorders including different types of dementia.  
Executive dysfunction, as measured by Trails B, is a prominent feature of vascular 
dementia. Research has been inconclusive regarding differences in executive 
impairment between AD and vascular dementia, and many consider this impairment 
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to be similar between the two types of dementia[350]. In addition ventricular 
expansion is often seen in vascular dementia, due to global atrophy. The candidate 
biomarkers here may therefore also be useful as early markers of vascular dementia. 
In fact a number of the biomarkers identified here fit a profile of vascular effects, for 
example; AIII, fibrinogen, clusterin, and various apolipoproteins. If these markers 
are specific to AD then they are still likely to be reflecting the influences of 
cardiovascular disease in contributing to and exacerbating AD pathology.  
It is also interesting to note that there was very minimal correlation between PiB PET 
DVR, Trails B and ventricular expansion. Only a moderate correlation was found 
between ventricle size and Trails B at T12, but no other correlations were reported 
between any DV at any time point. It was suggested that either the sensitivity of 
these measures differ or perhaps different forms of the same protein are related to the 
three DVs. However it is also possible that the subjects which show change in each 
of these variables are different, and therefore the lack of correlation would be 
unsurprising.  
Further experiments are necessary to determine the biomarkers specificity to AD, 
and for now it is important to remember that they may not be AD specific. Instead 
they should be considered only as markers of amyloid deposition, executive function 
decline, and brain atrophy, potentially useful for multiple disorders.  
6.4.5 Limitations of statistical methods 
Linear data. The statistical tests used for this study could only model linear data, and 
therefore proteins which showed non-linear changes over time were excluded. Some 
of these excluded proteins may be AD biomarkers, and these dynamic changes over 
time may be highly biologically interesting. It is important to develop and implement 
more advanced statistical methods which can model dynamic changes in protein 
concentration over time and test these proteins for biomarker ability. 
False discovery rate corrections. Throughout the discovery phase experiments false 
discovery rate (FDR) corrections were not applied. This was because the large 
number of statistical tests conducted would have resulted in an unachievable FDR 
threshold. Instead a p-value of <0.05 was considered, though this will have resulted 
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in many false positive findings. Future validation experiments are important to 
confirm true results and discard false positives. It is also important to note that p-
values and q-values are arbitrary cut-off points. Although it is necessary to use these 
values, proteins on the threshold of significance which still may be interesting are 
ignored.  
Outliers. In validation experiments extreme data outliers were excluded from 
analysis. It was important to remove these outliers for two reasons; firstly, so that the 
spread of data was normally distributed, and secondly, so that extreme values did not 
skew the results of the dataset. Removal of outliers therefore increases the accuracy 
of statistical tests and minimises their error. However there was no obvious reason 
here as to why these individual samples yielded extreme values and therefore it is 
possible that they may be legitimate data points. Though it is still unclear what 
should be done when a legitimate outlier is present, as removal increases statistical 
power but reduces validity. Further development of statistical models to include 
outliers is needed. 
Covariates. Six covariates were included in most of the statistical tests conducted, 
these were; age, gender, education (years), body mass index (BMI), cholesterol, and 
APOE ε4 status. All of these factors have known impacts upon the risk of AD, and 
were included as covariates to remove their influence and enable any relationship 
between protein and AD to be identified. However 6 is a large number of covariates 
to include, and may have resulted in decreased efficiency of the statistical tests or 
over-fitting of regression models. A stepped-approach, repeating the test multiple 
times with different covariates added, may have clarified their effects on the 
statistical tests. In addition, both APOE ε4 status and cholesterol were included as 
covariates, but both of these factors may be intrinsically linked as APOE ε4 carriers 
are thought to have higher cholesterol. This may have further reduced the efficiency 
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Appendices 
Appendix 1  
Baseline partial correlation results for 2DGE spots with PiB PET DVR. Spots 
ranked in order of significance based on p value. Spots highlighted in red are 
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X1515 -0.120 0.445 
X1417 -0.120 0.446 
X621 0.120 0.446 
X2086 0.119 0.448 
X995 0.119 0.448 
X1021 -0.119 0.449 
X644 -0.119 0.449 
X1725 0.119 0.450 
X1495 -0.118 0.451 
X2328 -0.118 0.451 
X1662 -0.118 0.452 
X2333 0.118 0.453 
X453 0.118 0.454 
X1392 -0.118 0.454 
X669 -0.118 0.454 
X1862 -0.117 0.455 
X1406 -0.117 0.457 
X396 0.117 0.458 
X1829 -0.117 0.458 
X1233 -0.116 0.460 
X802 -0.116 0.461 
X1488 -0.116 0.462 
X1203 0.116 0.462 
X998 0.116 0.462 
X2184 0.115 0.463 
X459 0.115 0.466 
X2138 -0.114 0.466 
X1391 0.114 0.466 
X1864 0.114 0.466 
X1695 -0.114 0.467 
X311 0.114 0.467 
X1191 -0.114 0.467 
X2294 -0.114 0.467 
X2313 -0.114 0.467 
X1252 0.114 0.469 
X1832 0.114 0.469 
X2198 0.113 0.471 
X892 -0.113 0.472 
X1347 -0.113 0.472 
X1594 -0.113 0.472 
X596 -0.113 0.472 
X908 0.112 0.474 
X2108 0.112 0.474 
X1936 0.112 0.474 
X1060 0.112 0.475 
X1699 0.112 0.477 
X884 -0.112 0.477 
X1245 -0.112 0.477 
X1915 0.111 0.478 
X1684 -0.111 0.479 
X1147 0.111 0.479 
X2283 0.111 0.480 
X1468 -0.111 0.480 
X906 0.111 0.480 
X826 -0.111 0.481 
X2332 0.110 0.483 
X863 0.110 0.483 
X1133 0.110 0.485 
X2353 0.110 0.486 
X1275 0.110 0.486 
X1989 -0.109 0.486 
X781 -0.109 0.487 
X1291 -0.109 0.487 
X1661 -0.109 0.488 
X1546 -0.109 0.488 
X2159 0.109 0.490 
X1631 -0.108 0.491 
X1122 0.108 0.491 
X1876 0.108 0.491 
X2341 -0.108 0.492 
X601 0.108 0.492 
X2177 -0.108 0.493 
X715 -0.108 0.493 
X893 -0.107 0.496 
X718 -0.107 0.496 
X712 0.107 0.498 
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X1342 -0.107 0.498 
X1103 -0.106 0.499 
X616 0.106 0.500 
X375 0.106 0.501 
X584 -0.106 0.502 
X2169 0.106 0.502 
X1117 -0.106 0.502 
X845 0.105 0.502 
X1741 0.105 0.503 
X773 0.105 0.505 
X1065 -0.105 0.505 
X1399 0.105 0.506 
X2244 0.104 0.506 
X587 -0.104 0.507 
X1521 0.104 0.508 
X742 -0.104 0.509 
X799 -0.104 0.510 
X1124 0.104 0.510 
X1901 0.103 0.511 
X2088 0.103 0.514 
X1510 0.102 0.515 
X2335 0.102 0.516 
X1222 -0.102 0.517 
X1094 -0.101 0.521 
X978 0.101 0.522 
X1514 -0.101 0.522 
X1390 0.101 0.522 
X1696 0.101 0.522 
X1075 0.100 0.523 
X2128 0.100 0.524 
X963 -0.100 0.525 
X965 -0.100 0.525 
X1161 -0.100 0.526 
X873 -0.100 0.526 
X1833 0.100 0.527 
X1874 0.100 0.527 
X1504 -0.099 0.528 
X1141 0.099 0.528 
X1373 0.099 0.529 
X1700 -0.099 0.529 
X1427 -0.099 0.530 
X1835 -0.099 0.531 
X1098 0.098 0.532 
X794 0.098 0.532 
X2007 0.098 0.532 
X2238 0.098 0.532 
X1742 -0.098 0.532 
X2091 0.098 0.533 
X1159 -0.098 0.533 
X2168 -0.098 0.534 
X836 -0.098 0.534 
X1822 0.098 0.534 
X1298 -0.098 0.535 
X1220 -0.097 0.536 
X2209 0.097 0.537 
X820 -0.097 0.538 
X2180 -0.097 0.538 
X656 0.097 0.539 
X2096 0.097 0.539 
X1381 0.096 0.540 
X928 0.096 0.540 
X1729 -0.096 0.543 
X637 0.096 0.543 
X527 0.096 0.543 
X1451 -0.096 0.543 
X1751 -0.096 0.544 
X2277 -0.095 0.545 
X1748 0.095 0.545 
X1831 -0.095 0.547 
X735 0.095 0.548 
X2256 -0.094 0.549 
X1079 -0.094 0.549 
X1186 -0.094 0.550 
X2278 0.094 0.550 
X1856 -0.093 0.553 
X743 0.093 0.553 
X911 -0.093 0.554 
X1469 -0.093 0.554 
X1367 -0.093 0.555 
X1320 -0.093 0.555 
X1698 -0.093 0.556 
X1781 0.093 0.556 
X1740 0.093 0.557 
X1677 -0.093 0.557 
X645 0.092 0.557 
X1140 0.092 0.557 
X2097 0.092 0.557 
X811 0.092 0.558 
X2171 0.092 0.558 
X501 0.092 0.558 
X2267 -0.092 0.559 
X1151 0.092 0.559 
X2125 -0.092 0.559 
X379 0.092 0.560 
X1846 0.092 0.560 
X1651 -0.092 0.560 
X1091 0.092 0.561 
X1246 -0.092 0.561 
X1590 -0.091 0.562 
X2185 0.091 0.563 
X1053 -0.091 0.563 
X1409 -0.091 0.563 
X1627 -0.090 0.566 
X1674 0.090 0.567 
X1278 -0.090 0.569 
X1274 0.089 0.571 
X1486 0.089 0.572 
X1383 -0.089 0.572 
X1045 -0.089 0.573 
X753 0.089 0.574 
X1968 -0.089 0.574 
X1572 -0.088 0.575 
X242 0.088 0.575 
X643 0.088 0.575 
X1752 0.088 0.576 
X1496 -0.087 0.579 
X1586 -0.087 0.579 
X655 -0.087 0.580 
X324 -0.087 0.580 
X1788 -0.087 0.580 
X1547 -0.087 0.581 
X719 -0.087 0.582 
X1290 -0.087 0.582 
X804 -0.086 0.583 
X2050 -0.086 0.583 
X1471 -0.086 0.583 
X916 0.086 0.585 
X943 0.086 0.585 
X1964 0.086 0.585 
X585 0.086 0.586 
X912 0.085 0.589 
X869 0.085 0.589 
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X1037 0.085 0.590 
X634 -0.085 0.591 
X1413 -0.085 0.591 
X1279 -0.084 0.592 
X829 0.084 0.594 
X1519 0.084 0.595 
X665 -0.083 0.597 
X603 0.083 0.597 
X786 -0.083 0.597 
X1414 0.083 0.598 
X933 0.083 0.599 
X1825 -0.083 0.599 
X2054 -0.083 0.600 
X1717 0.082 0.601 
X2124 -0.082 0.602 
X659 -0.082 0.602 
X1900 0.082 0.602 
X2242 -0.082 0.603 
X861 0.082 0.603 
X795 -0.082 0.605 
X1149 -0.082 0.605 
X1160 0.082 0.605 
X558 -0.081 0.605 
X1026 -0.081 0.606 
X1397 -0.081 0.606 
X1535 -0.081 0.607 
X1531 -0.081 0.608 
X1608 -0.081 0.609 
X2021 -0.081 0.609 
X817 0.080 0.610 
X2254 0.080 0.610 
X1830 0.080 0.611 
X1270 -0.080 0.611 
X1215 -0.080 0.611 
X2043 0.080 0.614 
X745 -0.079 0.615 
X2053 0.079 0.615 
X901 -0.079 0.617 
X1536 -0.079 0.618 
X1046 -0.079 0.618 
X750 0.078 0.619 
X1948 0.078 0.621 
X724 -0.078 0.622 
X1259 0.078 0.622 
X2235 0.077 0.623 
X1232 -0.077 0.624 
X1134 0.077 0.625 
X1257 -0.077 0.625 
X1047 0.077 0.626 
X491 0.076 0.629 
X694 -0.076 0.629 
X322 -0.076 0.630 
X1607 0.076 0.630 
X972 0.076 0.631 
X2214 0.076 0.631 
X1758 -0.075 0.632 
X1736 0.075 0.632 
X1385 -0.075 0.633 
X842 -0.075 0.633 
X1675 -0.075 0.634 
X860 -0.075 0.635 
X1483 -0.075 0.636 
X1679 -0.074 0.639 
X2120 -0.074 0.639 
X1541 -0.074 0.640 
X1757 -0.073 0.641 
X1061 -0.073 0.642 
X286 0.073 0.642 
X1697 -0.073 0.642 
X1689 -0.073 0.643 
X1640 -0.073 0.644 
X2037 0.073 0.644 
X1726 -0.073 0.644 
X989 0.073 0.645 
X769 -0.072 0.646 
X865 -0.072 0.647 
X1058 0.072 0.648 
X2203 -0.072 0.649 
X1092 -0.072 0.649 
X1182 0.071 0.651 
X664 0.071 0.651 
X589 -0.071 0.651 
X1745 0.071 0.651 
X1181 0.071 0.652 
X1288 -0.071 0.653 
X1480 -0.071 0.653 
X1102 0.071 0.654 
X2222 0.071 0.655 
X206 -0.071 0.655 
X1759 -0.070 0.655 
X2101 -0.070 0.655 
X1211 -0.070 0.655 
X661 -0.070 0.656 
X471 0.070 0.658 
X2016 -0.070 0.659 
X1881 0.069 0.660 
X1511 0.069 0.660 
X1587 0.069 0.661 
X1013 0.069 0.663 
X1169 0.069 0.663 
X2221 -0.069 0.664 
X1629 -0.068 0.665 
X1152 0.068 0.666 
X728 0.068 0.668 
X1269 -0.068 0.668 
X1137 -0.068 0.668 
X310 -0.068 0.668 
X1815 0.067 0.670 
X1112 -0.067 0.671 
X1081 0.067 0.671 
X2156 0.067 0.673 
X1351 -0.066 0.674 
X1737 -0.066 0.674 
X574 0.066 0.675 
X874 0.066 0.676 
X974 -0.066 0.677 
X777 0.066 0.677 
X1509 0.066 0.678 
X1771 -0.065 0.679 
X755 -0.064 0.685 
X2164 -0.064 0.686 
X848 0.063 0.688 
X2215 -0.063 0.689 
X2201 0.063 0.691 
X599 -0.063 0.691 
X969 -0.063 0.692 
X997 -0.062 0.693 
X713 -0.061 0.697 
X1939 0.061 0.698 
X810 0.061 0.698 
X1971 -0.061 0.699 
X996 0.061 0.700 
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X1623 -0.061 0.701 
X2118 -0.061 0.701 
X1543 0.060 0.702 
X867 0.060 0.702 
X1794 0.060 0.703 
X272 0.060 0.704 
X1490 -0.060 0.705 
X1457 -0.060 0.706 
X1715 -0.059 0.707 
X1579 0.059 0.707 
X1897 -0.059 0.709 
X2202 0.059 0.710 
X1176 -0.058 0.712 
X397 -0.058 0.712 
X480 0.058 0.713 
X1903 -0.058 0.713 
X1041 0.058 0.714 
X910 0.058 0.714 
X1156 -0.058 0.714 
X818 0.058 0.715 
X1705 0.058 0.716 
X1584 -0.057 0.717 
X1282 0.057 0.718 
X1379 -0.057 0.718 
X1135 0.057 0.720 
X2196 -0.056 0.721 
X305 0.056 0.722 
X1965 0.056 0.722 
X371 0.056 0.722 
X1129 -0.056 0.723 
X813 0.056 0.723 
X1157 0.056 0.724 
X590 0.055 0.726 
X2022 -0.055 0.726 
X2040 0.055 0.727 
X671 -0.055 0.728 
X2339 -0.055 0.728 
X2307 -0.055 0.729 
X1093 0.054 0.731 
X790 0.054 0.731 
X1635 0.054 0.732 
X966 -0.054 0.732 
X1879 0.053 0.736 
X675 -0.053 0.737 
X1503 0.053 0.738 
X1518 0.053 0.739 
X1766 -0.053 0.739 
X1281 -0.053 0.740 
X1407 0.052 0.740 
X887 0.052 0.741 
X809 -0.052 0.743 
X1308 -0.052 0.743 
X841 0.052 0.743 
X1783 -0.052 0.744 
X2293 -0.052 0.744 
X1801 -0.051 0.745 
X2199 -0.051 0.746 
X2013 0.051 0.747 
X2226 0.050 0.754 
X1733 0.049 0.754 
X1070 -0.049 0.755 
X875 0.049 0.755 
X635 0.049 0.757 
X1810 -0.049 0.758 
X1765 0.049 0.759 
X827 -0.048 0.760 
X1941 -0.048 0.760 
X668 -0.048 0.761 
X1422 -0.048 0.762 
X1481 0.048 0.763 
X662 0.047 0.764 
X946 0.047 0.765 
X2111 0.047 0.765 
X2146 0.047 0.766 
X2297 -0.047 0.766 
X1779 0.047 0.767 
X935 0.046 0.769 
X1138 -0.046 0.769 
X2273 0.046 0.769 
X1556 0.045 0.774 
X2014 0.045 0.775 
X767 -0.045 0.776 
X1089 -0.045 0.776 
X1744 -0.045 0.776 
X1738 -0.045 0.776 
X412 -0.045 0.777 
X378 0.044 0.778 
X1033 0.044 0.780 
X1077 -0.044 0.780 
X688 -0.044 0.780 
X1658 -0.044 0.782 
X731 0.044 0.783 
X1780 -0.043 0.785 
X1707 -0.043 0.785 
X792 0.043 0.786 
X1882 -0.043 0.786 
X1023 0.043 0.786 
X1398 0.042 0.788 
X1706 -0.042 0.788 
X1659 -0.042 0.789 
X904 0.042 0.790 
X789 -0.042 0.792 
X1981 0.041 0.796 
X2006 -0.041 0.797 
X2099 0.041 0.797 
X1229 0.040 0.798 
X793 -0.040 0.798 
X1216 -0.040 0.801 
X944 0.040 0.803 
X1430 0.039 0.803 
X1642 -0.039 0.805 
X684 -0.039 0.805 
X1492 0.039 0.805 
X1036 -0.039 0.806 
X604 0.038 0.810 
X1624 -0.038 0.811 
X576 0.038 0.812 
X947 -0.038 0.812 
X1512 -0.037 0.813 
X1522 0.037 0.814 
X973 0.037 0.816 
X2136 0.037 0.816 
X676 0.036 0.817 
X1581 -0.036 0.819 
X677 -0.036 0.819 
X1769 0.036 0.820 
X1210 0.036 0.821 
X666 -0.036 0.821 
X2337 0.036 0.821 
X2345 0.036 0.821 
X1714 -0.036 0.822 
X1083 0.035 0.822 
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X2147 0.035 0.823 
X771 0.035 0.823 
X1600 0.035 0.824 
X1183 -0.035 0.824 
X1606 0.035 0.825 
X403 0.035 0.826 
X400 0.035 0.826 
X857 -0.035 0.827 
X1165 -0.034 0.827 
X1212 0.034 0.829 
X828 -0.034 0.829 
X1463 0.034 0.832 
X1734 -0.033 0.832 
X222 -0.033 0.833 
X2213 0.033 0.833 
X1997 0.033 0.836 
X1643 -0.032 0.838 
X1598 -0.032 0.839 
X1743 -0.032 0.840 
X812 -0.032 0.840 
X2343 0.032 0.840 
X1816 -0.032 0.840 
X814 0.032 0.841 
X791 -0.032 0.842 
X1806 -0.031 0.843 
X2274 -0.031 0.844 
X1491 -0.031 0.844 
X1440 -0.031 0.845 
X1808 0.031 0.845 
X783 -0.031 0.846 
X926 0.030 0.847 
X1007 0.030 0.849 
X1958 0.030 0.849 
X2137 0.030 0.849 
X184 0.030 0.850 
X1688 0.030 0.852 
X2151 0.030 0.852 
X1018 -0.029 0.853 
X1104 0.029 0.856 
X2216 -0.028 0.858 
X1341 -0.028 0.858 
X1111 -0.028 0.858 
X1537 -0.028 0.858 
X1595 0.028 0.861 
X915 -0.028 0.862 
X2284 -0.027 0.863 
X1485 -0.027 0.863 
X1639 0.027 0.863 
X1153 -0.027 0.865 
X686 -0.027 0.865 
X1470 -0.027 0.865 
X1022 0.027 0.866 
X1171 -0.027 0.866 
X1150 0.027 0.866 
X2354 -0.027 0.866 
X896 0.026 0.868 
X1088 0.026 0.870 
X1507 0.026 0.872 
X816 0.026 0.872 
X2070 -0.025 0.872 
X1442 0.025 0.874 
X1208 0.025 0.874 
X1811 -0.025 0.875 
X1352 -0.024 0.877 
X1476 0.024 0.877 
X1940 0.024 0.878 
X636 -0.024 0.878 
X1223 0.024 0.879 
X1184 -0.024 0.879 
X1474 0.024 0.880 
X678 0.024 0.881 
X2299 0.023 0.882 
X1069 -0.023 0.883 
X1028 0.023 0.883 
X2102 -0.023 0.885 
X1782 -0.023 0.885 
X1589 -0.023 0.886 
X2126 0.022 0.887 
X800 -0.022 0.888 
X1668 -0.022 0.889 
X870 -0.022 0.889 
X1784 -0.022 0.890 
X2236 0.022 0.890 
X1530 0.022 0.890 
X1087 0.022 0.891 
X2211 -0.022 0.891 
X971 0.021 0.893 
X803 -0.021 0.894 
X990 0.021 0.894 
X1686 -0.021 0.896 
X993 0.020 0.899 
X1425 -0.020 0.899 
X598 -0.020 0.900 
X1704 -0.020 0.900 
X1131 0.020 0.900 
X1701 -0.019 0.902 
X1761 0.019 0.902 
X945 -0.019 0.903 
X1669 -0.019 0.904 
X948 0.019 0.905 
X679 0.019 0.905 
X640 -0.019 0.905 
X1016 0.019 0.905 
X942 -0.019 0.905 
X2172 -0.019 0.906 
X868 -0.018 0.908 
X1499 -0.018 0.908 
X709 0.018 0.909 
X646 -0.018 0.909 
X1549 0.018 0.910 
X898 -0.018 0.912 
X1193 -0.018 0.912 
X1865 0.018 0.912 
X1692 0.017 0.912 
X2246 0.017 0.912 
X629 -0.017 0.913 
X976 0.017 0.913 
X1166 -0.017 0.913 
X1294 0.017 0.913 
X1001 0.017 0.913 
X2025 -0.017 0.914 
X1754 -0.017 0.915 
X580 -0.017 0.915 
X1354 0.017 0.916 
X1172 0.017 0.916 
X1973 -0.016 0.917 
X1523 0.016 0.918 
X1545 -0.016 0.918 
X1456 -0.016 0.921 
X1612 -0.015 0.922 
X905 0.015 0.922 
X2336 -0.015 0.923 
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X871 0.015 0.924 
X849 -0.015 0.924 
X900 0.015 0.925 
X1691 0.015 0.926 
X1132 0.015 0.926 
X934 0.015 0.926 
X1720 0.015 0.927 
X1823 0.015 0.927 
X389 0.014 0.927 
X1753 -0.014 0.927 
X1963 0.014 0.929 
X913 -0.014 0.930 
X1803 -0.014 0.930 
X852 -0.014 0.931 
X2219 0.014 0.931 
X775 -0.013 0.932 
X1520 -0.013 0.932 
X1493 0.013 0.932 
X2033 0.013 0.935 
X1838 0.013 0.936 
X660 0.012 0.937 
X823 0.012 0.938 
X1014 -0.012 0.938 
X630 -0.012 0.939 
X1604 0.012 0.939 
X1473 0.012 0.940 
X1009 -0.012 0.940 
X2135 0.012 0.941 
X1723 0.012 0.941 
X663 -0.011 0.943 
X1638 -0.011 0.944 
X1494 -0.011 0.944 
X1972 0.011 0.944 
X1421 -0.011 0.946 
X602 -0.011 0.946 
X763 -0.010 0.948 
X1017 -0.010 0.948 
X1318 -0.010 0.949 
X1164 -0.010 0.950 
X797 -0.010 0.950 
X1095 -0.010 0.951 
X853 0.010 0.951 
X1115 0.010 0.952 
X772 0.010 0.952 
X1633 0.009 0.952 
X1072 0.009 0.953 
X1116 0.009 0.954 
X1175 -0.009 0.955 
X2127 0.009 0.956 
X1790 0.008 0.957 
X229 0.008 0.961 
X2148 -0.008 0.961 
X1428 0.008 0.961 
X1168 -0.008 0.962 
X1049 0.007 0.962 
X1187 0.007 0.963 
X1196 -0.007 0.964 
X2233 -0.007 0.965 
X2142 0.007 0.967 
X1814 -0.006 0.967 
X1605 -0.006 0.968 
X714 -0.006 0.970 
X931 -0.006 0.971 
X2230 0.006 0.971 
X1687 -0.006 0.972 
X597 0.006 0.972 
X1139 0.006 0.972 
X1305 -0.005 0.973 
X968 0.005 0.974 
X844 -0.005 0.974 
X1591 -0.005 0.975 
X1371 -0.005 0.976 
X846 -0.005 0.976 
X949 0.005 0.976 
X1800 0.005 0.977 
X1693 -0.004 0.977 
X1950 0.004 0.978 
X1107 0.004 0.979 
X1615 -0.003 0.983 
X2161 0.003 0.983 
X641 0.003 0.984 
X1415 -0.003 0.984 
X2338 -0.003 0.986 
X1363 0.002 0.988 
X1558 0.002 0.988 
X819 -0.002 0.988 
X1942 0.002 0.988 
X1454 0.001 0.994 
X1238 -0.001 0.994 
X1517 -0.001 0.996 
X1448 0.000 0.998 
X1601 0.000 0.999 
X1019 0.000 0.999 
X1323 0.000 1.000 
X1271 0.000 1.000 
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Appendix 2 
T6 partial correlation results for 2DGE spots with PiB PET DVR. Spots ranked 
in order of significance based on p value. Results highlighted in red are 



























X558 0.524 0.000 
X527 0.494 0.000 
X1699 -0.461 0.001 
X842 -0.454 0.001 
X808 -0.445 0.001 
X2063 -0.444 0.001 
X1309 -0.422 0.003 
X2267 0.383 0.007 
X1648 -0.383 0.007 
X831 -0.369 0.010 
X1054 -0.363 0.012 
X2177 0.360 0.012 
X1245 -0.360 0.012 
X1833 0.356 0.014 
X1787 0.353 0.014 
X869 -0.351 0.015 
X2209 0.348 0.016 
X815 0.342 0.018 
X875 -0.339 0.019 
X2344 -0.335 0.021 
X2345 -0.332 0.022 
X797 -0.332 0.022 
X1770 -0.331 0.023 
X1660 -0.330 0.024 
X1527 0.327 0.025 
X822 -0.324 0.027 
X1267 -0.322 0.027 
X1941 -0.318 0.029 
X1694 -0.314 0.032 
X1406 0.314 0.032 
X2271 0.312 0.033 
X802 -0.312 0.033 
X1394 0.311 0.034 
X949 0.311 0.034 
X1197 -0.311 0.034 
X1544 -0.310 0.035 
X1917 0.310 0.035 
X1334 -0.309 0.035 
X1619 -0.306 0.038 
X1695 -0.303 0.039 
X1409 -0.303 0.039 
X1763 -0.302 0.040 
X1298 0.300 0.041 
X1257 -0.300 0.042 
X819 0.298 0.043 
X1261 0.298 0.043 
X255 0.297 0.044 
X1615 0.294 0.046 
X1556 -0.294 0.046 
X1365 -0.293 0.047 
X1015 -0.293 0.047 
X791 -0.293 0.047 
X1696 0.291 0.049 
X1495 -0.290 0.050 
X1555 -0.289 0.050 
X1665 -0.289 0.051 
X1051 -0.288 0.051 
X716 -0.285 0.054 
X2348 -0.285 0.054 
X829 -0.285 0.054 
X2212 0.284 0.055 
X1661 -0.283 0.056 
X817 0.281 0.058 
X1528 0.280 0.059 
X890 0.280 0.059 
X2264 0.279 0.059 
X1165 -0.279 0.059 
X1792 -0.278 0.061 
X761 0.277 0.061 
X1966 0.277 0.062 
X1062 -0.276 0.063 
X1864 -0.275 0.064 
X2214 0.274 0.065 
X1343 -0.274 0.065 
X1790 0.273 0.066 
X830 -0.273 0.066 
X1607 -0.272 0.067 
X2308 0.271 0.069 
X948 0.270 0.069 
X355 0.270 0.070 
X717 -0.269 0.071 
X2141 -0.268 0.072 
X1408 -0.267 0.072 
X1202 -0.264 0.076 
X1253 -0.264 0.076 
X848 -0.264 0.076 
X781 -0.264 0.077 
X785 -0.263 0.077 
X1421 0.263 0.078 
X2246 -0.262 0.078 
X1631 0.260 0.081 
X1402 -0.259 0.083 
X1642 -0.255 0.087 
X1767 -0.255 0.087 
X1940 0.254 0.088 
X747 -0.254 0.089 
X1225 -0.254 0.089 
X902 -0.254 0.089 
X1608 0.253 0.090 
X2285 -0.252 0.092 
X1018 -0.252 0.092 
X1014 -0.251 0.093 
X1646 -0.250 0.094 
X1400 -0.250 0.095 
X1342 -0.249 0.095 
X480 0.249 0.096 
X758 -0.248 0.096 
X1482 -0.248 0.097 
X1710 0.246 0.099 
X1589 -0.245 0.101 
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X1224 0.244 0.102 
X874 -0.244 0.103 
X1418 0.244 0.103 
X793 -0.243 0.104 
X1846 -0.243 0.104 
X1769 -0.242 0.105 
X576 0.242 0.106 
X1875 -0.242 0.106 
X1318 -0.242 0.106 
X935 0.242 0.107 
X701 -0.241 0.107 
X533 -0.241 0.107 
X2187 0.240 0.109 
X951 0.240 0.109 
X2213 0.240 0.109 
X893 -0.240 0.109 
X1721 -0.240 0.110 
X742 0.240 0.110 
X783 -0.239 0.110 
X754 -0.239 0.111 
X1925 0.239 0.111 
X1017 -0.238 0.112 
X1601 0.238 0.113 
X2114 0.237 0.113 
X812 0.236 0.116 
X722 -0.235 0.117 
X1067 -0.235 0.117 
X825 -0.235 0.117 
X1666 -0.235 0.118 
X1182 -0.234 0.118 
X1356 -0.233 0.121 
X1295 -0.231 0.124 
X1396 -0.231 0.124 
X689 -0.231 0.124 
X811 0.230 0.126 
X1310 -0.230 0.126 
X1199 -0.229 0.127 
X698 -0.229 0.128 
X719 -0.227 0.130 
X434 0.227 0.130 
X1810 -0.227 0.131 
X1391 -0.226 0.132 
X1359 -0.226 0.133 
X1193 -0.225 0.134 
X1690 -0.225 0.135 
X1545 0.225 0.135 
X2255 -0.225 0.135 
X1649 -0.223 0.139 
X870 -0.223 0.139 
X1173 -0.222 0.140 
X1101 0.222 0.140 
X491 0.222 0.141 
X735 0.221 0.141 
X955 0.221 0.141 
X1713 0.221 0.142 
X1760 0.221 0.142 
X1069 -0.220 0.143 
X1579 0.220 0.144 
X1520 -0.219 0.146 
X1222 -0.218 0.147 
X757 -0.217 0.150 
X2137 -0.215 0.153 
X2025 -0.215 0.153 
X1788 0.215 0.154 
X2161 -0.215 0.154 
X1463 0.214 0.156 
X699 -0.214 0.156 
X2277 -0.214 0.156 
X1641 0.214 0.156 
X1610 0.213 0.158 
X1541 -0.212 0.160 
X1075 -0.211 0.162 
X1507 0.211 0.162 
X1061 -0.210 0.163 
X1747 -0.210 0.163 
X709 -0.210 0.163 
X1232 -0.210 0.164 
X790 -0.210 0.165 
X322 0.209 0.165 
X1404 -0.208 0.168 
X1324 -0.206 0.172 
X834 0.205 0.174 
X1606 -0.205 0.174 
X1855 -0.205 0.175 
X1200 -0.205 0.175 
X673 -0.205 0.176 
X850 -0.204 0.177 
X1008 0.204 0.177 
X891 0.204 0.177 
X884 0.203 0.179 
X2181 -0.203 0.180 
X1068 -0.203 0.180 
X1973 0.202 0.181 
X1585 0.202 0.182 
X2037 0.202 0.182 
X1742 -0.202 0.182 
X618 -0.201 0.183 
X777 -0.201 0.183 
X2236 -0.201 0.184 
X1926 0.201 0.184 
X2217 -0.201 0.184 
X1663 -0.201 0.185 
X656 -0.200 0.186 
X672 -0.200 0.187 
X1429 0.199 0.187 
X482 0.199 0.188 
X1453 0.199 0.189 
X2143 -0.199 0.189 
X2188 0.199 0.189 
X644 -0.198 0.190 
X882 -0.198 0.190 
X1262 -0.198 0.191 
X2036 0.197 0.192 
X1474 0.197 0.193 
X1637 -0.197 0.194 
X1263 -0.196 0.196 
X1398 -0.196 0.196 
X1338 0.195 0.197 
X956 0.195 0.198 
X688 -0.195 0.198 
X1740 -0.194 0.201 
X1715 0.193 0.202 
X1128 0.193 0.204 
X2006 0.192 0.205 
X1329 -0.192 0.205 
X1375 -0.192 0.206 
X1244 -0.191 0.208 
X1013 -0.191 0.208 
X1496 0.190 0.209 
X818 0.190 0.209 
X1252 0.189 0.211 
X953 0.189 0.211 
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X412 0.189 0.213 
X1761 -0.188 0.214 
X1234 -0.188 0.215 
X2124 0.187 0.217 
X828 -0.187 0.218 
X1815 -0.187 0.218 
X1605 0.187 0.218 
X912 0.187 0.218 
X1604 0.187 0.218 
X296 -0.186 0.219 
X1573 -0.186 0.220 
X403 -0.186 0.220 
X1755 0.186 0.221 
X1684 0.185 0.222 
X1550 -0.185 0.222 
X898 -0.185 0.223 
X1417 -0.185 0.224 
X986 0.184 0.224 
X2154 0.184 0.225 
X484 0.183 0.227 
X1486 0.183 0.228 
X799 -0.183 0.228 
X652 -0.182 0.229 
X2332 0.181 0.233 
X1828 -0.181 0.234 
X2157 0.180 0.235 
X206 0.180 0.236 
X806 -0.180 0.236 
X1854 -0.180 0.236 
X1219 -0.180 0.237 
X2125 0.179 0.238 
X957 0.179 0.239 
X899 -0.179 0.239 
X1113 -0.178 0.242 
X1094 -0.178 0.242 
X1320 -0.178 0.242 
X1617 -0.177 0.244 
X1353 -0.177 0.244 
X1040 0.177 0.245 
X1513 0.176 0.245 
X732 0.176 0.246 
X710 -0.176 0.246 
X868 0.176 0.247 
X2168 -0.176 0.247 
X1056 -0.176 0.248 
X1289 0.175 0.249 
X2352 -0.175 0.249 
X952 0.175 0.249 
X844 0.175 0.250 
X788 0.175 0.250 
X807 -0.175 0.250 
X2310 0.174 0.251 
X1137 -0.174 0.252 
X907 -0.174 0.252 
X1953 0.174 0.252 
X748 -0.174 0.253 
X813 0.174 0.253 
X1493 -0.173 0.255 
X823 0.173 0.256 
X1237 -0.172 0.258 
X2218 -0.172 0.258 
X658 -0.172 0.259 
X1508 0.171 0.262 
X1574 0.171 0.262 
X1399 0.170 0.264 
X792 0.170 0.264 
X1242 -0.170 0.265 
X1233 -0.170 0.265 
X1612 -0.169 0.267 
X1600 0.169 0.268 
X1145 -0.168 0.269 
X734 0.168 0.270 
X1370 -0.168 0.270 
X1609 0.168 0.271 
X1583 0.167 0.271 
X1337 -0.167 0.271 
X2201 -0.167 0.272 
X1241 0.167 0.274 
X671 -0.166 0.274 
X779 -0.166 0.275 
X1693 -0.166 0.275 
X1156 -0.166 0.276 
X1633 -0.166 0.276 
X1772 0.166 0.277 
X1519 -0.165 0.278 
X1771 -0.165 0.278 
X820 -0.165 0.279 
X728 0.165 0.279 
X616 -0.164 0.280 
X1768 -0.164 0.280 
X2204 0.164 0.281 
X1726 -0.164 0.281 
X2108 0.164 0.282 
X1038 0.164 0.283 
X1801 0.163 0.283 
X1662 -0.163 0.284 
X2202 0.163 0.285 
X1292 -0.163 0.285 
X1168 -0.163 0.285 
X1112 0.162 0.286 
X1230 0.162 0.287 
X2333 0.161 0.289 
X886 -0.161 0.289 
X1021 0.161 0.290 
X1638 -0.161 0.292 
X1001 -0.160 0.292 
X2328 0.160 0.294 
X585 0.160 0.294 
X2099 0.160 0.294 
X1215 -0.160 0.294 
X1258 -0.159 0.296 
X1354 -0.159 0.296 
X1773 -0.159 0.296 
X1959 0.159 0.296 
X1084 0.159 0.298 
X1119 -0.158 0.300 
X2331 -0.158 0.300 
X222 0.158 0.300 
X1194 -0.158 0.300 
X1536 0.158 0.301 
X1490 -0.158 0.301 
X816 -0.158 0.301 
X794 0.157 0.302 
X663 0.157 0.302 
X678 -0.157 0.304 
X1563 -0.157 0.304 
X1149 -0.157 0.304 
X885 0.157 0.304 
X389 0.156 0.305 
X827 0.156 0.305 
X1065 -0.156 0.305 
X910 0.156 0.306 
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X2189 -0.156 0.306 
X2102 0.156 0.307 
X696 0.156 0.307 
X1159 -0.155 0.308 
X1118 -0.155 0.308 
X2033 0.155 0.309 
X1736 -0.155 0.310 
X1675 -0.154 0.313 
X670 -0.154 0.314 
X810 0.153 0.314 
X2297 -0.153 0.315 
X1865 -0.153 0.315 
X1540 0.153 0.316 
X880 -0.153 0.317 
X1277 -0.152 0.319 
X1181 -0.152 0.320 
X1129 0.151 0.321 
X997 0.151 0.322 
X1582 0.151 0.322 
X1034 0.151 0.322 
X2278 -0.150 0.324 
X2233 -0.150 0.326 
X1286 -0.150 0.326 
X1698 0.150 0.326 
X662 -0.150 0.326 
X1835 -0.150 0.326 
X892 0.150 0.327 
X1900 0.149 0.330 
X1950 0.149 0.330 
X1517 -0.148 0.331 
X1107 0.148 0.331 
X1534 -0.148 0.333 
X2118 -0.147 0.336 
X805 -0.147 0.336 
X1125 0.147 0.336 
X966 -0.146 0.338 
X690 -0.146 0.338 
X750 0.146 0.338 
X1819 0.146 0.338 
X2054 -0.146 0.338 
X2180 -0.146 0.339 
X706 -0.146 0.339 
X1597 0.145 0.341 
X2082 0.145 0.341 
X1110 0.145 0.341 
X1115 -0.145 0.343 
X1187 -0.145 0.344 
X1807 -0.144 0.346 
X1708 0.144 0.346 
X2172 0.144 0.347 
X1278 0.143 0.348 
X1892 -0.143 0.348 
X1134 0.143 0.349 
X2041 0.143 0.349 
X1132 0.143 0.349 
X1754 -0.143 0.349 
X2022 -0.143 0.350 
X1723 0.143 0.351 
X769 0.142 0.351 
X1564 -0.142 0.351 
X1192 -0.142 0.353 
X841 0.142 0.353 
X1751 -0.142 0.353 
X1198 -0.142 0.354 
X628 -0.141 0.354 
X2109 -0.141 0.355 
X2269 0.140 0.358 
X677 -0.140 0.358 
X184 0.140 0.358 
X1628 -0.140 0.361 
X707 -0.140 0.361 
X590 0.139 0.362 
X1584 0.139 0.362 
X1111 0.139 0.363 
X1915 -0.139 0.364 
X665 -0.139 0.364 
X1139 -0.139 0.364 
X824 0.138 0.365 
X1078 -0.138 0.366 
X525 -0.138 0.366 
X836 0.138 0.368 
X1613 -0.138 0.368 
X1813 -0.137 0.368 
X1862 0.137 0.370 
X1716 0.137 0.371 
X789 0.136 0.372 
X1148 -0.136 0.373 
X1333 0.136 0.373 
X2343 0.136 0.373 
X601 -0.136 0.373 
X1706 0.136 0.373 
X1235 0.136 0.373 
X1332 -0.136 0.374 
X1102 0.136 0.374 
X2190 -0.136 0.374 
X1411 -0.136 0.375 
X1312 -0.136 0.375 
X708 -0.135 0.378 
X1727 -0.134 0.382 
X1901 0.134 0.382 
X471 0.134 0.382 
X944 0.133 0.383 
X1016 -0.133 0.383 
X1023 0.133 0.383 
X1368 -0.133 0.384 
X1669 0.133 0.385 
X1557 0.133 0.385 
X1074 -0.133 0.385 
X1958 0.133 0.385 
X606 0.133 0.385 
X1019 -0.133 0.385 
X1509 0.133 0.385 
X1383 0.133 0.386 
X1104 0.132 0.386 
X804 -0.132 0.387 
X1210 -0.132 0.387 
X970 -0.132 0.387 
X743 0.132 0.388 
X958 0.132 0.388 
X1906 -0.132 0.388 
X814 0.132 0.388 
X1451 -0.132 0.389 
X913 -0.131 0.390 
X2235 0.131 0.391 
X1457 -0.131 0.392 
X2182 -0.131 0.392 
X2274 -0.131 0.392 
X1414 0.131 0.392 
X928 0.131 0.392 
X1551 0.131 0.392 
X1195 -0.131 0.392 
X1308 -0.131 0.392 
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X998 0.131 0.393 
X1037 -0.131 0.393 
X2155 -0.131 0.393 
X911 -0.130 0.394 
X375 0.130 0.396 
X1028 -0.130 0.396 
X1752 0.130 0.396 
X1775 0.130 0.397 
X849 -0.129 0.400 
X1420 -0.128 0.402 
X2072 0.128 0.403 
X715 -0.128 0.403 
X731 -0.128 0.403 
X2028 0.128 0.404 
X697 -0.128 0.405 
X773 -0.127 0.405 
X1416 0.127 0.407 
X422 0.127 0.408 
X989 -0.127 0.408 
X2104 -0.126 0.411 
X1323 -0.126 0.411 
X1504 0.126 0.411 
X1729 0.125 0.413 
X1652 -0.125 0.413 
X1227 -0.125 0.414 
X1476 0.125 0.415 
X1714 -0.125 0.415 
X1777 -0.125 0.416 
X914 -0.125 0.416 
X529 -0.125 0.416 
X1939 -0.125 0.416 
X2179 -0.124 0.418 
X1758 -0.124 0.419 
X727 0.124 0.419 
X1090 0.123 0.421 
X1737 0.123 0.421 
X1236 -0.123 0.421 
X1307 0.123 0.422 
X2299 0.123 0.422 
X2253 0.123 0.423 
X2105 0.123 0.423 
X1562 -0.123 0.423 
X2304 0.123 0.424 
X702 -0.122 0.424 
X615 -0.122 0.424 
X1426 -0.122 0.425 
X1639 -0.122 0.426 
X1592 -0.122 0.426 
X655 -0.122 0.426 
X2216 -0.122 0.426 
X1271 0.122 0.426 
X1223 -0.121 0.429 
X1831 -0.121 0.430 
X988 0.121 0.430 
X2130 0.120 0.431 
X931 0.120 0.432 
X2279 0.120 0.432 
X1313 -0.120 0.432 
X1532 0.120 0.433 
X1989 0.120 0.434 
X1352 -0.120 0.434 
X1733 0.119 0.436 
X936 0.119 0.437 
X2242 -0.119 0.437 
X1531 0.119 0.437 
X961 0.119 0.438 
X1656 -0.119 0.438 
X858 0.119 0.439 
X1141 -0.118 0.440 
X1048 -0.118 0.441 
X1066 -0.118 0.442 
X926 0.118 0.442 
X1355 -0.118 0.443 
X1255 0.118 0.443 
X946 0.118 0.443 
X1734 0.117 0.443 
X879 -0.117 0.445 
X1739 -0.117 0.446 
X1704 0.117 0.446 
X1576 -0.117 0.446 
X2293 -0.116 0.449 
X726 -0.116 0.449 
X1288 -0.116 0.449 
X2010 0.116 0.449 
X2071 0.116 0.450 
X1602 0.116 0.450 
X925 0.115 0.452 
X1553 -0.115 0.452 
X921 0.115 0.452 
X1468 0.115 0.452 
X1594 0.115 0.453 
X1133 0.115 0.453 
X1103 0.114 0.456 
X619 -0.114 0.456 
X1700 -0.114 0.456 
X605 0.114 0.457 
X1554 0.114 0.457 
X1618 -0.114 0.458 
X2023 -0.114 0.458 
X1887 -0.114 0.458 
X1154 -0.114 0.458 
X934 0.114 0.458 
X2012 0.113 0.459 
X1357 -0.113 0.459 
X2250 0.113 0.462 
X2325 -0.113 0.462 
X1515 -0.113 0.462 
X881 0.112 0.464 
X1279 0.112 0.465 
X1724 0.112 0.465 
X1369 0.112 0.465 
X2042 0.112 0.467 
X846 0.111 0.467 
X845 0.111 0.468 
X1861 -0.111 0.469 
X1284 -0.111 0.469 
X840 0.111 0.470 
X972 -0.110 0.472 
X909 0.110 0.473 
X1470 0.110 0.473 
X1439 -0.110 0.474 
X2144 0.110 0.475 
X1083 -0.110 0.475 
X1135 -0.110 0.475 
X1560 -0.109 0.476 
X1522 0.109 0.476 
X2276 0.109 0.476 
X915 0.109 0.477 
X2164 0.108 0.482 
X1774 -0.108 0.482 
X772 -0.107 0.484 
X1902 0.107 0.485 
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X2318 0.107 0.486 
X649 -0.107 0.486 
X1351 -0.107 0.486 
X453 0.107 0.487 
X1003 0.107 0.487 
X1026 -0.106 0.489 
X1454 -0.106 0.489 
X1272 -0.106 0.490 
X2031 0.106 0.490 
X1057 -0.106 0.491 
X2219 -0.106 0.491 
X578 -0.105 0.493 
X2005 0.105 0.493 
X1172 -0.105 0.494 
X1176 -0.105 0.494 
X2268 -0.105 0.496 
X917 -0.105 0.496 
X1254 -0.104 0.496 
X2095 0.104 0.496 
X1524 -0.104 0.499 
X2147 -0.103 0.501 
X1869 -0.103 0.501 
X2106 0.103 0.501 
X733 0.103 0.504 
X1190 -0.102 0.505 
X1546 0.102 0.507 
X660 -0.102 0.507 
X950 0.102 0.508 
X1811 -0.101 0.509 
X1874 0.101 0.509 
X668 0.101 0.511 
X1108 0.101 0.511 
X1372 0.101 0.511 
X2349 0.101 0.511 
X766 0.101 0.512 
X852 0.101 0.512 
X1379 -0.100 0.513 
X1086 0.100 0.514 
X1741 -0.100 0.517 
X1623 -0.099 0.519 
X937 0.098 0.522 
X1085 0.098 0.524 
X1376 0.098 0.524 
X1936 -0.098 0.525 
X1410 -0.097 0.526 
X1071 0.097 0.528 
X896 0.097 0.529 
X1188 0.097 0.529 
X860 0.097 0.529 
X1373 -0.097 0.530 
X1791 -0.096 0.531 
X855 0.096 0.532 
X2053 0.096 0.532 
X1614 -0.096 0.533 
X1196 -0.096 0.533 
X324 0.096 0.534 
X1785 -0.096 0.534 
X861 0.095 0.535 
X1095 -0.095 0.537 
X1473 0.095 0.537 
X1800 0.095 0.537 
X661 -0.095 0.538 
X974 0.095 0.538 
X2240 0.095 0.538 
X1049 -0.094 0.539 
X2239 -0.094 0.539 
X1762 -0.094 0.539 
X1526 0.094 0.539 
X1302 -0.094 0.540 
X1256 0.094 0.540 
X310 0.094 0.540 
X1203 0.094 0.540 
X2295 -0.094 0.540 
X1371 0.094 0.541 
X2151 -0.094 0.542 
X459 -0.094 0.542 
X604 0.093 0.544 
X587 0.093 0.544 
X2044 0.093 0.545 
X992 -0.093 0.546 
X2016 0.093 0.547 
X1330 -0.092 0.548 
X633 -0.092 0.549 
X1480 0.092 0.551 
X1709 0.091 0.552 
X1432 -0.091 0.554 
X1131 -0.091 0.554 
X1651 -0.090 0.557 
X2231 0.090 0.558 
X978 0.090 0.558 
X2301 0.090 0.559 
X1109 0.090 0.559 
X985 0.089 0.560 
X903 0.089 0.561 
X2292 0.089 0.561 
X908 -0.089 0.561 
X2120 -0.089 0.564 
X1423 0.089 0.564 
X1643 -0.088 0.567 
X1464 0.088 0.569 
X1005 -0.087 0.570 
X627 0.087 0.571 
X1435 -0.087 0.572 
X1268 -0.087 0.572 
X887 0.087 0.572 
X1314 -0.087 0.573 
X2317 -0.086 0.574 
X1766 -0.086 0.575 
X371 0.086 0.576 
X1022 -0.086 0.576 
X636 -0.086 0.577 
X1166 0.085 0.578 
X2339 -0.085 0.579 
X1283 -0.085 0.580 
X1664 -0.085 0.580 
X872 -0.085 0.580 
X1466 -0.085 0.581 
X1304 -0.085 0.582 
X2014 0.085 0.582 
X621 -0.085 0.582 
X1367 0.084 0.584 
X642 -0.084 0.587 
X1780 0.083 0.589 
X2073 0.083 0.589 
X1150 -0.083 0.590 
X753 0.083 0.590 
X1228 -0.083 0.591 
X1184 -0.083 0.591 
X1072 -0.082 0.592 
X809 0.082 0.593 
X1138 -0.082 0.594 
X833 0.082 0.594 
  295 
  
X1676 -0.082 0.595 
X1503 0.081 0.597 
X1561 0.081 0.598 
X775 0.081 0.598 
X991 -0.081 0.598 
X1593 -0.081 0.598 
X1438 -0.081 0.598 
X1765 -0.081 0.598 
X2222 -0.081 0.599 
X1042 0.081 0.600 
X990 -0.081 0.601 
X943 0.080 0.601 
X1730 0.080 0.601 
X1220 -0.080 0.603 
X1401 0.079 0.606 
X1155 -0.079 0.606 
X1041 -0.079 0.607 
X400 -0.079 0.608 
X229 -0.079 0.609 
X1462 -0.078 0.610 
X686 -0.078 0.610 
X1595 0.078 0.611 
X2351 -0.078 0.611 
X1965 0.078 0.612 
X378 0.078 0.613 
X1812 0.077 0.617 
X1208 -0.077 0.617 
X1419 0.077 0.618 
X632 -0.077 0.618 
X1047 0.076 0.620 
X1667 0.076 0.620 
X1759 0.076 0.620 
X617 0.076 0.622 
X272 0.076 0.622 
X2174 -0.075 0.624 
X2238 -0.075 0.625 
X1778 0.075 0.625 
X1692 -0.075 0.626 
X1525 -0.075 0.627 
X1030 -0.075 0.627 
X1046 -0.075 0.627 
X694 -0.075 0.628 
X1678 0.074 0.629 
X2050 -0.074 0.629 
X1806 -0.074 0.632 
X1735 -0.074 0.633 
X1492 -0.074 0.633 
X798 -0.074 0.633 
X2354 0.073 0.633 
X1347 -0.073 0.634 
X821 0.073 0.635 
X826 0.073 0.637 
X1882 -0.073 0.637 
X1838 -0.072 0.638 
X2287 0.072 0.638 
X597 -0.072 0.639 
X1291 0.072 0.640 
X1581 -0.072 0.640 
X1657 0.072 0.641 
X1407 0.072 0.642 
X712 -0.072 0.642 
X1611 0.071 0.643 
X1036 0.071 0.643 
X1413 -0.071 0.644 
X1817 0.071 0.645 
X1674 -0.071 0.646 
X1374 -0.071 0.647 
X2226 -0.071 0.647 
X1757 0.071 0.647 
X2256 0.070 0.647 
X1629 -0.070 0.648 
X2128 0.070 0.648 
X1990 0.070 0.648 
X1162 -0.070 0.649 
X705 -0.070 0.649 
X1362 -0.070 0.649 
X1793 -0.070 0.650 
X1944 -0.070 0.650 
X995 0.070 0.651 
X1281 -0.069 0.652 
X2007 0.069 0.652 
X795 0.069 0.652 
X714 -0.069 0.653 
X1516 -0.069 0.654 
X2115 -0.069 0.654 
X681 0.069 0.655 
X2284 0.069 0.655 
X1728 -0.069 0.656 
X954 0.068 0.656 
X971 -0.068 0.656 
X1823 -0.068 0.660 
X1590 -0.068 0.660 
X1988 0.068 0.660 
X608 -0.067 0.662 
X1805 0.067 0.662 
X1007 -0.067 0.662 
X2123 0.067 0.662 
X1591 0.067 0.663 
X1063 -0.067 0.664 
X1073 -0.067 0.664 
X2203 -0.067 0.666 
X1538 0.067 0.666 
X2350 0.066 0.668 
X1160 0.066 0.668 
X1701 -0.066 0.669 
X1599 0.065 0.671 
X1081 0.065 0.672 
X1000 -0.065 0.672 
X963 0.065 0.673 
X669 0.065 0.674 
X1822 -0.065 0.674 
X1826 -0.064 0.676 
X1120 0.064 0.676 
X1523 0.064 0.677 
X1381 0.064 0.678 
X1321 -0.063 0.680 
X2159 0.063 0.681 
X2298 -0.063 0.682 
X432 0.063 0.682 
X1749 -0.063 0.682 
X1586 -0.063 0.682 
X1385 -0.063 0.682 
X1361 -0.063 0.683 
X1130 0.063 0.684 
X1717 0.063 0.684 
X1677 -0.063 0.684 
X1161 -0.062 0.685 
X1543 -0.062 0.685 
X778 -0.062 0.685 
X1942 -0.062 0.686 
X638 -0.062 0.686 
X1705 -0.062 0.687 
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X266 0.062 0.688 
X2210 -0.062 0.688 
X744 -0.062 0.688 
X1265 -0.062 0.688 
X999 0.062 0.689 
X2019 0.061 0.690 
X1045 0.061 0.692 
X1786 -0.061 0.692 
X2116 0.061 0.692 
X1186 0.061 0.693 
X1341 0.060 0.695 
X1485 -0.060 0.695 
X679 0.060 0.696 
X1180 -0.060 0.696 
X1033 -0.060 0.696 
X1448 -0.060 0.697 
X1738 -0.060 0.697 
X1659 -0.060 0.698 
X1282 0.060 0.698 
X1434 -0.060 0.698 
X574 0.060 0.699 
X945 0.059 0.700 
X1587 0.059 0.700 
X2032 0.059 0.701 
X1598 0.059 0.702 
X771 -0.059 0.703 
X1424 -0.059 0.703 
X2169 0.058 0.704 
X1164 0.058 0.704 
X851 0.058 0.708 
X1211 0.057 0.710 
X1566 -0.057 0.711 
X878 -0.057 0.711 
X1363 -0.057 0.712 
X1487 -0.057 0.713 
X1903 -0.057 0.714 
X1972 0.056 0.714 
X1092 0.056 0.715 
X1491 -0.056 0.716 
X305 0.056 0.716 
X1814 0.056 0.716 
X782 -0.056 0.717 
X774 -0.056 0.718 
X1547 0.056 0.718 
X2111 -0.056 0.718 
X906 -0.056 0.718 
X768 0.056 0.719 
X996 0.055 0.719 
X2070 -0.055 0.719 
X1856 0.055 0.719 
X1226 0.055 0.720 
X1879 0.055 0.720 
X1802 -0.055 0.721 
X1616 0.055 0.721 
X724 0.055 0.721 
X1012 0.055 0.722 
X1089 0.055 0.722 
X682 -0.055 0.722 
X1500 0.055 0.723 
X2341 0.055 0.723 
X1221 0.055 0.723 
X1331 -0.055 0.723 
X1392 0.054 0.724 
X591 -0.054 0.726 
X2098 0.054 0.728 
X1783 -0.054 0.728 
X2126 0.054 0.728 
X1218 -0.053 0.728 
X1305 -0.053 0.730 
X1275 -0.053 0.731 
X1687 0.053 0.732 
X968 -0.053 0.732 
X1140 -0.053 0.732 
X2021 0.053 0.733 
X1450 0.052 0.734 
X721 -0.052 0.735 
X1671 0.052 0.735 
X1622 0.052 0.736 
X635 -0.052 0.736 
X2185 0.052 0.737 
X2245 -0.052 0.738 
X2020 0.051 0.740 
X1377 0.051 0.740 
X646 -0.051 0.740 
X676 0.051 0.741 
X2024 -0.051 0.741 
X1422 -0.051 0.743 
X1273 -0.050 0.743 
X1440 -0.050 0.743 
X1997 0.050 0.743 
X648 0.050 0.744 
X1794 -0.050 0.745 
X594 -0.050 0.746 
X2087 -0.050 0.746 
X397 -0.050 0.747 
X1174 -0.049 0.748 
X1303 -0.049 0.749 
X1163 0.049 0.749 
X1152 -0.049 0.750 
X1818 -0.049 0.750 
X1481 0.049 0.751 
X1380 -0.049 0.751 
X1627 -0.049 0.752 
X1703 -0.049 0.752 
X1530 0.049 0.752 
X871 -0.048 0.753 
X1654 -0.048 0.754 
X657 0.048 0.755 
X1264 -0.048 0.755 
X1658 0.048 0.756 
X1857 -0.048 0.758 
X1825 0.048 0.758 
X1580 -0.047 0.759 
X2101 -0.047 0.761 
X2184 -0.046 0.765 
X2254 0.046 0.766 
X976 -0.046 0.766 
X2353 -0.046 0.767 
X1436 -0.046 0.767 
X1009 -0.046 0.768 
X2336 0.045 0.768 
X867 0.045 0.769 
X897 -0.045 0.770 
X1465 -0.045 0.771 
X965 0.045 0.772 
X675 -0.045 0.772 
X741 -0.045 0.772 
X918 0.045 0.773 
X1205 0.044 0.773 
X1624 0.044 0.773 
X599 -0.044 0.773 
X2049 -0.044 0.775 
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X1405 -0.044 0.775 
X2194 0.044 0.776 
X1010 -0.044 0.777 
X746 -0.044 0.778 
X1552 0.043 0.778 
X637 -0.043 0.779 
X2091 0.043 0.779 
X1691 0.043 0.780 
X1315 -0.043 0.780 
X281 0.043 0.781 
X1326 0.043 0.782 
X1170 -0.043 0.782 
X1229 0.042 0.783 
X1981 -0.042 0.784 
X740 0.042 0.785 
X738 -0.042 0.786 
X1968 0.042 0.786 
X387 0.042 0.787 
X2241 -0.042 0.788 
X2127 0.041 0.788 
X1830 -0.041 0.789 
X1171 -0.041 0.789 
X1478 0.041 0.790 
X1433 0.041 0.790 
X1191 -0.041 0.790 
X2138 0.041 0.791 
X1098 0.041 0.791 
X1299 -0.041 0.791 
X1549 -0.041 0.792 
X1126 0.041 0.792 
X1962 0.041 0.792 
X938 -0.041 0.792 
X2303 -0.040 0.794 
X1147 -0.040 0.794 
X602 0.040 0.794 
X654 0.040 0.794 
X1317 -0.040 0.795 
X873 -0.040 0.796 
X1270 0.040 0.796 
X1821 0.040 0.796 
X1506 0.040 0.797 
X1058 -0.040 0.798 
X1535 -0.039 0.798 
X2198 0.039 0.798 
X1204 0.039 0.799 
X1339 -0.039 0.800 
X620 0.039 0.801 
X2081 -0.039 0.801 
X1060 -0.039 0.801 
X993 0.039 0.802 
X1397 -0.039 0.802 
X2313 0.039 0.802 
X2347 0.039 0.803 
X755 0.038 0.804 
X2314 -0.038 0.805 
X718 -0.038 0.805 
X1668 0.038 0.806 
X625 0.037 0.809 
X1521 0.037 0.809 
X2013 -0.037 0.810 
X1123 -0.037 0.812 
X1964 -0.037 0.813 
X607 -0.036 0.814 
X2281 -0.036 0.814 
X1963 0.036 0.816 
X603 -0.036 0.816 
X659 -0.036 0.817 
X1360 0.036 0.817 
X1588 -0.036 0.818 
X969 -0.035 0.818 
X2330 -0.035 0.819 
X1293 -0.035 0.819 
X947 -0.035 0.820 
X1269 0.035 0.820 
X1006 0.035 0.821 
X386 0.035 0.822 
X786 -0.035 0.823 
X905 -0.034 0.823 
X1702 -0.034 0.824 
X2221 -0.033 0.829 
X684 -0.033 0.830 
X1296 -0.033 0.832 
X1685 -0.032 0.833 
X2337 -0.032 0.834 
X1719 0.032 0.834 
X1816 -0.032 0.836 
X857 0.032 0.836 
X501 0.032 0.837 
X2326 0.032 0.837 
X2237 0.032 0.837 
X598 -0.032 0.837 
X405 -0.032 0.838 
X994 0.031 0.839 
X1029 -0.031 0.840 
X1753 0.031 0.840 
X1789 0.031 0.841 
X1345 0.031 0.841 
X1471 0.031 0.841 
X571 0.031 0.841 
X2097 -0.031 0.841 
X1499 -0.031 0.843 
X930 -0.030 0.844 
X1124 -0.030 0.844 
X876 0.030 0.845 
X2103 0.030 0.846 
X1848 -0.030 0.846 
X942 0.030 0.848 
X1548 0.029 0.850 
X1442 0.029 0.852 
X2140 0.029 0.852 
X639 0.029 0.853 
X1829 -0.029 0.853 
X1621 0.028 0.854 
X393 0.028 0.854 
X1146 0.028 0.855 
X1425 0.028 0.856 
X1505 -0.028 0.857 
X916 -0.028 0.857 
X1808 -0.028 0.858 
X2085 0.027 0.859 
X987 0.027 0.859 
X1350 -0.027 0.859 
X2045 0.027 0.860 
X1679 0.027 0.861 
X1494 -0.027 0.861 
X2040 0.027 0.863 
X1427 -0.026 0.864 
X680 -0.026 0.866 
X745 -0.026 0.866 
X1897 -0.026 0.866 
X2244 -0.025 0.869 
X1043 -0.025 0.869 
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X1837 -0.025 0.870 
X1849 0.025 0.870 
X643 -0.025 0.871 
X2215 -0.025 0.872 
X1558 0.025 0.872 
X1294 -0.025 0.873 
X900 0.025 0.873 
X1640 -0.025 0.874 
X626 0.024 0.874 
X1744 0.024 0.876 
X2335 0.024 0.876 
X1344 0.024 0.877 
X2152 -0.023 0.879 
X1577 -0.023 0.879 
X1743 0.023 0.879 
X894 -0.023 0.880 
X1121 0.023 0.880 
X396 0.023 0.880 
X2199 -0.023 0.881 
X739 0.023 0.882 
X933 0.023 0.883 
X1686 -0.023 0.883 
X800 -0.023 0.884 
X1756 0.022 0.884 
X1106 -0.022 0.885 
X1175 -0.022 0.885 
X1032 -0.022 0.885 
X973 -0.022 0.886 
X1537 -0.022 0.887 
X1053 0.022 0.887 
X1050 0.022 0.887 
X1510 0.022 0.887 
X2048 -0.022 0.888 
X1620 0.022 0.889 
X1431 0.021 0.890 
X1311 -0.021 0.890 
X1246 -0.021 0.891 
X1836 0.021 0.891 
X1079 0.021 0.891 
X1731 0.021 0.891 
X1153 -0.021 0.892 
X379 0.021 0.892 
X1212 0.021 0.894 
X1881 -0.021 0.894 
X1876 -0.020 0.895 
X983 0.020 0.896 
X1239 0.020 0.896 
X1732 0.020 0.897 
X687 0.020 0.897 
X2026 0.020 0.898 
X2196 0.019 0.899 
X2193 -0.019 0.900 
X2283 -0.019 0.900 
X1274 -0.019 0.901 
X1169 0.019 0.901 
X1216 -0.019 0.901 
X311 -0.019 0.901 
X1650 -0.019 0.903 
X664 -0.019 0.903 
X2338 0.019 0.903 
X1488 -0.018 0.905 
X595 0.018 0.905 
X630 -0.018 0.906 
X763 0.018 0.907 
X1784 0.018 0.907 
X1287 0.018 0.907 
X2086 0.018 0.907 
X1803 -0.018 0.907 
X1929 -0.018 0.907 
X1127 0.018 0.908 
X1122 -0.018 0.909 
X1412 -0.018 0.909 
X2296 -0.017 0.910 
X1746 -0.017 0.910 
X713 0.017 0.910 
X1077 -0.017 0.911 
X1697 0.017 0.911 
X2119 -0.017 0.912 
X634 0.017 0.912 
X641 0.017 0.912 
X1718 -0.017 0.912 
X1512 -0.017 0.913 
X1259 0.017 0.914 
X1635 0.016 0.915 
X767 -0.016 0.915 
X1483 -0.016 0.916 
X1725 -0.016 0.916 
X752 0.016 0.917 
X1689 0.016 0.918 
X1518 -0.016 0.918 
X685 -0.016 0.919 
X596 -0.016 0.920 
X645 -0.015 0.921 
X593 0.015 0.921 
X1213 0.015 0.921 
X2211 -0.015 0.921 
X1948 0.015 0.921 
X1779 0.015 0.922 
X1459 -0.015 0.922 
X2136 0.015 0.922 
X1645 -0.015 0.922 
X1088 -0.015 0.922 
X580 0.015 0.924 
X629 0.015 0.924 
X1064 0.015 0.924 
X1039 0.015 0.925 
X2096 -0.014 0.926 
X1456 0.014 0.926 
X2232 0.014 0.926 
X1390 0.014 0.926 
X1565 0.014 0.927 
X2088 0.014 0.928 
X1720 0.014 0.928 
X1781 -0.014 0.928 
X895 -0.014 0.930 
X765 0.013 0.932 
X1238 -0.013 0.933 
X1093 0.013 0.933 
X1099 -0.013 0.934 
X1247 -0.013 0.934 
X1386 -0.013 0.935 
X839 -0.013 0.935 
X1087 0.012 0.936 
X2156 -0.012 0.937 
X863 -0.012 0.937 
X725 0.012 0.937 
X1070 -0.012 0.939 
X589 -0.012 0.939 
X2171 0.012 0.940 
X1189 0.012 0.940 
X1387 0.012 0.940 
X904 0.011 0.942 
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X1863 0.011 0.942 
X1151 -0.011 0.943 
X584 0.011 0.943 
X1542 0.011 0.943 
X1167 -0.011 0.944 
X1428 -0.011 0.945 
X1251 0.010 0.946 
X2294 0.010 0.946 
X2148 0.010 0.947 
X1076 -0.010 0.947 
X1748 -0.010 0.947 
X770 0.010 0.948 
X667 0.010 0.949 
X1890 0.010 0.949 
X1782 0.010 0.951 
X653 0.010 0.951 
X1183 -0.009 0.951 
X2146 0.009 0.952 
X1688 -0.009 0.952 
X381 0.009 0.953 
X1052 0.009 0.954 
X1091 0.009 0.955 
X1745 -0.009 0.955 
X1290 -0.009 0.955 
X853 0.009 0.956 
X1971 0.008 0.956 
X1927 -0.008 0.957 
X1707 0.008 0.958 
X2315 -0.008 0.958 
X1415 -0.008 0.959 
X622 -0.008 0.959 
X1185 0.008 0.960 
X609 0.008 0.960 
X624 -0.008 0.960 
X2142 -0.008 0.960 
X2273 0.008 0.960 
X1982 0.007 0.962 
X2043 -0.007 0.963 
X532 0.007 0.964 
X866 0.007 0.965 
X1575 -0.007 0.966 
X1316 0.007 0.966 
X2307 -0.006 0.966 
X1157 -0.006 0.968 
X749 0.006 0.969 
X1572 0.006 0.970 
X1809 0.006 0.971 
X803 0.006 0.971 
X977 -0.005 0.972 
X1207 -0.005 0.973 
X1297 0.005 0.974 
X1644 -0.005 0.976 
X1795 -0.005 0.976 
X2135 -0.005 0.976 
X2311 -0.004 0.977 
X1260 0.004 0.977 
X1930 -0.004 0.978 
X939 0.004 0.978 
X865 0.004 0.979 
X2275 0.004 0.980 
X1511 -0.004 0.981 
X1393 -0.004 0.982 
X1117 -0.003 0.983 
X1570 -0.003 0.983 
X286 -0.003 0.984 
X1430 0.003 0.984 
X1680 -0.002 0.989 
X640 -0.002 0.989 
X545 -0.002 0.990 
X692 -0.002 0.991 
X610 0.002 0.991 
X1158 -0.002 0.991 
X1479 0.002 0.991 
X1201 -0.002 0.992 
X1514 -0.001 0.993 
X631 0.001 0.993 
X242 0.001 0.994 
X2280 -0.001 0.994 
X2230 -0.001 0.995 
X1501 -0.001 0.995 
X666 -0.001 0.995 
X901 0.001 0.996 
X1469 -0.001 0.996 
X1636 0.001 0.997 
X1832 0.001 0.997 
X1489 0.000 0.999 
X1116 0.000 1.000 
X1059 0.000 1.000 
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Appendix 3 
T12 partial correlation results for 2DGE spots with PiB PET DVR. Spots 
ranked in order of significance based on p value. Results highlighted in red are 



























X2143 -0.533 0.000 
X1309 -0.500 0.000 
X630 -0.468 0.000 
X635 -0.439 0.001 
X1110 0.428 0.002 
X598 -0.424 0.002 
X1496 0.424 0.002 
X966 -0.423 0.002 
X1780 0.415 0.002 
X899 -0.410 0.003 
X381 -0.406 0.003 
X1171 -0.398 0.004 
X1500 0.392 0.004 
X589 -0.391 0.004 
X1718 0.390 0.004 
X969 -0.389 0.005 
X2141 -0.388 0.005 
X996 -0.385 0.005 
X1549 0.382 0.006 
X593 -0.380 0.006 
X911 -0.377 0.006 
X584 -0.369 0.008 
X2177 0.366 0.008 
X1015 -0.365 0.009 
X596 -0.364 0.009 
X1377 0.360 0.010 
X1597 0.359 0.010 
X1593 0.359 0.010 
X1557 0.356 0.011 
X386 -0.353 0.011 
X641 -0.353 0.011 
X642 -0.350 0.012 
X1112 0.349 0.012 
X1710 -0.342 0.015 
X1662 -0.340 0.015 
X1303 -0.339 0.015 
X587 -0.337 0.016 
X685 -0.335 0.017 
X629 -0.334 0.017 
X272 -0.331 0.019 
X1399 0.329 0.019 
X2024 -0.329 0.020 
X1929 0.328 0.020 
X2040 -0.327 0.020 
X993 -0.327 0.020 
X2235 0.325 0.021 
X1129 0.322 0.022 
X585 0.321 0.023 
X1170 -0.318 0.024 
X1580 0.317 0.025 
X1738 -0.317 0.025 
X705 -0.315 0.026 
X1172 -0.312 0.027 
X634 -0.311 0.028 
X1963 0.310 0.029 
X1617 0.309 0.029 
X1017 -0.309 0.029 
X1299 0.308 0.030 
X1078 -0.307 0.031 
X1067 -0.303 0.033 
X1402 -0.302 0.034 
X640 -0.299 0.035 
X2214 0.296 0.038 
X1966 0.295 0.038 
X525 -0.293 0.040 
X1762 -0.293 0.040 
X971 -0.292 0.041 
X905 -0.290 0.042 
X1362 0.289 0.043 
X906 -0.289 0.043 
X1367 0.288 0.044 
X1474 0.286 0.045 
X669 -0.286 0.045 
X1071 0.285 0.046 
X654 -0.283 0.047 
X281 -0.283 0.048 
X826 -0.279 0.051 
X2111 -0.279 0.052 
X631 -0.278 0.052 
X910 -0.278 0.052 
X1814 0.276 0.054 
X1404 -0.275 0.055 
X766 0.275 0.055 
X1741 -0.275 0.055 
X1018 -0.271 0.059 
X1290 -0.270 0.060 
X913 -0.270 0.060 
X707 -0.269 0.061 
X874 -0.269 0.061 
X633 -0.268 0.062 
X1111 -0.268 0.062 
X1010 0.268 0.062 
X597 -0.268 0.062 
X1724 0.267 0.063 
X1339 -0.267 0.063 
X1277 -0.266 0.064 
X1521 -0.266 0.064 
X1548 0.265 0.065 
X643 -0.265 0.065 
X904 -0.263 0.067 
X686 -0.263 0.068 
X626 -0.262 0.068 
X1400 -0.262 0.069 
X1588 0.261 0.070 
X590 0.260 0.070 
X1063 -0.260 0.071 
X1748 0.260 0.071 
X1777 0.255 0.076 
X1408 -0.254 0.078 
X1463 -0.253 0.080 
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X1374 0.252 0.080 
X1903 0.252 0.081 
X2147 -0.252 0.081 
X754 -0.252 0.081 
X2268 -0.251 0.081 
X710 -0.251 0.081 
X1679 0.251 0.082 
X1723 0.251 0.082 
X1394 0.251 0.083 
X2049 -0.250 0.083 
X1486 0.250 0.083 
X2125 -0.250 0.084 
X1466 0.250 0.084 
X1590 -0.249 0.084 
X680 0.249 0.084 
X1070 -0.249 0.085 
X2275 -0.247 0.087 
X2010 -0.247 0.087 
X1379 -0.247 0.087 
X816 -0.247 0.087 
X1258 -0.247 0.087 
X379 -0.247 0.088 
X266 -0.246 0.089 
X625 -0.245 0.090 
X480 0.245 0.090 
X1621 0.245 0.090 
X1968 0.245 0.090 
X690 -0.245 0.091 
X1057 -0.244 0.091 
X1396 -0.244 0.092 
X2045 -0.243 0.093 
X1094 -0.243 0.093 
X1139 -0.241 0.096 
X1692 0.241 0.096 
X1816 0.240 0.098 
X2023 -0.240 0.098 
X972 -0.239 0.098 
X999 -0.239 0.099 
X968 -0.239 0.099 
X1657 0.238 0.100 
X1612 -0.238 0.100 
X2142 -0.238 0.100 
X925 -0.237 0.101 
X1192 0.236 0.103 
X791 -0.235 0.105 
X2317 -0.235 0.105 
X2044 -0.235 0.105 
X2053 -0.235 0.106 
X1598 0.235 0.106 
X936 0.234 0.106 
X1169 -0.234 0.106 
X1014 -0.234 0.107 
X1068 -0.233 0.107 
X2281 -0.233 0.108 
X1691 0.233 0.108 
X1828 -0.233 0.108 
X1528 0.232 0.109 
X2341 -0.232 0.110 
X1524 -0.231 0.111 
X1906 -0.231 0.111 
X1997 -0.231 0.111 
X2211 -0.231 0.112 
X891 -0.230 0.113 
X985 -0.229 0.114 
X1613 -0.229 0.115 
X1508 0.228 0.115 
X753 0.228 0.116 
X1161 -0.228 0.116 
X2120 -0.228 0.117 
X1392 0.227 0.117 
X2250 0.227 0.119 
X2226 0.227 0.119 
X2081 0.226 0.119 
X2155 0.226 0.119 
X1331 -0.226 0.120 
X2209 0.224 0.122 
X1054 -0.224 0.123 
X2273 -0.224 0.124 
X1902 0.223 0.125 
X1049 -0.222 0.126 
X712 -0.222 0.127 
X610 -0.221 0.128 
X628 -0.221 0.128 
X1393 -0.220 0.131 
X772 -0.220 0.131 
X1238 0.219 0.131 
X1390 -0.219 0.132 
X1153 -0.219 0.132 
X2315 -0.219 0.132 
X2063 -0.218 0.134 
X656 -0.218 0.134 
X708 -0.218 0.135 
X1047 -0.217 0.135 
X1013 -0.217 0.136 
X2271 -0.217 0.136 
X855 -0.216 0.137 
X1246 -0.216 0.137 
X657 0.216 0.138 
X998 -0.215 0.140 
X668 -0.215 0.141 
X1023 -0.215 0.141 
X1618 0.214 0.141 
X2140 -0.214 0.142 
X1022 -0.214 0.142 
X1809 0.213 0.144 
X2087 -0.213 0.144 
X1737 -0.212 0.145 
X1499 -0.212 0.146 
X580 -0.212 0.146 
X679 -0.212 0.146 
X1312 -0.212 0.146 
X951 0.210 0.149 
X1247 -0.210 0.149 
X1084 -0.210 0.149 
X696 0.210 0.150 
X1163 -0.209 0.151 
X702 -0.209 0.152 
X2109 -0.209 0.152 
X2244 0.208 0.153 
X638 -0.208 0.153 
X2054 -0.208 0.154 
X621 -0.207 0.156 
X1782 0.206 0.158 
X665 -0.206 0.158 
X1310 -0.206 0.159 
X939 0.205 0.159 
X1099 -0.205 0.159 
X2007 -0.205 0.159 
X1507 0.205 0.161 
X1195 -0.205 0.161 
X1821 0.205 0.161 
X2159 0.204 0.163 
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X1510 0.204 0.163 
X594 -0.204 0.163 
X822 0.204 0.163 
X2082 0.203 0.165 
X1646 -0.202 0.166 
X1648 -0.202 0.167 
X1685 -0.202 0.167 
X1716 0.202 0.167 
X1818 0.202 0.168 
X1518 0.201 0.168 
X1397 -0.201 0.169 
X1135 -0.201 0.169 
X1775 -0.200 0.170 
X2025 -0.200 0.171 
X2184 0.200 0.171 
X2102 0.200 0.172 
X765 0.200 0.172 
X1637 -0.199 0.172 
X1244 -0.199 0.173 
X1043 -0.199 0.173 
X1196 -0.199 0.174 
X706 -0.198 0.176 
X1337 -0.197 0.178 
X1227 -0.197 0.178 
X602 0.196 0.179 
X1551 0.196 0.179 
X1357 -0.196 0.180 
X2348 -0.196 0.180 
X676 0.196 0.180 
X1092 -0.196 0.180 
X2126 -0.196 0.180 
X659 -0.195 0.181 
X2036 -0.195 0.181 
X1271 0.195 0.182 
X1639 -0.195 0.182 
X1052 -0.195 0.183 
X2190 -0.194 0.184 
X533 0.194 0.184 
X1773 -0.194 0.184 
X976 -0.194 0.184 
X1470 0.194 0.185 
X1376 0.194 0.185 
X1283 0.193 0.186 
X574 -0.193 0.186 
X1803 0.193 0.187 
X886 -0.193 0.188 
X763 -0.192 0.189 
X1958 0.192 0.190 
X928 0.191 0.192 
X601 0.190 0.194 
X2085 0.190 0.194 
X1927 0.190 0.195 
X1579 0.189 0.196 
X1587 0.189 0.197 
X2043 -0.189 0.197 
X1687 -0.189 0.198 
X1167 -0.189 0.198 
X1808 0.188 0.198 
X1645 -0.188 0.200 
X1915 0.187 0.200 
X1926 0.187 0.201 
X902 -0.187 0.202 
X848 -0.187 0.202 
X471 0.187 0.202 
X1128 0.187 0.203 
X1465 0.187 0.203 
X1026 -0.187 0.203 
X844 0.186 0.204 
X678 -0.186 0.205 
X1489 -0.186 0.205 
X2137 -0.185 0.206 
X1823 0.185 0.206 
X1633 -0.185 0.206 
X1771 0.185 0.206 
X2240 0.185 0.207 
X1278 -0.185 0.207 
X1623 -0.185 0.208 
X1046 -0.184 0.208 
X1222 -0.184 0.209 
X403 -0.183 0.211 
X2203 0.183 0.212 
X748 -0.183 0.212 
X1781 0.183 0.212 
X1787 0.183 0.212 
X758 -0.183 0.213 
X305 -0.182 0.214 
X1756 0.181 0.216 
X1338 -0.181 0.216 
X2095 0.181 0.217 
X921 -0.181 0.218 
X1059 -0.180 0.218 
X1134 0.180 0.218 
X1757 0.180 0.218 
X2218 -0.179 0.221 
X2231 0.179 0.222 
X947 -0.179 0.223 
X1573 -0.179 0.223 
X1695 -0.179 0.223 
X637 -0.179 0.223 
X746 -0.178 0.224 
X1454 -0.178 0.224 
X898 -0.177 0.226 
X2156 -0.177 0.229 
X1190 -0.177 0.229 
X2339 -0.176 0.230 
X1785 0.176 0.231 
X1053 -0.175 0.232 
X852 0.174 0.235 
X2331 0.173 0.238 
X1353 -0.173 0.239 
X1950 0.172 0.242 
X558 0.172 0.243 
X595 0.171 0.243 
X722 -0.170 0.246 
X1168 -0.170 0.246 
X645 -0.170 0.247 
X2096 -0.170 0.247 
X1426 -0.170 0.247 
X1173 -0.168 0.252 
X2313 -0.168 0.252 
X963 -0.168 0.252 
X694 -0.168 0.253 
X1314 -0.168 0.254 
X1650 0.166 0.258 
X1805 0.166 0.258 
X1356 -0.166 0.258 
X2304 0.166 0.258 
X184 -0.166 0.259 
X1925 0.165 0.261 
X725 -0.165 0.261 
X885 -0.165 0.262 
X1715 0.165 0.263 
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X1421 -0.164 0.264 
X1538 0.164 0.264 
X1727 0.163 0.267 
X741 -0.163 0.267 
X1422 0.163 0.268 
X1036 -0.163 0.269 
X974 -0.162 0.270 
X1802 0.162 0.271 
X1042 -0.162 0.271 
X2237 -0.162 0.271 
X1825 0.162 0.271 
X944 -0.161 0.273 
X1523 -0.161 0.273 
X887 0.161 0.274 
X1604 0.161 0.275 
X973 -0.161 0.275 
X1959 0.160 0.276 
X1930 0.160 0.278 
X2144 -0.160 0.278 
X1032 0.160 0.278 
X1619 0.159 0.279 
X2239 0.159 0.279 
X2198 -0.159 0.280 
X1581 0.159 0.280 
X779 -0.159 0.280 
X1610 0.159 0.280 
X757 0.159 0.281 
X1678 0.158 0.282 
X2115 -0.158 0.282 
X1713 0.158 0.283 
X1154 0.158 0.284 
X733 0.157 0.286 
X661 -0.156 0.289 
X2194 0.156 0.289 
X1255 -0.156 0.291 
X1698 0.155 0.291 
X627 -0.155 0.292 
X1663 -0.155 0.292 
X1520 -0.154 0.296 
X1572 -0.153 0.298 
X1668 0.153 0.299 
X1158 -0.153 0.299 
X484 0.153 0.300 
X1401 0.153 0.300 
X1832 -0.153 0.300 
X2298 -0.152 0.302 
X1073 -0.152 0.302 
X1942 -0.152 0.303 
X1819 0.151 0.304 
X2345 -0.151 0.304 
X1307 0.151 0.305 
X609 -0.150 0.307 
X945 -0.150 0.308 
X1189 0.150 0.309 
X2246 0.150 0.309 
X649 0.150 0.310 
X1810 0.149 0.311 
X387 -0.149 0.311 
X1029 -0.149 0.312 
X1725 -0.148 0.314 
X2292 -0.148 0.314 
X938 -0.148 0.315 
X1794 -0.148 0.315 
X2086 0.148 0.315 
X798 -0.148 0.317 
X1811 0.147 0.318 
X1410 -0.147 0.318 
X1223 0.147 0.319 
X1273 0.147 0.320 
X1462 0.147 0.320 
X1917 0.147 0.320 
X1892 0.146 0.321 
X1973 0.146 0.321 
X1175 -0.146 0.321 
X2104 0.146 0.322 
X1690 -0.146 0.323 
X1552 0.146 0.323 
X1448 0.146 0.323 
X1341 -0.145 0.325 
X845 -0.145 0.326 
X1141 -0.145 0.326 
X1768 -0.145 0.327 
X1743 0.143 0.331 
X1450 0.143 0.331 
X2245 -0.143 0.331 
X1611 -0.143 0.332 
X692 -0.143 0.332 
X1990 -0.143 0.332 
X2187 0.143 0.333 
X1439 -0.143 0.333 
X1245 -0.143 0.333 
X2014 -0.143 0.334 
X2118 0.143 0.334 
X1405 -0.143 0.334 
X2127 -0.143 0.334 
X1730 -0.142 0.335 
X950 0.142 0.335 
X1480 -0.142 0.336 
X1076 -0.142 0.336 
X1531 0.142 0.337 
X667 -0.141 0.338 
X1159 0.141 0.339 
X1412 -0.141 0.339 
X2274 0.141 0.339 
X1411 -0.141 0.339 
X1676 -0.141 0.341 
X670 -0.141 0.341 
X1564 0.140 0.341 
X2221 0.140 0.342 
X1108 0.140 0.344 
X2037 -0.139 0.347 
X2006 -0.139 0.347 
X2026 -0.139 0.348 
X2091 -0.138 0.350 
X400 -0.138 0.351 
X1471 0.137 0.353 
X740 -0.137 0.355 
X1409 -0.137 0.355 
X1642 -0.136 0.356 
X991 -0.136 0.356 
X942 -0.136 0.356 
X1848 0.136 0.357 
X786 -0.136 0.358 
X663 -0.136 0.359 
X1033 -0.135 0.359 
X1624 -0.135 0.360 
X2352 0.135 0.361 
X624 -0.135 0.361 
X988 0.135 0.362 
X1491 -0.135 0.362 
X2215 0.134 0.363 
X1039 -0.134 0.363 
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X422 -0.134 0.364 
X1304 0.133 0.366 
X2204 0.133 0.367 
X1191 -0.133 0.369 
X1609 -0.132 0.370 
X1282 -0.132 0.370 
X1758 -0.132 0.371 
X1887 0.132 0.371 
X1289 -0.132 0.372 
X1296 0.132 0.372 
X1430 -0.132 0.373 
X983 -0.132 0.373 
X895 -0.131 0.374 
X1016 -0.131 0.374 
X432 -0.131 0.374 
X2335 -0.131 0.375 
X1438 -0.131 0.377 
X1440 -0.131 0.377 
X773 -0.130 0.377 
X2311 0.130 0.378 
X1759 -0.129 0.381 
X788 -0.129 0.382 
X1087 -0.129 0.383 
X1599 0.129 0.384 
X2088 -0.129 0.384 
X1106 0.129 0.385 
X2332 -0.128 0.385 
X749 -0.128 0.385 
X1215 -0.128 0.386 
X389 -0.128 0.386 
X1156 0.128 0.386 
X946 -0.128 0.388 
X778 -0.127 0.389 
X1562 0.127 0.390 
X545 -0.127 0.390 
X603 -0.127 0.390 
X1308 0.127 0.391 
X1103 -0.126 0.393 
X1849 0.126 0.393 
X1806 0.126 0.393 
X687 0.126 0.395 
X1941 0.126 0.395 
X615 -0.126 0.396 
X1614 0.125 0.397 
X2168 0.125 0.397 
X1117 -0.125 0.398 
X1152 -0.125 0.398 
X1414 0.125 0.398 
X1251 0.125 0.400 
X1817 0.124 0.400 
X884 0.124 0.401 
X1464 0.124 0.401 
X1684 0.124 0.401 
X1856 -0.124 0.402 
X2349 0.124 0.402 
X2276 0.124 0.403 
X795 0.124 0.403 
X738 -0.124 0.403 
X1005 0.123 0.405 
X1066 0.123 0.405 
X1494 0.123 0.405 
X1352 -0.123 0.405 
X1813 0.123 0.405 
X1607 0.123 0.405 
X664 -0.123 0.405 
X1347 0.123 0.406 
X242 0.123 0.406 
X858 0.123 0.406 
X1506 0.123 0.407 
X396 -0.123 0.407 
X1600 0.122 0.408 
X1212 0.122 0.408 
X1631 0.122 0.409 
X1561 -0.122 0.409 
X1779 0.122 0.409 
X1131 -0.122 0.409 
X1890 0.122 0.409 
X970 -0.122 0.410 
X2217 -0.122 0.411 
X1391 0.121 0.412 
X2280 -0.121 0.412 
X809 0.121 0.412 
X861 0.121 0.413 
X1260 -0.121 0.415 
X591 -0.121 0.415 
X1732 -0.121 0.415 
X1121 -0.120 0.418 
X658 0.120 0.418 
X1345 -0.120 0.419 
X1210 -0.120 0.419 
X1504 0.119 0.420 
X1133 0.119 0.421 
X744 0.119 0.423 
X397 -0.118 0.424 
X860 0.118 0.425 
X2050 0.118 0.425 
X718 -0.118 0.426 
X2071 0.118 0.427 
X607 0.117 0.428 
X869 -0.117 0.429 
X701 0.117 0.430 
X1228 -0.117 0.431 
X1774 -0.117 0.431 
X1224 0.116 0.432 
X1233 0.116 0.433 
X371 -0.116 0.433 
X617 -0.115 0.436 
X1040 0.115 0.437 
X770 0.115 0.437 
X1317 0.115 0.437 
X1962 0.115 0.439 
X1742 -0.114 0.440 
X311 -0.114 0.440 
X1264 -0.114 0.440 
X662 -0.114 0.440 
X1323 -0.114 0.442 
X1398 -0.114 0.442 
X2135 0.114 0.442 
X2283 0.114 0.443 
X953 0.113 0.445 
X1125 0.113 0.446 
X1666 -0.113 0.446 
X833 -0.113 0.447 
X1833 0.113 0.447 
X2242 -0.113 0.448 
X2285 0.112 0.448 
X1665 -0.112 0.448 
X817 0.112 0.448 
X618 -0.112 0.448 
X1822 0.112 0.448 
X1298 0.112 0.450 
X616 -0.112 0.450 
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X1093 -0.112 0.451 
X1755 0.111 0.452 
X1407 0.111 0.453 
X1418 -0.111 0.453 
X1675 0.111 0.453 
X1359 0.111 0.454 
X1262 -0.111 0.454 
X1536 0.110 0.456 
X994 -0.110 0.458 
X599 0.110 0.458 
X1428 -0.109 0.460 
X1778 0.109 0.460 
X1001 -0.109 0.463 
X1527 0.109 0.464 
X1265 -0.108 0.465 
X727 -0.108 0.466 
X2172 -0.108 0.466 
X1537 -0.108 0.468 
X688 -0.107 0.469 
X605 -0.107 0.469 
X1582 0.107 0.471 
X2016 -0.107 0.472 
X1021 -0.107 0.472 
X1736 -0.106 0.473 
X1981 -0.106 0.473 
X1638 -0.106 0.473 
X1555 0.106 0.474 
X2116 -0.106 0.475 
X1791 0.106 0.475 
X1788 -0.106 0.476 
X2238 0.105 0.478 
X1261 0.105 0.478 
X434 -0.105 0.480 
X799 -0.105 0.480 
X2151 -0.105 0.480 
X620 -0.105 0.481 
X324 -0.104 0.481 
X606 -0.104 0.481 
X1763 -0.104 0.481 
X2048 -0.104 0.482 
X1707 -0.104 0.482 
X1211 0.104 0.483 
X1651 0.104 0.484 
X1160 -0.103 0.486 
X745 0.103 0.486 
X1372 0.103 0.486 
X1515 0.103 0.487 
X1831 0.103 0.487 
X1095 -0.103 0.488 
X810 0.103 0.489 
X1635 -0.103 0.489 
X1767 -0.103 0.489 
X1659 -0.103 0.489 
X1104 0.103 0.489 
X1369 0.102 0.489 
X1162 -0.102 0.490 
X1468 0.102 0.490 
X1749 0.102 0.491 
X2032 -0.102 0.491 
X1869 0.102 0.491 
X797 -0.102 0.491 
X825 0.102 0.492 
X2232 0.102 0.493 
X1313 -0.101 0.495 
X937 0.101 0.496 
X1293 0.101 0.497 
X2295 0.100 0.498 
X774 0.100 0.499 
X1699 -0.100 0.499 
X1269 0.100 0.499 
X2219 -0.100 0.501 
X1380 0.100 0.501 
X1180 0.099 0.502 
X1286 -0.099 0.503 
X689 -0.099 0.503 
X2351 -0.099 0.503 
X1835 0.099 0.505 
X2161 0.099 0.505 
X892 -0.099 0.506 
X1234 -0.099 0.506 
X1164 -0.099 0.506 
X1451 0.099 0.507 
X646 -0.097 0.511 
X1622 -0.097 0.512 
X1288 -0.097 0.512 
X255 -0.097 0.515 
X1575 0.096 0.516 
X721 -0.096 0.517 
X1115 -0.096 0.517 
X820 -0.095 0.521 
X652 0.095 0.521 
X907 -0.095 0.521 
X2114 0.095 0.521 
X1140 -0.095 0.521 
X2123 0.095 0.522 
X1708 -0.095 0.523 
X1252 -0.095 0.524 
X824 -0.095 0.524 
X1492 -0.094 0.525 
X1545 -0.094 0.525 
X1865 -0.094 0.525 
X1360 -0.094 0.527 
X1065 0.094 0.527 
X1605 0.094 0.528 
X2269 -0.094 0.528 
X807 -0.094 0.529 
X1761 -0.093 0.530 
X2333 -0.093 0.532 
X1200 0.093 0.533 
X1584 0.092 0.534 
X1769 0.092 0.535 
X872 -0.092 0.535 
X2344 0.092 0.535 
X1045 -0.092 0.536 
X1009 -0.091 0.539 
X808 0.091 0.539 
X841 0.091 0.539 
X728 -0.091 0.540 
X453 -0.091 0.541 
X990 -0.091 0.541 
X1363 -0.091 0.542 
X1406 0.090 0.544 
X943 -0.090 0.544 
X1553 0.090 0.544 
X1514 0.090 0.544 
X2296 -0.090 0.545 
X1721 0.090 0.546 
X1383 0.090 0.546 
X1606 0.090 0.546 
X1733 -0.089 0.548 
X805 -0.089 0.548 
X1720 -0.089 0.549 
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X2181 -0.089 0.550 
X1731 0.089 0.550 
X783 -0.088 0.551 
X915 -0.088 0.553 
X1424 0.088 0.554 
X1294 -0.088 0.554 
X1953 0.088 0.555 
X1062 -0.088 0.555 
X673 -0.087 0.556 
X1085 -0.087 0.556 
X926 0.087 0.558 
X684 0.087 0.559 
X1790 0.087 0.559 
X955 -0.087 0.560 
X1595 -0.086 0.560 
X2307 0.086 0.561 
X1686 0.086 0.561 
X286 0.086 0.561 
X726 -0.086 0.563 
X1413 0.086 0.563 
X1268 -0.086 0.564 
X1315 -0.086 0.564 
X2031 -0.085 0.565 
X1517 0.085 0.566 
X653 0.085 0.566 
X1881 0.085 0.566 
X1284 0.085 0.567 
X750 0.085 0.567 
X1116 -0.085 0.568 
X1700 0.085 0.569 
X2189 -0.085 0.569 
X849 -0.084 0.570 
X1473 0.084 0.571 
X1344 0.084 0.571 
X1661 -0.084 0.571 
X1481 0.084 0.572 
X1387 0.084 0.574 
X1735 -0.083 0.576 
X789 -0.083 0.576 
X699 0.083 0.576 
X1652 -0.083 0.577 
X2325 -0.083 0.577 
X739 -0.083 0.577 
X1783 0.083 0.578 
X2005 -0.083 0.578 
X578 0.083 0.578 
X2353 -0.082 0.579 
X1236 -0.082 0.579 
X1148 -0.082 0.580 
X1760 0.082 0.582 
X1863 -0.081 0.584 
X1479 0.081 0.584 
X1354 0.081 0.585 
X1577 -0.081 0.585 
X1124 -0.081 0.585 
X1751 0.081 0.586 
X2310 0.081 0.587 
X965 -0.081 0.587 
X1846 0.081 0.587 
X2347 0.081 0.588 
X2293 0.080 0.588 
X1677 0.080 0.588 
X1229 0.080 0.589 
X1482 0.080 0.589 
X806 -0.080 0.591 
X755 -0.080 0.592 
X1503 -0.080 0.592 
X576 -0.080 0.592 
X767 0.080 0.593 
X412 -0.079 0.594 
X1201 -0.079 0.594 
X1207 0.078 0.598 
X814 0.078 0.599 
X1259 0.078 0.600 
X2328 -0.078 0.601 
X1242 -0.078 0.601 
X842 0.078 0.601 
X1051 -0.078 0.602 
X1525 0.077 0.603 
X1151 -0.077 0.605 
X747 -0.077 0.605 
X1864 -0.076 0.608 
X1792 0.076 0.608 
X1197 0.076 0.608 
X2337 -0.076 0.609 
X777 -0.076 0.609 
X1534 -0.076 0.610 
X682 -0.076 0.610 
X1585 0.076 0.611 
X782 -0.076 0.611 
X1205 0.075 0.612 
X1789 0.075 0.613 
X752 -0.075 0.614 
X1183 -0.075 0.615 
X977 -0.075 0.615 
X1122 -0.075 0.615 
X1836 0.074 0.616 
X2185 0.074 0.616 
X2222 -0.074 0.618 
X1939 0.074 0.619 
X1649 -0.074 0.620 
X1267 -0.074 0.621 
X1589 -0.073 0.622 
X1370 -0.073 0.622 
X781 -0.073 0.623 
X1838 0.073 0.623 
X2013 -0.073 0.623 
X1056 -0.073 0.625 
X900 -0.072 0.626 
X2287 0.072 0.626 
X802 -0.072 0.628 
X1640 -0.072 0.629 
X1726 -0.072 0.630 
X296 0.072 0.630 
X1829 -0.071 0.632 
X863 0.071 0.632 
X622 -0.071 0.632 
X1253 0.071 0.632 
X1081 -0.071 0.633 
X1532 0.071 0.634 
X1547 -0.071 0.635 
X375 -0.071 0.635 
X1427 0.070 0.636 
X1541 -0.070 0.637 
X957 -0.070 0.637 
X1385 -0.070 0.638 
X1861 0.070 0.638 
X871 -0.070 0.638 
X935 0.070 0.638 
X2033 -0.070 0.639 
X222 0.070 0.639 
X1187 0.070 0.639 
  307 
  
X677 0.070 0.640 
X2279 0.070 0.640 
X1801 -0.070 0.640 
X785 0.070 0.640 
X1086 0.069 0.640 
X2216 -0.069 0.641 
X1897 0.069 0.641 
X1554 0.069 0.642 
X1060 0.069 0.643 
X2099 0.069 0.644 
X1034 0.069 0.644 
X2318 -0.069 0.644 
X2022 -0.069 0.645 
X878 0.068 0.646 
X2236 0.068 0.646 
X604 -0.068 0.647 
X1000 -0.068 0.648 
X2297 -0.068 0.648 
X1113 -0.068 0.648 
X1038 -0.068 0.649 
X1429 -0.068 0.649 
X800 -0.068 0.649 
X1982 0.068 0.649 
X1373 0.068 0.649 
X1270 0.068 0.650 
X672 -0.067 0.650 
X2108 0.067 0.651 
X666 0.067 0.651 
X1765 0.067 0.653 
X803 -0.067 0.653 
X697 -0.067 0.653 
X1628 -0.067 0.654 
X1807 0.067 0.655 
X1436 0.066 0.655 
X1072 -0.066 0.655 
X1433 0.066 0.656 
X1717 0.066 0.658 
X709 -0.066 0.659 
X1188 0.066 0.659 
X1165 0.065 0.660 
X2196 -0.065 0.660 
X931 0.065 0.662 
X698 -0.065 0.662 
X1964 0.065 0.662 
X1664 0.064 0.666 
X2106 0.064 0.667 
X1218 -0.064 0.667 
X819 0.064 0.667 
X1166 -0.064 0.667 
X714 -0.064 0.667 
X1365 -0.064 0.668 
X890 -0.064 0.668 
X1291 0.064 0.669 
X952 0.063 0.670 
X1900 0.063 0.671 
X1815 0.063 0.672 
X1204 0.063 0.672 
X1375 0.063 0.673 
X1442 0.063 0.673 
X834 0.062 0.676 
X879 -0.062 0.676 
X1570 0.062 0.677 
X2350 0.062 0.679 
X1118 -0.061 0.681 
X840 -0.061 0.682 
X715 -0.061 0.683 
X1127 -0.061 0.683 
X1048 -0.061 0.684 
X1766 -0.061 0.684 
X2199 -0.061 0.684 
X793 -0.061 0.684 
X1459 -0.060 0.685 
X830 0.060 0.685 
X1012 0.060 0.685 
X2098 0.060 0.685 
X2028 -0.059 0.689 
X1944 0.059 0.690 
X2299 -0.059 0.691 
X1857 -0.059 0.693 
X1830 -0.059 0.693 
X1971 -0.059 0.693 
X1297 -0.058 0.695 
X1058 -0.058 0.696 
X1542 -0.058 0.696 
X1457 -0.058 0.698 
X2254 -0.058 0.698 
X608 -0.058 0.698 
X1434 0.058 0.699 
X948 0.058 0.699 
X846 -0.057 0.700 
X1126 -0.057 0.701 
X1279 0.057 0.703 
X1221 -0.056 0.709 
X405 0.055 0.710 
X1318 -0.055 0.710 
X1090 -0.055 0.711 
X2255 0.055 0.712 
X868 0.055 0.712 
X1729 -0.055 0.712 
X1627 0.055 0.713 
X1295 0.055 0.713 
X1371 -0.054 0.714 
X655 -0.054 0.715 
X1030 -0.054 0.717 
X1198 -0.054 0.718 
X1311 -0.053 0.720 
X529 -0.053 0.721 
X1381 -0.053 0.722 
X1316 -0.053 0.724 
X1419 0.052 0.728 
X527 0.052 0.729 
X2019 0.051 0.730 
X894 -0.051 0.730 
X571 0.051 0.731 
X1879 0.051 0.731 
X2148 -0.051 0.733 
X2343 -0.051 0.733 
X1940 0.051 0.733 
X1793 0.051 0.734 
X1703 -0.051 0.734 
X2174 0.051 0.734 
X1719 0.050 0.735 
X1123 -0.050 0.735 
X1671 -0.050 0.736 
X1705 0.050 0.736 
X1263 -0.050 0.737 
X893 0.050 0.737 
X2354 -0.050 0.737 
X829 0.050 0.739 
X870 -0.050 0.739 
X1697 0.050 0.739 
X918 0.050 0.739 
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X2338 -0.050 0.740 
X1469 0.049 0.741 
X1656 -0.049 0.742 
X1689 -0.049 0.742 
X1137 -0.049 0.743 
X681 0.049 0.744 
X1770 0.048 0.745 
X1333 0.048 0.746 
X1693 -0.048 0.746 
X1669 0.048 0.747 
X853 -0.048 0.748 
X1305 -0.048 0.748 
X1543 0.048 0.748 
X1254 0.048 0.749 
X632 -0.048 0.749 
X2230 0.048 0.749 
X491 0.047 0.750 
X828 -0.047 0.750 
X821 0.047 0.751 
X1837 0.047 0.751 
X1202 -0.047 0.752 
X229 -0.047 0.752 
X1176 0.046 0.756 
X1592 0.046 0.756 
X1007 0.046 0.757 
X1425 0.046 0.759 
X2136 -0.046 0.759 
X378 -0.046 0.760 
X1754 -0.045 0.761 
X1688 -0.045 0.762 
X1431 -0.045 0.762 
X1006 -0.045 0.762 
X1563 -0.045 0.763 
X1574 -0.045 0.763 
X1530 -0.045 0.764 
X1146 0.045 0.764 
X1526 0.045 0.764 
X934 -0.045 0.764 
X811 -0.045 0.764 
X2241 -0.045 0.765 
X1077 0.045 0.765 
X768 -0.044 0.765 
X1752 0.044 0.767 
X671 -0.044 0.769 
X719 0.044 0.769 
X2154 -0.044 0.769 
X1088 0.044 0.770 
X1747 -0.043 0.770 
X1453 0.043 0.771 
X880 -0.043 0.772 
X1216 -0.043 0.773 
X827 0.043 0.774 
X310 -0.043 0.775 
X1423 -0.043 0.775 
X735 -0.043 0.775 
X1643 -0.042 0.777 
X2193 0.042 0.778 
X393 0.042 0.779 
X1098 0.042 0.779 
X1182 0.042 0.779 
X909 -0.042 0.780 
X1199 -0.042 0.780 
X792 -0.041 0.782 
X908 -0.041 0.785 
X732 0.041 0.785 
X2179 -0.041 0.785 
X1003 0.041 0.785 
X903 0.041 0.786 
X1948 0.040 0.787 
X1826 0.040 0.789 
X2138 -0.040 0.789 
X1456 0.040 0.789 
X501 -0.040 0.790 
X459 0.039 0.791 
X2072 -0.039 0.793 
X2180 -0.039 0.794 
X1132 0.039 0.794 
X873 -0.038 0.797 
X1658 0.038 0.797 
X2326 -0.038 0.797 
X1435 0.038 0.798 
X1037 -0.038 0.799 
X1784 0.038 0.799 
X989 -0.038 0.799 
X2041 -0.038 0.799 
X997 0.038 0.800 
X1493 -0.038 0.801 
X1544 0.037 0.801 
X2277 0.037 0.801 
X2267 0.037 0.802 
X1208 0.037 0.803 
X639 0.037 0.804 
X1566 0.037 0.804 
X713 -0.037 0.804 
X1241 0.037 0.806 
X1326 -0.036 0.806 
X644 -0.036 0.807 
X1147 -0.036 0.807 
X769 -0.036 0.807 
X1602 -0.036 0.810 
X1150 0.036 0.811 
X956 -0.035 0.812 
X1654 0.035 0.814 
X995 -0.035 0.816 
X804 0.035 0.816 
X1432 -0.034 0.817 
X2253 0.034 0.818 
X2097 -0.034 0.818 
X1329 0.034 0.818 
X916 -0.034 0.819 
X1415 -0.034 0.819 
X1667 0.034 0.819 
X1734 0.034 0.820 
X1257 0.034 0.821 
X1875 -0.034 0.822 
X857 -0.034 0.822 
X1594 -0.034 0.822 
X1714 0.033 0.822 
X818 0.033 0.823 
X1583 -0.033 0.824 
X2021 0.033 0.825 
X1629 -0.033 0.826 
X1074 -0.032 0.828 
X866 0.032 0.829 
X1420 0.032 0.829 
X1186 -0.032 0.830 
X1119 -0.032 0.832 
X2210 0.031 0.833 
X1772 -0.031 0.834 
X1230 0.031 0.834 
X1495 -0.031 0.835 
X1616 0.031 0.836 
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X1368 -0.031 0.836 
X1620 0.030 0.838 
X1226 0.030 0.840 
X1522 -0.030 0.840 
X1239 -0.030 0.840 
X1145 -0.030 0.840 
X1519 -0.030 0.842 
X660 -0.030 0.842 
X1237 -0.030 0.842 
X914 0.030 0.842 
X724 -0.030 0.843 
X1386 -0.029 0.844 
X1292 -0.029 0.844 
X2213 0.029 0.845 
X775 -0.029 0.845 
X1079 -0.029 0.845 
X1704 0.029 0.847 
X2105 -0.029 0.848 
X1615 0.028 0.849 
X1194 -0.028 0.849 
X2128 0.028 0.849 
X1728 0.028 0.849 
X2130 -0.028 0.851 
X2264 -0.028 0.852 
X1795 0.028 0.852 
X2256 0.028 0.853 
X2201 -0.028 0.854 
X1694 0.027 0.855 
X930 -0.027 0.856 
X978 0.027 0.856 
X1560 -0.027 0.857 
X2212 -0.027 0.858 
X1483 -0.027 0.859 
X1028 0.026 0.859 
X961 -0.026 0.859 
X1185 0.026 0.861 
X2182 -0.026 0.863 
X1321 -0.026 0.863 
X1485 0.026 0.863 
X1812 0.026 0.863 
X901 -0.026 0.864 
X619 0.026 0.864 
X1355 -0.026 0.864 
X206 -0.025 0.865 
X1334 0.025 0.867 
X1089 0.025 0.868 
X717 -0.025 0.869 
X1275 -0.025 0.869 
X2169 0.025 0.869 
X1862 0.024 0.870 
X815 -0.024 0.872 
X1193 0.024 0.872 
X1050 -0.024 0.873 
X731 -0.023 0.875 
X322 -0.023 0.875 
X1256 -0.023 0.877 
X532 -0.023 0.877 
X1608 0.023 0.877 
X1696 -0.023 0.878 
X851 -0.023 0.879 
X1342 -0.023 0.880 
X1901 -0.022 0.880 
X1102 -0.022 0.881 
X1512 -0.022 0.881 
X881 -0.022 0.881 
X2336 -0.022 0.885 
X933 0.022 0.885 
X1184 -0.022 0.885 
X2202 0.022 0.885 
X734 0.021 0.886 
X1157 -0.021 0.886 
X917 0.021 0.887 
X1350 -0.021 0.888 
X1565 0.021 0.888 
X1509 -0.020 0.891 
X1636 -0.020 0.892 
X1478 -0.020 0.892 
X865 0.020 0.895 
X2314 0.020 0.895 
X1740 -0.020 0.895 
X1235 -0.020 0.896 
X1680 -0.019 0.896 
X1320 -0.019 0.898 
X2188 0.019 0.898 
X1709 0.019 0.899 
X1272 0.019 0.899 
X1109 -0.019 0.899 
X958 -0.019 0.900 
X1155 -0.019 0.901 
X2070 -0.018 0.902 
X850 -0.018 0.903 
X1488 -0.018 0.903 
X2152 -0.018 0.906 
X813 0.018 0.906 
X1416 -0.017 0.907 
X2294 0.017 0.909 
X742 -0.017 0.909 
X2308 -0.017 0.910 
X790 0.017 0.910 
X2012 -0.017 0.911 
X1075 0.017 0.911 
X912 -0.017 0.911 
X1558 -0.016 0.912 
X1745 0.016 0.914 
X2278 0.016 0.914 
X1008 0.016 0.915 
X1855 0.016 0.917 
X1225 0.015 0.918 
X1324 -0.015 0.919 
X2171 -0.015 0.920 
X1302 0.015 0.920 
X1701 -0.015 0.921 
X1130 0.015 0.921 
X2284 0.015 0.921 
X1203 0.015 0.922 
X2233 0.014 0.925 
X1476 0.014 0.925 
X1120 0.014 0.927 
X1535 -0.014 0.927 
X1882 0.013 0.928 
X823 -0.013 0.929 
X897 -0.013 0.930 
X716 0.013 0.932 
X1644 -0.013 0.933 
X882 -0.012 0.933 
X1213 -0.012 0.934 
X675 -0.012 0.934 
X743 -0.012 0.935 
X1988 0.012 0.938 
X1674 0.012 0.938 
X1936 0.011 0.939 
X1487 -0.011 0.940 
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X1511 -0.011 0.940 
X1219 0.011 0.941 
X1972 -0.011 0.941 
X2073 -0.011 0.944 
X2303 0.010 0.944 
X1744 0.010 0.944 
X794 0.010 0.944 
X831 -0.010 0.945 
X1232 0.010 0.945 
X986 -0.010 0.946 
X867 0.010 0.947 
X648 -0.010 0.948 
X1591 0.010 0.948 
X1516 0.010 0.949 
X2020 0.009 0.950 
X1041 -0.009 0.953 
X1220 -0.009 0.953 
X1061 -0.008 0.955 
X2042 0.008 0.955 
X2119 -0.008 0.955 
X1546 -0.008 0.958 
X1702 0.008 0.958 
X1330 0.008 0.958 
X1149 -0.008 0.958 
X1351 0.008 0.959 
X1019 -0.008 0.960 
X1505 -0.007 0.960 
X2157 -0.007 0.962 
X482 0.007 0.962 
X1138 0.007 0.962 
X954 0.007 0.962 
X2146 -0.007 0.963 
X1287 -0.007 0.963 
X1854 0.007 0.964 
X1786 0.007 0.964 
X1107 -0.007 0.965 
X992 0.006 0.966 
X987 -0.006 0.966 
X1739 -0.006 0.967 
X1501 0.006 0.967 
X896 0.006 0.968 
X1490 0.006 0.970 
X771 -0.005 0.971 
X1281 0.005 0.973 
X1361 -0.005 0.973 
X875 0.005 0.973 
X1556 -0.005 0.973 
X355 0.005 0.973 
X1513 -0.005 0.974 
X836 0.005 0.975 
X1069 -0.004 0.976 
X812 0.004 0.976 
X1746 0.004 0.976 
X1586 0.004 0.977 
X1101 -0.004 0.977 
X1181 -0.004 0.978 
X1706 -0.004 0.979 
X2164 0.004 0.979 
X2301 -0.004 0.981 
X1091 0.003 0.982 
X1550 0.003 0.982 
X1641 0.003 0.982 
X876 0.003 0.982 
X1753 0.003 0.986 
X1064 -0.003 0.986 
X1601 0.002 0.987 
X1083 0.002 0.988 
X636 -0.002 0.989 
X2101 -0.002 0.990 
X1965 -0.002 0.990 
X1274 -0.002 0.990 
X1989 -0.002 0.991 
X2330 0.002 0.991 
X1332 0.002 0.991 
X839 0.002 0.991 
X949 0.002 0.991 
X1874 0.001 0.993 
X761 -0.001 0.994 
X1540 0.001 0.994 
X1660 -0.001 0.994 
X1174 0.001 0.995 
X2103 0.001 0.996 
X1876 0.001 0.996 
X2124 -0.001 0.997 
X1343 0.000 0.998 
X1417 0.000 0.999 
X1800 0.000 0.999 
X1576 0.000 1.000 
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Appendix 4 
Mixed effects regression model results for 2DGE protein spots with ventricular 
expansion whilst controlling for age, gender, education, BMI, cholesterol, and 
APOE ε4 status. Results highlighted in red are statistically significant (p<0.05)
Spot ID Coefficient p value 
X1595 -5622.09 0.000543 
X1948 -10591.9 0.001269 
X1406 -6316.04 0.003753 
X767 -4875.01 0.004717 
X1068 6049.642 0.00568 
X1586 -4200.86 0.006049 
X1643 5407.359 0.009337 
X1470 -4813.45 0.015904 
X1351 4521.493 0.021022 
X1412 -3934.76 0.021512 
X1590 -3594.51 0.025876 
X865 -5258.35 0.025906 
X2174 4028.063 0.026012 
X988 -4212.2 0.026781 
X471 4921.971 0.027109 
X2292 4607.122 0.028906 
X1435 -3311.15 0.032718 
X1837 4719.904 0.033362 
X1495 -4054.4 0.033829 
X2157 7679.915 0.034074 
X1297 5368.935 0.036631 
X1284 3836.693 0.038436 
X1165 5265.663 0.041349 
X993 -4304.7 0.041744 
X1624 4594.943 0.044159 
X1694 -3550.88 0.045329 
X432 4430.796 0.045723 
X1550 -6216.19 0.046278 
X1689 -3310.46 0.046992 
X1050 6968.624 0.047168 
X1156 4743.363 0.047843 
X1085 7165.327 0.04795 
X1501 -3377.37 0.048327 
X594 -3201.58 0.049544 
X1022 5436.878 0.049806 
X2273 -3992.37 0.050451 
X1076 5985.901 0.053714 
X1094 6383.062 0.054898 
X1383 4246.399 0.056165 
X1157 4739.194 0.056975 
X675 3515.251 0.05819 
X974 -2931.14 0.058468 
X1072 -3797.68 0.058818 
X1953 -5191.78 0.058825 
X1098 8977.226 0.063296 
X655 -2911.18 0.063617 
X1393 -4428.25 0.063666 
X871 -4058.53 0.064081 
X1185 4359.69 0.064508 
X857 -3756.79 0.064711 
X707 -3565.94 0.0648 
X2271 -3281.74 0.065169 
X1138 -2827.22 0.06519 
X2041 3378.931 0.066164 
X1183 4461.255 0.066275 
X1659 -3287.81 0.066621 
X1211 3773.424 0.066699 
 X873 -4842.2 0.067062 
 X899 5354.945 0.067491 
X1623 -3985.04 0.068188 
X1218 -2835.35 0.0683 
X2239 3928.585 0.068727 
X1735 -4612.22 0.069243 
X1729 6673.395 0.069594 
 X599 -4935.04 0.070069 
X1392 -3829.12 0.071827 
X2141 -4465.62 0.07234 
X1450 -3333.22 0.072773 
X1585 -5107.03 0.07397 
 X936 -2528.91 0.075443 
X1180 3802.491 0.075855 
 X602 -3920.61 0.076899 
X1621 -4451.58 0.077248 
X1525 -3161.23 0.078128 
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X1215 2990.882 0.078762 
X1790 3104.454 0.078937 
 X952 -2193.71 0.079183 
X2328 -3105.4 0.081037 
X1635 -4043.76 0.081694 
X1617 -4767.63 0.082 
X1229 -4595.71 0.083981 
X1019 5080.788 0.086018 
X2256 3708.893 0.086186 
X1756 5591.949 0.086814 
X1135 8381.993 0.088321 
X1075 -3150.21 0.088725 
X1439 -3042.39 0.09082 
X1414 3735.296 0.091499 
X1212 3618.714 0.091817 
X1442 -4734.79 0.09221 
 X657 -2759.94 0.094686 
X1765 -5172.27 0.094989 
 X911 4231.903 0.097169 
 X823 -2970.18 0.097611 
X1147 6903.477 0.098462 
X1549 5091.182 0.098489 
X1090 6058.121 0.100084 
 X690 -3417.51 0.101038 
X1714 -5532.08 0.102309 
X1615 -3300.13 0.102452 
X1739 6618.229 0.102475 
X1201 -2721.57 0.102508 
X1315 -2240.35 0.103523 
X1691 -3562.1 0.104178 
X1003 -2118.79 0.104183 
X1184 3787.602 0.104398 
X2196 -3485.41 0.104554 
X1732 4893.654 0.105406 
X2338 3175.738 0.10627 
X2171 4218.307 0.106934 
 X879 -3462.87 0.107372 
X1930 3537.058 0.107707 
X1010 -2437.41 0.108848 
X1687 -3229.52 0.109378 
 X393 -3156.24 0.110197 
X1034 4056.637 0.110681 
X1309 3197.237 0.111774 
X2188 6251.088 0.112486 
X2161 -3144.95 0.113426 
X1664 -4195.7 0.114741 
X1620 -3118.13 0.115314 
X1216 -2479.18 0.115822 
 X891 -2414.09 0.119582 
X1344 2243.964 0.120368 
X1343 2378.565 0.120973 
X1152 3892.141 0.121918 
 X712 2724.017 0.123447 
 X673 -3050.23 0.125584 
X2213 -4598.99 0.125859 
X1115 -2443.74 0.126276 
X1294 -4071.24 0.126503 
 X622 2220.947 0.126755 
X1418 -2841.41 0.127352 
X2147 5830.636 0.129884 
X1166 5533.744 0.130048 
X1761 3647 0.132524 
X1341 5236.845 0.133771 
X1690 -4462.8 0.135347 
X2214 4881.636 0.135456 
X1355 2556.09 0.137334 
X2049 2282.706 0.137501 
 X878 -3864.59 0.138908 
X1198 -3355.1 0.139836 
 X839 -5687.82 0.142806 
X2217 4357.275 0.142866 
X1140 5220.295 0.143259 
X1704 4457.621 0.145279 
X1703 4668.424 0.146002 
X1553 -2596.94 0.147118 
X2102 2000.333 0.147341 
X1759 -3034.48 0.147876 
X2287 2940.228 0.148426 
X1537 -3015.06 0.148558 
 X779 -3219.45 0.148576 
 X714 3239.88 0.149491 
 X772 -4290.46 0.150705 
X1715 4688.973 0.152586 
 X626 2085.236 0.155937 
X1244 -3302.1 0.157835 
X1777 2892.195 0.158515 
X2025 2268.061 0.15894 
X1752 5050.394 0.15916 
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 X783 -2117.5 0.159955 
X2245 3940.864 0.160611 
X1151 5991.582 0.161403 
X1028 4430.791 0.162016 
 X750 -2260 0.162309 
X2119 4020.342 0.162854 
X1728 5240.548 0.163316 
X2177 3281.673 0.16359 
 X670 -2514.18 0.163691 
X2098 6309.752 0.165729 
 X973 -3634.06 0.166031 
X1317 2841.523 0.166322 
X1260 -2780.7 0.167895 
X1519 -2104.38 0.168784 
 X709 2962.913 0.169861 
 X968 -3746.68 0.170181 
X1042 -3305.25 0.170873 
X1774 2628.187 0.171658 
X1817 2778.795 0.173151 
 X652 -2183.73 0.173919 
X2114 1819.101 0.174896 
X2111 3933.008 0.176926 
X1496 4147.424 0.177281 
X1111 -1931.33 0.178214 
 X667 -2645.53 0.181959 
X1356 1943.803 0.182025 
X1512 3385.594 0.182443 
 X681 3333.105 0.183536 
X1959 2587.052 0.183989 
 X953 -1530.89 0.184953 
X1262 -3179.47 0.185071 
X2347 -2783.41 0.185134 
X2043 1995.551 0.185336 
 X644 -2189.23 0.185527 
X1073 3130.145 0.186706 
X1368 -1839.67 0.186884 
X1391 2767.842 0.189369 
X1645 2996.761 0.189879 
X1304 -1588.44 0.190136 
X1246 2367.352 0.190324 
 X597 -2907.46 0.19048 
X1754 4977.321 0.190815 
X1126 4846.904 0.191177 
X2198 -2790.82 0.192694 
 X965 -3848.85 0.19396 
X1614 -3225.18 0.194225 
 X576 -2422.78 0.194312 
X1273 3810.71 0.195524 
X1302 3957.764 0.195898 
X1552 -3969.05 0.19718 
 X403 -2716.05 0.198386 
X2330 3129.598 0.200209 
X1503 -2593.51 0.200527 
X2233 2380.648 0.201066 
 X634 1707.635 0.201649 
X1706 3901.194 0.202139 
X2128 -2507.83 0.202885 
 X641 1615.871 0.203661 
 X620 1685.886 0.204359 
 X676 3286.244 0.204477 
X1307 4746.029 0.205224 
 X890 -2650.5 0.205906 
X1828 -3301.98 0.206215 
X2005 2791.939 0.206259 
X1818 2642.95 0.207156 
X2203 -2618.2 0.207166 
X1741 4644.845 0.207518 
X2040 1718.39 0.208774 
X1527 -2980.28 0.20901 
 X824 -3285.47 0.209484 
X2344 2556.709 0.209777 
X1482 -2392.38 0.209793 
X1117 -1824.61 0.209878 
 X976 -3011.43 0.210141 
X1091 5148.262 0.210364 
 X904 3431.283 0.21038 
X2140 -2765.06 0.210397 
 X578 -2730.13 0.210698 
X1854 2563.808 0.212484 
X1811 3947.106 0.213811 
 X829 -2252.98 0.214408 
X1489 -2386.42 0.215011 
X1705 3619.708 0.21708 
 X721 1948.564 0.21814 
X2024 1907.046 0.218679 
X1397 -2243.29 0.219651 
 X731 3296.137 0.220045 
X1815 2433.939 0.220086 
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X2072 -2983.48 0.220309 
 X868 -2911.91 0.221686 
X1106 4105.781 0.222282 
 X808 -2266.86 0.222285 
 X913 4115.099 0.222356 
X2033 3384.864 0.222885 
X1131 6203.287 0.223098 
X1679 -2741 0.223594 
X2216 4489.522 0.224022 
X1121 4075.36 0.224388 
X1148 5461.285 0.225078 
X1139 5576.388 0.228878 
 X791 -2235.21 0.229318 
 X812 1859.643 0.230902 
 X624 1517.513 0.230925 
X1971 2837.168 0.231424 
X1485 2933.773 0.231859 
 X825 -2112.03 0.233064 
 X734 3656.823 0.233106 
X2044 1482.433 0.233311 
X1026 -4303.54 0.233866 
 X738 -2347.22 0.235203 
 X621 1877.696 0.235367 
X1637 -2506.26 0.236275 
 X918 4061.227 0.236512 
X2028 2651.976 0.236521 
X1897 -3205.91 0.237236 
X2318 2410.364 0.237398 
X1825 2214.846 0.238777 
 X807 -2286.37 0.239244 
X1644 -2570.81 0.240565 
X1657 2754.885 0.241079 
X1518 -3769.15 0.24244 
X1582 -2810.02 0.242526 
X1251 3020.872 0.243252 
X1232 2108.589 0.243666 
 X909 -1741.75 0.245045 
X2181 -1707.52 0.2459 
X1227 2116.013 0.246048 
X1141 4712.193 0.246418 
X1675 3021.092 0.2466 
X1462 -2297.61 0.246809 
X2048 1164.905 0.250424 
 X378 2134.121 0.251358 
X1398 -1971.66 0.252123 
X1434 -2475.89 0.25225 
 X589 -2313.85 0.254831 
X1310 2059.026 0.255658 
X1326 1990.56 0.255953 
X1807 2026.4 0.256626 
X1247 -2148.69 0.257735 
X2332 1589.762 0.258571 
X1848 -3387.82 0.25904 
X2045 1587.976 0.259707 
X2333 1929.163 0.260781 
X1018 3519.352 0.26136 
X1401 -2019.42 0.261366 
X1048 3965.868 0.261431 
 X558 -2514.03 0.261521 
X1127 4227.179 0.26207 
 X977 -2411.34 0.262662 
X1431 -1945.58 0.263217 
X1014 2837.694 0.263552 
X1371 -2811.18 0.264371 
X1861 2201.678 0.265099 
X1556 -1754.37 0.267103 
X1070 2350.805 0.267324 
X2152 1934.529 0.268231 
 X845 -1930.33 0.268653 
X1083 3024.441 0.268757 
X1782 2820.086 0.26894 
X1661 1987.346 0.270477 
 X994 -3030.76 0.272199 
X1958 2345.55 0.272378 
X1583 -2295.94 0.273913 
X1755 3435.717 0.274082 
X1680 -2207.14 0.275013 
 X970 -2591.94 0.275186 
 X939 1282.338 0.275577 
X1012 -1524.62 0.275604 
 X802 -1795.66 0.276402 
X1720 -2697.12 0.279758 
 X755 -2752.18 0.281395 
X1733 -2634.27 0.282059 
X1222 -1819.39 0.282687 
 X688 -2238.12 0.283638 
X2351 1748.033 0.28425 
X2297 -1478.94 0.284687 
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X1594 2650.387 0.28708 
X1122 4010.704 0.287114 
 X910 -2936.52 0.287613 
X1267 -2059.29 0.288705 
X2185 2733.821 0.290591 
X1008 -1965.68 0.291142 
X1059 -1730.23 0.29115 
X1093 3718.866 0.292715 
X1064 -2460.43 0.293461 
X1033 2439.563 0.293508 
 X682 -2103.55 0.295472 
X2210 -2628.32 0.295611 
X1054 2321.932 0.296475 
X1678 -2228 0.299486 
X1255 2675.541 0.299632 
 X811 1647.571 0.300528 
 X892 -1708.94 0.300646 
X1515 2391.69 0.302889 
X1086 4694.336 0.303107 
 X692 -1873.04 0.303848 
X1275 -2745.56 0.304391 
X1256 2410.575 0.304409 
 X713 -1641.57 0.304547 
X1669 2624.171 0.305801 
X1036 1013.304 0.306422 
X1652 1693.032 0.306515 
X1405 -2689.41 0.306901 
 X803 -2742.9 0.308252 
 X648 2434.186 0.309354 
X2118 3064.384 0.30995 
X2281 -1721.16 0.310973 
X1089 2338.095 0.311284 
X1517 -2770.12 0.311355 
X1555 -2345.13 0.312946 
X1736 3541.375 0.314804 
X1196 -1519.91 0.315811 
 X659 -2350.2 0.316473 
X1303 2294.154 0.317093 
 X603 -1833.79 0.317502 
X1570 2256.143 0.31768 
X1598 2432.448 0.317847 
X2226 -1175.71 0.31838 
X1713 -2080.11 0.318408 
X1763 2938.645 0.318428 
 X861 -2104.2 0.318824 
X1605 2800.42 0.319685 
X1333 3120.585 0.321209 
X1023 2335.373 0.321714 
X1557 -3112.95 0.321752 
X2190 2148.547 0.322648 
 X972 -2546.65 0.325638 
X2063 -2033.53 0.326213 
 X680 1429.118 0.326228 
X1700 2654.658 0.327334 
X1130 3359.859 0.328021 
X1037 2783.79 0.328776 
X1390 -1911.99 0.329814 
X1658 -2263.7 0.33265 
X1174 2236.075 0.332701 
X1528 -2184.29 0.332921 
 X687 -2004.23 0.333611 
X2276 -2731.22 0.333784 
X1562 -1938.86 0.334453 
X2199 1474.933 0.335653 
 X636 -1580.78 0.335712 
 X587 -1744.02 0.336703 
 X609 1854.642 0.33703 
 X491 -2629.73 0.338093 
 X954 -1295.03 0.338135 
X1381 -1245.56 0.338715 
X2336 2215.33 0.339835 
 X951 -1301.63 0.339838 
X1874 -1883.17 0.340397 
X1981 -1641.47 0.341088 
X1463 -1697.86 0.342929 
 X387 1328.371 0.343008 
X1771 -1868.91 0.343486 
X1753 4320.955 0.343608 
X2104 2311.911 0.344329 
X1407 -2264.33 0.344468 
 X453 2215.699 0.346032 
X1474 -2541.74 0.347765 
X1619 -2225.94 0.350342 
X1723 1994.852 0.350348 
X1654 -2033.36 0.352999 
 X635 1243.48 0.353633 
 X836 -1745.31 0.355307 
 X617 1390.475 0.355469 
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X1879 -1764.67 0.357497 
 X666 -1345.93 0.357897 
X1436 -2068.32 0.358963 
X1254 -2057.39 0.35947 
 X797 -1632.22 0.35965 
 X874 -1977.67 0.359971 
X1150 -2367.91 0.360092 
X1107 4231.851 0.360249 
X1599 -2643.43 0.361301 
 X646 -1908.73 0.363838 
X1701 2367.159 0.364366 
X2350 2494.914 0.364553 
X1149 2207.843 0.366759 
X2343 3334.459 0.368704 
X2106 3110.583 0.369211 
X1065 1810.386 0.369253 
 X745 -1523.34 0.370128 
X1129 -2558.5 0.372134 
 X855 -1604.14 0.372268 
X1481 2016.209 0.373223 
X1650 -2018.91 0.37391 
X1925 1913.625 0.373929 
X2120 2567.99 0.374135 
X1261 -2389.41 0.375547 
 X629 1570.573 0.375859 
 X989 -1777.12 0.377841 
X2103 942.3249 0.378033 
X1088 3111.193 0.378836 
X1788 2000.973 0.379048 
 X724 2763.2 0.379112 
X1514 1837.818 0.379418 
X1566 -1662.69 0.380194 
X1305 2036.075 0.380301 
X2285 1396.131 0.380337 
X1543 -1734.21 0.380413 
X2169 3019.316 0.380893 
X1787 1410.774 0.381077 
X1573 -1504.78 0.382489 
X2218 -2714.31 0.383226 
X1271 1976.409 0.383581 
X1521 -1592.92 0.384597 
X1780 -2249.08 0.385232 
X1544 -1632.63 0.385923 
X1363 -1767.26 0.387094 
X2314 1843.46 0.387332 
X1146 -1913.29 0.388643 
 X778 2467.935 0.390233 
 X931 -1156.58 0.390848 
X2310 -1970.33 0.390913 
X1584 -1915.48 0.391041 
X2242 -2608.25 0.391211 
X2124 2354.928 0.393026 
 X867 -1729.64 0.39308 
X1274 2282.306 0.393643 
X1001 -2002.65 0.393926 
X1466 -1890.56 0.39407 
X1361 -1794.11 0.394328 
X1419 2265.739 0.395077 
X1006 1355 0.396512 
 X625 1272.748 0.396737 
 X653 -1477.91 0.398074 
X1917 -2511.91 0.39818 
X1057 1458.044 0.398808 
X2295 1764.272 0.399916 
X2082 -2098.94 0.400699 
 X826 -2334.6 0.400972 
 X885 1607.467 0.401925 
 X785 -1281.86 0.401989 
X1375 -1617.92 0.402442 
 X640 967.6473 0.403499 
X1950 -1913.11 0.403939 
X1021 2235.492 0.405046 
X1170 -1661.87 0.407887 
X1548 2516.47 0.408226 
X1791 1233.3 0.408232 
X1926 1881.972 0.408525 
X2215 2638.144 0.411293 
 X580 -1257.63 0.411352 
X1269 -2017 0.412946 
X1745 -1394.72 0.414317 
X2222 1194.647 0.414588 
 X719 -1207.65 0.414844 
X1189 1937.234 0.414944 
X1642 -1674.07 0.416223 
X2230 -1938.53 0.416534 
X1499 -1157.43 0.416829 
 X963 -2065.26 0.41696 
X1766 2393.811 0.417722 
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 X905 2523.432 0.419092 
X1591 1636.899 0.419337 
 X950 -1079.49 0.420294 
X2202 1731.96 0.420732 
 X769 -1745.53 0.421011 
X1677 -1560.8 0.423062 
X1627 -1949.47 0.423313 
X1719 2212.736 0.423718 
 X598 -1617.25 0.423752 
 X434 1775.134 0.423831 
 X985 -1554.35 0.423941 
X2274 1315.876 0.423959 
 X545 -1975.08 0.424893 
X1287 1334.882 0.426113 
X1823 1395.764 0.426855 
X1708 -1988.57 0.426991 
X1671 -1475.42 0.427194 
 X998 -1821.56 0.429141 
X2136 -1345.51 0.429646 
X2275 -1663.74 0.429987 
X1321 -1713.4 0.430884 
 X619 -1325.35 0.430975 
 X860 -1769.77 0.431293 
X1427 -2342.54 0.431656 
X2313 1873.622 0.43211 
 X804 -1535.16 0.432298 
 X948 1296.677 0.434165 
X1056 1161.465 0.434533 
X1760 1727.837 0.436599 
X1030 1871.6 0.437176 
 X311 1414.386 0.437957 
X1693 -2053.4 0.438361 
X1505 -1234.72 0.438871 
X2354 1559.797 0.439229 
X1535 -1433.62 0.43943 
X1069 -1429.07 0.44026 
X2151 1277.627 0.440325 
 X229 -1792.72 0.440852 
X2036 -1834.91 0.440921 
X1123 3028.259 0.440969 
X1296 -2515.44 0.441318 
X1604 1840.282 0.441441 
 X672 -1629.34 0.442072 
X2264 1689.427 0.4421 
X1810 1099.415 0.442203 
X2023 1407.94 0.442716 
X1281 1219.172 0.442813 
 X774 2133.067 0.443189 
X2088 -1746.97 0.44544 
X2137 1648.772 0.445984 
X1716 -1541.13 0.446406 
X2231 4348.562 0.447478 
X1830 1709.266 0.44793 
 X697 -1447.66 0.448887 
X1592 1553.432 0.449408 
X1540 1504.683 0.451369 
X1334 1609.571 0.453004 
X1724 -1826.02 0.455687 
 X532 1313.359 0.456171 
X2085 3809.256 0.456365 
X2335 1176.412 0.457177 
X1589 -1197.43 0.458569 
 X917 1199.631 0.460294 
X1510 -1924.32 0.460725 
X1289 1466.479 0.462204 
 X886 -2655.52 0.46271 
X1268 1035.881 0.462971 
 X322 -1266.24 0.463544 
X2337 -1154.31 0.464705 
X1649 -1570.69 0.465306 
 X992 -1432.99 0.465881 
X1009 -2775.3 0.466182 
X1725 -1727.67 0.466188 
X1409 -1617.29 0.466574 
X1454 -1887.69 0.467417 
X1338 1302.039 0.468616 
 X184 1537.25 0.468771 
X1270 -1265.32 0.468794 
X1053 1500.555 0.46929 
X1377 1246.774 0.469581 
 X765 1816.816 0.470961 
X1041 1823.204 0.472277 
 X484 -1967.27 0.47481 
X1345 1034.248 0.476525 
X1038 1093.806 0.476984 
X1520 -1212.37 0.477694 
X1767 1459.326 0.478122 
X1613 -1136.29 0.478547 
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X1095 1642.981 0.478582 
 X604 1250.685 0.479915 
X1113 1344.215 0.480037 
X1362 -2007.63 0.481212 
X1990 1279.086 0.481247 
 X830 -1278.41 0.481561 
X2204 2096.268 0.481638 
 X661 1420.437 0.482522 
X1744 2045.438 0.483153 
X1440 1243.574 0.484341 
X1283 1983.75 0.486281 
X1846 1281.473 0.486774 
X1234 -1583.06 0.487036 
X1162 -1845.78 0.489079 
X1597 1890.091 0.489146 
X2209 1954.969 0.49018 
 X844 1290.253 0.490991 
X1581 1524.04 0.491219 
X1738 2202.317 0.492521 
X1692 -1789.37 0.492618 
 X851 3463.658 0.493121 
 X753 1487.426 0.493684 
X1964 1524.685 0.494475 
 X627 1092.562 0.494695 
X1628 -1938.53 0.495054 
X1182 1446.399 0.49625 
 X908 -1654.51 0.497586 
 X725 -1334.98 0.497646 
 X527 -1377.63 0.498474 
 X606 1013.217 0.49878 
X2254 -1000.34 0.499435 
X1108 2064.669 0.50032 
X1674 -1884.57 0.500457 
X2235 1686.591 0.50181 
 X781 -1155.63 0.501866 
X1029 1165.948 0.502202 
X1773 -1303.72 0.502561 
 X615 -1120.64 0.503893 
X2127 -1353.25 0.504552 
 X978 -1547.16 0.504595 
X1331 1400.015 0.505853 
X1421 -1257.95 0.506138 
 X422 1029.689 0.506413 
X1191 2001.159 0.507937 
 X501 1647.844 0.508544 
X2006 1231.243 0.50916 
X2125 1440.022 0.510562 
X1015 1358.479 0.510936 
X2053 -1244.96 0.51095 
 X645 -1018.11 0.512714 
 X699 -1321.36 0.516477 
 X810 1257.016 0.517199 
 X272 -1223.94 0.518775 
X1052 1855.541 0.520083 
X1277 -1510.61 0.522512 
X1109 -1062.89 0.522674 
X2278 1254.863 0.523433 
X1963 1608.644 0.525146 
 X590 1649.602 0.526499 
X1299 1226.062 0.526686 
 X893 -1392.21 0.527986 
X2155 -1081.82 0.530141 
 X809 1069.837 0.530228 
X1648 1311.852 0.530417 
X1045 -1339.48 0.531077 
 X848 1210.675 0.531129 
 X815 -951.612 0.531674 
X1785 1227.722 0.53423 
 X907 1822.977 0.534816 
X1793 -1035.06 0.535486 
 X255 -1567.27 0.535608 
X1779 1452.691 0.535766 
X1369 -1252.41 0.535845 
X1717 1434.516 0.536071 
X1058 1366.088 0.537934 
 X818 -1162.02 0.538208 
 X902 -1050.76 0.538912 
X1831 863.6649 0.540632 
 X628 -1030.98 0.540903 
X2311 1500.799 0.541523 
X1832 -1687.17 0.542742 
 X766 1377.015 0.543067 
X1686 -1552.56 0.543129 
X1486 1619.487 0.543814 
X1430 1202.737 0.544245 
X1875 -1220.36 0.546018 
X1278 1412.453 0.546437 
 X286 -994.124 0.546524 
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 X584 -1117.19 0.546801 
 X706 -1346.83 0.548248 
X1423 -949.085 0.549758 
 X679 -1244.61 0.549819 
X1688 -952.851 0.550473 
 X938 -605.48 0.550531 
 X770 -2322.34 0.550856 
X1805 1617.422 0.553519 
 X961 792.2874 0.554234 
X1813 1042.975 0.554595 
 X991 -1487.58 0.555069 
X1792 -1635.97 0.555288 
X1078 -1090 0.555999 
X1410 -1376.4 0.556847 
X1360 -1528.7 0.558874 
 X805 -1215.06 0.559617 
 X757 -1238.03 0.560801 
X1168 943.1871 0.561169 
X1663 -1037.32 0.563063 
 X684 -1061.64 0.563331 
X2353 -931.064 0.563504 
X1795 3144.77 0.565205 
X1972 1583.82 0.565756 
X1007 -1162.54 0.566433 
X1538 1391.058 0.567028 
 X642 818.269 0.567205 
 X788 -1427.38 0.567401 
X1855 1040.453 0.56873 
X2232 -1072.29 0.569492 
X1318 -1109.87 0.569788 
X2317 -1277.94 0.569801 
X1292 -1178.32 0.570159 
X1936 -1769.45 0.570277 
X1892 -1631.56 0.570444 
X2071 -1470.78 0.570832 
 X820 -1012.75 0.572702 
X1154 1636.585 0.572912 
 X840 2963.836 0.573422 
 X966 -1708.06 0.573823 
 X916 909.326 0.573938 
X1451 -1078.25 0.574382 
X2031 1200.163 0.575942 
X1746 1866.932 0.575945 
X1087 1927.132 0.576358 
X1220 955.9944 0.576776 
X1982 -1048.71 0.576899 
X1856 -916.438 0.577023 
X1312 -1158.87 0.577159 
 X771 1202.803 0.577353 
X1286 1185.08 0.578167 
X2109 1272.387 0.579317 
X1968 1473.698 0.580409 
X1208 -1313.7 0.581246 
X1457 1099.863 0.581487 
 X638 -916.616 0.582978 
X1380 -865.312 0.584313 
X1429 -1033.05 0.584759 
X1379 -1069.59 0.585287 
 X662 1200.699 0.585735 
X1241 1056.489 0.586317 
X1602 1200.394 0.586386 
 X799 -1089.85 0.586651 
 X735 1873.619 0.586684 
X1228 710.8075 0.587333 
X1651 -1710.82 0.587467 
X1636 1208.567 0.587576 
X1480 -989.603 0.587802 
 X733 1065.167 0.587952 
X1579 2001.115 0.588716 
X1298 -1068.5 0.588924 
X1017 1432.03 0.589235 
 X798 900.3707 0.589911 
X1547 -1079.97 0.590008 
X1159 1291.902 0.590717 
X1145 -945.171 0.590839 
X1016 1624.586 0.591117 
X1339 1048.35 0.593095 
 X903 1421.102 0.594997 
 X858 2908.416 0.595491 
X2081 3301.727 0.595729 
X2095 1348.009 0.596085 
X1600 1527.408 0.596478 
X2299 -1186.8 0.598192 
X1727 1388.707 0.598722 
 X958 -705.94 0.599351 
 X671 -934.895 0.599793 
 X752 -972.594 0.600062 
 X242 -1291.69 0.601516 
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 X895 847.3783 0.603377 
X1133 1546.497 0.604384 
X2026 831.9059 0.604968 
X1350 1525.214 0.606011 
X1506 1667.715 0.606233 
 X896 810.8058 0.606812 
X2250 -867.452 0.606848 
X1560 -976.279 0.60895 
 X643 709.9129 0.609127 
 X206 -1203.19 0.610851 
X1032 421.4112 0.611672 
X1320 1126.393 0.612402 
X1459 -837.418 0.612607 
 X631 716.1765 0.613489 
 X389 685.0028 0.6138 
X1631 -1433.28 0.613952 
X1770 1033.101 0.614006 
 X716 -1024.29 0.61415 
 X660 -932.575 0.614914 
X1901 1168.37 0.615027 
X1769 -1078.72 0.615159 
X2130 -1105.66 0.615908 
X1660 -857.775 0.615912 
X1370 870.9328 0.616835 
X2164 -1799.32 0.617981 
 X947 1098.657 0.618229 
 X900 -914.493 0.618348 
 X841 2133.809 0.61907 
 X949 734.5422 0.619145 
X1902 837.5229 0.620363 
X1942 -1664.33 0.620461 
X1611 -1390.33 0.62083 
X2283 -1145.06 0.621719 
X1778 1153.759 0.622169 
X1490 -909.745 0.623143 
X2219 -1613.48 0.62343 
X1656 -874.28 0.624496 
X1432 -764.503 0.626035 
 X914 -811.081 0.627435 
 X793 -1071.19 0.627548 
 X381 947.33 0.629766 
X1399 1174.139 0.631676 
X2240 945.9727 0.631742 
X1530 -989.889 0.631895 
X1522 -1258.76 0.632156 
 X744 -910.235 0.633866 
X1929 -1065.1 0.634056 
 X754 1031.422 0.634408 
 X983 1060.56 0.634737 
X1365 -876.047 0.634875 
 X749 947.4549 0.635427 
X1386 980.2302 0.635789 
 X884 1124.962 0.636377 
 X875 -901.38 0.637746 
X2349 955.1688 0.638104 
X1966 -1411.57 0.638374 
X1245 926.4108 0.640764 
 X782 -703.546 0.641528 
 X324 -832.354 0.64172 
X2194 1221.456 0.642698 
X1789 673.246 0.644296 
X1092 1181.57 0.645068 
 X850 -806.484 0.645412 
X1415 1018.432 0.647347 
X1313 1209.55 0.648494 
 X708 -1000.08 0.649077 
X1775 947.4218 0.649381 
X2091 658.1428 0.649798 
X1665 789.8999 0.650149 
X2179 599.8795 0.65056 
X1067 995.2769 0.651495 
X1709 -1524.45 0.651656 
X1181 1140.124 0.651819 
 X933 757.3331 0.652876 
 X656 -764.15 0.653121 
X1468 -1369.45 0.653709 
X1783 -757.118 0.654482 
X1200 -773.168 0.654616 
X1838 -763.007 0.655376 
X2241 988.3398 0.656717 
 X849 -712.253 0.657398 
X1158 1272.247 0.658686 
X1469 -789.056 0.660315 
X1806 -1108.39 0.661582 
X1536 -1089.86 0.663577 
 X937 -538.29 0.664412 
X1821 1115.718 0.665084 
 X678 -840.287 0.66617 
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X1385 -640.953 0.666418 
X1532 -941.892 0.667448 
X2019 676.0631 0.668402 
X1575 777.0948 0.669609 
 X822 815.6328 0.670223 
X1164 1483.58 0.670507 
 X926 1695.411 0.670509 
X1438 748.2073 0.671625 
X2126 -1299.89 0.671835 
X1668 984.1185 0.672591 
 X632 721.9627 0.673342 
X2180 696.8975 0.676002 
X1864 -891.841 0.676319 
X2221 720.0273 0.676432 
X2168 -879.813 0.677612 
 X853 1133.11 0.6777 
X1387 -753.032 0.678088 
X1563 -749.126 0.678943 
X1137 -885.787 0.679152 
X1308 879.6785 0.680461 
X1062 -754.064 0.681379 
X1523 -647.185 0.682155 
 X722 1018.705 0.683508 
 X710 734.66 0.684656 
 X901 -740.167 0.684898 
X2148 696.9545 0.685197 
X1941 1227.995 0.685834 
X1263 -756.056 0.68595 
X1927 850.0864 0.688592 
 X665 -626.497 0.689357 
X1063 786.3148 0.691701 
X1802 -691.476 0.691752 
X1962 -1047.69 0.692147 
X1546 835.9572 0.693171 
X1721 937.5299 0.693458 
X1233 867.5647 0.694173 
 X668 -599.147 0.696709 
X1258 637.4382 0.697761 
 X828 -613.597 0.698698 
X2086 -1050.26 0.699172 
 X794 -1187.15 0.699845 
X1316 -614.28 0.701258 
 X789 -1068.38 0.701425 
X1881 -629.875 0.701847 
X1695 -849.696 0.701881 
 X618 -609.17 0.702897 
X1702 1042.883 0.703086 
X1534 798.022 0.703124 
X1622 -934.14 0.703435 
X1476 -645.668 0.705213 
X1836 784.8502 0.705213 
X1186 921.5429 0.705662 
X1819 727.1167 0.705778 
 X894 630.0571 0.70633 
 X897 950.6775 0.706901 
X1915 -732.756 0.707607 
X1857 748.4208 0.707701 
X2050 -723.261 0.709131 
X1887 -1011.97 0.710713 
X1167 630.6129 0.71233 
X1545 -908.219 0.712688 
X1748 -1079.62 0.713676 
 X396 639.7294 0.714089 
X1606 -941.636 0.714877 
X1803 571.2752 0.714891 
X1758 1019.905 0.715138 
X1816 763.9177 0.715448 
 X689 -911.612 0.716222 
X2308 -801.028 0.716831 
 X705 -777.423 0.716889 
X1047 -818.435 0.717244 
X1265 -484.898 0.717469 
 X987 -698.376 0.717825 
X1311 930.6467 0.717977 
X1359 -575.567 0.718035 
X2184 977.5964 0.718204 
X2182 -554.393 0.719 
X1046 -838.254 0.721623 
X1944 -1151.18 0.722021 
X1593 -836.253 0.722112 
X1125 931.4654 0.722518 
 X571 -908.069 0.72261 
X1493 667.2954 0.722971 
X1749 -848.086 0.72396 
 X995 -819.932 0.724411 
 X882 -827.056 0.726 
X1509 -647.878 0.726101 
X1188 777.6244 0.726104 
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X1124 1511.015 0.726483 
 X880 -573.545 0.727318 
X1473 -777.758 0.727738 
 X942 858.9673 0.727951 
X1587 668.6679 0.728513 
X1743 -603.717 0.728655 
X1194 569.8091 0.729642 
X1574 -652.115 0.730318 
X1751 -719.597 0.730736 
X1483 -598.053 0.731979 
X2253 -410.131 0.73285 
 X717 642.7127 0.733982 
X2010 -551.315 0.734517 
X1453 725.8983 0.735302 
X1640 649.6549 0.735712 
X1203 769.033 0.736835 
X1876 -756.589 0.737106 
X2246 -640.927 0.737194 
X1110 858.9159 0.737397 
X1155 1002.084 0.737723 
 X739 570.6472 0.737849 
X2255 -635.661 0.738491 
X2172 619.8744 0.738504 
X1040 -1094.07 0.738935 
X1066 742.5681 0.739555 
 X310 714.4787 0.739637 
X2016 626.4131 0.739793 
X1676 755.0548 0.741914 
X1013 874.7625 0.741996 
X1965 -921.113 0.74249 
 X616 -525.813 0.742987 
X1531 805.3223 0.743053 
 X792 -1047.08 0.743782 
X1734 -789.712 0.745326 
X1112 -863.293 0.747766 
X2042 -456.884 0.748471 
X1757 -814.275 0.748668 
 X412 -711.472 0.750962 
X1259 764.5473 0.751177 
X1610 -741.374 0.751736 
X1408 -658.165 0.752472 
X1288 567.1613 0.753483 
 X355 -649.366 0.75609 
 X827 -522.04 0.756484 
 X482 854.3272 0.757194 
 X608 -550.515 0.758367 
X1524 -625.064 0.758458 
X1160 847.8006 0.75924 
X1696 583.9559 0.760129 
X1081 672.8428 0.760448 
X1376 565.3247 0.760522 
X1829 -687.419 0.760545 
X2007 -674.387 0.760824 
 X768 723.8149 0.761122 
X1718 746.8532 0.762276 
X1332 526.667 0.763682 
X1809 -437.973 0.765869 
 X986 -662.618 0.7662 
X1781 550.2846 0.766934 
 X630 438.8665 0.766999 
X2277 -641.559 0.76702 
X1195 418.7065 0.76935 
 X813 450.8554 0.769352 
X1071 866.1299 0.769565 
X1132 737.3277 0.769631 
 X649 -457.66 0.773432 
X1000 598.6635 0.773614 
X1051 1016.543 0.773848 
X1373 -543.988 0.774427 
 X593 -577.382 0.775106 
X1118 -435.23 0.775337 
X1225 -661.249 0.775806 
X2096 927.1608 0.777099 
X1253 -475.371 0.777301 
X1707 878.7675 0.778205 
X1210 742.436 0.779359 
 X574 405.5547 0.779875 
X1865 -502.643 0.780901 
X2108 632.4652 0.781123 
 X816 694.5971 0.781197 
X2339 -590.18 0.783536 
X1616 -614.115 0.78419 
X1239 560.4086 0.784216 
X1726 -703.903 0.785484 
 X726 528.6894 0.786879 
 X296 -671.129 0.787048 
X1367 -699.571 0.787473 
 X777 -720.857 0.787775 
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X1882 385.5282 0.789878 
X1731 731.2014 0.790994 
X1102 -1008.89 0.791699 
X1465 -719.174 0.792414 
X1236 593.0837 0.792763 
 X969 -719.839 0.792847 
 X281 -465.397 0.793361 
X1190 708.9608 0.794278 
 X806 -491.548 0.794636 
 X585 694.7104 0.79567 
X1128 -672.397 0.797704 
X1084 580.0307 0.79805 
X1005 -320.776 0.798524 
X1662 584.1716 0.798673 
X1192 -377.56 0.799946 
X1742 549.9151 0.800825 
 X846 -482.109 0.801238 
 X935 354.5893 0.80195 
X2280 -580.891 0.802078 
X1413 -507.516 0.803206 
X1667 533.5605 0.803215 
X1900 441.1272 0.804141 
X1456 -529.344 0.805225 
X1272 501.4238 0.8055 
X1511 557.3315 0.805823 
X1554 472.5376 0.805869 
X2159 862.8925 0.806682 
X1542 -588.596 0.806946 
X2143 713.2341 0.807358 
X2146 556.6245 0.807656 
 X790 -522.619 0.809162 
 X921 -798.754 0.809231 
X1784 -746.844 0.809257 
 X747 427.6633 0.809776 
X1426 -463.729 0.809832 
 X833 -1011.45 0.809956 
X2341 -377.561 0.810116 
X1417 -638.366 0.810821 
X2144 653.4941 0.812121 
X1282 -662.507 0.81299 
 X728 648.0082 0.813553 
X1492 249.9134 0.814169 
 X637 316.5608 0.814259 
X2326 -396.152 0.814487 
X1641 -490.28 0.814551 
 X887 -363.37 0.814639 
 X740 -411.91 0.815109 
X1786 410.6249 0.815419 
 X633 -315.129 0.815883 
X1049 -521.949 0.816007 
 X718 -438.147 0.817011 
X2142 -667.06 0.817163 
X2116 1015.573 0.817256 
X2345 594.3198 0.817885 
X1153 561.6793 0.818098 
 X800 -619.599 0.819025 
 X397 289.2743 0.819126 
 X996 -477.816 0.81945 
X1491 -433.948 0.819925 
X2101 559.697 0.820815 
X1347 518.3837 0.821538 
 X459 411.8932 0.822775 
 X842 481.4205 0.822985 
X1372 -460.378 0.824553 
X1576 -412.573 0.825327 
X1290 -407.021 0.825557 
X2303 471.8941 0.825873 
 X763 -448.317 0.828308 
X1448 -410.846 0.828434 
 X529 -358.089 0.829073 
 X925 223.135 0.830129 
X1171 372.7849 0.830288 
X1890 373.2281 0.830838 
X1187 638.7854 0.831074 
 X819 350.9119 0.83221 
X1226 -428.629 0.833992 
X1516 442.0169 0.834651 
X1526 -549.008 0.834966 
X2123 281.6916 0.835406 
X2212 -448.231 0.835766 
X1997 -407.907 0.836457 
X1464 -463.343 0.836482 
X2244 514.2093 0.836675 
X1940 -585.813 0.838003 
X1354 383.4628 0.839655 
X1342 259.9921 0.839865 
X1580 719.6204 0.839879 
 X601 -434.523 0.841337 
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X1939 -454.422 0.84147 
X1116 -292.329 0.841846 
X2021 -382.405 0.841888 
 X997 313.0383 0.84222 
X2193 -436.996 0.843409 
 X814 -379.982 0.843815 
X1822 389.6095 0.844558 
 X715 -330.675 0.844835 
X1478 352.7233 0.848121 
X1103 453.9119 0.848234 
X1176 -294.466 0.848555 
X1043 -495.61 0.849323 
X1404 -531.643 0.849707 
X1488 -298.184 0.850501 
X1849 467.4207 0.850568 
X1541 -291.495 0.850621 
 X999 -450.068 0.850782 
X1629 396.3771 0.850799 
X1684 428.7705 0.852202 
X1242 300.7376 0.852294 
X1808 -311.87 0.852363 
X1119 277.654 0.85296 
 X664 -287.769 0.853245 
 X610 -319.799 0.853549 
 X944 442.9916 0.854659 
X1747 513.2768 0.855811 
X1202 268.975 0.856462 
 X405 280.0812 0.85786 
X2293 388.3732 0.85829 
X1134 520.0504 0.858592 
X2097 -769.382 0.858833 
X2013 324.178 0.858873 
 X727 -328.549 0.860184 
X2352 260.8484 0.861508 
X1323 -310.165 0.861805 
X1175 260.4311 0.861961 
X1104 442.1519 0.864059 
X1835 -304.679 0.864587 
X1199 225.7633 0.865072 
 X990 -389.963 0.865307 
X1291 334.1842 0.865836 
X1060 751.4761 0.866242 
 X930 163.0172 0.86697 
X2156 469.6325 0.868285 
X1101 319.7788 0.869556 
 X746 -245.943 0.873832 
 X605 279.2275 0.873986 
 X677 -255.373 0.875004 
X2020 240.5219 0.875177 
X2105 413.4809 0.875393 
X1577 -301.693 0.876378 
X1504 -323.8 0.876569 
X2268 -357.907 0.876885 
X1213 329.5876 0.877413 
X2238 -495.105 0.877862 
X2135 -299.616 0.877888 
X1906 -338.255 0.878923 
X1433 -390.989 0.879218 
X1221 -310.563 0.879436 
X1801 303.3999 0.87953 
X1646 -269.194 0.879547 
 X928 -193.281 0.87992 
X1337 262.6798 0.880057 
X1487 258.6499 0.88057 
X1163 362.2223 0.881195 
X1794 -630.488 0.882554 
 X696 -253.856 0.882902 
 X971 -378.947 0.883325 
X1772 287.4712 0.8834 
 X758 -348.893 0.885137 
 X946 -313.978 0.88596 
X1989 241.9845 0.886721 
 X955 174.0794 0.887098 
X2070 445.5092 0.887681 
 X741 214.8608 0.888848 
X1161 -329.489 0.88929 
X1988 -265.457 0.890066 
X1197 257.9715 0.890654 
 X386 267.2063 0.891653 
X1400 356.8474 0.891695 
X1558 -268.653 0.89196 
 X525 -242.475 0.892553 
X2296 310.5414 0.893273 
X2348 -269.751 0.893655 
 X869 216.8056 0.895543 
 X876 -321.209 0.895676 
X1357 260.2563 0.895735 
X2014 239.4571 0.896575 
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X1508 -373.181 0.897175 
X1869 256.1749 0.897229 
 X934 250.6152 0.897702 
X1561 -251.112 0.899179 
X2189 -262.005 0.899997 
X2331 -390.54 0.900122 
 X654 -186.485 0.901394 
X1394 -247.296 0.901921 
X1238 272.1593 0.902944 
 X371 -217.388 0.903143 
X1697 398.8772 0.903371 
X2032 -254.517 0.903484 
 X698 -243.591 0.904232 
X1471 212.6994 0.904242 
X2301 261.2752 0.904262 
X1295 202.5706 0.905105 
X1264 232.8579 0.905924 
 X866 -304.335 0.906461 
 X480 -282.631 0.906612 
X2294 -220.753 0.906897 
X1500 -269.328 0.908095 
 X732 220.0932 0.908513 
X1737 413.3015 0.908765 
X2211 268.9537 0.908801 
 X863 177.3955 0.910759 
X1077 -342.974 0.911013 
X1862 239.9313 0.911361 
X1219 -253.696 0.911591 
X2298 -247.391 0.912046 
 X775 -193.63 0.912548 
X1572 -246.198 0.912939 
 X748 186.863 0.913233 
X1638 -221.253 0.913252 
X2138 -251.066 0.913471 
X1565 243.1627 0.914844 
X1329 172.1257 0.915939 
 X686 -197.706 0.916366 
X1551 -235.976 0.916924 
X1173 149.2174 0.91735 
X1402 -255.056 0.917974 
X1416 156.0833 0.921064 
 X222 220.9175 0.922509 
X1863 -206.449 0.92487 
 X912 208.5125 0.925754 
 X742 152.3477 0.926445 
X1588 230.7858 0.926936 
 X831 142.4797 0.929703 
X1973 -247.291 0.930661 
X2201 153.4555 0.931565 
 X663 138.1163 0.93177 
X1235 148.0633 0.931821 
 X834 145.4414 0.932131 
X2307 -173.76 0.932451 
X1074 168.1899 0.932789 
X1374 156.5623 0.93301 
 X533 134.5933 0.93348 
 X685 148.5927 0.934475 
X2236 -266.149 0.934573 
X1833 -219.769 0.935211 
 X702 -171.116 0.935677 
X1633 -173.966 0.93581 
X1120 242.9958 0.93594 
X1762 186.4948 0.936335 
X1710 158.4841 0.936669 
X1279 -155.156 0.936872 
X1237 163.1091 0.938465 
X2099 254.3287 0.938867 
X1699 -157.669 0.939568 
X1257 -140.486 0.939618 
X1507 219.3428 0.940495 
 X945 168.3976 0.940827 
X1618 -188.121 0.940916 
X2073 309.217 0.940961 
 X773 204.5357 0.942077 
 X817 -136.521 0.943082 
X1172 -138.569 0.944462 
 X821 -122.329 0.944499 
X1330 113.6929 0.945655 
 X305 124.8999 0.947056 
X1424 105.2995 0.947172 
X1204 161.0859 0.947306 
X1698 -190.333 0.948653 
 X956 94.58924 0.949267 
 X658 -118.097 0.950955 
X1730 -201.012 0.952555 
X1826 104.9896 0.955357 
 X400 73.99089 0.955391 
 X881 155.3812 0.955722 
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 X639 89.77402 0.956119 
X1768 -103.532 0.956388 
 X872 120.4217 0.95663 
 X596 79.10773 0.956679 
X2325 -105.062 0.957136 
X1513 107.2435 0.957371 
X1353 75.24139 0.957544 
X1740 226.9389 0.958974 
X1612 92.31631 0.959325 
X2187 -166.303 0.959818 
X2284 150.4963 0.95992 
 X701 -91.356 0.961051 
X1411 -97.4383 0.961614 
X1422 122.9423 0.961626 
X1564 -100.979 0.962706 
X1814 -99.2122 0.96376 
X1061 -85.3552 0.963807 
 X595 -78.6051 0.964703 
X1903 95.04678 0.965934 
X1099 119.4821 0.966934 
 X795 108.9447 0.967173 
X2115 103.4144 0.968703 
X1608 77.61087 0.969044 
 X898 -62.2222 0.969845 
X1609 80.20866 0.970574 
X1252 66.97674 0.971056 
X1039 -116.623 0.97155 
 X607 -64.5055 0.972171 
X1800 88.18686 0.972887 
X1425 93.63283 0.972943 
X1428 74.8305 0.973496 
X1230 76.78729 0.97449 
 X943 -59.7876 0.976053 
 X915 44.15613 0.977083 
X1169 61.25235 0.97846 
 X957 33.70035 0.978823 
X1601 66.55009 0.978981 
 X591 41.28908 0.979331 
X1352 -64.8627 0.979951 
 X743 45.76671 0.979995 
X1324 -36.3951 0.98008 
X1812 -45.5168 0.980278 
X2237 -39.5564 0.981069 
 X852 47.16845 0.981171 
X2154 75.13063 0.981758 
X1193 38.41487 0.981771 
X1205 -50.8706 0.982337 
X1666 68.7371 0.982504 
X2279 -34.5333 0.982615 
X2269 29.32353 0.98452 
 X906 57.25713 0.985525 
X1396 50.26508 0.986303 
 X669 -26.8968 0.98654 
X2267 35.4187 0.986965 
X2022 -31.9668 0.987501 
X1685 40.88756 0.98824 
X2037 -35.5344 0.989372 
 X379 -28.0324 0.989543 
X1293 -19.1071 0.989966 
 X870 28.3704 0.990247 
X2054 -25.1596 0.99029 
X1224 -26.0106 0.99039 
X1607 -27.8701 0.991313 
X1494 17.28814 0.991697 
 X375 17.17769 0.99244 
 X786 -22.4411 0.992746 
 X761 -20.9905 0.992807 
X1479 -18.8593 0.99351 
X1314 -12.5083 0.993961 
X1420 12.06012 0.99571 
 X266 -7.38643 0.996352 
X2087 15.09858 0.99698 
X2304 7.114496 0.997404 
X1207 4.405727 0.998574 
X1639 -2.56442 0.998826 
X2012 -2.6815 0.998996 
 X694 3.0466 0.999068 
X1223 1.925792 0.999159 
X1079 1.258233 0.999667 
X2315 0.892933 0.999683 
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Appendix 5  
Mixed effects regression model results for 2DGE protein spots with Trails B 
decline whilst controlling for age, gender, education, BMI, cholesterol, and 
APOE ε4 status. Results highlighted in red are statistically significant (p<0.05)
Spot ID Coefficient p-value 
X779 -38.8492329 0.000129 
X1138 -22.6147243 0.001265 
X2187 44.18654861 0.0014 
X767 -25.8127413 0.001442 
X1543 -24.764491 0.002762 
X849 -21.3638027 0.00312 
X1307 39.64948297 0.003603 
X1302 35.67988648 0.004902 
X1644 -25.9229164 0.005499 
X2184 30.82080343 0.005551 
X1656 -23.4113819 0.005726 
X1492 -13.7809576 0.006758 
X1368 -16.3115874 0.007011 
X1228 -15.2270665 0.007089 
X1758 34.06306507 0.00758 
X1595 -19.2328974 0.008156 
X2256 26.91087468 0.008471 
X324 21.46611472 0.010289 
X865 -29.0653696 0.011975 
X1639 -19.9488006 0.012429 
X2188 33.83091186 0.01316 
X1538 -26.5877435 0.013985 
X2142 30.02389939 0.014312 
X2111 32.17498689 0.014767 
X1879 21.76259571 0.015948 
X688 -22.5864682 0.016207 
X1095 -25.6577157 0.01682 
X1401 -20.7567029 0.016832 
X1134 29.60979672 0.01701 
X2232 19.88615869 0.017103 
X1037 30.89805589 0.017657 
X1036 10.48178108 0.017812 
X2031 23.28869105 0.017885 
X782 -16.1362958 0.01847 
X2091 15.10258622 0.018686 
X1694 -19.6434596 0.019307 
X682 21.61107032 0.020827 
X1427 -27.5135054 0.022179 
X1755 32.18365359 0.023301 
X1297 25.36407848 0.024246 
X1359 -16.9147605 0.024872 
X1693 -25.2178795 0.024905 
X1057 -17.2591557 0.025338 
X887 -16.0460346 0.0256 
X2274 -16.9932297 0.026973 
X1590 -15.6650304 0.027109 
X1296 30.42412166 0.027331 
X763 -20.2976746 0.027794 
X2341 16.15078578 0.028154 
X1495 -19.4584054 0.029494 
X1347 -22.9767284 0.029749 
X1511 -22.0383665 0.029792 
X1499 -14.3737404 0.030476 
X804 -19.2768316 0.030818 
X1431 -16.0895998 0.031042 
X1743 16.75944942 0.031338 
X661 19.48381126 0.031421 
X1785 -20.2840052 0.032761 
X1990 16.74274954 0.032982 
X1283 25.48531274 0.034231 
X1640 -17.5831067 0.034311 
X1671 -18.6216857 0.035148 
X1463 -17.197246 0.036268 
X1196 -12.9554852 0.037104 
X1649 -19.6685034 0.037119 
X663 15.35375583 0.038327 
X758 -20.7793545 0.039644 
X1732 27.0881448 0.040093 
X1163 -23.3349569 0.040317 
X1631 -24.5003442 0.041297 
X1153 -22.6541249 0.042028 
X931 12.40310856 0.042028 
X1271 21.49938078 0.042199 
X813 14.51678027 0.042937 
  328 
  
X1459 -15.3047626 0.043009 
X1367 22.66852487 0.044395 
X1022 23.26224815 0.044732 
X2255 -18.3771034 0.044869 
X2202 -19.0059032 0.046178 
X1516 -19.4738434 0.046449 
X793 -20.0510331 0.047364 
X2210 -21.0433851 0.047386 
X1513 -18.3121775 0.047616 
X2250 -16.7490082 0.048107 
X811 14.1477596 0.049033 
X799 -18.3947516 0.049093 
X1058 -19.7344176 0.049152 
X815 13.96285968 0.049244 
X839 -31.5325736 0.049551 
X2216 30.87618328 0.050843 
X928 11.52143845 0.051728 
X1846 16.38286773 0.053083 
X719 -13.6649045 0.053213 
X1989 15.43901732 0.053644 
X1294 -21.2881567 0.05453 
X2141 -20.7835935 0.055151 
X803 23.59822883 0.056316 
X1172 -17.1847256 0.056601 
X1778 19.79563049 0.057367 
X1034 21.59019667 0.058733 
X628 14.79059366 0.058836 
X1706 26.29756272 0.060223 
X806 -16.4849148 0.060351 
X1754 32.54747624 0.061658 
X1501 -14.6766732 0.061925 
X626 13.07010337 0.06194 
X1195 -11.4496826 0.062108 
X2097 32.07763767 0.062631 
X1361 -17.9785541 0.064456 
X1321 -18.8440379 0.064981 
X2281 -14.1022067 0.065435 
X1793 -13.4827742 0.066424 
X1638 -16.1393269 0.066684 
X1279 -15.6692222 0.067428 
X810 15.78082565 0.068012 
X1116 -11.9213865 0.068812 
X1230 19.8045132 0.069065 
X1718 21.73640013 0.069245 
X935 12.09259595 0.069292 
X1068 18.23925214 0.069969 
X2072 -20.2265139 0.070912 
X903 20.69093145 0.071509 
X1642 -16.5411967 0.071558 
X311 -15.8321965 0.072042 
X1173 -12.0331718 0.072242 
X880 -13.1682389 0.073637 
X1586 -12.6936145 0.076131 
X222 -19.0348038 0.076482 
X1665 -13.6752597 0.0776 
X802 -14.048936 0.078663 
X1313 21.56313842 0.07955 
X1251 19.61495406 0.079598 
X1223 -14.8176963 0.081568 
X1197 -13.6458325 0.084717 
X2294 14.62388346 0.084901 
X669 12.85074435 0.085086 
X1534 -16.5454477 0.085513 
X1802 12.88100848 0.086545 
X1812 15.17448516 0.086613 
X1926 15.88872753 0.087354 
X1652 -12.8705725 0.087832 
X1731 20.72787895 0.087885 
X934 15.6387975 0.088586 
X809 13.26978638 0.089993 
X1468 -23.9341146 0.090028 
X1663 -13.7376669 0.090955 
X990 16.73134178 0.091398 
X2299 -17.6621613 0.091608 
X2179 -9.45203611 0.092367 
X2028 15.57403795 0.092982 
X1115 -11.8269199 0.09336 
X1541 -12.3203364 0.095346 
X2106 26.11147112 0.095772 
X1083 -20.0608041 0.096447 
X1950 -17.9097486 0.096867 
X1432 -12.0852781 0.097935 
:X875 -14.7582921 0.098502 
X1816 16.18626741 0.098963 
:X925 7.94272415 0.09936 
X1661 -13.6919237 0.099417 
X1462 -14.4604783 0.099654 
X1637 -14.7903927 0.099978 
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X532 -13.0789761 0.101123 
X819 12.38665101 0.102802 
X1618 -17.3981789 0.103456 
X2278 -14.6566801 0.1037 
X1315 -10.1113831 0.104959 
X1331 -14.8512555 0.10529 
X1341 21.15867166 0.107124 
X1692 -18.1862673 0.107603 
X1691 -15.719558 0.107799 
X1746 23.15264803 0.109265 
X1019 18.73529152 0.109268 
X1733 -17.6241556 0.109602 
X1064 -16.7243011 0.111764 
X1487 12.86397286 0.112851 
:X668 11.41903747 0.113192 
X1407 -17.2226875 0.113195 
X1316 -11.4292991 0.113492 
X1528 -16.9535813 0.113623 
:X869 -12.0286365 0.11486 
X1436 -15.6432746 0.115439 
:X654 11.139853 0.115798 
X1277 16.51290604 0.116433 
:X814 12.6656376 0.116609 
:X911 17.05836143 0.116846 
:X873 -18.9090463 0.117069 
:X685 13.39151691 0.117571 
:X917 11.5279635 0.119718 
:X808 -12.8975393 0.120858 
:X658 -13.579753 0.12121 
X1393 -16.5683286 0.122631 
X1390 -13.8755888 0.122753 
:X769 15.22494131 0.122753 
X2103 7.802328818 0.123086 
:X608 13.18733559 0.123159 
X1081 -15.2959794 0.123748 
X1148 28.16524932 0.124139 
X2345 -18.3041135 0.126535 
:X375 12.56933698 0.128298 
:X371 12.39425129 0.128501 
X2310 16.13316298 0.129527 
X2138 16.06246909 0.130293 
X1581 -16.1125853 0.130313 
X2303 -14.6625017 0.131082 
:X666 -9.46527577 0.131905 
X2348 -12.9291925 0.132021 
:X893 -15.5072437 0.13253 
X1212 14.7466763 0.133042 
X1236 -15.1213434 0.133139 
X1675 17.18799639 0.133146 
:X798 -12.1608759 0.133881 
X2180 -10.2629314 0.134543 
X1290 13.01124538 0.134961 
X1420 -15.885986 0.135112 
X2185 16.15005141 0.135425 
:X715 -11.3957978 0.136325 
X1448 13.22640673 0.137568 
:X827 11.44033516 0.139141 
X1014 15.38329778 0.139187 
X1317 12.93820808 0.140345 
X1862 14.14569728 0.14078 
:X948 11.4031606 0.140917 
:X772 -18.6540721 0.141358 
X1267 -12.741541 0.141891 
X1749 -15.9625809 0.14204 
X2098 27.82251625 0.142801 
X1781 12.47867895 0.145177 
X1857 12.12925872 0.145913 
X1355 -11.4697404 0.148983 
X1252 12.47533176 0.149596 
:X949 9.637173595 0.149994 
X1520 11.6520741 0.151431 
X1023 15.07632597 0.151848 
X2048 6.933909537 0.151884 
:X255 -14.8368226 0.153616 
X2014 12.03381778 0.153651 
X2022 -13.2408077 0.153939 
X1966 -18.9821463 0.154372 
X1763 18.63723998 0.154385 
X1270 -11.880342 0.155609 
X1659 -11.2023511 0.156603 
X1194 -9.78505131 0.156663 
:X850 -11.2816477 0.157304 
X1045 13.30795149 0.158255 
:X930 6.415151121 0.162462 
:X812 10.4323152 0.162677 
:X480 -15.8397629 0.165749 
X1253 -10.4961975 0.165802 
X1729 22.84954491 0.16607 
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X2213 -18.6904251 0.166094 
X1861 13.20301212 0.166422 
:X643 -8.81407461 0.167452 
X1863 13.72867626 0.167785 
X1069 -11.2736985 0.169355 
X1333 16.78634275 0.169687 
X1363 -12.084194 0.169697 
X1330 -10.6617251 0.169776 
X1295 -9.78767259 0.169827 
X1369 -12.5501285 0.170169 
X2301 14.18848901 0.17113 
X2236 -18.8628264 0.172133 
X1187 18.78862649 0.172782 
X2199 9.428193338 0.17297 
X1222 -10.5159269 0.173756 
X1544 -12.4398437 0.173932 
X1744 18.27639986 0.175735 
X1056 -9.15329106 0.176492 
X1201 -10.2863845 0.17676 
X1397 -12.5986891 0.177719 
X2293 12.75178395 0.178489 
X2279 -10.1705815 0.178594 
X2221 10.83861056 0.178805 
X1810 8.879460103 0.179074 
X1738 17.59987687 0.179697 
X1193 -9.40221197 0.180163 
X2238 -20.2767103 0.180579 
:X726 12.27475093 0.180995 
:X777 -17.0732447 0.181626 
X1737 21.61842072 0.18175 
:X627 10.13593803 0.182003 
X1573 -10.1869455 0.182317 
:X971 -14.88485 0.182484 
X2135 11.28756091 0.182642 
X1623 -12.4849799 0.184334 
:X620 8.101896801 0.184792 
X1973 17.75182476 0.185417 
X1566 -11.9330395 0.185567 
X1813 10.77274005 0.1856 
X1809 8.958296458 0.185913 
X1418 -11.4714006 0.186912 
X1128 -15.9806057 0.187236 
:X860 -12.8040402 0.188358 
:X597 12.11186736 0.189386 
X1556 -9.85961247 0.189578 
X1204 14.50771342 0.190711 
X1848 -16.8172647 0.191297 
:X622 8.805085732 0.191903 
:X184 -13.0060613 0.193732 
:X630 -8.7020248 0.193969 
:X665 -7.85152633 0.194291 
X1766 -16.5075902 0.195665 
X1117 -8.39156349 0.196078 
X2043 9.209855506 0.196274 
:X296 16.04148711 0.196577 
X1434 -12.7150024 0.196688 
X1257 -10.463082 0.196875 
:X754 -12.1684473 0.197237 
X1186 14.35723945 0.197265 
X2032 11.66944227 0.197892 
:X831 -9.6120284 0.199129 
:X969 -15.7688202 0.199447 
X1900 -9.65068873 0.199765 
:X946 12.89120664 0.200118 
X1309 11.79987399 0.200278 
:X926 22.28398302 0.200358 
X1075 -10.6971107 0.201676 
X1505 -9.33938459 0.203167 
X1724 13.66845425 0.204911 
:X879 -13.0750763 0.20553 
X2156 -15.703727 0.206478 
X2099 19.07467278 0.207767 
X1561 11.43928784 0.208218 
:X355 12.54585849 0.20977 
X1735 -13.4774259 0.211192 
X1379 -10.8460871 0.211406 
X2218 17.09035673 0.211572 
:X713 -8.85827659 0.212829 
X1376 -10.3116164 0.212892 
X1021 13.79677795 0.213706 
:X739 9.613352896 0.215693 
X1503 -11.5162849 0.215809 
:X618 -9.07054627 0.216313 
X1417 -13.6931978 0.218697 
:X885 -10.8865922 0.219727 
X2157 18.62867879 0.219826 
:X966 -16.8385043 0.221003 
X2168 -11.7111521 0.222963 
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:X621 8.719148375 0.222976 
X1042 12.74201178 0.223005 
:X712 9.766261899 0.223049 
X2026 -9.30261821 0.223586 
X2330 14.73413843 0.223755 
X1789 8.202305498 0.224026 
X1775 11.26243004 0.226048 
X1767 10.95435501 0.226169 
X1372 -11.8342808 0.226236 
:X396 9.67060785 0.227429 
X1012 7.95583722 0.228199 
X1719 14.83531854 0.228305 
:X942 13.13246882 0.228494 
X2254 -7.30285323 0.229663 
:X989 11.46353341 0.230742 
X2071 -14.4870267 0.232719 
:X727 10.53616366 0.234252 
:X788 -13.3294803 0.234922 
X1284 10.28905504 0.235625 
X2353 -8.73772509 0.236267 
:X578 -12.6783581 0.236645 
X1514 -11.0792415 0.237193 
X1373 9.24784233 0.238322 
:X659 12.14106217 0.238682 
:X866 -13.7310924 0.238932 
X1739 18.69911878 0.239347 
X2244 13.32876038 0.239377 
X2337 8.54437793 0.242851 
X2118 15.08216153 0.242969 
X1709 18.05526347 0.243795 
X1207 12.36103698 0.244529 
X2233 -9.85124386 0.24511 
:X606 7.858704796 0.245563 
X2005 12.27190867 0.246043 
X1704 14.70895044 0.246043 
X2070 16.2117565 0.24717 
X1494 -8.75271763 0.248975 
X1352 -13.0565553 0.249225 
:X624 6.826444993 0.249855 
X1890 -8.98828045 0.249908 
X1028 14.92586072 0.249983 
X1202 -7.40327869 0.250191 
X1504 -11.1740886 0.251488 
X1756 15.06430707 0.25171 
X1784 15.45596741 0.251886 
X1059 -8.77290518 0.251919 
X1540 -10.2404981 0.252049 
X1688 -8.49009145 0.252139 
:X745 9.085413744 0.253252 
:X820 9.119203983 0.253581 
X2307 10.28466074 0.254484 
:X794 -15.5350724 0.254808 
X2217 14.82449578 0.256638 
X2331 16.56894804 0.257843 
X1473 11.17842141 0.257992 
:X434 -11.2978123 0.258495 
:X867 -11.0951342 0.258564 
X1577 -10.4914 0.259236 
X1375 9.199328181 0.262716 
X2212 11.60956151 0.263048 
X1832 13.80743697 0.263275 
X1874 -10.1489492 0.264511 
X1753 21.64702712 0.264797 
:X938 5.296130309 0.265696 
X1159 -12.041106 0.26621 
X1051 16.42904919 0.266416 
X1438 -9.25117162 0.266468 
X1046 11.37834068 0.26672 
:X740 9.358152084 0.267059 
X1343 -7.93574652 0.268311 
:X617 7.521187991 0.268802 
:X821 8.938662625 0.26936 
X1189 -11.5334921 0.269422 
:X797 -9.26687935 0.269728 
:X824 13.35750485 0.269837 
X1171 -9.18267101 0.269973 
X1535 -8.03382863 0.270341 
:X892 8.25460421 0.271572 
X1822 9.560881148 0.271661 
X1293 -7.51541037 0.271775 
:X681 12.43221012 0.271815 
X1450 -9.37454088 0.272311 
:X671 -8.74013157 0.27292 
:X714 11.29557189 0.272984 
X1169 -10.8659594 0.273428 
X2146 11.00401437 0.273709 
X1609 -11.1451148 0.274722 
X2333 8.258981974 0.275491 
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:X453 10.67243339 0.275792 
:X852 9.221678566 0.276004 
X1237 -10.4708192 0.276531 
X1168 7.938011629 0.277267 
:X933 8.723227999 0.277283 
:X995 11.42508993 0.277401 
X1170 -9.93111222 0.279174 
X1818 10.22136989 0.280439 
X1770 10.14024676 0.280762 
X1429 -8.48240927 0.281195 
X1864 10.03618684 0.281937 
:X898 -8.13709503 0.282259 
X1901 -10.8996281 0.28242 
X1635 -11.0040518 0.282462 
X1013 -11.4420229 0.284831 
X1150 -12.8848012 0.287248 
X1664 -12.9566804 0.287853 
X1017 11.99977705 0.288502 
X1524 -10.0282728 0.288639 
X1613 -7.4506635 0.289162 
X1350 11.57717011 0.29191 
X1854 9.073772273 0.292115 
X1385 -7.10893456 0.292403 
X1600 13.2386042 0.292962 
X1771 -9.57458485 0.293389 
:X604 8.449755991 0.293625 
X1344 -6.80070917 0.293641 
:X387 6.799220171 0.294276 
X1112 -11.9738996 0.296223 
:X851 21.16977183 0.296378 
X1679 -10.5524694 0.296972 
X1953 -12.7106779 0.297033 
X2194 -12.1360181 0.297132 
X1092 -11.8913582 0.297275 
X2021 -9.68092127 0.297492 
X2087 18.02264282 0.298277 
X1362 13.06049132 0.301328 
:X783 -7.00763095 0.301811 
X1542 -10.9241076 0.30251 
X1175 7.281007774 0.303344 
X1090 15.42421382 0.303706 
:X825 8.424019247 0.305743 
X1715 14.66343733 0.30577 
X1485 11.15448805 0.305935 
X1787 -7.56617129 0.305975 
X1147 17.79414108 0.306539 
X1107 18.79582988 0.306647 
:X721 -7.46352023 0.30707 
X1218 -6.55762843 0.30811 
X1823 8.301265903 0.308774 
X1587 -9.71235944 0.309094 
X1564 9.542965946 0.309096 
X1483 8.067277303 0.309195 
X1412 -8.79190098 0.309412 
X1416 -7.69114233 0.310233 
X1968 -11.3698035 0.31094 
X1332 -8.13908005 0.311123 
X2298 -9.14577288 0.312051 
X1982 8.369540241 0.312785 
:X242 -11.7446478 0.313486 
X1936 -14.1200781 0.313857 
:X805 -9.64686615 0.317001 
X1658 -10.021347 0.317953 
X2215 -13.3392262 0.318116 
X2285 -7.50910555 0.318598 
:X963 11.3206921 0.319221 
:X863 -7.59393654 0.319585 
X1646 -7.76341325 0.320386 
:X636 7.781295069 0.320459 
X2041 8.434062273 0.320541 
X1435 -7.25686044 0.320578 
X1451 -8.88156375 0.320805 
X1256 10.09654129 0.322637 
X1356 -6.44095529 0.323154 
:X725 9.464806232 0.323421 
X1769 9.43354002 0.32425 
X1902 -7.3142972 0.324536 
X1167 -7.77349304 0.325268 
X1676 -10.0447961 0.32551 
X1726 -10.7946667 0.326446 
X1768 8.088695409 0.327266 
X1305 10.46942598 0.327407 
X1788 9.324813399 0.327919 
:X591 7.737648079 0.329039 
X1118 -6.67129657 0.331263 
:X834 7.596155229 0.332459 
X2332 6.074840392 0.333771 
X1174 -10.0919228 0.334299 
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:X733 8.903627732 0.335468 
X1723 -8.77782861 0.336992 
X1377 -7.30726387 0.339361 
X2352 -6.68253668 0.339486 
:X896 5.931991775 0.339843 
:X752 8.657098488 0.340305 
:X881 11.70560423 0.341073 
X1660 -7.03806928 0.343692 
X2016 7.991717444 0.343779 
X2086 -11.1908455 0.344555 
:X728 11.41584276 0.345695 
X2088 -9.58577581 0.346609 
:X574 6.073100209 0.348255 
X1415 -8.93670489 0.348326 
X1563 7.937615952 0.348733 
:X709 -9.64436716 0.348772 
:X998 9.185819585 0.350969 
X1811 12.58682761 0.351008 
:X653 7.972739677 0.351078 
X1826 7.689854939 0.351138 
:X732 8.42017528 0.35158 
:X987 8.419863538 0.352267 
:X861 -8.33766989 0.353666 
X1184 -9.81107896 0.354297 
X1552 11.82374769 0.354341 
X1192 -6.49859266 0.354407 
X1762 -9.52068404 0.355767 
X1425 -11.1346182 0.355801 
X2050 8.698833958 0.356436 
X1108 -12.2599779 0.357987 
X1779 9.376229543 0.358207 
:X598 8.08406429 0.358708 
X1589 -6.29398025 0.359026 
:X673 8.721364026 0.359354 
X2126 -12.498157 0.360603 
X2174 -7.29429933 0.360759 
X1146 -8.73397964 0.36122 
X1667 9.239101857 0.361227 
X1030 10.34180482 0.361485 
X1748 -10.917731 0.361836 
X1807 7.045574885 0.362093 
X1131 17.69230346 0.364001 
X1835 -6.9703175 0.365966 
X1016 10.60437408 0.367557 
X1648 -7.8043041 0.368313 
X2343 14.45616743 0.368748 
X1849 -10.1033571 0.369847 
:X937 5.05633065 0.37045 
:X642 -5.46180343 0.37063 
X2144 11.02141319 0.371581 
X1716 -8.38518231 0.371649 
X2169 14.33118935 0.372991 
X1281 -6.3952814 0.373223 
X2245 -12.5631948 0.37405 
X1546 7.847228406 0.374556 
:X978 -8.44447099 0.374619 
X1728 14.66362205 0.376677 
X2189 -8.17724636 0.377157 
X1181 -10.6311748 0.377668 
X2338 7.836266987 0.377851 
X2033 10.091285 0.378503 
X1814 8.720979436 0.379014 
:X816 -10.0795982 0.380449 
X1392 -7.55996878 0.380976 
X1032 3.380871143 0.381457 
X2120 10.37739904 0.381607 
:X655 -5.98104627 0.382748 
X1282 -12.2257524 0.382879 
X1527 -9.195213 0.382991 
X1091 14.32563297 0.383073 
:X874 -8.84729402 0.383597 
X1026 13.40624386 0.383728 
X1734 -9.29776455 0.383939 
:X633 5.450870899 0.384341 
X1156 9.190776486 0.385739 
X1005 -5.11798374 0.386259 
X2140 -8.72923109 0.386968 
X1304 -5.02459 0.387 
X2143 -11.2500253 0.38798 
X1430 7.741470886 0.389071 
:X842 -8.74235599 0.389213 
X1292 8.219899936 0.389596 
:X882 -9.34930368 0.389855 
X1491 7.097762163 0.389894 
X1759 -8.28218629 0.39138 
:X954 5.338081065 0.391641 
X2085 19.20174419 0.391685 
:X593 7.767347406 0.391967 
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X2161 -7.58161316 0.39197 
X2044 4.885374424 0.392108 
:X599 -10.9797623 0.393949 
X1584 -8.92550798 0.395914 
X2328 -6.93520011 0.396697 
:X731 10.10467629 0.396955 
X1015 7.454960907 0.397357 
X2347 8.122084687 0.398399 
X1125 9.243024337 0.399788 
X2109 -9.00874178 0.3999 
X1703 11.57706117 0.40044 
:X601 -8.77520735 0.400845 
X1777 7.234672948 0.40377 
X1740 13.91833191 0.404109 
:X310 7.997642999 0.405632 
X1892 11.72116011 0.405888 
X1765 -11.0723899 0.408188 
X1033 8.869715418 0.40829 
X1641 -8.10826816 0.40868 
:X944 9.199411655 0.408888 
X1599 10.54856728 0.409074 
X1575 -6.66634159 0.409338 
X1752 13.07690918 0.409408 
:X895 5.570781925 0.409537 
:X890 -8.07032773 0.41048 
X1698 -9.64544076 0.412321 
X1374 -7.25158648 0.414645 
X1060 15.04399865 0.41486 
X1585 -10.3946221 0.415334 
:X977 -7.7080325 0.416581 
X2276 -9.87443117 0.417427 
:X936 5.327347377 0.418188 
:X991 9.070867425 0.418431 
X2148 5.691986119 0.418452 
X1925 7.318387393 0.41967 
:X999 8.23601801 0.42028 
X1530 7.995279622 0.421207 
X1594 -8.45126819 0.422238 
X1160 9.849175064 0.422335 
:X602 8.88119447 0.423061 
X1612 -6.01090822 0.423309 
:X945 8.349266109 0.424333 
X1774 7.124403399 0.424898 
X1423 -5.87695941 0.425265 
X1157 -9.25319952 0.425881 
X1620 -7.22197156 0.425886 
X1224 -7.35527482 0.426923 
X1588 -9.06425178 0.428026 
X1003 -4.90126606 0.429184 
X1085 11.80504308 0.429646 
X2264 -7.68581977 0.432168 
:X716 -7.36544468 0.432646 
:X757 -7.62281075 0.433552 
:X710 -6.40248625 0.434067 
X1205 7.759854412 0.435648 
X1939 7.78586367 0.436127 
X1554 -6.87043729 0.436271 
X1825 6.657540284 0.436398 
X1457 -7.11529063 0.436569 
X2242 10.97857472 0.436917 
:X648 8.319972739 0.436942 
X1512 -8.70443408 0.437928 
:X894 5.625898308 0.438325 
X1439 -6.66947396 0.439092 
X1428 -7.26361018 0.439114 
:X786 -9.33840527 0.439204 
:X734 10.31495941 0.441101 
X1410 -7.53374501 0.443982 
X1419 8.80856774 0.444822 
X2012 -7.70675372 0.446037 
X1856 -5.87653772 0.446346 
:X625 5.250333176 0.446945 
X1286 7.402883304 0.448479 
X1310 6.178863832 0.448622 
X1180 -7.54689697 0.44947 
:X679 -6.8195847 0.449514 
X1971 -8.12389937 0.450469 
X1109 5.620035923 0.45103 
X2297 -4.90038776 0.452443 
X1829 -7.48621777 0.454175 
X1615 -7.14732898 0.454463 
X1137 -7.13589562 0.454831 
X1948 -11.0370923 0.455491 
X1668 7.603688393 0.455707 
X1381 -4.23929898 0.456164 
:X952 4.416906234 0.457574 
X1133 9.022473821 0.457716 
X1697 10.49850342 0.457977 
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X1326 -5.8279481 0.458523 
X1717 7.184866623 0.459295 
X2154 -10.5125023 0.459463 
X1828 -8.29730891 0.461524 
X2246 -7.17357497 0.46154 
X2209 10.02485519 0.461558 
X2007 7.713478867 0.462175 
X2271 -6.18774681 0.462484 
X2171 8.592057962 0.464542 
X1471 -5.7509709 0.465471 
X2006 5.992860541 0.465961 
X1940 -9.89116261 0.466147 
:X857 -6.71052893 0.46666 
:X501 8.348611961 0.468494 
X1324 4.911626923 0.468609 
X1351 -6.52111208 0.468781 
X1093 11.98700559 0.468828 
:X605 5.618285093 0.470051 
:X943 6.827700446 0.470669 
:X432 -7.25406794 0.471063 
:X698 6.200505524 0.472456 
X1702 8.421489727 0.473353 
X1509 -6.18010612 0.473433 
X1139 14.03234669 0.473598 
X2287 -6.79266493 0.473922 
X1705 8.896597009 0.474187 
:X724 9.81844927 0.47566 
:X792 10.02245737 0.475678 
X2253 -3.27848562 0.475828 
X1466 -7.21518845 0.476821 
X1246 -5.92965182 0.478078 
X1120 -8.07125305 0.480489 
X2211 7.4359613 0.48052 
X1135 13.78181061 0.480862 
:X974 -4.95498065 0.481957 
X1010 5.028220668 0.482724 
:X953 3.823040446 0.482894 
X1773 6.184840254 0.484838 
:X901 5.844112565 0.485181 
X1424 -5.98415756 0.485551 
X1191 -10.109796 0.486342 
X1551 7.383247003 0.486824 
X2049 4.837984903 0.486859 
X1040 -10.3402538 0.488512 
:X902 5.520620167 0.490232 
:X848 -6.2821061 0.490337 
:X778 -9.10590618 0.490924 
X1233 -6.61086538 0.491272 
:X631 4.500186682 0.492043 
X1636 -7.06061759 0.492058 
X2313 7.017082879 0.492598 
X2137 6.860014074 0.493398 
:X596 -4.34770138 0.493447 
X1103 -7.4729758 0.493574 
X2268 -7.3668853 0.493892 
X1098 13.98506047 0.494144 
X1383 6.389933609 0.494678 
:X826 8.95943428 0.495081 
X1707 8.902520584 0.4958 
:X823 -5.44010155 0.496425 
X1353 -4.57157381 0.497253 
:X701 5.556994395 0.49792 
X1405 -7.33416669 0.498229 
X2269 4.574467132 0.498369 
:X706 6.776752089 0.498831 
X1342 4.028272089 0.499088 
:X525 -5.79035566 0.499434 
:X910 -8.17746458 0.499498 
X1149 7.237316837 0.500004 
X1018 8.203172647 0.500528 
:X997 -4.87031369 0.500744 
:X853 -8.6605903 0.501165 
:X909 4.503413921 0.502504 
X1220 -4.69945844 0.502944 
:X589 6.085706747 0.503498 
X1803 -4.83169433 0.503905 
X1624 7.099060974 0.505044 
X1476 -5.55763873 0.505221 
X1482 -6.1867572 0.50537 
X1602 6.922688565 0.50573 
X1760 6.851975537 0.50654 
X1245 -5.75220677 0.506686 
X1255 8.255909254 0.506747 
X1084 -6.66358766 0.506749 
X1929 7.091614706 0.507527 
:X635 -4.01611115 0.50769 
X1782 -7.8514408 0.509611 
X1110 -7.59220418 0.51038 
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X1102 10.40553468 0.511765 
:X422 -4.85787422 0.512007 
X1287 -4.7273869 0.512624 
X1275 -8.23791997 0.514244 
X1227 -5.62293172 0.514316 
:X908 -6.63641783 0.514975 
X2025 -4.82934456 0.516414 
X2152 4.419601731 0.516554 
X1786 5.364287436 0.51722 
:X634 -3.89456273 0.51914 
X1474 -8.309346 0.519189 
:X676 7.206795448 0.521685 
X2102 4.053464838 0.521992 
:X836 5.273783204 0.522189 
X1708 7.471443831 0.523349 
X1269 6.687634288 0.525499 
:X637 3.946276798 0.525886 
X1244 -6.69208591 0.526173 
X1291 -6.07166408 0.527848 
X1101 -5.88935236 0.527937 
X1815 5.799584592 0.528063 
X1387 -5.08636441 0.528098 
:X717 5.519741183 0.529042 
X2119 8.616753124 0.529136 
:X755 -7.2048056 0.529161 
:X947 6.555568476 0.529176 
:X672 -7.32122463 0.529742 
X1622 -7.19877276 0.530906 
X1360 -7.13483244 0.53285 
X1221 6.347152203 0.534335 
X1232 5.292528009 0.535521 
X1008 -5.30351135 0.535578 
:X748 -4.92760048 0.535817 
X1188 -6.02284424 0.536454 
X1545 -7.09398667 0.536745 
X1710 -5.99047222 0.536976 
X2230 -6.49804551 0.538028 
:X484 -7.90941925 0.538486 
:X871 -6.64874346 0.539565 
:X707 5.197575741 0.540341 
:X771 6.04158859 0.540358 
X1962 7.729882496 0.54121 
X1855 4.747454502 0.542326 
X1453 -6.1744263 0.54336 
X1456 -6.04312278 0.543631 
X2226 3.404808728 0.544408 
:X807 -5.3999229 0.544425 
X1817 5.635013604 0.544867 
X1329 -4.65433894 0.545903 
X1736 9.024747084 0.546726 
X1657 5.756332707 0.546801 
:X696 -4.57433754 0.549271 
X2237 4.704956414 0.549316 
X1525 -5.13291315 0.549897 
X1727 7.236115644 0.551112 
X1522 7.201884431 0.551744 
X1721 6.313640621 0.55212 
:X576 5.438777871 0.552299 
:X968 6.988699767 0.553033 
:X789 -7.13301215 0.553671 
X1289 5.127132425 0.553762 
X1548 8.007680441 0.553763 
X1617 7.325511386 0.554792 
:X914 4.494629539 0.555057 
X2317 5.423680366 0.556292 
X1536 6.436905106 0.557322 
X2023 4.791164876 0.557544 
X2296 6.284056269 0.558461 
X1099 -7.3332762 0.55871 
X2284 8.378675712 0.559148 
X1700 6.794942996 0.559226 
X1299 -5.3069858 0.560513 
:X785 -4.15476636 0.560783 
:X840 11.84917369 0.561087 
:X738 5.11315704 0.561487 
X1821 6.689793019 0.561549 
X2241 -6.26726401 0.562304 
:X904 6.72718101 0.562648 
:X616 -4.3449428 0.562739 
X1071 -7.72070247 0.563919 
X1690 -7.36746227 0.563927 
X2267 -6.21426889 0.564019 
X1887 7.283672564 0.564564 
X1650 -5.93646024 0.564813 
X2204 7.175542202 0.565057 
:X381 5.068007715 0.565281 
X1337 -4.53629119 0.567955 
X2196 -5.87507875 0.568652 
  337 
  
X2053 4.80473937 0.568748 
:X386 5.327772599 0.574085 
X1550 -7.85176273 0.575394 
X1235 4.107385751 0.576244 
X1713 5.474857407 0.576823 
:X742 -4.13443857 0.57782 
:X891 -4.19392372 0.57792 
:X844 4.880518007 0.577996 
X1009 9.180287313 0.579123 
:X610 4.285627967 0.57955 
X1610 -6.14045715 0.582018 
:X818 4.982928208 0.583016 
X1104 -6.52125149 0.583382 
:X670 4.651376683 0.58537 
X1006 -4.06443733 0.585403 
:X690 5.195796125 0.586637 
X1394 4.902475436 0.587789 
X1234 5.435541824 0.588391 
:X662 5.295375604 0.588671 
X1203 -5.66408901 0.589976 
:X702 5.232907921 0.589991 
X1154 6.664323961 0.590816 
X2190 4.527232485 0.592317 
X2037 6.118096309 0.5957 
X2350 -6.90378979 0.596606 
:X378 -4.60912595 0.598073 
X2013 4.450111447 0.599685 
X1129 -6.41517884 0.600228 
X1897 6.74768186 0.601203 
:X993 5.29029931 0.603262 
X1547 -4.46324451 0.604353 
:X459 4.441197878 0.604627 
X2235 -6.09336845 0.604772 
X1616 -5.21398299 0.604801 
X2292 -5.09786038 0.605032 
X1686 5.837323159 0.606263 
:X743 4.434551608 0.606463 
X1515 -5.55915609 0.608307 
X1278 -5.49672554 0.608855 
X1318 -4.45487014 0.609138 
:X921 7.310446547 0.609141 
:X393 -4.96635885 0.609931 
X1274 6.022228466 0.610995 
X1791 3.407089704 0.613926 
X1413 -4.82851552 0.615361 
X2128 4.514616227 0.61784 
:X878 -6.00100984 0.618567 
X1470 -4.71950837 0.619371 
X1666 -6.72594348 0.620098 
X1145 4.167315891 0.620579 
X1065 -4.38416445 0.622771 
X1422 -5.73869911 0.62344 
X1066 -4.62575803 0.624546 
X1238 -4.89859978 0.625449 
:X686 4.176084525 0.627422 
X1837 4.575903686 0.627453 
:X913 6.986156767 0.628861 
X1433 -5.02573767 0.629481 
X1696 -4.43531254 0.629501 
X1553 -4.11797019 0.629512 
X1532 -4.69586863 0.629562 
X1576 -4.00245817 0.629658 
X1478 -4.13590964 0.629697 
:X649 -3.6069247 0.63064 
X1073 -4.95173772 0.631855 
:X822 -4.19852826 0.632355 
:X684 4.142392942 0.632951 
X2219 6.656110279 0.633399 
X1094 6.003634434 0.634185 
:X678 -4.45585399 0.635029 
:X765 5.391002692 0.635801 
:X545 5.17757244 0.63643 
X1054 -4.97455345 0.636825 
X1216 -3.1708406 0.638476 
:X405 3.429669168 0.63872 
:X961 2.858325437 0.638734 
X1320 -4.96778471 0.640086 
X1311 5.095416874 0.640299 
X1741 7.722039932 0.641665 
X1507 -5.6893437 0.642412 
X1906 5.080283985 0.6428 
:X886 7.378477387 0.642919 
X1720 4.831085654 0.642969 
:X718 3.989406453 0.643133 
X1465 -5.87169041 0.644099 
:X533 -3.44147192 0.64481 
X1067 4.76394587 0.645321 
X1508 -5.76485973 0.645366 
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X1761 -5.26242351 0.645933 
:X379 -4.34981482 0.647572 
:X645 3.33931619 0.64961 
X2335 3.228649068 0.651005 
X1865 3.783967622 0.651096 
X1190 -5.31575721 0.65198 
:X677 -3.33389207 0.652201 
X1496 6.445643079 0.653627 
X1598 -5.19603803 0.653771 
X2336 4.789225109 0.653883 
:X992 4.113681424 0.653965 
:X965 -6.13764335 0.655045 
X1680 -4.07570571 0.655284 
X1062 -3.68258428 0.65606 
:X689 -5.07019454 0.657369 
X1651 -6.69929277 0.657443 
X1480 -3.52019138 0.658639 
:X639 -3.52386563 0.658912 
:X986 4.00536822 0.658912 
X1493 -3.63610085 0.659224 
X1629 4.297713192 0.660217 
X1549 -6.08135191 0.660578 
X1570 -4.47641948 0.660869 
X1215 -3.46449053 0.661 
:X305 3.991723013 0.662891 
:X705 4.103785761 0.665476 
X1339 -3.96824715 0.666653 
X1126 6.292266521 0.667173 
:X845 3.247011227 0.667384 
X2081 -11.3130399 0.667731 
X1633 4.563952506 0.667996 
X1007 3.967898986 0.66886 
:X988 -3.99470245 0.668886 
:X994 5.133030312 0.669239 
X2182 -2.84681285 0.670057 
:X870 4.594996103 0.670361 
X1479 4.589134071 0.671299 
X1176 -3.05244688 0.671375 
X1162 5.342443545 0.671557 
:X899 4.777187173 0.67237 
X1518 6.608147927 0.673205 
:X491 5.31450369 0.673291 
:X206 -4.64043369 0.673759 
X1489 -3.52980868 0.674031 
X1783 3.190598993 0.674459 
X1526 -4.97141329 0.674647 
:X594 -3.23127595 0.674991 
X1882 -2.96638346 0.67563 
:X585 -5.26709674 0.675933 
X1272 -3.8863379 0.677102 
:X580 2.984631402 0.677865 
X1800 -5.25765216 0.679546 
X1127 6.150416269 0.681024 
X1608 -3.89529495 0.683592 
X1039 5.661220353 0.684172 
X1454 -5.00190358 0.684299 
X1972 -5.03970492 0.68436 
X1614 -4.55186237 0.684484 
X1357 3.533211848 0.686014 
X1225 4.33631724 0.68745 
X1684 4.256513331 0.688144 
:X958 2.511565902 0.68898 
X1677 -3.69803739 0.689976 
X1942 -5.82547058 0.690347 
X2214 -5.31323084 0.691354 
:X897 4.482906957 0.691441 
X2172 3.193256927 0.692998 
:X587 3.278387922 0.693784 
X1323 3.267639126 0.694372 
X1654 -3.82493005 0.694516 
X2136 3.120043299 0.694714 
X1038 2.710997908 0.695366 
X2222 2.693072381 0.697199 
X1687 -3.59798235 0.697476 
:X603 3.409664984 0.697596 
X1265 -2.37725938 0.698072 
X1808 2.943523673 0.699435 
:X403 -3.76691938 0.700106 
:X773 -4.89239394 0.700224 
X1560 3.294616622 0.702429 
:X746 2.798015021 0.702816 
X2198 -3.81370407 0.70302 
X1831 -2.41076364 0.705584 
X1111 -2.56849876 0.706416 
X1838 -3.05532538 0.706697 
:X699 3.402548121 0.706871 
X2177 4.305227554 0.707139 
X1089 -3.96651473 0.707334 
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:X389 2.302160209 0.709467 
X1000 3.537094268 0.710973 
:X697 3.188670403 0.713714 
:X972 4.268962448 0.713803 
X1772 3.224121081 0.713929 
X1200 2.906859644 0.714356 
X1264 -3.01396189 0.714544 
X1048 5.275654862 0.714928 
X2045 2.33199386 0.715274 
:X983 3.519083922 0.715855 
X1254 -3.60398487 0.716578 
:X817 -3.17286962 0.717661 
:X708 3.524478696 0.719988 
X1669 -3.59144547 0.720288 
X2125 3.663891352 0.720633 
X1442 -4.48545299 0.720676 
X1881 -2.76849389 0.721148 
X1365 -2.93204036 0.721361 
X1386 -3.08356053 0.721746 
X1338 -2.93999796 0.724263 
X1132 -3.71768836 0.724268 
:X766 3.86785376 0.725978 
:X955 2.036619104 0.725994 
X1555 3.681543066 0.726172 
:X656 -2.77667946 0.72674 
:X747 2.804995563 0.727585 
X2010 -2.8106044 0.728835 
X2201 -2.81026881 0.72985 
:X876 -3.87367512 0.730186 
:X800 4.073313991 0.730533 
X1619 3.783444948 0.730859 
:X906 4.555463899 0.732237 
X2063 3.26485579 0.733225 
:X770 5.65208752 0.733573 
X1521 -2.78165291 0.733659 
X1113 2.988810265 0.734293 
X1063 3.159131981 0.734673 
X1414 -3.62331274 0.734942 
X2318 3.233950515 0.735743 
X1151 5.901648616 0.736777 
X2314 3.232538954 0.73774 
X2354 3.19408687 0.740971 
X1408 3.025998018 0.741772 
X1915 3.148737987 0.74231 
:X976 3.600117341 0.742427 
X1562 -2.97903664 0.745419 
X1312 -3.01065187 0.745582 
X1510 -3.88489411 0.745731 
X1490 2.739109066 0.747222 
:X400 1.998479056 0.747853 
X1592 -3.14071061 0.748903 
:X768 -3.39576153 0.74891 
:X675 -2.58634307 0.750272 
X1579 4.824030383 0.751437 
:X970 3.360707546 0.752763 
X1226 -2.84017345 0.75458 
:X858 7.148879003 0.755422 
X1165 3.639367588 0.755435 
:X286 -2.39716504 0.755463 
X2082 3.519809153 0.755601 
X1699 3.038069359 0.755969 
X2073 -5.10435775 0.755988 
X1523 2.13545379 0.756447 
X1833 3.944568045 0.756754 
X1695 3.159677213 0.75722 
X1199 1.890336244 0.758408 
:X652 2.383432753 0.758537 
:X629 -2.51540573 0.758602 
X2024 2.211578312 0.75917 
X1643 -2.74507375 0.759866 
X1519 2.097009755 0.760348 
X2155 2.370442071 0.760376 
X2295 2.87374609 0.761434 
X1959 2.589435648 0.761575 
X1166 4.759358048 0.762298 
X1053 -2.53581216 0.76373 
:X529 -2.18702092 0.764755 
:X722 3.327159132 0.766128 
:X322 -2.34806021 0.769348 
:X939 1.553634059 0.772658 
:X781 -2.21928154 0.773548 
X1298 -2.49691522 0.774246 
X1198 2.902177073 0.774884 
X2315 2.91147661 0.775348 
X2344 2.70130971 0.775989 
:X775 -2.38261563 0.776331 
X1792 -3.21100937 0.777638 
X1106 -3.93855622 0.778209 
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X1273 3.64765298 0.778678 
X1152 -3.16266698 0.778822 
X1757 3.420708381 0.779625 
X1380 2.082137888 0.780302 
X1869 2.563546184 0.781879 
X2151 -1.88736354 0.78395 
X2036 2.90897108 0.784074 
X1029 -2.25114833 0.784317 
X1041 3.153905569 0.784915 
X1079 -3.85614466 0.785482 
:X482 3.372244351 0.786055 
X1464 2.732384929 0.7866 
:X753 -2.68881812 0.787712 
:X571 3.191084686 0.788025 
X1819 -2.42308165 0.789352 
X1122 4.088087963 0.790082 
X1930 2.681590668 0.790213 
X1730 3.90197308 0.792072 
X2181 -1.76640345 0.792854 
X2277 -2.50570242 0.793234 
X2164 -4.22466568 0.794494 
X1161 2.701331177 0.794669 
:X833 -4.35804949 0.795196 
X1396 -3.07245853 0.796468 
:X657 2.030337985 0.799722 
:X687 -2.24968281 0.799999 
:X619 1.908726482 0.802378 
X1488 1.869642984 0.80322 
X1506 -3.34944202 0.803277 
:X915 -1.83463476 0.803586 
X1262 -2.71240684 0.806021 
X1580 -3.98902629 0.80645 
:X916 1.840135799 0.806539 
X1801 -2.08109433 0.807529 
X1674 3.064911745 0.808194 
X1121 3.216496797 0.810549 
X1795 4.991942929 0.810623 
X1354 -2.07244956 0.810776 
:X749 2.201790715 0.812644 
X2054 -2.26981219 0.81268 
:X907 3.053542469 0.813271 
X1409 -2.38251329 0.813875 
:X615 1.760723362 0.813978 
X1486 2.482707269 0.814101 
X1558 -1.99282161 0.814288 
X1565 2.319486508 0.8143 
X2020 -1.67467183 0.814729 
:X471 -2.44775373 0.815454 
X2095 -2.69432676 0.815577 
X1593 2.458931519 0.817258 
X1074 -2.26673008 0.817772 
:X527 -2.27147558 0.819235 
:X791 -1.9597071 0.821393 
:X956 1.492207849 0.823393 
X1628 -2.84657925 0.823761 
:X632 1.815902957 0.824489 
X1260 1.997387935 0.825597 
X1751 2.140876066 0.826295 
:X640 1.182117959 0.826397 
:X951 1.329736639 0.828036 
:X829 -1.77797737 0.828236 
X1219 2.186341627 0.828939 
X2115 2.551216406 0.830346 
X2325 -1.96031699 0.830484 
X2101 -2.47191876 0.834183 
X2193 -2.1788478 0.834407 
:X584 -1.80878929 0.835048 
X2040 1.251978019 0.835314 
X1406 2.135338251 0.835703 
:X905 -2.74701825 0.835925 
:X607 -1.78539147 0.835992 
X1078 -1.77581453 0.836503 
:X985 1.831422935 0.837527 
X2104 2.359822195 0.837869 
X1790 -1.54687476 0.838158 
X1958 1.863059212 0.838301 
X1794 -3.16693254 0.839708 
X1605 2.689055116 0.840137 
X2147 3.212336798 0.840573 
X1689 1.61658793 0.841166 
:X830 -1.68294486 0.841832 
X2123 1.263459077 0.842605 
X1061 1.701241034 0.842964 
:X761 -2.18006119 0.843604 
:X660 1.594955999 0.845197 
X1678 -1.87215564 0.846348 
X1208 -2.01992988 0.846854 
:X855 -1.49580869 0.847826 
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:X266 1.425864483 0.85168 
:X272 1.668025866 0.851909 
X1621 -2.24156557 0.852179 
X1645 1.840712805 0.852913 
X2304 1.763478334 0.855141 
:X912 1.897879632 0.85615 
X1997 -1.59703678 0.859966 
X2108 1.942834883 0.86035 
X1119 1.21157513 0.861526 
:X957 1.008447112 0.861678 
X1001 1.846706506 0.863614 
X1241 -1.4145228 0.863979 
X1399 -1.91001854 0.864576 
X2124 1.941914023 0.865935 
X1404 1.858366517 0.867226 
X1402 1.743988747 0.868188 
X1263 1.385116095 0.868238 
:X397 -0.98498935 0.868387 
X1591 -1.58760518 0.869673 
:X412 -1.74663926 0.870086 
X1261 1.838189354 0.870279 
X1050 2.501268029 0.870662 
X1745 -1.28955037 0.871295 
X2275 1.534090003 0.871712 
:X609 -1.40623077 0.871726 
X1574 -1.3458884 0.873886 
X1742 -1.58343853 0.874782 
:X641 -0.88220019 0.876486 
X1411 1.422762059 0.878354 
:X558 -1.69739333 0.878996 
X1088 -2.22113749 0.8812 
:X664 1.055671892 0.881355 
X2105 1.779912994 0.88149 
X2042 0.986163381 0.881618 
X1141 -2.60216748 0.882937 
X1944 -2.24414064 0.883466 
X2130 -1.46153069 0.886363 
X2339 -1.38155629 0.886401 
X1239 -1.18304899 0.888771 
X1805 -1.75113369 0.889992 
X1247 -1.11689051 0.890523 
X1685 1.774314934 0.890618 
:X667 -1.21887673 0.890633 
:X900 1.141721417 0.890829 
X1398 1.131358202 0.890861 
X1164 2.132378436 0.891581 
X1076 1.714368339 0.89209 
X2116 2.556244652 0.892176 
:X741 0.986392924 0.892224 
X1087 1.729953342 0.893433 
X1314 1.004904711 0.894561 
X1268 0.793863034 0.895193 
X2240 -1.23506164 0.895231 
X2239 -1.29093699 0.896452 
X1981 -1.00020461 0.898227 
:X646 -1.16988891 0.89959 
X2351 0.93687806 0.901388 
X1806 -1.3904802 0.902441 
X2096 -1.52979689 0.904915 
X1421 1.084348294 0.905324 
X1124 1.989221381 0.907937 
X1070 -1.02822571 0.91151 
X2019 0.826705602 0.911647 
X1043 1.257405171 0.912113 
X1400 1.188928205 0.912369 
X1714 1.471355317 0.913716 
X1229 1.242043943 0.913896 
X1391 1.051396884 0.91466 
X1965 1.385364526 0.915852 
X1963 -1.27351164 0.917067 
:X692 -0.85091142 0.918734 
X1371 -1.10641011 0.919281 
X1611 1.217021606 0.919498 
X2308 -1.04839258 0.920981 
X1517 1.247196031 0.922517 
X1537 -0.85114293 0.924237 
X1780 1.024575731 0.924393 
X1288 -0.69309995 0.925306 
X1875 0.817902973 0.926347 
X1481 -0.98232202 0.926702 
X1662 -0.9191046 0.927111 
X2280 0.882590187 0.928921 
X1242 0.645481451 0.929327 
X1701 -0.98377216 0.929803 
X1072 0.776588714 0.931304 
:X680 0.619746722 0.931478 
:X774 1.063145463 0.932316 
X1182 -0.84958457 0.933864 
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X1183 -0.96786185 0.934006 
X2159 1.257269275 0.93592 
X1426 -0.67176363 0.93596 
:X735 1.168369664 0.937554 
:X694 -0.78906418 0.937752 
:X790 0.77489208 0.937782 
:X828 0.592260043 0.939113 
X1259 -0.78429488 0.93925 
:X918 -0.99959685 0.941539 
:X950 0.441295275 0.942657 
X1185 0.758272694 0.944101 
X1210 0.803822827 0.944182 
X2326 0.551143429 0.945301 
X1964 -0.72567239 0.947262 
X1049 0.582599945 0.947765 
:X846 0.548044224 0.94879 
X1572 0.665288467 0.94919 
X1531 -0.67423805 0.951505 
X2203 0.589790967 0.95171 
X1927 0.561072008 0.952418 
X1747 -0.71094554 0.952876 
:X644 -0.46152078 0.954708 
X2127 0.508734807 0.954735 
X1052 -0.70614063 0.955492 
X1988 -0.4757422 0.956873 
X1582 -0.60008274 0.957752 
X2283 -0.54342619 0.958987 
X1941 -0.71548807 0.959175 
X1158 -0.63310969 0.959268 
:X872 0.510706337 0.959882 
X1830 -0.52515111 0.96055 
X2273 -0.46077589 0.960734 
X1606 -0.55330566 0.961244 
X1876 0.552048935 0.961385 
X1334 0.445990402 0.961477 
X2231 1.083704745 0.961591 
X1130 0.678010784 0.962331 
:X973 0.544172521 0.963574 
X1077 -0.62901434 0.963629 
:X590 0.515756009 0.965429 
:X638 -0.32180622 0.966621 
:X281 -0.3460116 0.967237 
X1500 0.436303737 0.968755 
X1903 -0.38313915 0.969383 
X1345 -0.23909499 0.972355 
X1440 0.268213686 0.97348 
:X868 0.35978437 0.974024 
X1469 0.258245702 0.974431 
X1047 0.275230398 0.975191 
X1627 -0.35036184 0.975441 
:X841 -0.56396341 0.976778 
X1601 0.302515039 0.978571 
X1308 0.218800032 0.981764 
X2349 0.221921725 0.981876 
:X750 -0.16723165 0.982602 
X2114 -0.11368621 0.984563 
X1597 -0.23636679 0.984697 
X1583 0.188039938 0.985001 
X1140 0.257955273 0.986546 
X1213 0.171094851 0.98683 
X1607 0.196039278 0.987103 
:X996 0.137927873 0.987851 
:X795 0.186615876 0.987895 
X1836 -0.12347142 0.988948 
X1557 -0.17692707 0.990048 
X1211 0.111519939 0.990465 
X2311 -0.13052645 0.990634 
:X744 0.102703129 0.990813 
X1155 0.122546884 0.99257 
:X229 0.082056012 0.993504 
X1604 0.08497529 0.994035 
:X595 -0.06087833 0.994152 
X1725 -0.07640855 0.994159 
:X884 0.074676101 0.994764 
X1258 -0.04427388 0.995062 
X1086 0.07826602 0.996419 
X1917 0.031965091 0.998167 
X1370 -0.01784706 0.998191 
X1123 -0.02741152 0.998622 
X1303 -0.00535596 0.999583 
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Appendix 6  
Baseline partial correlation results for proteins with PiB PET DVR. Proteins 
ranked in order of significance based on p value. Proteins highlighted in red are 



























Complement C4 B -0.498 0.022 
Leucine rich alpha 2 glycoprotein 0.607 0.022 
Zinc alpha 2 glycoprotein. 0.478 0.025 
Ig kappa chain C region 0.455 0.035 
Fibrinogen beta chain -0.471 0.038 
Fibrinogen alpha chain -0.429 0.050 
Apolipoprotein A IV -0.420 0.056 
Beta 2 microglobulin 0.482 0.068 
Hemopexin. 0.364 0.107 
Alpha 1 antitrypsin 0.362 0.109 
Ig alpha 1 chain C region 0.457 0.123 
Immunoglobulin lambda like polypeptide 5 -0.454 0.127 
Angiotensinogen -0.407 0.140 
Serotransferrin 0.321 0.162 
Serum.albumin -0.376 0.179 
  344 
  
Vitamin D binding protein -0.342 0.227 
Protein AMBP 0.250 0.288 
Alpha 1 acid glycoprotein 1 0.226 0.338 
Complement C3 -0.164 0.519 
Kininogen 1 0.142 0.555 
Alpha 1B glycoprotein 0.159 0.576 
Antithrombin III 0.129 0.626 
Apolipoprotein E 0.108 0.717 
Transthyretin 0.072 0.765 
Alpha 2 HS glycoprotein 0.068 0.868 
Apolipoprotein A I 0.033 0.912 
Inter alpha trypsin inhibitor heavy chain H4 -0.025 0.917 
Alpha 1 acid glycoprotein 2 0.026 0.932 
Retinol binding protein 4 -0.020 0.947 
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Appendix 7  
T6 partial correlation results for proteins with PiB PET DVR. Proteins ranked 
in order of significance based on p value. Proteins highlighted in red are 



























Complement.C3 -0.567 0.017 
Fibrinogen alpha chain -0.477 0.042 
Leucine rich alpha 2 glycoprotein -0.503 0.100 
Complement C4 B -0.410 0.119 
Alpha 1 acid glycoprotein 1 -0.382 0.122 
Fibrinogen beta chain -0.364 0.158 
Platelet basic protein 0.572 0.163 
Apolipoprotein L1 -0.452 0.310 
Carbonic anhydrase 1 0.348 0.327 
Inter alpha trypsin inhibitor heavy chain H4 -0.214 0.413 
Angiotensinogen -0.290 0.423 
Alpha 1 antitrypsin -0.208 0.426 
Transthyretin -0.206 0.431 
Serum albumin -0.249 0.467 
Zinc alpha 2 glycoprotein -0.181 0.506 
  346 
  
Hemopexin -0.164 0.534 
Apolipoprotein A I 0.211 0.542 
Ig kappa chain C region 0.210 0.544 
Beta 2 microglobulin -0.190 0.562 
Retinol binding protein 4 0.195 0.575 
Kininogen 1 -0.142 0.591 
Antithrombin III -0.152 0.627 
Apolipoprotein A IV -0.127 0.658 
Alpha 1B glycoprotein 0.123 0.726 
Vitamin D binding protein 0.121 0.731 
Ig alpha 1 chain C region 0.110 0.769 
Apolipoprotein E -0.129 0.771 
Alpha 1 acid glycoprotein 2 0.096 0.785 
Immunoglobulin lambda like polypeptide 5 0.074 0.845 
Protein AMBP 0.008 0.977 
Serotransferrin 0.006 0.981 
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Appendix 8  
T12 partial correlation results for proteins with PiB PET DVR. Proteins ranked 
in order of significance based on p value. Proteins highlighted in red are 



























Alpha 1 acid glycoprotein 2 0.520 0.043 
Beta 2 microglobulin 0.574 0.047 
Complement C4 B -0.391 0.079 
Ig lambda 2 chain C regions -0.548 0.142 
Apolipoprotein A I -0.349 0.196 
Apolipoprotein E -0.373 0.203 
Alpha 1 acid glycoprotein 1 0.275 0.225 
Protein AMBP -0.277 0.235 
Complement C3 -0.294 0.251 
Leucine rich alpha 2 glycoprotein 0.315 0.271 
Serum albumin -0.292 0.271 
Angiotensinogen 0.354 0.285 
Carbonic anhydrase 1 -0.337 0.312 
Immunoglobulin lambda like polypeptide 5 -0.287 0.369 
Fibrinogen alpha chain -0.194 0.428 
  348 
  
Retinol binding protein 4 0.286 0.504 
Ig alpha 1 chain C region -0.195 0.575 
Transthyretin -0.104 0.657 
Fibrinogen beta chain -0.102 0.663 
Alpha 1 antitrypsin -0.098 0.676 
Kininogen 1 -0.096 0.682 
Serotransferrin -0.096 0.683 
Ig kappa chain C region -0.111 0.698 
Hemopexin -0.053 0.822 
Vitamin D binding protein -0.047 0.860 
Alpha 1B glycoprotein 0.048 0.869 
Inter alpha trypsin inhibitor heavy chain H4 0.034 0.885 
Zinc alpha 2 glycoprotein -0.030 0.901 
Apolipoprotein A IV -0.026 0.917 
Antithrombin III 0.013 0.964 
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Appendix 9  
Mixed-effects regression model results for protein values with sMRI brain 
regions. Proteins ranked in order of significance based on p value. Proteins 
highlighted in red are statistically significant (p<0.05), those highlighted in 



























Antithrombin III -1674.270 0.002 
Zinc alpha 2 glycoprotein 1022.783 0.034 
Alpha 1 acid glycoprotein 1 1155.158 0.100 
Apolipoprotein A IV 754.236 0.123 
Serum albumin -842.335 0.183 
Alpha 1B glycoprotein -696.896 0.185 
Hemopexin 992.420 0.215 
Inter alpha trypsin inhibitor heavy chain H4 -745.905 0.243 
Apolipoprotein E 704.077 0.337 
Retinol binding protein -607.918 0.378 
Immunoglobulin lambda like polypeptide 5 -1015.044 0.379 
Carbonic anhydrase 1 -714.182 0.462 
Beta 2 microglobulin -567.921 0.472 
Serotransferrin 387.691 0.491 
Complement C4 B -280.900 0.572 
  350 
  
Angiotensinogen -348.233 0.643 
Vitamin D binding protein -377.917 0.647 
Complement C3 -154.896 0.708 
Kininogen 1 -161.744 0.711 
Ig kappa chain C region -200.456 0.747 
Transthyretin 183.803 0.768 
Ig alpha 1 chain C region -277.887 0.779 
Protein AMBP 172.022 0.827 
Fibrinogen alpha chain 81.552 0.883 
Fibrinogen beta chain -77.361 0.913 
Leucine rich apha 2 glycoprotein 75.268 0.920 
Alpha 1 acid glycoprotein  -47.026 0.959 
Alpha 1 antitrypsin -30.093 0.970 
Apolipoprotein A I -5.310 0.992 
Entorhinal 
cortex 
Retinol binding protein -294.493 0.138 
Carbonic anhydrase 1 -388.814 0.144 
Hemopexin -270.117 0.150 
Beta 2 microglobulin -221.820 0.222 
Protein AMBP -187.763 0.315 
Apolipoprotein A IV 120.353 0.337 
  351 
  
Alpha 1 acid glycoprotein  -162.265 0.436 
Fibrinogen alpha chain 94.967 0.446 
Zinc alpha 2 glycoprotein -84.956 0.474 
Angiotensinogen -122.007 0.523 
Fibrinogen beta chain 97.195 0.548 
Vitamin D binding protein -94.479 0.556 
Immunoglobulin lambda like polypeptide 5 134.057 0.563 
Serotransferrin -74.784 0.564 
Serum albumin 78.278 0.565 
Antithrombin III 52.168 0.651 
Alpha 1B glycoprotein -53.058 0.674 
Ig alpha 1 chain C region 69.891 0.678 
Transthyretin 55.985 0.694 
Alpha 1 acid glycoprotein 1 34.998 0.829 
Apolipoprotein A I 23.754 0.859 
Complement C3 -16.957 0.877 
Complement C4 B 12.694 0.903 
Ig kappa chain C region 14.095 0.924 
Apolipoprotein E 11.218 0.933 
Inter alpha trypsin inhibitor heavy chain H4 12.459 0.933 
  352 
  
Kininogen 1 7.504 0.940 
Alpha 1 antitrypsin -9.582 0.959 
Leucine rich apha 2 glycoprotein 3.043 0.984 
Frontal Grey 
Alpha 1 acid glycoprotein 1 8162.499 0.044 
Zinc alpha 2 glycoprotein 5446.128 0.052 
Complement C3 -5151.136 0.053 
Antithrombin III -5367.144 0.106 
Apolipoprotein A I -4968.396 0.144 
Carbonic anhydrase 1 -7007.675 0.186 
Fibrinogen alpha chain -3804.693 0.217 
Protein AMBP 5056.038 0.278 
Transthyretin 3324.963 0.351 
Alpha 1 antitrypsin 4004.326 0.390 
Leucine rich apha 2 glycoprotein 3212.731 0.410 
Vitamin D binding protein 3398.218 0.415 
Serotransferrin -2083.871 0.520 
Fibrinogen beta chain -2507.811 0.530 
Serum albumin -1814.472 0.584 
Alpha 1B glycoprotein 1677.655 0.593 
Kininogen 1 1225.610 0.625 
  353 
  
Apolipoprotein E 2270.769 0.634 
Apolipoprotein A IV 1445.794 0.649 
Hemopexin 1827.956 0.694 
Inter alpha trypsin inhibitor heavy chain H4 -1023.951 0.782 
Alpha 1 acid glycoprotein  1324.076 0.797 
Complement C4 B -603.843 0.826 
Beta 2 microglobulin 1051.266 0.836 
Ig kappa chain C region -833.660 0.842 
Retinol binding protein -626.144 0.894 
Ig alpha 1 chain C region 597.817 0.916 
Angiotensinogen 456.199 0.920 
Immunoglobulin lambda like polypeptide 5 -76.176 0.990 
Grey matter 







Alpha 1 acid glycoprotein 1 
15315.96
9 0.177 
Apolipoprotein A IV 9779.601 0.266 
Alpha 1 antitrypsin 
13312.34
3 0.305 
  354 
  




Transthyretin 9382.220 0.345 
Leucine rich apha 2 glycoprotein 9775.410 0.400 
Fibrinogen alpha chain -7005.888 0.424 
Apolipoprotein A I -7399.148 0.428 
Serotransferrin -6735.623 0.453 
Complement C3 -4496.194 0.547 
Retinol binding protein -7994.273 0.556 
Beta 2 microglobulin -7459.334 0.607 
Immunoglobulin lambda like polypeptide 5 -8176.370 0.615 
Alpha 1B glycoprotein 4177.441 0.629 
Kininogen 1 -2868.078 0.682 
Protein AMBP 5188.974 0.691 
Ig kappa chain C region -4125.730 0.725 
Complement C4 B -2466.340 0.749 
Fibrinogen beta chain -3438.829 0.761 
Hemopexin 3756.727 0.770 
Apolipoprotein E 3368.329 0.804 
Serum albumin -1872.537 0.842 
  355 
  
Ig alpha 1 chain C region 3023.688 0.847 
Angiotensinogen -1719.328 0.893 
Inter alpha trypsin inhibitor heavy chain H4 1272.129 0.901 
Vitamin D binding protein -396.520 0.975 
Alpha 1 acid glycoprotein  -240.615 0.987 
Hippocampus 
Apolipoprotein E 285.516 0.034 
Serum albumin -209.756 0.069 
Inter alpha trypsin inhibitor heavy chain H4 -208.944 0.080 
Leucine rich apha 2 glycoprotein -212.601 0.138 
Beta 2 microglobulin -204.808 0.166 
Kininogen 1 106.461 0.192 
Complement C4 B 115.753 0.222 
Vitamin D binding protein -158.752 0.268 
Alpha 1B glycoprotein -136.935 0.269 
Apolipoprotein A IV -118.836 0.270 
Apolipoprotein A I 111.146 0.301 
Immunoglobulin lambda like polypeptide 5 -203.815 0.312 
Protein AMBP 145.816 0.338 
Serotransferrin 73.568 0.484 
Retinol binding protein 118.755 0.513 
  356 
  
Alpha 1 acid glycoprotein 1 82.165 0.532 
Complement C3 50.243 0.566 
Fibrinogen alpha chain -55.886 0.582 
Antithrombin III -34.112 0.701 
Fibrinogen beta chain -47.047 0.703 
Ig alpha 1 chain C region -54.914 0.771 
Ig kappa chain C region 39.446 0.789 
Zinc alpha 2 glycoprotein 18.494 0.844 
Alpha 1 acid glycoprotein  33.676 0.853 
Transthyretin 20.926 0.858 
Angiotensinogen -24.583 0.865 
Alpha 1 antitrypsin 12.708 0.933 
Carbonic anhydrase 1 -6.971 0.972 
Hemopexin 1.225 0.994 
Inferior occipital 
gyrus 
Transthyretin 786.319 0.025 
Apolipoprotein A IV 539.710 0.087 
Alpha 1 antitrypsin 681.389 0.144 
Antithrombin III -408.261 0.214 
Alpha 1B glycoprotein -360.329 0.255 
Protein AMBP 522.973 0.269 
  357 
  
Leucine rich apha 2 glycoprotein 436.640 0.280 
Retinol binding protein -480.713 0.281 
Serotransferrin -345.560 0.286 
Zinc alpha 2 glycoprotein 280.151 0.335 
Apolipoprotein E 454.122 0.377 
Inter alpha trypsin inhibitor heavy chain H4 299.692 0.417 
Serum albumin -259.967 0.423 
Immunoglobulin lambda like polypeptide 5 -417.429 0.479 
Ig kappa chain C region -235.349 0.590 
Complement C3 136.680 0.611 
Beta 2 microglobulin -242.656 0.635 
Fibrinogen beta chain -190.035 0.643 
Ig alpha 1 chain C region -231.953 0.653 
Complement C4 B 124.832 0.669 
Apolipoprotein A I -135.695 0.692 
Carbonic anhydrase 1 -188.641 0.723 
Angiotensinogen 152.864 0.744 
Hemopexin 140.732 0.767 
Vitamin D binding protein -113.691 0.800 
Fibrinogen alpha chain 71.724 0.822 
  358 
  
Alpha 1 acid glycoprotein 1 77.279 0.850 
Alpha 1 acid glycoprotein  -62.994 0.907 
Kininogen 1 -16.186 0.949 
Insula 
Apolipoprotein A IV 1086.778 0.039 
Kininogen 1 -787.277 0.055 
Retinol binding protein -1026.712 0.185 
Antithrombin III -591.128 0.228 
Beta 2 microglobulin -844.844 0.314 
Immunoglobulin lambda like polypeptide 5 -955.488 0.322 
Apolipoprotein A I 567.214 0.358 
Leucine rich apha 2 glycoprotein 606.041 0.384 
Alpha 1B glycoprotein 445.584 0.416 
Zinc alpha 2 glycoprotein 365.126 0.445 
Complement C3 333.027 0.449 
Alpha 1 acid glycoprotein  -663.555 0.452 
Protein AMBP -569.412 0.471 
Inter alpha trypsin inhibitor heavy chain H4 427.392 0.488 
Serotransferrin -344.973 0.524 
Alpha 1 antitrypsin 449.056 0.560 
Ig alpha 1 chain C region 505.060 0.583 
  359 
  
Apolipoprotein E 343.769 0.596 
Transthyretin 278.950 0.638 
Carbonic anhydrase 1 -394.927 0.650 
Serum albumin 234.687 0.687 
Fibrinogen alpha chain 195.339 0.698 
Fibrinogen beta chain -203.714 0.763 
Vitamin D binding protein 212.866 0.776 
Complement C4 B 96.248 0.837 
Hemopexin -160.298 0.840 
Ig kappa chain C region 86.031 0.898 
Angiotensinogen -19.506 0.980 
Alpha 1 acid glycoprotein 1 15.628 0.982 
Medial frontal 
gyrus 
Antithrombin III -1312.703 0.027 
Serotransferrin -1124.889 0.063 
Transthyretin 1037.397 0.120 
Apolipoprotein A I -699.521 0.273 
Complement C3 -505.150 0.311 
Ig kappa chain C region -680.593 0.370 
Alpha 1 acid glycoprotein  -929.914 0.400 
Zinc alpha 2 glycoprotein 454.694 0.402 
  360 
  
Hemopexin -726.993 0.405 
Vitamin D binding protein 649.475 0.443 
Serum albumin -475.280 0.499 
Protein AMBP 593.878 0.504 
Apolipoprotein E 472.361 0.513 
Complement C4 B 339.882 0.520 
Carbonic anhydrase 1 -405.442 0.686 
Apolipoprotein A IV 190.120 0.754 
Angiotensinogen 261.523 0.775 
Alpha 1B glycoprotein -144.151 0.826 
Leucine rich apha 2 glycoprotein -154.386 0.840 
Fibrinogen alpha chain -105.515 0.852 
Beta 2 microglobulin -175.217 0.854 
Alpha 1 antitrypsin 161.163 0.855 
Immunoglobulin lambda like polypeptide 5 -216.071 0.863 
Ig alpha 1 chain C region 165.393 0.882 
Fibrinogen beta chain -105.006 0.888 
Kininogen 1 61.372 0.897 
Alpha 1 acid glycoprotein 1 32.629 0.966 
Inter alpha trypsin inhibitor heavy chain H4 -27.974 0.968 
  361 
  
Retinol binding protein 23.802 0.978 
Middle frontal 
gyrus 
Alpha 1B glycoprotein -1750.054 0.033 
Antithrombin III -2063.618 0.036 
Alpha 1 acid glycoprotein  -2241.501 0.078 
Apolipoprotein E 2980.132 0.081 
Complement C4 B 1088.344 0.193 
Serum albumin -977.810 0.207 
Ig alpha 1 chain C region -1734.727 0.212 
Leucine rich apha 2 glycoprotein -1095.689 0.257 
Carbonic anhydrase 1 1024.451 0.335 
Inter alpha trypsin inhibitor heavy chain H4 -985.275 0.357 
Fibrinogen beta chain -989.972 0.395 
Angiotensinogen -922.676 0.395 
Zinc alpha 2 glycoprotein 652.253 0.423 
Immunoglobulin lambda like polypeptide 5 -1104.741 0.485 
Ig kappa chain C region -891.026 0.486 
Vitamin D binding protein -712.462 0.498 
Protein AMBP 835.977 0.540 
Serotransferrin -509.982 0.588 
Complement C3 429.430 0.608 
  362 
  
Transthyretin 478.932 0.645 
Apolipoprotein A IV -396.374 0.667 
Apolipoprotein A I -266.011 0.800 
Kininogen 1 165.021 0.821 
Alpha 1 acid glycoprotein 1 243.918 0.836 
Retinol binding protein -170.043 0.886 
Alpha 1 antitrypsin 175.235 0.897 
Fibrinogen alpha chain 120.116 0.898 
Hemopexin 157.235 0.907 
Beta 2 microglobulin -8.248 0.995 
Middle occipital 
gyrus 
Complement C3 -833.235 0.029 
Zinc alpha 2 glycoprotein 873.585 0.056 
Ig kappa chain C region 1256.919 0.063 
Alpha 1B glycoprotein 815.878 0.098 
Fibrinogen alpha chain -643.438 0.162 
Hemopexin 1020.627 0.168 
Ig alpha 1 chain C region 903.454 0.273 
Apolipoprotein A I -479.990 0.354 
Inter alpha trypsin inhibitor heavy chain H4 491.474 0.388 
Serotransferrin 427.795 0.394 
  363 
  
Complement C4 B -365.833 0.396 
Retinol binding protein 659.040 0.403 
Leucine rich apha 2 glycoprotein 512.528 0.418 
Serum albumin 431.057 0.420 
Alpha 1 acid glycoprotein 1 458.229 0.466 
Alpha 1 antitrypsin 488.504 0.492 
Carbonic anhydrase 1 639.370 0.494 
Transthyretin -371.671 0.498 
Protein AMBP 461.900 0.532 
Apolipoprotein E 438.687 0.546 
Apolipoprotein A IV 297.537 0.549 
Fibrinogen beta chain -322.429 0.600 
Immunoglobulin lambda like polypeptide 5 390.510 0.667 
Beta 2 microglobulin -268.248 0.733 
Alpha 1 acid glycoprotein  237.052 0.759 
Antithrombin III -118.881 0.799 
Angiotensinogen 130.456 0.869 
Vitamin D binding protein 92.754 0.900 
Kininogen 1 12.165 0.975 
Middle temporal Zinc alpha 2 glycoprotein 1869.463 0.036 
  364 
  
gyrus 
Ig kappa chain C region -2493.314 0.041 
Antithrombin III -1672.213 0.060 
Transthyretin 1823.895 0.097 
Alpha 1 acid glycoprotein 1 1824.746 0.150 
Alpha 1 antitrypsin 1766.816 0.221 
Alpha 1B glycoprotein -1188.874 0.275 
Leucine rich apha 2 glycoprotein 1411.602 0.302 
Kininogen 1 773.697 0.316 
Complement C4 B 860.946 0.334 
Apolipoprotein E 1150.840 0.379 
Hemopexin 1254.299 0.383 
Protein AMBP 1184.561 0.412 
Serotransferrin -814.375 0.415 
Complement C3 621.849 0.431 
Immunoglobulin lambda like polypeptide 5 1261.304 0.499 
Ig alpha 1 chain C region -1113.430 0.514 
Angiotensinogen -737.001 0.557 
Alpha 1 acid glycoprotein  970.468 0.562 
Fibrinogen beta chain -610.032 0.624 
Serum albumin -343.188 0.758 
  365 
  
Apolipoprotein A I -313.398 0.763 
Inter alpha trypsin inhibitor heavy chain H4 336.041 0.768 
Beta 2 microglobulin 264.130 0.848 
Retinol binding protein 243.064 0.877 
Vitamin D binding protein -75.927 0.958 
Apolipoprotein A IV -51.763 0.958 
Carbonic anhydrase 1 23.307 0.990 
Fibrinogen alpha chain 9.779 0.992 
Orbito frontal 
gyrus 
Carbonic anhydrase 1 -3932.504 0.006 
Alpha 1 acid glycoprotein 1 2431.306 0.013 
Zinc alpha 2 glycoprotein 1487.389 0.035 
Leucine rich apha 2 glycoprotein 1746.057 0.079 
Complement C3 -1120.828 0.083 
Apolipoprotein A I -1105.925 0.149 
Alpha 1B glycoprotein 954.225 0.210 
Apolipoprotein A IV 723.421 0.353 
Retinol binding protein -1083.733 0.363 
Alpha 1 antitrypsin 1023.450 0.365 
Transthyretin 783.153 0.368 
Serum albumin -746.732 0.377 
  366 
  
Fibrinogen alpha chain -666.611 0.385 
Hemopexin 984.197 0.394 
Beta 2 microglobulin -1057.282 0.410 
Vitamin D binding protein 854.167 0.433 
Complement C4 B -478.093 0.453 
Alpha 1 acid glycoprotein  902.352 0.460 
Angiotensinogen -782.863 0.545 
Ig alpha 1 chain C region -657.545 0.616 
Antithrombin III -320.411 0.694 
Inter alpha trypsin inhibitor heavy chain H4 -344.071 0.703 
Immunoglobulin lambda like polypeptide 5 -428.562 0.776 
Protein AMBP 288.964 0.805 
Fibrinogen beta chain -176.382 0.858 
Ig kappa chain C region -145.919 0.888 
Serotransferrin -108.322 0.892 
Apolipoprotein E -55.949 0.961 
Kininogen 1 -11.311 0.985 
Parahippocampa
l gyrus 
Alpha 1 acid glycoprotein 1 231.366 0.035 
Apolipoprotein A IV -172.073 0.036 
Carbonic anhydrase 1 -181.096 0.141 
  367 
  
Fibrinogen alpha chain -121.331 0.155 
Vitamin D binding protein -145.056 0.180 
Zinc alpha 2 glycoprotein 90.858 0.252 
Alpha 1B glycoprotein 78.700 0.324 
Immunoglobulin lambda like polypeptide 5 -130.159 0.379 
Kininogen 1 48.346 0.474 
Apolipoprotein A I 58.277 0.484 
Antithrombin III 59.335 0.486 
Inter alpha trypsin inhibitor heavy chain H4 -66.317 0.509 
Transthyretin -62.453 0.519 
Alpha 1 acid glycoprotein  80.419 0.529 
Serotransferrin 51.875 0.558 
Protein AMBP 63.044 0.625 
Angiotensinogen 42.529 0.649 
Leucine rich apha 2 glycoprotein -44.662 0.651 
Hemopexin 57.799 0.655 
Complement C4 B 34.589 0.656 
Ig kappa chain C region 49.957 0.660 
Retinol binding protein 27.747 0.746 
Serum albumin 19.246 0.812 
  368 
  
Alpha 1 antitrypsin 24.908 0.843 
Ig alpha 1 chain C region -12.851 0.913 
Apolipoprotein E 12.332 0.925 
Complement C3 7.066 0.925 
Beta 2 microglobulin -8.820 0.939 
Fibrinogen beta chain 2.822 0.979 
Superior frontal 
gyrus 
Antithrombin III -1079.660 0.077 
Transthyretin 1146.474 0.081 
Fibrinogen beta chain -1200.061 0.101 
Zinc alpha 2 glycoprotein 807.779 0.135 
Alpha 1 antitrypsin 1170.160 0.176 
Complement C3 -583.246 0.181 
Leucine rich apha 2 glycoprotein 1125.198 0.182 
Angiotensinogen 1076.367 0.219 
Vitamin D binding protein 865.695 0.328 
Protein AMBP 835.587 0.344 
Alpha 1 acid glycoprotein 1 609.656 0.427 
Serum albumin -543.510 0.443 
Serotransferrin -460.125 0.452 
Apolipoprotein A I -447.985 0.484 
  369 
  
Fibrinogen alpha chain -409.532 0.495 
Immunoglobulin lambda like polypeptide 5 -654.442 0.535 
Ig kappa chain C region -374.687 0.602 
Beta 2 microglobulin -452.766 0.624 
Kininogen 1 -220.870 0.641 
Retinol binding protein -346.343 0.684 
Inter alpha trypsin inhibitor heavy chain H4 229.895 0.741 
Apolipoprotein E 181.062 0.753 
Carbonic anhydrase 1 -325.654 0.780 
Complement C4 B 118.805 0.824 
Ig alpha 1 chain C region 164.488 0.850 
Hemopexin 124.896 0.887 
Apolipoprotein A IV 86.017 0.888 
Alpha 1 acid glycoprotein  109.605 0.916 
Alpha 1B glycoprotein -49.030 0.943 
Superior 
occipital gyrus 
Beta 2 microglobulin -1331.366 0.026 
Zinc alpha 2 glycoprotein 631.023 0.152 
Alpha 1 antitrypsin 922.986 0.180 
Leucine rich apha 2 glycoprotein 684.812 0.191 
Vitamin D binding protein -638.090 0.259 
  370 
  
Immunoglobulin lambda like polypeptide 5 -849.349 0.293 
Alpha 1 acid glycoprotein 1 628.388 0.301 
Ig alpha 1 chain C region -638.796 0.369 
Hemopexin 610.406 0.387 
Apolipoprotein A I 379.366 0.408 
Antithrombin III 339.027 0.423 
Fibrinogen alpha chain -377.602 0.425 
Apolipoprotein A IV -362.028 0.440 
Ig kappa chain C region -491.130 0.453 
Protein AMBP -520.949 0.455 
Angiotensinogen -423.926 0.479 
Retinol binding protein -488.201 0.495 
Serotransferrin 286.538 0.552 
Alpha 1B glycoprotein 274.825 0.594 
Transthyretin 269.619 0.611 
Complement C4 B 154.428 0.713 
Carbonic anhydrase 1 -292.201 0.721 
Alpha 1 acid glycoprotein  226.948 0.751 
Complement C3 114.462 0.780 
Serum albumin -111.469 0.815 
  371 
  
Apolipoprotein E 148.571 0.821 
Fibrinogen beta chain 100.136 0.867 
Kininogen 1 47.004 0.899 
Inter alpha trypsin inhibitor heavy chain H4 43.660 0.937 
Superior parietal 
lobule 
Alpha 1 acid glycoprotein 1 2192.198 0.113 
Retinol binding protein -2310.716 0.166 
Alpha 1 antitrypsin 2022.199 0.197 
Serum albumin 1416.545 0.224 
Carbonic anhydrase 1 -2153.369 0.291 
Serotransferrin -1142.365 0.294 
Alpha 1B glycoprotein 1136.205 0.297 
Ig alpha 1 chain C region 1626.940 0.304 
Inter alpha trypsin inhibitor heavy chain H4 1256.625 0.310 
Leucine rich apha 2 glycoprotein 1104.245 0.333 
Apolipoprotein A IV 1006.405 0.345 
Fibrinogen alpha chain -977.430 0.346 
Zinc alpha 2 glycoprotein 869.623 0.374 
Apolipoprotein A I -997.339 0.379 
Apolipoprotein E -1144.884 0.434 
Ig kappa chain C region 1018.482 0.493 
  372 
  
Angiotensinogen 1040.589 0.494 
Hemopexin -1047.350 0.506 
Complement C4 B -606.765 0.517 
Transthyretin 733.268 0.544 
Vitamin D binding protein -529.796 0.692 
Beta 2 microglobulin 546.913 0.730 
Complement C3 -265.293 0.764 
Alpha 1 acid glycoprotein  531.605 0.773 
Kininogen 1 -231.612 0.785 
Protein AMBP -279.257 0.859 
Fibrinogen beta chain -180.945 0.895 
Antithrombin III 46.455 0.961 
Immunoglobulin lambda like polypeptide 5 -18.822 0.991 
Superior 
temporal gyrus 
Alpha 1 antitrypsin 2688.158 0.021 
Zinc alpha 2 glycoprotein 1584.460 0.027 
Apolipoprotein A I -1502.111 0.078 
Protein AMBP 1856.802 0.114 
Alpha 1 acid glycoprotein 1 1580.022 0.129 
Transthyretin 1239.329 0.169 
Leucine rich apha 2 glycoprotein 1016.667 0.372 
  373 
  
Antithrombin III -675.444 0.379 
Hemopexin 1021.150 0.391 
Fibrinogen alpha chain -630.790 0.427 
Apolipoprotein E -791.521 0.475 
Complement C3 -412.470 0.544 
Beta 2 microglobulin 739.197 0.556 
Fibrinogen beta chain 574.072 0.571 
Apolipoprotein A IV 445.775 0.586 
Serotransferrin -448.328 0.587 
Kininogen 1 240.290 0.707 
Immunoglobulin lambda like polypeptide 5 613.570 0.713 
Alpha 1B glycoprotein 250.394 0.761 
Inter alpha trypsin inhibitor heavy chain H4 280.299 0.765 
Retinol binding protein -375.275 0.775 
Complement C4 B -206.962 0.782 
Alpha 1 acid glycoprotein  385.531 0.782 
Serum albumin -197.062 0.832 
Ig kappa chain C region 151.536 0.880 
Ig alpha 1 chain C region 66.002 0.966 
Vitamin D binding protein 49.465 0.968 
  374 
  
Carbonic anhydrase 1 -33.599 0.982 
Angiotensinogen -18.330 0.987 
Temporal white 
matter 
Complement C4 B 6407.603 0.024 
Complement C3 5502.655 0.054 
Apolipoprotein A IV -6250.117 0.063 
Apolipoprotein E 7557.176 0.107 
Vitamin D binding protein -6314.692 0.184 
Carbonic anhydrase 1 6842.000 0.210 
Kininogen 1 3317.437 0.211 
Alpha 1B glycoprotein -4342.025 0.217 
Zinc alpha 2 glycoprotein -3169.034 0.307 
Fibrinogen alpha chain 2478.934 0.458 
Apolipoprotein A I 2690.749 0.463 
Serotransferrin -2494.448 0.473 
Ig alpha 1 chain C region -3867.088 0.488 
Alpha 1 acid glycoprotein  3613.592 0.512 
Immunoglobulin lambda like polypeptide 5 -4169.684 0.516 
Serum albumin -1663.811 0.635 
Leucine rich apha 2 glycoprotein -1996.579 0.652 
Alpha 1 acid glycoprotein 1 1496.980 0.729 
  375 
  
Fibrinogen beta chain 1346.796 0.753 
Beta 2 microglobulin 1122.373 0.835 
Angiotensinogen -956.758 0.863 
Antithrombin III 530.447 0.876 
Alpha 1 antitrypsin 724.316 0.883 
Retinol binding protein -691.507 0.893 
Ig kappa chain C region 474.355 0.914 
Protein AMBP -516.268 0.918 
Hemopexin -390.881 0.938 
Inter alpha trypsin inhibitor heavy chain H4 -293.132 0.941 
Transthyretin 55.015 0.988 
Temporal grey 
matter 
Antithrombin III -3831.437 0.075 
Zinc alpha 2 glycoprotein 3379.500 0.092 
Ig kappa chain C region -4767.157 0.099 
Serotransferrin -3558.946 0.112 
Transthyretin 3893.704 0.116 
Alpha 1 antitrypsin 4125.468 0.205 
Angiotensinogen -3077.365 0.321 
Alpha 1 acid glycoprotein 1 2763.282 0.333 
Apolipoprotein A I -2176.729 0.353 
  376 
  
Alpha 1B glycoprotein -2077.850 0.361 
Serum albumin -1968.453 0.430 
Retinol binding protein -2679.767 0.458 
Complement C4 B 1218.093 0.538 
Ig alpha 1 chain C region -2491.813 0.538 
Carbonic anhydrase 1 -2444.430 0.548 
Beta 2 microglobulin -1965.678 0.555 
Apolipoprotein A IV 1302.199 0.564 
Apolipoprotein E 1724.021 0.595 
Protein AMBP 1739.249 0.598 
Leucine rich apha 2 glycoprotein 1164.202 0.704 
Fibrinogen beta chain -960.126 0.731 
Alpha 1 acid glycoprotein  -1228.701 0.735 
Vitamin D binding protein -982.117 0.762 
Immunoglobulin lambda like polypeptide 5 1241.549 0.774 
Fibrinogen alpha chain -624.911 0.779 
Complement C3 314.042 0.867 
Hemopexin -411.010 0.899 
Kininogen 1 109.804 0.950 
Inter alpha trypsin inhibitor heavy chain H4 68.062 0.979 
  377 
  
Ventricles 
Transthyretin -3403.640 0.053 
Immunoglobulin lambda like polypeptide 5 -5204.793 0.123 
Vitamin D binding protein -3336.643 0.177 
Inter alpha trypsin inhibitor heavy chain H4 -2322.304 0.199 
Carbonic anhydrase 1 -3337.188 0.207 
Angiotensinogen -2317.640 0.230 
Kininogen 1 -1361.551 0.274 
Protein AMBP -2485.887 0.283 
Fibrinogen beta chain -1977.789 0.301 
Ig alpha 1 chain C region -2834.357 0.330 
Alpha 1 antitrypsin -2150.634 0.352 
Retinol binding protein -2042.170 0.410 
Zinc alpha 2 glycoprotein -1105.050 0.435 
Beta 2 microglobulin -1714.765 0.462 
Complement C4 B -920.346 0.533 
Alpha 1B glycoprotein -794.486 0.540 
Serotransferrin 954.139 0.552 
Leucine rich apha 2 glycoprotein 1209.070 0.558 
Apolipoprotein A I 765.805 0.627 
Serum albumin -614.895 0.722 
  378 
  
Hemopexin 667.929 0.770 
Alpha 1 acid glycoprotein 1 -423.763 0.833 
Apolipoprotein E -443.797 0.862 
Alpha 1 acid glycoprotein  -308.140 0.909 
Apolipoprotein A IV 83.792 0.958 
Ig kappa chain C region 96.788 0.965 
Complement C3 50.679 0.971 
Antithrombin III 28.504 0.985 
Fibrinogen alpha chain 24.335 0.987 
White matter 
Complement C4 B 
19633.82
9 0.047 


















  379 
  
Carbonic anhydrase 1 
17892.85
8 0.325 
Kininogen 1 8446.239 0.355 
Apolipoprotein A I 9396.433 0.452 
Serum albumin -8600.830 0.455 








Alpha 1 acid glycoprotein  
12263.92
5 0.521 
Fibrinogen alpha chain 7024.067 0.541 
Alpha 1 acid glycoprotein 1 7892.272 0.596 








Transthyretin -5242.456 0.689 
Ig kappa chain C region 5872.217 0.711 
Protein AMBP -4938.887 0.774 
  380 
  
Antithrombin III 3294.428 0.779 
Beta 2 microglobulin 5319.824 0.789 
Serotransferrin -2968.155 0.803 
Inter alpha trypsin inhibitor heavy chain H4 -3247.519 0.810 
Fibrinogen beta chain 2645.114 0.858 
Retinol binding protein -2944.127 0.869 
Alpha 1 antitrypsin -2653.073 0.876 
Angiotensinogen 2801.078 0.882 









Complement C4 B 
11173.49
0 0.134 
Transthyretin 8667.316 0.342 
Kininogen 1 5590.794 0.378 
Apolipoprotein A IV -7044.113 0.382 
Alpha 1B glycoprotein -7270.308 0.421 
Complement C3 5395.289 0.426 
Serotransferrin -6053.175 0.458 
  381 
  




Alpha 1 acid glycoprotein 1 6937.563 0.499 
Protein AMBP 7782.606 0.503 
Zinc alpha 2 glycoprotein 4342.417 0.539 
Serum albumin -5359.814 0.565 
Angiotensinogen 7264.572 0.578 
Alpha 1 acid glycoprotein  7481.937 0.630 
Retinol binding protein 5838.821 0.650 
Ig kappa chain C region -4341.216 0.667 
Fibrinogen alpha chain -3213.537 0.684 
Vitamin D binding protein -4057.288 0.757 
Carbonic anhydrase 1 4741.474 0.776 
Ig alpha 1 chain C region -3606.615 0.812 
Apolipoprotein A I -2157.080 0.812 
Hemopexin 2001.291 0.862 
Leucine rich apha 2 glycoprotein 1898.549 0.872 
Alpha 1 antitrypsin 1746.116 0.883 
Fibrinogen beta chain 284.483 0.978 
Inter alpha trypsin inhibitor heavy chain H4 260.735 0.978 
  382 
  
Beta 2 microglobulin 185.455 0.989 
  383 
  
Appendix 10  
Mixed-effects regression model results for protein values with cognitive 
measures. Proteins ranked in order of significance based on p value. Proteins 
highlighted in red are statistically significant (p<0.05), those highlighted in 
































Fibrinogen alpha chain -3.049 0.020 
Inter alpha trypsin inhibitor heavy chain H4 -2.628 0.073 
Zinc alpha 2 glycoprotein 1.592 0.182 
 Apolipoprotein A IV -1.403 0.185 
 Apolipoprotein E -1.722 0.259 
Complement C4 B 1.202 0.280 
 Alpha 1 antitrypsin 1.702 0.346 
Vitamin D binding protein -1.132 0.359 
Angiotensinogen -1.018 0.384 
Serum albumin -1.216 0.387 
Transthyretin 1.177 0.409 
Complement C3 -0.905 0.420 
Fibrinogen beta chain -0.921 0.452 
Retinol binding protein 1.590 0.452 
  384 
  
 Alpha 1acid glycoprotein 1 -1.157 0.481 
Carbonic anhydrase 1 -1.001 0.509 
Alpha 1 acid glycoprotein 0.914 0.540 
Ig kappa chain C region -1.058 0.552 
Apolipoprotein A I 0.499 0.579 
Antithrombin III -0.386 0.682 
Ig alpha 1 chain C region -0.780 0.738 
Beta 2 microglobulin -0.411 0.738 
Leucine rich alpha 2 glycoprotein 0.384 0.767 
Serotransferrin -0.348 0.802 
Kininogen 1 0.219 0.825 
Alpha 1B glycoprotein 0.266 0.844 
Hemopexin -0.287 0.883 
Immunoglobulin lambda like polypeptide 5 0.359 0.885 
Protein AMBP 0.077 0.968 
Card Rotation 
Total 
Alpha 1B glycoprotein 17.800 0.018 
Ig alpha 1 chain C region 31.781 0.024 
Inter alpha trypsin inhibitor heavy chain H4 22.418 0.051 
Ig kappa chain C region 26.584 0.060 
 Apolipoprotein A IV 19.940 0.066 
  385 
  
Vitamin D binding protein 22.162 0.103 
Angiotensinogen 16.004 0.136 
Beta 2 microglobulin 14.873 0.148 
Alpha 1 acid glycoprotein 17.693 0.173 
Leucine rich alpha 2 glycoprotein 12.042 0.181 
 Alpha 1acid glycoprotein 1 14.334 0.244 
Serum albumin 8.027 0.273 
Fibrinogen beta chain 13.322 0.287 
Antithrombin III 9.986 0.311 
Protein AMBP 12.862 0.368 
Carbonic anhydrase 1 9.110 0.387 
Fibrinogen alpha chain 9.300 0.391 
Immunoglobulin lambda like polypeptide 5 12.366 0.433 
 Alpha 1 antitrypsin 10.271 0.461 
Apolipoprotein A I 4.672 0.511 
Hemopexin 8.511 0.543 
Zinc alpha 2 glycoprotein 5.186 0.555 
Retinol binding protein -6.012 0.560 
 Apolipoprotein E 9.304 0.599 
Complement C3 4.130 0.639 
  386 
  
Transthyretin 3.892 0.721 
Complement C4 B 1.752 0.851 
Kininogen 1 -1.221 0.876 
Serotransferrin 1.354 0.897 
CESD 
Immunoglobulin lambda like polypeptide 5 -5.123 0.067 
Leucine rich alpha 2 glycoprotein 1.856 0.243 
Kininogen 1 1.552 0.302 
Vitamin D binding protein -1.845 0.338 
Carbonic anhydrase 1 -1.993 0.341 
 Alpha 1acid glycoprotein 1 -2.020 0.392 
Serum albumin -1.249 0.416 
Angiotensinogen -1.246 0.456 
Inter alpha trypsin inhibitor heavy chain H4 1.513 0.482 
 Alpha 1 antitrypsin 2.003 0.487 
Antithrombin III 1.162 0.501 
Ig alpha 1 chain C region 1.794 0.504 
Apolipoprotein A I 0.808 0.554 
Alpha 1 acid glycoprotein 1.085 0.560 
 Apolipoprotein E -1.687 0.580 
Beta 2 microglobulin -0.926 0.638 
  387 
  
 Apolipoprotein A IV -0.856 0.666 
Retinol binding protein 1.026 0.670 
Protein AMBP -1.050 0.708 
Transthyretin 0.750 0.718 
Fibrinogen alpha chain 0.654 0.747 
Hemopexin -0.754 0.785 
Zinc alpha 2 glycoprotein -0.436 0.801 
Fibrinogen beta chain -0.475 0.836 
Ig kappa chain C region 0.407 0.881 
Serotransferrin -0.166 0.935 
Complement C3 -0.120 0.939 
Complement C4 B 0.067 0.968 
Alpha 1B glycoprotein -0.009 0.996 
California verbal 
learning test 
Inter alpha trypsin inhibitor heavy chain H4 12.382 0.048 
Alpha 1 acid glycoprotein 
-
17.320 0.053 
Fibrinogen alpha chain 8.839 0.058 
 Apolipoprotein E 12.611 0.060 
Zinc alpha 2 glycoprotein -8.749 0.063 
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11.642 
Serotransferrin -8.128 0.159 
 Alpha 1 antitrypsin -9.833 0.180 
Angiotensinogen 11.244 0.189 
Fibrinogen beta chain -7.367 0.253 
Immunoglobulin lambda like polypeptide 5 
-
11.451 0.263 
Carbonic anhydrase 1 10.350 0.301 
 Alpha 1acid glycoprotein 1 -6.745 0.330 
Ig alpha 1 chain C region 9.292 0.333 
 Apolipoprotein A IV 4.738 0.347 
Antithrombin III -3.686 0.384 
Apolipoprotein A I 3.822 0.476 
Hemopexin -5.356 0.499 
Serum albumin -3.819 0.533 
Leucine rich alpha 2 glycoprotein -4.281 0.569 
Retinol binding protein -3.850 0.633 
Complement C4 B 1.467 0.755 
Ig kappa chain C region 1.736 0.811 
Vitamin D binding protein -1.594 0.829 
Kininogen 1 -0.476 0.909 
  389 
  
Beta 2 microglobulin -0.744 0.935 
Transthyretin 0.325 0.956 
Alpha 1B glycoprotein -0.219 0.964 
Digit span 
backwards 
Transthyretin -2.034 0.032 
Serum albumin 1.874 0.037 
 Apolipoprotein A IV -1.688 0.038 
Beta 2 microglobulin -1.855 0.145 
Fibrinogen beta chain -1.510 0.152 
Vitamin D binding protein 1.417 0.161 
Carbonic anhydrase 1 1.907 0.186 
Serotransferrin 1.136 0.189 
 Alpha 1 antitrypsin -1.551 0.201 
Alpha 1B glycoprotein 0.991 0.243 
Inter alpha trypsin inhibitor heavy chain H4 -1.075 0.271 
Protein AMBP -1.322 0.291 
Alpha 1 acid glycoprotein -1.388 0.304 
Zinc alpha 2 glycoprotein -0.729 0.305 
Ig kappa chain C region -0.757 0.411 
 Apolipoprotein E 0.954 0.412 
Fibrinogen alpha chain -0.603 0.466 
  390 
  
Ig alpha 1 chain C region 1.098 0.474 
Hemopexin 0.659 0.607 
Apolipoprotein A I -0.455 0.611 
Leucine rich alpha 2 glycoprotein -0.507 0.641 
Angiotensinogen -0.409 0.712 
 Alpha 1acid glycoprotein 1 0.385 0.720 
Antithrombin III 0.190 0.777 
Complement C4 B -0.143 0.850 
Complement C3 -0.132 0.854 
Retinol binding protein 0.198 0.880 
Kininogen 1 0.096 0.883 
Immunoglobulin lambda like polypeptide 5 0.158 0.911 
Digit span 
forwards 
Serotransferrin 1.574 0.101 
Beta 2 microglobulin -2.254 0.134 
 Apolipoprotein A IV -1.388 0.142 
Hemopexin 2.090 0.149 
Carbonic anhydrase 1 1.794 0.199 
Inter alpha trypsin inhibitor heavy chain H4 -1.189 0.265 
 Alpha 1acid glycoprotein 1 1.278 0.290 
Serum albumin 1.044 0.291 
  391 
  
Fibrinogen beta chain -1.141 0.325 
Alpha 1B glycoprotein 0.844 0.362 
Transthyretin -0.900 0.376 
Complement C4 B 0.580 0.483 
 Apolipoprotein E 0.900 0.491 
Immunoglobulin lambda like polypeptide 5 0.947 0.534 
Vitamin D binding protein 0.638 0.542 
Ig alpha 1 chain C region 1.005 0.548 
Retinol binding protein 0.898 0.563 
Antithrombin III 0.399 0.567 
Ig kappa chain C region -0.520 0.610 
Apolipoprotein A I -0.437 0.683 
Kininogen 1 0.284 0.684 
Fibrinogen alpha chain -0.243 0.788 
Angiotensinogen 0.220 0.857 
Alpha 1 acid glycoprotein 0.219 0.886 
Leucine rich alpha 2 glycoprotein 0.098 0.935 
 Alpha 1 antitrypsin -0.076 0.953 
Protein AMBP 0.068 0.962 
Zinc alpha 2 glycoprotein 0.015 0.986 
  392 
  
Complement C3 -0.002 0.998 
Fluency categories 
Retinol binding protein -3.460 0.021 
Zinc alpha 2 glycoprotein -1.574 0.043 
 Apolipoprotein A IV 1.637 0.098 
Hemopexin -2.122 0.100 
Carbonic anhydrase 1 -3.400 0.106 
Ig kappa chain C region 1.400 0.159 
Serotransferrin -1.312 0.188 
Alpha 1 acid glycoprotein -1.711 0.283 
Antithrombin III 0.829 0.331 
Kininogen 1 -0.526 0.506 
Beta 2 microglobulin -0.663 0.561 
Angiotensinogen 0.551 0.565 
 Apolipoprotein E 0.641 0.629 
Ig alpha 1 chain C region 0.352 0.690 
Alpha 1B glycoprotein 0.404 0.701 
Fibrinogen beta chain -0.445 0.720 
Complement C4 B -0.224 0.763 
Serum albumin 0.289 0.771 
Immunoglobulin lambda like polypeptide 5 -0.410 0.797 
  393 
  
Leucine rich alpha 2 glycoprotein 0.156 0.817 
Apolipoprotein A I 0.201 0.825 
Fibrinogen alpha chain 0.223 0.827 
Vitamin D binding protein 0.215 0.849 
Transthyretin 0.191 0.852 
Complement C3 0.138 0.868 
Inter alpha trypsin inhibitor heavy chain H4 -0.146 0.888 
 Alpha 1acid glycoprotein 1 0.161 0.893 
Protein AMBP -0.064 0.962 
 Alpha 1 antitrypsin 0.046 0.973 
Fluency letters 
Ig kappa chain C region 3.378 0.001 
Serum albumin 2.010 0.058 
Leucine rich alpha 2 glycoprotein 2.140 0.062 
Kininogen 1 1.319 0.093 
Antithrombin III 1.546 0.104 
Immunoglobulin lambda like polypeptide 5 3.032 0.119 
Angiotensinogen 1.913 0.126 
 Alpha 1acid glycoprotein 1 1.545 0.189 
Alpha 1B glycoprotein 1.430 0.190 
Retinol binding protein -1.328 0.290 
  394 
  
Protein AMBP 1.371 0.300 
 Alpha 1 antitrypsin 1.340 0.320 
Apolipoprotein A I -0.787 0.402 
Ig alpha 1 chain C region 1.011 0.476 
Inter alpha trypsin inhibitor heavy chain H4 0.731 0.477 
Fibrinogen alpha chain -0.600 0.538 
Transthyretin 0.616 0.541 
 Apolipoprotein E 0.714 0.561 
Fibrinogen beta chain 0.634 0.598 
Complement C4 B -0.409 0.610 
Alpha 1 acid glycoprotein 0.651 0.691 
Vitamin D binding protein -0.509 0.696 
Hemopexin 0.425 0.746 
Serotransferrin 0.303 0.761 
Beta 2 microglobulin 0.369 0.781 
Complement C3 -0.160 0.828 
Carbonic anhydrase 1 0.278 0.898 
 Apolipoprotein A IV -0.031 0.976 
Zinc alpha 2 glycoprotein 0.015 0.985 
MMSE Leucine rich alpha 2 glycoprotein -1.110 0.010 
  395 
  
Fibrinogen alpha chain 1.010 0.065 
Zinc alpha 2 glycoprotein -0.846 0.070 
Complement C3 0.797 0.073 
 Apolipoprotein E 1.480 0.080 
Immunoglobulin lambda like polypeptide 5 -1.123 0.136 
Apolipoprotein A I 0.404 0.175 
Vitamin D binding protein 0.827 0.226 
Inter alpha trypsin inhibitor heavy chain H4 0.712 0.226 
Angiotensinogen 0.564 0.227 
 Alpha 1 antitrypsin -0.720 0.334 
Kininogen 1 -0.402 0.335 
Carbonic anhydrase 1 0.497 0.353 
Protein AMBP -0.701 0.359 
 Alpha 1acid glycoprotein 1 -0.603 0.375 
Alpha 1 acid glycoprotein -0.474 0.453 
Hemopexin -0.526 0.498 
 Apolipoprotein A IV 0.357 0.499 
Ig alpha 1 chain C region -0.480 0.539 
Ig kappa chain C region 0.378 0.613 
Antithrombin III -0.203 0.654 
  396 
  
Serotransferrin -0.117 0.836 
Transthyretin -0.111 0.849 
Serum albumin 0.078 0.855 
Fibrinogen beta chain 0.113 0.858 
Retinol binding protein -0.063 0.910 
Beta 2 microglobulin 0.057 0.927 
Complement C4 B 0.024 0.958 




Vitamin D binding protein 4.997 0.007 
Serum albumin 2.562 0.118 
Zinc alpha 2 glycoprotein -2.131 0.129 
 Apolipoprotein E -3.672 0.132 
Immunoglobulin lambda like polypeptide 5 4.357 0.136 
Protein AMBP -3.394 0.140 
 Alpha 1 antitrypsin -2.863 0.207 
Kininogen 1 -1.589 0.218 
Transthyretin -2.188 0.220 
Fibrinogen alpha chain 1.866 0.299 
Alpha 1B glycoprotein 1.545 0.335 
Alpha 1 acid glycoprotein -2.386 0.368 
  397 
  
Ig alpha 1 chain C region 1.801 0.385 
Fibrinogen beta chain -1.643 0.405 
Beta 2 microglobulin 1.373 0.464 
Retinol binding protein -1.367 0.532 
Complement C3 -0.848 0.544 
Carbonic anhydrase 1 1.382 0.584 
Apolipoprotein A I -0.738 0.587 
Complement C4 B -0.764 0.599 
Inter alpha trypsin inhibitor heavy chain H4 -0.850 0.653 
Antithrombin III -0.590 0.694 
Hemopexin -0.721 0.752 
Leucine rich alpha 2 glycoprotein 0.380 0.825 
 Alpha 1acid glycoprotein 1 -0.435 0.829 
 Apolipoprotein A IV 0.332 0.843 
Serotransferrin -0.279 0.871 
Ig kappa chain C region 0.299 0.885 
Angiotensinogen 0.142 0.941 
Trails A 
Alpha 1B glycoprotein -3.077 0.189 
Complement C4 B 2.793 0.193 
Ig alpha 1 chain C region -4.689 0.235 
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 Alpha 1acid glycoprotein 1 -3.597 0.244 
Ig kappa chain C region -3.508 0.267 
Leucine rich alpha 2 glycoprotein -2.477 0.338 
Hemopexin -3.031 0.401 
 Apolipoprotein A IV -2.176 0.410 
Beta 2 microglobulin -2.647 0.441 
Fibrinogen beta chain 2.314 0.454 
Apolipoprotein A I -1.990 0.457 
Antithrombin III 1.802 0.459 
Complement C3 -1.498 0.488 
Transthyretin 1.783 0.508 
Kininogen 1 1.033 0.590 
 Alpha 1 antitrypsin 1.798 0.598 
Angiotensinogen 1.683 0.617 
Protein AMBP 1.773 0.624 
Retinol binding protein 1.847 0.643 
Inter alpha trypsin inhibitor heavy chain H4 1.230 0.670 
Serum albumin -0.865 0.712 
Immunoglobulin lambda like polypeptide 5 -1.465 0.725 
Carbonic anhydrase 1 -1.006 0.743 
  399 
  
Alpha 1 acid glycoprotein -1.103 0.763 
Serotransferrin -0.700 0.789 
Zinc alpha 2 glycoprotein 0.230 0.914 
 Apolipoprotein E 0.429 0.915 
Vitamin D binding protein -0.248 0.938 
Fibrinogen alpha chain 0.077 0.977 
Trails B 
Fibrinogen alpha chain 
-
26.689 0.008 
 Apolipoprotein A IV 
-
22.119 0.025 
 Apolipoprotein E 
-
21.913 0.086 
Ig alpha 1 chain C region 
-
22.102 0.117 
 Alpha 1 antitrypsin 19.303 0.119 
Fibrinogen beta chain 
-
13.911 0.174 
Leucine rich alpha 2 glycoprotein 12.127 0.294 






Alpha 1B glycoprotein -7.034 0.435 
  400 
  
Carbonic anhydrase 1 9.067 0.464 
Apolipoprotein A I -6.267 0.485 
 Alpha 1acid glycoprotein 1 -7.641 0.494 
Beta 2 microglobulin -6.944 0.527 
Serum albumin -4.931 0.561 
Protein AMBP 6.857 0.597 
Ig kappa chain C region -5.477 0.618 
Vitamin D binding protein -5.212 0.618 
Zinc alpha 2 glycoprotein 3.640 0.640 
Hemopexin 5.536 0.666 
Complement C3 -2.887 0.690 
Transthyretin 2.634 0.788 
Complement C4 B 2.066 0.798 
Retinol binding protein 3.038 0.816 
Alpha 1 acid glycoprotein 2.550 0.840 
Antithrombin III 1.517 0.853 
Immunoglobulin lambda like polypeptide 5 -1.677 0.912 
Serotransferrin 0.715 0.940 
Kininogen 1 0.008 0.999 
 
 
